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Abstract 
The role of donor CD4 T lymphocyte  
chimerism in lung transplant recipients       Olivera Gjorgjimajkoska 
Long-term outcomes for lung transplantation remain disappointing; as many 
as 50% of lung transplant recipients develop progressive Bronchiolitis 
Obliterans Syndrome (BOS) by 5 years after transplant. In the last decade, 
several experimental and clinical studies have demonstrated that cellular and 
humoral autoimmune responses to ‘self’ antigens may play a causative role in 
the onset of BOS. Work from our research group has highlighted a novel 
mechanism for triggering autoimmunity following transplantation. In a murine 
model of chronic heart rejection, transplant-induced autoimmunity - 
characterised by production of class-switched anti-nuclear effector 
autoantibody responses was dependent upon provision of help from donor 
CD4 T cells that were passengers within the graft. However, the fate of the 
donor passenger CD4 T cells in clinical organ transplantation is unclear.  
 
To assess whether a similar mechanism may occur in human transplant 
recipients, I have studied the presence and the impact of passenger donor 
CD4 T cells on the development of humoral auto- and alloimmune responses 
in a prospective cohort of primary lung transplant recipients (n=21). The 
development of autoantibody and, in particular, the specificity of target 
autoantigens was also evaluated in a lung transplant patients with either 
established grade 2-3 BOS (n=10), or without BOS (n=10).   
 
My work suggests that the presence of donor CD4 T cell chimerism in the 
peripheral blood of lung transplant recipients is a uniform phenomenon. Donor 
CD4 T lymphocytes were consistently detected in the recipients’ peripheral 
blood during the first post-operative month; however, the number of 
detectable donor CD4 T cells fluctuated over time, and varied between 
individual lung transplant recipients. In a follow-up period of one year after 
transplantation, three distinct patterns of donor CD4 T cell chimerism were 
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observed: short (donor CD4 T cells detectable for up to six weeks after 
transplantation, n=13), intermediate (donor CD4 T cells detectable between 
three to six months after transplantation, n=3) and long-lasting chimerism 
(donor CD4 T cells detectable for more than six months after transplantation, 
n=5). Surprisingly, the degree of HLA mismatching and the predicted NK cell 
alloreactivity did not correlate with the longevity of donor CD4 T cell 
chimerism, and did not influence the development of BOS. Furthermore, 
transcriptomic analysis of the donor CD4 T cell population consisted of a 
heterogenous mixture of different CD4 T cell sub-types, with no consistent 
pattern evident in patients with short and long lasting donor CD4 T cell 
chimerism. 
 
The assessment of the humoral autoimmune responses revealed unexpected 
findings. Anti-nuclear IgG autoantibody levels were greater in the recipients’ 
sera before the transplant, when compared to sera sampled at one and 12 
months after transplantation, but the titre of pre-transplant anti-nuclear 
autoantibody did not correlate with the subsequent development of BOS. 
Similar findings were observed in the retrospective cohort of 24 lung and 18 
heart and lung transplant recipients. Assessment of the repertoire of 
pretransplant autoantibody did however suggest that a unique set of 
autoantigens were targeted in those patients that subsequently developed 
BOS.  
 
The involvement of donor CD4 T cell in the development of transplant-induced 
autoimmunity and augmentation of humoral alloimmunity was not confirmed in 
human lung transplant recipients and the role of donor CD4 T chimerism 
remains unclear. However, solid organ transplant recipients are subjected to 
highly potent T-cell depleting immunosuppressive drugs that can alter the 
number and function of T cells. This may obviate the impact of donor CD4 T 
cell chimerism in the development of transplant-induced autoimmunity. 
Understanding the clinical relevance of the autoantibody repertoire present at 
the time of transplant may, however, hold potential in identifying recipients 
with predisposition to develop BOS, and may therefore possibly provide a 
window of opportunity for targeted immunosuppression.   
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1 Chapter 1 
 
 
 
Introduction 
  
 2 
1.1 A brief history of lung transplantation 
   
The earliest attempts to transplant heart and lungs in the experimental animal 
model date from the beginning of the 20th century. In 1905, Alexis Carrel 
performed the first successful heterotopic heart-lung block transplantation into 
the neck of a recipient cat, reviewed by Stolf, 2017 [1]. It took over 50 years of 
extensive experimental research before lung transplantation moved from 
animal models to humans.  
 
The pioneering work of Dr James Hardy laid the foundation of lung 
transplantation in humans. After seven years of experimental work Dr Hardy 
and colleagues obtained the first ethical permission to perform lung 
transplantation in a human recipient.  On the 11th of June in 1963 at the 
University of Mississippi Medical Centre they performed the first single-lung 
transplant. The patient was later identified as a convicted prisoner who died 
18 days after the transplant due to renal failure and infection with good lung 
function and no evidence of rejection [2].   
 
During the 1970s and early 1980s lung transplantation suffered its own 
setbacks and proved more challenging since most allografts were lost due to 
post-operative surgical complications and allograft rejection [3]. During this 
period less than 40 lung transplants were performed worldwide without any 
long-term survivors.  
 
After years of additional experimental animal work in 1981, Bruce Reitz and 
Norman Shumway performed the first successful heart and lung transplant in 
a patient with primary pulmonary hypertension who survived for many years 
after transplantation. The patient was a newspaper executive who later wrote 
a book detailing his story of this amazing medical accomplishment [4]. During 
the mid-1980s the Toronto lung transplant group published their experience 
with successful single-lung transplants in patients with pulmonary fibrosis [5] 
reviving the hope that lung transplantation could become a visible therapeutic 
option.  
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The number of human lung transplants performed grew dramatically during 
the late 1980s to the late 1990s; however, since then lung transplant activity 
has plateaued, mainly due to the limited number of suitable lung donors. The 
limited number of available donors has led to the development of living donor 
lung transplant programmes and increased use of lungs previously deemed 
unsuitable for transplantation; including the use of donors after circulatory 
death (DCD) and use of lungs after prior assessment and reconditioning 
during ex vivo lung perfusion (EVLP).  
 
Over the last four decades, improved surgical techniques, development of 
immunosuppression regimens and highly sensitive antibody screening 
strategies have significantly improved the early clinical outcome; however, 
development of progressive lung allograft dysfunction manifesting as 
bronchiolitis obliterans syndrome (BOS) limits survival to only 50% at 5 years 
after lung transplantation [6].  
 
1.2 Pathogenesis and risk factors for development of bronchiolitis 
obliterans syndrome  
 
BOS is a disease of multifactorial etiology; it is believed that it represents the 
end result of repeated immune and non-immune related injury to the allograft. 
Factors that contribute to the development of BOS have been classified as: 
alloimmune-independent and immune-dependent [7] including both 
alloimmune and autoimmune responses.  
 
1.2.1 Alloimmune-independent contributing factors for development of BOS 
 
The lung is a vulnerable organ due to the constant exposure to environmental 
agents, such as inhaled dust, toxins, infectious material and irritants, which 
when inhaled could promote local inflammation and tissue damage. 
Alloantigen-independent factors such as infections, gastroesophageal reflux 
disease and primary graft dysfunction are the main factors that increase the 
risk for development of BOS.   
 4 
1.2.1.1 Infections as a contributing factor for development of BOS 
 
Infections are the leading cause of morbidity and mortality in lung transplant 
recipients (LTR). Due to the highly potent immunosuppression regimens all 
solid organ transplant recipients suffer increased incidence of infections [8]; 
nevertheless, lungs are more prone to infections, and this largely contributes 
to several factors unique to lung allografts. Firstly, lungs are in constant 
contact with environmental antigens, second, exposure of the allograft to 
previously colonised native airways, and lastly, denervation of the lung during 
the surgical procedure leading to impaired cough reflex [9]. These factors 
together with the immunosuppressed state of the recipients provide an ideal 
environment for development of opportunistic infections.     
 
Lung allografts are the most susceptible to infections during the first post-
operative months. In a retrospective study of 51 lung transplant recipients, a 
total of 71 infection episodes were reported, of which 42% occurred within the 
first 3 months and 75% during the first year after transplantation [10]. Bacterial 
pneumonia is the most common post-transplant complication [11], followed by 
infection with cytomegalovirus (CMV) with incidence ranging from 50% to 75% 
in comparison to the incidence of CMV infections in kidney transplant patients 
ranging between 8 and 32% [12]. Recipients of donor CMV seropositive are at 
highest risk for CMV infection [12]. The CMV infects various cells and elicits 
innate and adaptive immune responses, both cellular and humoral.  
 
Post-transplant Infections with human respiratory syncytial virus (RSV) have 
been associated with acute allograft rejection and development of BOS [13]. 
The respiratory epithelial cell infection with RSV induces innate immune 
mechanism via TLR4, a potent activator of Th1 driven adaptive immunity, 
characterised by increased production of IFN-γ, TNF-α and IL-2 production 
and cytotoxic T cell responses [14]. Activation of the adaptive immune 
responses leads to viral clearance. However, due to the immunosuppression 
regimens LTRs have impaired production of IL-2 resulting in inadequate viral 
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clearance and epithelial cell damage, thus, subsequently contributing to 
allograft dysfunction [15].  
 
Another common post-transplant complication in LTRs is the development of 
posttransplant lymphoproliferative disorder (PTLD) due to infection with the 
Epstein-Barr virus. The incidence of PTLD in LTRs ranges between 6.2 and 
9.4% and is in correlation with the level of immunosuppression and time after 
lung transplantation [16].   
 
Bacterial pneumonia is the most common infection in LTRs in the early post-
operative period. The most common bacterial isolates are Staphylococcus 
aureus and Acinetobacter [17]. Amongst the fungal infections with an 
incidence of 32% are the infections with the Aspergillus species [17]. Post-
transplant complication with fungal infections usually occurs at the site of 
anastomosis as a result of transmitted infection from the donor or the native 
lung may serve as a reservoir in the case of single lung transplantation.  
 
1.2.1.2 Gastroesophageal reflux disease and BOS  
 
Gastroesophageal reflux disease (GERD) is a mucosal inflammatory diseases 
caused by the stomach acids reflux into the esophagus. It occurs in variety of 
lung diseases prior to transplantation especially in patients with idiopathic 
pulmonary disease (IPF) [18] and cystic fibrosis (CF) [19]. The incidence of 
GERD is even more common after lung transplantation, presumably due to an 
intraoperative vagal nerve injury and continuous use of immunosuppression 
such as cyclosporine A and prednisolone. It is not clear whether GERD 
directly contributes to the pathogenesis of BOS; nevertheless, several reports 
have shown that GERD was associated with worse pulmonary function after 
lung transplantation [20]. Patients treated with surgical fundoplication (a 
surgical procedure that prevents stomach acid reflux into the esophagus) had 
improved lung function, suggesting the involvement of GERD in the 
development of BOS [21]. Experimental studies in a rat lung transplant model, 
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in which bile acid was directly aspirated into the transplanted lung, led to 
lymphocytic lung inflammation and allograft rejection [22].  
 
It is possible that prolonged contact of the airways with the gastric content 
may lead to epithelial lung injury, thus creating a local up-regulated 
inflammatory milieu. Increased levels of bile acids in bronchoalveolar lavage 
(BAL) has been associated with alveolar neutrophilia [23]. These findings 
support the role of GERD in the development of BOS, presumably by 
augmenting the non-alloimmune and alloimmune responses.    
 
1.2.1.3 Ischemia-reperfusion-induced injury and BOS 
 
Ischemia-reperfusion-induced (IRI) injury is characterised by non-specific 
alveolar damage, lung edema and hypoxemia occurring within the first 72 
hours after lung transplantation [24]. IRI represents a main cause of primary 
graft dysfunction that in its most severe form is a leading cause of morbidity 
and mortality after lung transplantation. Over the years, improvements in lung 
preservation techniques and development of a new preservation solution 
specifically designed to support the lungs have reduced the incidence of 
primary graft dysfunction from 30% to less than 15% [24, 25]. IRI is a two-
stage process, a period of cold ischemic storage and reperfusion following 
revascularisation of the graft. The allograft cold storage is kept as short as 
possible and usually for lung transplantation ranges between 4 and 8 hours.  
 
Although, cold storage is essential for organ preservation, it is associated with 
a number of events such as oxidative stress, sodium pump inactivation, 
intracellular calcium overload, iron release and cell death. These processes 
may lead to up-regulation of cell surface molecules and release of 
inflammatory mediators that can activate the passenger donor cells and 
recipient leukocytes following reperfusion [25].  
 
The pro-inflammatory conditioning of the lung is further amplified by a number 
of physiological changes that occur in brain-death donors; including 
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hemodynamic instability, endocrine abnormalities, hypothermia, 
coagulopathy, pulmonary dysfunction, and electrolyte imbalances [26]. As a 
consequence, these events lead to upregulation of cell adhesion molecules 
and activation of passenger macrophages.  
 
Macrophages are antigen-presenting cells of the innate immune system; their 
activation leads to release of proinflammatory cytokines such as IL-1, IL-6, IL-
8, IL-12, IL-18, TNF-α and INF-γ [27]. In human lung transplantation, IL-8 has 
been shown to be upregulated in the BAL and lung tissue of DCD donors [28]. 
The level of IL-8 has been associated with the increase incidence of primary 
graft dysfunction [28, 29]. Moreover, release of pro-inflammatory cytokines 
initiates recruitment and activation of neutrophils and T lymphocytes that 
further amplify the inflammatory process resulting in tissue damage. Thus, as 
a consequence at the time of implantation the allograft is already armed with 
vigorously active immune responses that may further augment alloimmune 
responses.  
 
1.2.2 Immune-dependent contributing factors for development of BOS  
 
Immune recognition of antigenic differences between the recipient-donor pair 
plays a major role in the development of BOS and the strength of alloimmune 
responses is influenced by the degree of HLA mismatching, episodes of acute 
rejection and its underlining cellular and/or humoral mechanisms involved and 
pre-existence of donor specific HLA antibodies. In the following Sections I will 
describe the role of HLA mismatching, allorecognition pathways and types of 
allograft rejection as contributing factors for development of BOS.   
 
1.2.2.1 HLA mismatching 
 
The immunological events that initiate allograft rejection occur due to the 
recognition of antigenic differences in the Major Histocompatibility Complex 
(MHC) molecules between the host and transplanted organ. The main 
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function of the MHC molecules is presentation of self and foreign (non-self) 
antigens in the form of short peptides to T lymphocytes. 
 
The MHC region comprises of group of genes found on the short arm of 
chromosome six and it represents the most studied region of the human 
genome. It spans over four megabases and contains more than 250 
expressed genes, making it the most polymorphic and diverse region of the 
human genome [30].   
 
The MHC region contains three clusters of genes: class I, class II and class 
III. The genes found within class I and class II region encode for proteins also 
know as Human Leukocyte Antigens (HLA) whereas the genes in the class III 
portion encode for immune related proteins such as complement factors (C2, 
C4A, C4B), lymphotoxin alpha and beta, heat-shock proteins (HSP70), and 
others; and none of these proteins are involved in antigen presentation [31].  
 
MHC class I molecules are encoded by three genetic loci HLA-A, -B and Cw, 
consisting of two non-covalently linked polypeptide chains. The alpha heavy 
chain is a highly polymorphic glycoprotein anchored to the cell membrane and 
associated with β2-microglobulin, which is encoded by a non-polymorphic 
gene located on chromosome 15. The heavy chain α1 and α2 domains fold 
together creating a cleft, known as peptide-binding site [32]. Thus, 
polymorphism within these two domains determines the type of peptides that 
bind to the HLA class I antigens. In contrast, the α3 domain is highly 
conserved and acts as a ligand for CD8 co-receptor expressed on T 
lymphocytes. MHC class I molecules are expressed on all nucleated cells and 
present short (8-10 amino acids in length) endogenous peptides to CD8 T 
cells [32, 33].  
 
There are other class I loci, however, knowledge about their function is only 
beginning to emerge. Amongst these is HLA-G expressed on placental 
trophoblast cells and it represents the only known ligand for activating 
KIR2DL4 receptor expressed on all natural killer (NK) cells [34], implicating 
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their role in fetal development during early pregnancy [35]. HLA-E, -F and -G, 
termed as non-classical HLA class I antigens serve as a ligands for NK cell 
receptors [36, 37]. Their role in solid organ transplantation is unclear.         
 
The genes that encode class II molecules HLA-DR, -DQ and -DP are 
clustered within the class II region of the MHC. The MHC class II molecules 
consist of two polypeptide chains, α and β both anchored to the cell 
membrane. In the MHC class II molecules the α1 and β1 domain form the 
peptide-binding site and the most polymorphic part of the molecule lies within 
the β1 domain [38]. In contrast to MHC class I molecules, the MHC class II 
molecules are mainly expressed on professional antigen presenting cells 
(APC) including macrophages, dendritic cells (DCs) and B cells and present 
peptides (13 to 25 amino acids in length) derived from exogenous antigens 
[38, 39]. The β2 domain is highly conserved and associates with CD4 co-
receptor on T lymphocytes, making them restricted to HLA class II interaction. 
In addition, HLA class II expression can be induced in other cell types such as 
endothelial and epithelial cells by IFN-γ and TNF-α [40].  
 
The extensive polymorphism of HLA has evolved due to evolutionary pressure 
to ensure efficient binding and presentation of a vast array of peptides derived 
from potentially pathogenic organisms, thus provoking strong immune 
responses and eradication of pathogenic organisms. Therefore, particular 
HLA genes have evolved differently according to geographic regions and 
ethnic groups. Contrary to this, the differences within the HLA class I and 
class II genes between recipient-donor pair represent a limiting factor for 
successful solid organ and bone marrow transplantation.   
 
Evidence for their involvement as the major transplantation antigens arose 
from transplants performed between genetically related individuals [41]. In the 
early 1970s and 1980s graft survival correlates with the number of HLA 
mismatched antigens between donor and recipient, with 90% of graft survival 
in transplants performed between HLA identical siblings compared to 60% of 
patients who received a full HLA mismatched graft [41, 42].  
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Nevertheless, 10% of kidney transplant patients who received graft from HLA 
identical sibling reject the graft and up to 40% of HLA identical bone marrow 
patients experience acute graft-versus-host disease (GvHD), most likely due 
to polymorphism in proteins other than the MHC molecules itself, termed as 
minor histocompatibility (mH) antigens [43, 44]. These antigens are presented 
by the MHC class I and class II molecules and represent targets for 
allorecognition. There are several mH antigens recognised, in bone marrow 
transplantation the male HY antigen has been associated with severe GvHD 
in an HLA identical sibling pair [45]. The role of mH antigens in solid organ 
transplantation is not clear. 
 
In a hope to improve graft survival in many countries across the world HLA 
matching has been incorporated in the organ allocation scoring criteria. In 
addition, minimising the number of HLA mismatched antigens between the 
recipient and donor limits the potential for patient sensitisation to HLA 
antigens, which is of great importance for patients requiring more than one 
transplant.  
 
However, since the introduction of sophisticated immunosuppression 
regiments incorporating calcineurine inhibitors (cyclosporine, tacrolimus), anti-
proliferative agents (azathioprine, mycophenolate mofetil (MMF), sirolimus, 
everolimus) and both polyclonal and monoclonal antibodies (anti-thymocyte 
globulin, Basiliximab, Daclizumab, Almtuzumab) the short-term graft survival 
of all solid organ transplants has improved significantly [46]. Nowadays, the 
United Kingdom national average one-year kidney graft survival is around 
96% vs 98% for deceased and living kidney transplants, respectively [47].  
 
Historically, in renal transplantation, HLA matching played an important role in 
organ allocation; patients with 000-mis-matched kidneys (HLA-A/B/DR) have 
significantly improved graft survival in comparison to poorly matched grafts 
[48]. Nevertheless, in the current era of modern immunosuppression the 
impact of HLA matching has been rendered [49], which in the United Kingdom 
has resulted in changes in the kidney offering and matching criteria [47, 50].  
 
 11 
In comparison to kidney transplantation, HLA matching has not been taken 
into consideration for allocation of thoracic organs, due to shorter ischemia 
time and a smaller donor pool. Tendrich et al., and others have demonstrated 
that HLA matching is not associated with prolonged graft survival in heart 
transplant recipients [51, 52]. In contrast, analysis from the UNOS/ISHLT 
Thoracic Registry showed that HLA matching has a beneficial impact on graft 
survival in heart and single-lung transplant patients; primarily matching at 
HLA-A and DR loci [53]. In other studies, matching for HLA-A [54] or HLA-DR 
loci [55] has been associated with reduced incidence of BOS; whereas 
Yamada et al., have showed that the number of HLA mismatches is an 
independent risk factor for development of BOS [56]  
 
Although the data available is conflicting, it is important to bear in mind that 
allorecognition of non-self-donor HLA antigens is the basis for initiation of 
alloimmune responses [57]. 
 
1.2.2.2 Allorecognition           
 
Allorecognition refers to detection of same-species, non-self antigens by the 
host immune system. It is primarily driven by the ability of the recipient T cells 
to recognise both intact donor MHC molecules on donor antigen presenting 
cells, known as direct pathway of allorecognition; and processed donor 
derived MHC peptides presented in the form of self-MHC peptide complexes, 
an indirect pathway [58]. The two pathways of allorecognition differ in their 
cellular mechanism.  
 
1.2.2.2.1 Direct pathway of allorecognition  
 
Direct pathway of allorecognition is unique to transplantation in a sense that it 
differs from the conventional rule of self-MHC restriction. It has been 
proposed that the direct allorecognition may result from cross-reactivity of T 
cell receptor (TcR) specific for self-MHC molecules with an allogeneic MHC 
molecule. Lombardi et al., have shown that high a proportion of T cell primary 
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alloresponses are the result of previously primed T cells, implying that the 
cells have previously been primed against foreign antigens in the context of 
self-MHC molecules [59].  
 
The high precursor frequency of T cells with reactivity to allogeneic MHC 
molecules can be measured in vitro in a mixed leukocyte reaction (MLR) and 
represents in vivo analogue to acute allograft rejection [60]. Two hypotheses 
have been proposed to explain this phenomenon; “high determinant 
hypothesis” where the allogeneic MHC molecules itself, independent of the 
peptide bound plays a major ligand for alloreactive T cells [61], and “multiple 
binary complex hypotheses” primarily driven by the peptide bound on the 
MHC molecule [62, 63].  
 
A single MHC molecule can display a diverse array of peptides; this would 
mean that a single allogeneic MHC molecule could stimulate a large number 
of alloreactive T cells with specificity for an individual peptide-MHC complex.  
The priming of recipient T cells with direct allospecificity depends on 
interaction with stimulated passenger donor dendritic cells (DCs) in the 
secondary lymphoid organs [64]. Removal of donor DCs from the graft by 
“parking” the graft in the intermediate recipient before re-transplantation into a 
second recipient leads to loss of immunogenicity and prolonged graft survival 
[65]. Whereas transfer of donor DCs restores the immunogenicity [65] and 
provokes allograft rejection. This experimental evidence suggests that acute 
allograft rejection occurring early after transplantation is dependent on the 
presence of donor derived DCs passenger within the allograft.  
 
Activated donor DCs express both MHC class I and class II molecules and 
other co-stimulatory molecules that can facilitate priming and activation of the 
recipient CD4 and CD8 T cell with direct allospecificity in a 3-cell cluster, 
allowing a conventional CD8 T cell activation [66]. Activated direct pathway 
CD8 T cells can mediate cell killing by inducing apoptosis via Fas activation 
[67], or cell lysis in an IFN-γ dependent manner [68]. Moreover, Kreisel et al., 
have showed that naïve cytotoxic CD8 T cells with direct allospecificity can 
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mediate cell killing via direct interaction with the graft endothelial cells and 
independently of CD4 T cell help [69].  
 
Evidence that CD4 T cells are involved in direct allorecognition comes from 
the experimental work where reconstitution of Rag1 -/- mice (mice do not 
have mature CD4 or CD8 T cells) with syngeneic CD4 T cells leads to 
rejection of MHC class II expressing cardiac grafts but not MHC class II 
deficient grafts [70]. Moreover, reconstitution of Rag1 -/- MHC class II -/- mice 
with CD4 T cells lead to graft rejection, suggesting that CD4 T cell with direct 
allospecificity are sufficient to mediate allograft rejection since these mice are 
unable to mediate MHC class II restricted indirect allorecognition and do not 
have CD8 T cells [70].     
 
Furthermore, recipient CD4 T cells with direct allospecificity can also mediate 
allograft rejection by initiating a Delayed Type IV hypersensitivity (DTH) 
response [70], thus resulting in recruitment and activation of macrophages, 
neutrophils and natural killer (NK) cells.  
  
It is believed that the direct pathway is important in acute rejection but its 
contribution to chronic rejection is debatable due to the short lifespan of 
passenger donor DCs. Thus, absence of donor DCs diminishes the effector 
capacity of recipient CD4 and CD8 T cells with direct allospecificity. Reduction 
in the frequency of both CD4 and CD8 T cells with direct allospecificity has 
been demonstrated in heart transplant recipients with progressive coronary 
artery disease [71], suggesting that an alternative pathway is responsible for 
the ongoing alloimmune responses.    
1.2.2.2.2 Indirect pathway of allorecognition  
 
Indirect pathway of allorecognition refers to recognition of allogeneic MHC 
molecules after they have been internalised, processed and presented in the 
context of self-MHC peptide complexes, analogue to conventional T cell 
response to foreign antigens [72]. The term “indirect allorecognition” refers 
exclusively to recognition of allogeneic MHC peptides, although this pathway 
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can allow recognition of other donor derived polymorphic peptides such as 
minor histocompatibility antigens (mHA).  
     
The frequency of CD4 T cells with indirect allospecificity accounts for a very 
small proportion (1-5%) of the T cell repertoire in comparison to the T cells 
with direct allospecificity [73]; however, following clonal expansion of indirect 
alloreactive T cells and a rapid decline of direct alloresponses following loss of 
donor DCs this deference becomes insignificant. Inaba et al., have shown 
donor DCs within the lymph nodes are rapidly phagocytosed and presented 
by the recipient DCs [74], thus donor DCs migratory to secondary lymphoid 
organs provide a source of donor antigens for indirect allorecognition [75].       
 
In MHC class II deficient mice donors, Auchincloss et al. have demonstrated 
the involvement of CD4 T cells with indirect allospecificity in allograft rejection 
[76]. They showed that class II deficient skin grafts were rapidly rejected by 
recipients that were previously depleted of CD8 T cells and since donor grafts 
lacked class II antigens, their results indicated that CD4 T cells with indirect 
allospecificity were responsible for skin graft rejection. Furthermore, they 
showed that in the absence of direct alloresponses the indirect pathway alone 
could result in a rapid acute allograft rejection [76].  
 
The indirect pathway is likely to be predominant in the later post-transplant 
period and probably plays a predominant role in the progression of chronic 
allograft vasculopathy (CAV), months or years after transplantation [72, 77].          
Clinically, activation of the indirect pathway has been linked with development 
of chronic rejection, as evidenced by increased frequency of T cells with 
indirect allospecificity in patients with chronic heart, kidney and liver transplant 
rejection [77, 78], whereas no difference in the frequencies of direct pathway 
CD4 T cells was observed between patients with chronic rejection and 
patients with stable allograft function.  
 
Indirect pathway CD4 T cells play a central role in mediating chronic allograft 
rejection by providing help for initiation of humoral responses and production 
of class-switched alloantibodies. 
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“cognate” interaction between CD4 T cell-receptor and the MHC class 
II/peptide complex expressed on B cells [79, 80]. This interaction leads to 
generation of alloantigen-specific B cells and production of alloantibodies. 
Indirect CD4 T cells can differentiate into a subpopulation of follicular T cells 
that are able to enter the B cell follicles and sustain the germinal center 
reaction [80]. A subset of B cells differentiates into long-lived antibody 
producing plasma cells that produce alloantibody for many years, making 
them the main source of donor specific antibody (DSA) responsible for 
recipient sensitisation and chronic rejection. The role of B cells is further 
discussed in Section 1.2.3. 
  
Conventional CD4 T cells are also able to provide help for CD8 T cell 
activation via APCs that co-express both CD4 and CD8 T cell epitopes [81, 
82] in the same fashion as direct pathway allorecognition, where donor APCs 
expressing class I and class II antigens are able simultaneously to engage 
with CD4 and CD8 T cells in a 3-cell cluster. In the context of transplantation, 
the mechanism of how indirect CD4 T cells provide help for activation of direct 
CD8 T cells [83] is not clear. An alternative pathway called semi-direct 
pathway of allorecognition has been most recently described, and is based on 
the ability of dendritic cells to acquire intact MHC-peptide complexes from 
other dendritic cells or endothelial cells [84]. The semi-direct pathway 
postulates that recipient DCs acquire donor MHC-peptide complexes by 
membrane capture, resulting in chimeric recipient DCs that co-express intact 
donor class I and class II molecules as well as self-MHC molecules armed 
with processed donor MHC peptides. Under these circumstances, the 
recipient DCs are able to simultaneously activate both the recipient CD4 and 
CD8 T cells with direct allospecificity and the recipient CD4 T cells with 
indirect allospecificity, thus allowing delivery of help for direct CD8 T cell 
activation [58, 85]. The significance of the semi-direct pathway in allograft 
rejection is not established, but it could provide sustained stimulation of 
directly reactive CD4 and CD8 T cells, even after donor APC have diminished. 
Nevertheless, the evidence of direct CD8 T cell involvement in the 
development of chronic rejection is limited [86].                  
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1.2.2.3 Lung allograft rejection  
 
Based on the time of onset, allograft rejection is classified as hyperacute, 
acute and chronic (Figure 1.1). Hyperacute rejection develops within minutes 
to hours after transplantation, as a result of recipient pre-sensitisation to donor 
tissue antigens [87] or as a result of preformed antibodies against ABO blood 
group antigens [88]. Binding of the preformed antibodies to ABO and/or MHC 
antigens expressed on the graft endothelial cells activate the classical 
complement pathway, resulting in edema, graft cell death, recruitment of 
inflammatory cells, platelet accumulation and microvascular thrombosis. The 
characteristic features of hyperacute lung rejection include small vessel 
vasculitis, intra-alveolar hemorrhage, platelet and fibrin thrombi, capillary 
congestion with neutrophils and macrophages and antibody deposition [89]. 
These processes lead to graft ischemia, necrosis and graft failure; in some 
cases fatal outcomes have been reported. Historically, hyperacute rejection 
has mainly been observed in kidney [90] and heart transplant recipients [91]. 
Nevertheless, to date seven cases of hyperacute rejection have been 
reported in lung transplant recipients of whom 6 have resulted in death 
occurring within 4 to 77 hours after transplantation [89, 92-94]. Nowadays, 
hyperacute rejection occurs rarely due to widespread use of very sensitive 
antibody screening methodologies that can detect and identify recipients 
preformed circulating DSA and confirmatory ABO compatibility testing.  
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Figure 1.1 Time of onset and type of rejection in lung transplant recipients. 
(Image adapted from Martinu et al., 2009)   
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1.2.2.3.1 Characterisation of acute rejection in lung transplant recipients  
 
Despite the significant advances in the development of highly potent 
immunosuppression regimens, acute allograft rejection affects up to 55% of 
lung transplant recipients within the first year after transplantation [6]; and, 
represents the most significant risk factor for development of BOS.  
 
Acute rejection can occur within a few days to years after transplantation, 
mainly as a consequence of T cell alloresponse to foreign MHC antigens 
(acute cellular rejection (ACR)) and/or activation of humoral immune 
responses and production of alloantibody with specificity to donor HLA 
antigens (acute antibody-mediated rejection (AAMR)). In clinical settings 
usually a mixture of both effector arms (cellular and humoral) are observed in 
recipients experiencing acute rejection.   
 
In lung transplantation, acute cellular rejection is characterised by lymphocytic 
perivascular or peribronchiolar mononuclear cell infiltrates in the lung tissue 
[95]. Due to the non-specific nature of the symptoms diagnosis of AR in lung 
transplant recipients is not always clear, thus firstly it is important to exclude 
symptoms associated with infection rather than rejection. Amongst various 
tests available bronchoscopy with transbronchial biopsy has proven to be the 
most accurate test for diagnosis of acute cellular rejection [95]; its significance 
has been highlighted by the fact that a relatively high percentage of Grade A2 
acute rejection has been detected in asymptomatic patients during 
surveillance bronchoscopies [96]. The clinical significance of asymptomatic 
low-grade acute rejection is considered as not harmful in long-term outcomes. 
In a prospective study of 184 lung transplant recipients Hopkins et al., have 
confirmed A1 histological lesions in 279 biopsies sampled from 128 recipients; 
of those only 24 A1 biopsies were symptomatic. Detailed histopathologic 
features for diagnosis and grading of acute lung rejection are presented in 
Table 1.1.     
 
The pathophysiological changes associated with humoral rejection are less 
clear and in some cases inconclusive due to the fact that not all features of 
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AMR may be present at one time point making diagnosis very challenging. 
Numerous studies evaluating the immunoglobulin and complement deposition 
in the subendothelial space have shown that detection of complement 
products C1q, C3d and/or C4d are associated with presence of HLA 
alloantibodies, allograft dysfunction and development of BOS [97, 98]. 
However, evidence of C3d and C4d deposition without the presence of HLA 
antibodies has been reported in lung transplant recipients with non-
alloimmune lung injury including infection and primary graft dysfunction [98]; 
thus making their appearance not very conclusive biomarker for AMR. In 
general, pathologic finding of small vessel intimitis or endothelialitis together 
with immunohistochemical staining for complement deposition, presence of 
DSA and allograft dysfunction is strong evidence for antibody-mediated 
rejection requiring treatment [99]. The classification of AMR is presented in 
Figure 1.2.        
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Table 1.1 Histopathological grading of lung rejection. (Table adapted from Martinu et al., 
2009)    
 
TABLE 1.
PATHOLOGIC GRADING OF LUNG REJECTION
Category Grade Meaning Appearance
A: acute rejection 0 None Normal lung parenchyma
1 Minimal Inconspicuous small mononuclear perivascular
infiltrates
2 Mild More frequent, more obvious, perivascular infiltrates,
eosinophils may be present
3 Moderate Dense perivascular infiltrates, extension into
interstitial space, can involve endothelialitis,
eosinophils, and neutrophils
4 Severe Diffuse perivascular, interstitial, and air-space
infiltrates with lung injury. Neutrophils may be
present.
B: airway inflammation 0 None No evidence of bronchiolar inflammation
1R Low grade Infrequent, scattered or single layer mononuclear
cells in bronchiolar submucosa
2R High grade Larger infiltrates of larger and activated lymphocytes
in bronchiolar submucosa. Can involve eosinophils
and plasmacytoid cells.
X Ungradable No bronchiolar tissue available
C: Chronic airway rejection –
obliterative bronchiolitis
0 Absent If present describes intraluminal airway obliteration
with fibrous connective tissue
1 Present
D: Chronic vascular rejection –
accelerated graft vascular
sclerosis
Not graded Fibrointimal thickening of arteries and poorly cellular
hyaline sclerosis of veins. Usually requires open lung
biopsy for diagnosis.
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Figure 1.2 Antibody-mediated rejection (AMR) classification according to the presence 
or absence of diagnostic features and presence (clinical) or absence (sub-clinical) of 
allograft dysfunction. (Image adapted from Benzimra et al., 2017)    
 
 
Treatment of lung acute cellular rejection consists of increased 
immunosuppression with pulse-steroids and in some transplant centres, in 
addition to steroid use treatment for acute cellular rejection incorporates 
monoclonal and/or polyclonal antibody therapy such as antithymocyte globulin 
(ATG), Basiliximab (anti-CD25 monoclonal antibody) and alemtuzumab (anti-
CD52 monoclonal antibody) [100]. In comparison, humoral rejection is non-
responsive to steroids or T cell depleting reagents [101]. Current treatment 
regimens for AMR incorporate plasmapheresis and intravenous 
immunoglobulin (IVIG) and possibly monoclonal antibodies such as rituximab 
[100]. Rituximab is an anti-CD20 monoclonal antibody that depletes B cell 
from the peripheral circulation but it has no effect on plasma cells due to the 
luck of CD20 cell surface expression. The clinical use of rituximab has been 
previously reviewed [102]. In lung transplantation, rituximab has demonstrated 
efficacy at reducing the development of HLA antibody post-transplant in 
patients that undergo humoral rejection [103]. Contrary to this, in a 
randomized controlled study the use of rituximab, as an induction therapy in 
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renal transplant recipients was associated with increased incidence of acute 
cellular rejection in comparison to the renal transplant control group that 
received daclizumab (anti-CD25 monoclonal antibody), (83% vs. 14%), 
possibly as a result of pan-B cell depletion including depletion of regulatory B 
cells at the time of transplantation [104].  
 
1.2.2.3.2 Chronic allograft vasculopathy  
 
Chronic rejection (CR) also known as chronic allograft vasculopathy (CAV) is 
the main factor that limits long-term graft survival. Chronic rejection develops 
within the relatively short period after transplantation (months to years) and 
typically is characterised by the development of severe intimal hyperplastic 
lesions that consist of smooth muscle cells, macrophages, monocytes and T 
lymphocytes [105, 106]. The progressive luminal narrowing affects the 
vascular flow resulting in ischemic damage of the graft with organ-specific 
pathology. CR affects all allografts and its development is manifested as a 
gradual deterioration in function. CR affects up to 30% - 40% of heart 
allografts [107], 20% of kidney, up to 17% liver [108] and up to 55% of lung 
allografts [109] within 5 years after transplantation.  
   
In lung transplantation chronic rejection is characterised by the development 
of obliterative bronchiolitis (OB) leading to progressive airway obstruction and 
deterioration in pulmonary function, a condition known as Bronchiolitis 
Obliterans Syndrome (BOS) [110]. BOS was first described at Stanford 
University in heart-lung transplant recipients who developed a progressive 
deterioration in forced expiratory volume in 1 s (FEV1) [111]. Development of 
BOS is a major post-transplant complication in lung transplant recipients and 
is a leading cause of death. The median time of diagnosis is 16 to 20 months 
after transplantation. BOS affects more than 20% of recipients one year after 
transplantation, and up to 60% of recipients who survive 5 years after 
transplantation. It accounts for 30% of all deaths [112] and survival at 5 years 
after transplantation is 20% to 40% lower in recipients that develop BOS in 
comparison to recipients that remain free from the disease [112].  
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BOS is a disease of multifactorial etiology; it is believed that it represents the 
end result of repeated immune and non-immune related injury to the allograft. 
Table 1.2 summarises the probable and potential risk factors associated with 
development of BOS [113].  
 
 
Probable 
 
Potential 
Acute rejection 
CMV pneumonitis 
HLA mismatching 
Lymphocytic bronchitis/bronchiolitis 
Noncompliance with medications 
Primary graft dysfunction  
CMV infection (without pneumonitis) 
Donor antigen-specific activity 
Epstein-Barr virus reactivation 
Etiology of native lung disease 
Gastroesophageal reflux 
Older donor age 
Pneumonia (bacterial, viral, fungal) 
Ischemia-reperfusion injury 
Recurrent infections  
 
Table 1.2 Probable and potential risk factors associated with development of 
bronchiolitis obliterans syndrome. (Table adapted from Hayes, D., 2011)    
 
 
Diagnosis of BOS is based on histopathologic features and pulmonary 
function tests. Nevertheless, due to the patchy nature of the disease, BOS is 
difficult to diagnose using transbronchial biopsy, thus BOS is defined as 
irreversible decline in FEV1 of at least 20% of the baseline FEV1 levels, 
according to the 1993 classification grading system of the International 
Society of Heart and Lung Transplantation (ISHLT) [110]. The 1993 ISHLT 
classification system was modified in 2002 and incorporated measurement of 
midexpiratory flow (FEF 25-75) of > 70% of baseline to be more sensitive for 
early detection of BOS [114]. In the latest revision of ISHLT classification 
system the ISHLT, American Thoracic Society and European Respiratory 
Society committee members have acknowledged that a substantial cohort of 
patients and histopathological changes do not fit the previous definition of 
BOS. It is expected that a broad definition of chronic lung allograft dysfunction 
(CLAD) together with the recognition of different clinical entities may clarify 
the pathophysiologic mechanisms that lead to CLAD. These may lead to new 
strategies for patient management, which may improve long-term survival 
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after lung transplantation. However, this classification has not been approved 
yet, therefore, in this thesis patient graft dysfunction is defined as BOS 
according to the ISHLT classification system of 2002 (Table 1.3) [113].          
 
 
BOS Stage Classification 
0 FEV1 > 90% of baseline & FEF25-75% > 75% of baseline 
 
0-p* FEV1 81-90% of baseline &/or FEF25-75% ≤ 75% of baseline 
 
1 FEV1 66-80% of baseline 
 
2 FEV1 51-65% of baseline 
 
3 FEV1 ≤ 50% of baseline 
*0-p = potential BOS, 
 
Table 1.3 Bronchiolitis obliterans syndrome classification. (Table adapted from 
Hayes, D., 2011)    
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1.2.3 Humoral responses 
 
The contribution of humoral responses in the development of BOS is 
increasingly recognised. B cells play a central role in orchestrating the 
humoral immune response in multiple ways: alloantibody production and 
differentiation into antibody-producing plasma cells, maintenance of long-term 
humoral memory, antigen presentation, formation of tertiary lymphoid organs 
(TLOs) and secretion of pro- and anti-inflammatory cytokines. A brief 
description of the B cell subsets, B cell development, B cell activation and 
antibody production will be discussed next. The clinical significance of allo- 
and autoantibody in solid organ transplantation and the mechanism of 
antibody-mediated injury are described in Chapter 6.       
 
1.2.3.1 B cell subsets 
 
B cells originate from the pluripotent hematopoietic stem cells in the bone 
marrow where they undergo several developmental stages involving 
rearrangement of immunoglobulin gene region and production of functional 
membrane bound B-cell receptor (BCR) [115]. Immature B cells characterised 
by cell surface expression of CD21low CD23low IgDlow IgMhigh HSA+ [116, 117] 
are released from the bone marrow and join the transitional B cell 
compartment in the spleen where they continue their maturation process and 
differentiate into two distinct populations; follicular (FO) B cells and marginal 
zone (MZ) B cells that mediate T-dependent and T-independent responses 
[118], respectively, both constitute B2 lineage. MZ B cells are retained in the 
spleen, whereas FO B cells recirculate through the blood and lymphatic 
system [119].   
 
To ensure generation of mature B cells that are non-responsive to self-
antigens, developing B cells undergo positive and negative selection via 
antigen-independent and antigen-dependent signaling pathway, respectively. 
There are four possible fates for developing B cells bearing BCR that strongly 
binds to self-antigens: clonal deletion (cell death by apoptosis), receptor 
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editing (process that initiates further light chain gene rearrangement and 
replacement of self-reactive BCR with new non-self reactive BCR), cells enter 
the state of anergy or unresponsiveness (self reactive but unresponsive BCR) 
and immunological ignorance [115], Figure 1.3.  
 
Another B cell subpopulation derived from B2 lineage has been described, 
called regulatory B cells or Bregs. These cells have been described as high 
IL-10 producers and may act in an immunosuppressive fashion to provide 
control in autoimmune disease [120, 121], regulation of germinal centre 
reaction and in transplant settings they may modulate allograft immune 
responses [120].        
 
The second lineage of B cells, called B1 cells, derive from B1 progenitors in 
fetal livers and reside in the peritoneal and pleural cavity. B1 cells produce 
polyreactive natural IgM antibodies directed against T-independent antigens 
and they do not require T cell help to elicit antibody production [122]. B1 cells 
secrete antibodies against ABO blood group antigens [123], and polyreactive 
IgA antibodies that contribute to mucosal immunity [124].       
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Figure 1.3 B cell development and mechanisms of tolerance to self-antigens.  
B cells originate in the bone marrow (BM) where they undergo three 
developmental stages (pro-B, pre-B and immature B cell). In the BM immature B 
cell with strong reactivity to self-antigens undergo clonal deletion or receptor 
editing (process that initiates further light chain gene rearrangement and 
replacement of self-reactive BCR with new non-self reactive BCR). Immature B 
cells expressing B-cell receptor (BCR) that are not self-reactive are released from 
the BM to enter the transitional B-cell pool in the spleen where they undergo 
further differentiation into mature B cells. In the periphery transitional 1 and 2 
(T1/T2) B cells with strong self-reactivity are clonally deleted or enter the state of 
anergy or unresponsiveness (self reactive but unresponsive BCR). Non self-
reactive B cells develop into mature B cells that can recirculate through the blood 
and lymphatic system where they can encounter antigen and enter the secondary 
lymphoid organs (SLOs) through the T cell-rich area of the spleen known as 
periarteriolar lymphoid sheath (PALS) to eventually reside in the germinal center 
(GC) B cell follicle. The GC reaction gives rise to isotype-switched memory B cells 
and long-lived antibody producing plasma cells. (Image adapted from Hoffman, W. 
et al., 2016) 
 
 
 
 
 28 
1.2.3.2 B cell activation and antibody production 
 
Mature naïve B cells continuously recirculate through the peripheral blood and 
lymphatic system and enter secondary lymphoid organs (SLOs) through the T cell-
rich area of the spleen, known as periarteriolar lymphoid sheath (PALS), to gain 
access into B cell follicle where they can encounter antigen and interact with 
follicular DCs (FDCs) and sinus-associated macrophages [119]. 
 
Naïve B cell activation requires two signals: the first signal is received via BCR 
signaling pathway that is initiated by receptor aggregation due to antigen binding and 
the second signal is received through cognate interaction with follicular CD4 T cells 
at the T-B cell border. Upon activation B cells can differentiation into extrafollicular 
or germinal center (GC) driven memory B cells and long lived plasma cells 
(LLPCs) [125].  
 
Signaling through the BCR activates members of the receptor associated Src 
family of protein tyrosine kinases such as Blk, Fyn and Lyn [126]. Activated 
kinases phosphorylate the BCR Ig-α and Ig-β cytoplasmic tail carrying 
tyrosine-based activation motifs (ITAMs), which allows recruitment and 
activation of cytosolic protein kinase Syk [127]. Syk phosphorylates target 
proteins to initiate a cascade of intracellular signaling pathways leading to 
calcineurin activation and NFAT translocation to the nucleus, activation of 
MAPK/ERK pathway and activation of Ca2+-dependent protein kinase that 
activates NF-κB1 pathway [127].  
 
These signals initiate metabolic and transcriptional changes resulting in BCR-
antigen complex internalisation and delivery into the endosome, endosomal 
antigen processing (antigen is degraded into peptides and loaded onto MHC 
class II molecules), upregulation of MHC class II/peptide complexes 
expressed on the cell surface and gene transcription leading to induction of 
co-stimulatory molecules that enable B cell to receive stimulatory signals 
through cognate interaction with Tfh [125].   
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T-cell help to B cells is provided via engagement of B cell MHC class II-
peptide complex with TCR and ligation of co-stimulatory molecules such as 
CD40L-CD40, B7 (CD86)-CD28, ICOSL-ICOS, PDL-1PD-1 and IL-21R-IL21 
which leads to formation of immunological synapse. Upregulation of the 
transcription factor B-cell lymphoma 6 (Bcl-6) directs B cell migration back to 
the follicle where B cells rapidly proliferate and produce activation-induced 
cytidine deaminase (AID), an enzyme which is essential for somatic 
hypermutation (SHM), class-switch recombination, affinity maturation and 
generation of high-affinity class-switched memory B cells and antibody 
producing plasma cells [128].  
 
The clinical importance of allo- and autoantibody in solid organ transplantation 
and the mechanisms of antibody-mediated injury are described in Chapter 6.    
 
1.3 Chimerism in solid organ transplantation  
 
Significant numbers of donor-derived haematopoietic cells that are not flushed 
from the graft during retrieval are transferred to the recipient at the time of 
transplantation. The presence and co-existence of these cells in the blood and 
tissues of allograft recipients forms a state called chimerism. Thus, chimerism 
refers to co-existence of two or more genetically distinct cell populations. 
Depending on the number of chimeric cells present; the terms micro- and 
macrochimerism have been used to describe chimeric population present at 
less than 1% or greater than 1% of the total number of cells, respectively 
[129].   
 
Evidence for presence of donor chimerism in the circulation of solid organ 
allograft recipients was first demonstrated with karyotyping studies in female 
liver transplant recipients who have received an organ from a male cadaveric 
donor [130, 131]. Donor leukocyte microchimerism has been documented in 
human liver [130], kidney [132, 133], lung and heart [134] transplant 
recipients, intestinal and multivisceral transplantation [135].  
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In solid organ transplantation presence of donor microchimerism includes a 
population of donor T cells [132]; their possible existence is supported by the 
recent demonstration that T cells migrate through non-lymphoid organs [136]. 
Functionally and phenotypically, these cells comprise a mixture of naïve, 
effector and memory T cells [136].  
 
The number and type of lymphocyte distribution present in non-lymphoid 
organs has been studied in discarded human hearts and lungs. Analysis of 
mononuclear cell distribution in donor heart tissue has demonstrated that CD4 
T cells are the most common cell type of all leukocytes present in the tissue; 
and the majority of this cell population expressed high levels of CD45RO cell 
surface molecule [137], which represents a marker of memory T cells [138].  
 
Furthermore, Richter et al., have studied passenger mononuclear cells in both 
the human donor lung tissue itself and the lung associated regional lymph 
nodes [139]. They have identified two main sources of lymphocytes; one 
derived from the lung associated lymphoid tissue (LALT) mainly comprising of 
resting T and B cells and the second cell populations derived from the lung 
tissue itself, comprising of activated lymphocyte and monocytes/macrophage 
population expressing high levels of HLA-DR and CD45RO markers; and 
adhesion molecules including LFA-1, VLA-4 and ICAM-1 [139], suggesting 
that these cells can migrate throughout the tissue.   
          
Since the first evidence of donor chimerism in liver transplant recipients in 
1969 [131], numerous studies have reported the presence of chimerism 
following solid organ transplantation; however, the precise role of its existence 
is unclear. In 1992, Starzl et al., postulated that transfer of leukocytes from the 
donor can create a state of systemic mixed allogeneic chimerism that, if 
persistent, promotes graft acceptance and resistance to cellular and humoral 
rejection [131].  Despite these observations, the role of passenger leukocytes 
in solid organ transplantation remains unclear; and conflicting evidence has 
been reported that in some settings donor-derived passenger leukocytes can 
initiate graft rejection [140] whereas in others they can contribute to graft 
acceptance [130, 131]. Furthermore, donor chimerism can occasionally trigger 
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onset of graft-vs-host disease (GvHD) [141]. In solid organ transplantation, 
GvHD is a rare post-transplant complication; nevertheless, detrimental 
outcomes have been documented in liver and lung transplant patients [142, 
143].     
 
Win et al., in our department used a murine model of chronic heart graft 
rejection to study how donor CD4 T cells that were passengers within the 
heart graft influenced the host response to the graft. In Win’s model, the donor 
bm12 strain varies from the C57BL/6 (B6) recipient by three amino acid 
residues in the MHC class II I-A antigen (human HLA-DQ). Bm12 heart 
allografts are rejected slowly (median survival time 50 days), and this rejection 
was associated with the development of graft vascular pathology consisting of 
progressive intimal thickening and luminal narrowing. In addition, there was 
histologic evidence of humoral vascular rejection, characterised by C4d 
complement and IgG endothelial deposition. No evidence of rejection was 
observed in syngeneic transplants or the bm12 allografts transplanted into 
either MHC class II gene knockout mice or B cell-deficient recipients. Further 
experiments revealed that the B6 recipients did not develop circulating IgG 
alloantibodies but instead developed long-lasting IgG antinuclear 
autoantibody [144].  
 
To investigate the involvement of T-cell-dependent responses; B6 recipients 
were primed with synthetic allopeptide corresponding to the disparate region 
of the I-Abm12 antigen 14 days prior to transplantation with a bm12 heart 
allograft. Bm12 heart grafts were rejected more rapidly than in unprimed, 
control recipients, but without evidence of alloantibody development. 
Moreover, despite the rapid rejection, the levels of circulating IgG 
autoantibodies were not augmented. These experiments suggested that 
development of autoantibody is independent of indirect pathway T cell 
responses. Given that indirect-pathway is thought to be the only means by 
which CD4 T cell help for alloantibody production is provided [79, 80], this 
result was surprising and suggested that an alternative mode of help was 
responsible for the development of autoantibody in the bm12-B6 model. On 
the basis that adoptive transfer of bm12 splenocytes triggers lupus-like 
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humoral autoimmunity in B6 recipient mice [145], the potential role of 
passenger donor CD4 T cells in the provision of help to host B cells was 
investigated. Surprisingly, transplantation with heart allografts from donor 
bm12 mice that either were depleted of CD4 T cells prior to heart allograft 
procurement or were genetically deficient in T and B cells did not prompt 
autoantibody production and heart allograft survival was prolonged [144].  
 
Win et al., concluded that in their model, help for autoantibody production was 
provided via a direct cognate interaction between the donor CD4 T cells and 
the recipient auto-reactive B cells, thereby replicating the normal interaction 
between a self-restricted host helper CD4 T cell and B cell [144]. Win’s 
studies further demonstrated that the autoantibody contributed to the 
development of chronic allograft vasculopathy.  
 
The aim of my thesis was therefore to address whether a similar mechanism 
may occur in human transplant recipients. We chose to examine the role of 
donor CD4 T cells in lung transplant recipients, because the lung graft is a 
large and leucocyte rich organ. In assessing the potential contribution of 
donor CD4 T cells to human allograft rejection, it was first necessary to 
demonstrate the presence of donor CD4 T cells in the lung recipient’s 
circulation following transplantation. 
 
The question raised by our previous study is whether a similar mechanism is 
responsible for the development of autoantibody in human transplant 
recipients. To our knowledge, specifically the role of donor passenger CD4 T 
cells has not been formally studied in clinical transplantation. 
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1.4 Aims and objectives  
 
Previous work in our department has highlighted a novel mechanism for how 
help for development of de novo autoimmunity following transplantation is 
delivered to recipient auto-reactive B cells. In Win et al., model help for 
autoantibody production was provided via a direct cognate interaction 
between the donor CD4 T cells passenger within the graft and the recipient 
auto-reactive B cells. Thus, the overall objective of my work was to assess 
whether a similar mechanism may occur in human lung transplant recipients.  
 
My first aim was to assess the presence and longevity of donor CD4 T cell 
chimerism in the peripheral blood of primary lung transplant recipients by 
targeting the donor HLA class I (HLA-A and/or HLA-B) mismatched antigens 
with human monoclonal HLA antibodies.    
 
Furthermore, I wanted to investigate whether the number of HLA mismatched 
antigens between the recipient and donor pairs and the recipient-vs-donor NK 
cell alloreactivity affects the donor CD4 T cell dynamics. Along with this, I 
wanted to also characterise the donor-derived CD4 T cell subsets using RT-
PCR gene expression analysis of flow-sorted donor CD4 T cells.      
 
My third aim was to investigate the humoral allo- and auto-immune responses 
in lung transplant recipients and their possible correlation with the presence of 
donor CD4 T cell chimerism; and, in turn, how this influences the development 
of BOS. In parallel to this, I aimed to evaluate clinically relevant autoantibody 
profile in long-term survivors of lung and heart and lung transplant recipients 
with functioning allograft and free from BOS and recipients with established 
BOS by utilizing high-density protein arrays for autoantibody profiling. The 
protein arrays have the potential to serve as a tool to identify new biological 
targets that can be used to identify patients that are more likely to undergo 
chronic rejection.  
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Materials and Methods 
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2.1 Study design and participants  
 
This is a cohort observational study. Prior to commencement the 
Cambridgeshire 4 Ethics Committee, Papworth Hospital Research and 
Development Department and the University of Cambridge Research and 
Development Department ethically approved the study. In addition, this study 
was registered with the NIHR Clinical Research Network Portfolio.       
 
All patients waiting for primary deceased donor lung or heart and lung 
transplantation at Papworth Hospital, Papworth Everard, Cambridge, United 
Kingdom who fulfilled the study participant inclusion criteria were given written 
and verbal information about the study. In addition, patients that had 
undergone lung or heart and lung transplantation prior to commencement of 
the study were also informed.  
 
Study Participant Inclusion Criteria:  
• Participant is willing and able to give informed consent for participation 
in the study. 
• Male or Female, age 16 years or above.  
• Diagnosed with lung or heart and lung failure, and listed for primary 
lung or heart and lung transplantation; or have undergone primary lung 
or heart and lung transplantation prior to commencement of the study.  
 
Patients who had already had two or more transplants were not eligible for 
participation in this study.  
 
All participants that took part in this study gave full, informed written consent 
for the clinical intervention, experimental investigations and collection of 
demographic and clinical information from patients’ medical records and 
electronic databases. A copy of the Participant Information Sheet and 
Consent Form is attached as Appendix 1.  
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The study cohort consists of two groups of patients:  
 
• Pre-transplant group - patients were recruited whilst waiting for 
deceased donor lung or heart and lung transplantation at Papworth 
Hospital. 
 
• Post-transplant group - patients were recruited after primary lung or 
heart and lung transplantation. All patients were transplanted at 
Papworth Hospital between 1986 and 2011.  
 
2.2 Blood collection  
 
Patients’ peripheral blood was obtained by venipuncture.  Blood samples (40 
ml) for cell separation were collected in 10 ml Coagulation Sodium Citrate S-
Monovette® (0.106 molar solution) tubes (SARSTEDT, S-Monovette®, 
Germany). Blood samples (10 ml) for serum separation were collected in 9 ml 
serum sample tubes (SARSTEDT Natural S-Monovette®, Germany). 
 
2.3 Cell and serum preparation 
 
All cell preparation techniques were performed using Lympholyte®-H density 
gradient (1.0770 ± 0.001 g/cm3 at 22°C) separation medium (Cedarlane® 
Laboratories Ltd., Burlington, Canada), referred to as “separation medium” 
unless otherwise stated. Centrifugation was performed in a Megafuge 1.0R 
(Heraeus Instrument, DJB Labcare Ltd., UK). Following separation the cells 
were re-suspended in RPMI 1640 (Roswell Park Memorial Institute) tissue 
culture medium (GibcoTM, Invitrogen, Paisley, UK) with 10% fetal calf serum 
(FCS) (Biowest Ltd., Ringmer, East Sussex, UK), referred to as “culture 
medium” unless otherwise stated. Cells were counted in Neubauer cell 
counting chambers (Hawksley, Lancing, Sussex, UK), Section 2.3.5.  
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2.3.1 Density gradient separation of human peripheral blood mononuclear 
cells (PBMC) 
 
PBMC were separated using separation medium specifically designed for the 
isolation of viable lymphocytes from human peripheral blood. The blood was 
diluted with phosphate buffered saline (PBS) (ratio 1:1) and layered over 10 
ml of cell separation medium in a 50 ml centrifuge tube. Centrifugation was 
performed for 20 minutes (mins) at 800g. After centrifugation, the lymphocyte 
layer at the interphase was aspirated and transferred into a 15 ml centrifuge 
tube. The cells were washed with PBS and further centrifuged at 1000g for 10 
mins. Supernatant was discarded and the cells were re-suspended and 
washed in PBS at 600g for 5 mins. Finally, the supernatant was discarded 
and the cells were re-suspended in 5 ml culture medium for further analysis.    
 
2.3.2 Splenocytes separation 
 
Surplus donor spleen samples were obtained from the Tissue Typing 
Laboratory, Addenbrooke’s Hospital, Cambridge, UK (Addenbrooke’s Tissue 
Typing Laboratory). The spleen was cut into pieces and flushed with 40 ml 
culture medium using a 20 ml syringe with needle. The cell suspension was 
collected and the splenocytes were separated in the same manner as PBMC 
separation protocol (Section 2.3.1).  
 
2.3.3 Lymph node cell separation  
 
Surplus donor lymph node samples were obtained from Addenbrooke’s 
Tissue Typing Laboratory. The lymph nodes were flushed with 40 ml culture 
medium using a 20 ml syringe. The cell suspension was collected into 15 ml 
centrifugation tubes and centrifuged for 10 min at 800g. After centrifugation, 
the supernatant was discarded and the cells were re-suspended and washed 
with PBS for 5 min at 600g. Finally, the supernatant was discarded and the 
cells were re-suspended in 5 ml culture medium for further analysis.  
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2.3.4 Separation of passenger mononuclear cells from the Ex Vivo Lung 
Perfusion (EVLP) leucocyte filter 
 
The EVLP leucocyte filter is attached to the EVLP circuit during the whole 
procedure; at the end of the procedure, the leukocyte filter was removed and 
stored overnight in RPMI media at 4°C. Mononuclear cells were flushed out of 
the filter with 40 ml cold culture medium (RPMI) using a 20 ml syringe. The 
cell suspension was collected into 15 ml centrifugation tubes and centrifuged 
for 10 min at 800g. After centrifugation, the supernatant was discarded and 
the cells were re-suspended and washed with PBS for 5 min at 600g. 
Following the washing step the mononuclear cells were re-suspended in 5 ml 
culture medium and cell count was performed (Section 2.3.5). Flow cytometric 
analysis was performed to characterise the mononuclear cells (Section 2.4.4).  
 
2.3.5 Cell count 
 
Cells were counted in Neubauer cell counting chambers (Hawksley, Lancing, 
Sussex, UK). 5 µl of cell suspension was diluted in 95 µl of 0.4% Trypan Blue 
cell counting solution (ThermoFisher Scientific, CA, USA; live cells do not take 
Trypan Blue), dilution factor 1:20.  Using a pipette, 10 µl of Trypan Blue-
treated cell suspension was applied to the Neubauer chamber counting grid 
and the Neubauer chamber was placed on the microscope stage. Unstained 
live cells were counted in 5 big squares. The number of cells in the original 
cell suspension was calculated by the following formula: Cell/ml = Number of 
cells counted x 10,000 (grid volume) x 20 (dilution factor).  
 
2.3.6 Serum separation 
 
Blood samples obtained for serum separation were centrifuged for 10 mins at 
400g. Without disturbing the cell layer the serum was aspirated, transferred 
into 2 ml micro tubes (SARSTEDT Micro tube 2ml, Germany) and stored at      
-80°C until further analysis. 
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2.4 Flow cytometry  
 
Flow cytometric analysis was carried out using 5 x 105 target cells per flow 
cytometry tube (BD Falcon, Franklin Lakes, NJ, USA unless otherwise 
stated). Cells were washed with 1 ml FACS buffer (PBS + 0.1% sodium azide 
+ 0.1 % bovine serum albumin (BSA), Sigma-Aldrich, St. Louis, MO, USA). 
Staining with monoclonal antibodies (mAb) was carried out at 4°C for 30 mins, 
in the dark. After staining was completed, cells were re-suspended in FACS 
buffer for flow cytometric analysis. Cells were analysed fresh (without 
fixatives) using BD FACSCantoTM flow cytometer with BD FACSDiva 
software (both Becton Dickinson, San Jose, CA, USA unless otherwise 
stated). Specific flow cytometry protocols are described below.     
 
2.4.1 Selection of human monoclonal HLA antibody using flow cytometric 
analysis 
 
Donor HLA class I mismatched antigens were used as target antigens to 
distinguish between recipient and donor cells using biotin-conjugated human 
monoclonal HLA antibody (Table 2.1); a kind gift of Prof Frans H.J. Claas and 
Dr Arend Mulder (Leiden University Medical Center, Leiden, Netherlands). 
The monoclonal HLA antibodies were supplied as purified biotinylated 
immunoglobulins. In brief, human hybridomas were established from B-
lymphocytes of HLA antibody-seropositive, multiparous women by EBV 
transformation. The HLA specificities of mAbs were determined by 
complement-dependent cytotoxicity against a panel (n > 240) of serologically 
HLA typed PBMCs. The specificity of HLA mAb was also tested using 
recipient peripheral blood samples obtained prior to transplantation and donor 
lymphocytes obtained from spleen or lymph nodes at the time of donation.        
 
In brief, cells were stained with 10 µl of biotin-conjugated human HLA mAbs, 
followed by APC-conjugated streptavidin (Table 2.1). Cells were washed twice 
with FACS buffer before and after staining with APC-conjugated streptavidin. 
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Flow cytometric analysis was performed using BD FACSCantoTM flow 
cytometer with BD FACSDiva software. Antibodies that bind to more than 
95% of donor lymphocytes, but did not bind to the patient lymphocytes 
obtained before transplantation, were selected, and used for detection of 
donor CD4 T lymphocytes in the patients’ peripheral blood after 
transplantation (Figure 2.1).         
 
Table 2.1 Panel of biotin-conjugated human HLA monoclonal antibodies used 
for detection of donor CD4 T lymphocytes in recipients’ peripheral blood after 
transplantation. 
Clone- HLA-Specificity Lot No. Concentration 
µg/ml 
BVK1F9 B8 6482 50µg/ml 
DK7C11 B12 6484 50µg/ml 
GV5D1 A1/A9 (not A*24:03, A80) 6910 50µg/ml 
MUS4H4 Bw4/A24/A25/A32 6483 50µg/ml 
SN230G6 A2/B17 6877 50µg/ml 
SN607D8 A2/A28 6876 50µg/ml 
BVK5C4 A9 6743 50µg/ml 
JOK3H5 B40/B21/B13/B12/B41/B70 6746 50µg/ml 
BRO11F6 A11/A3/A24 6874 50µg/ml 
HDG8D9 B51/B35 6875 50µg/ml 
VTM1F11 B27/B7/B60 6911 50µg/ml 
IND2D12 B15/B35/B21/B70 6747 50µg/ml 
OK2F3 A3 6748 50µg/ml 
OK6H10 B15/B21/B56/B35/B72 6744 50µg/ml 
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Figure 2.1 A representative graph of human HLA monoclonal antibody testing 
using flow cytometry. A) Recipient and B) donor lymphocytes obtained prior to 
transplantation were stained with biotin-conjugated human HLA mAbs with specificity to donor 
HLA-B44 antigen. HLA-B44 expressing cells were detected with APC-conjugated streptavidin. 
 
2.4.2 Flow cytometric analysis for detection of donor CD4 T lymphocytes in 
patients’ peripheral blood after transplantation (Chimerism analysis) 
 
Patients’ PBMC were separated as described previously (Section 2.3.1). 
Cellular Fc receptor non-specific antibody binding was blocked with purified 
anti-FcγR antibody; cells were incubated in the dark at 4°C for 15 mins (1:10 
dilution). Following Fc receptor blocking step, cells were washed and re-
suspended in FACS buffer at 5 x 105 cells per tube for each control test 
sample; the remaining cells were used for detection of donor CD4 T 
lymphocytes. Each control sample was incubated with: CD3 FITC-labeled, 
CD4 PE-labeled and double positive CD3-FITC/CD4-PE labeled primary anti-
human monoclonal antibodies (Table 2.2). Patients’ test samples obtained 
after transplantation, together with the patients’ and respective donor cells 
obtained prior to transplantation, were incubated with primary biotin-
conjugated human monoclonal HLA antibodies (Table 2.1); followed by APC-
conjugated streptavidin (Table 2.2). The recipients’ and respective donor cells 
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obtained prior to transplantation served as a negative and positive control, 
respectively. Lastly, the cells were incubated with CD3 FITC-labeled and CD4 
PE-labeled mAbs. Cells were washed twice with FACS buffer before and after 
staining. The control samples were re-suspended in 300 µl of FACS buffer, 
while the test samples were re-suspended in FACS buffer at 1 x 107 cell per 
ml.   
  
Table 2.2 Anti-human monoclonal antibodies used for detection of CD4 T 
lymphocytes using flow cytometric analysis.   
Antibody Conjugate Clone Working 
dilution 
Source 
FcγR - 130-059-901 1: 10 Miltenyi Biotec Inc. 
CD3 FITC  HIT3a 1:100 BD PharmingenTM 
CD4 PE RPA-T4 1:100 BD PharmingenTM 
Streptavidin- APC - 1:1000 Invitrogen 
 
The flow cytometric plot was set to include all PBMC; based on the forward 
and side scatter parameters lymphocyte population was gated and 20,000 
cells were recorded for all control samples. Doublets were excluded. An 
additional gate was set to include cells stained positive for expression of CD3 
and CD4 cell surface marker. Donor CD4 T lymphocytes were detected as a 
subpopulation of double positive (CD3/CD4) recipient T lymphocytes. 
Depending on the blood sample size, whenever possible 1,000,000 recipient 
CD4 T lymphocytes were recorded. The number of donor CD4 T lymphocytes 
detected in recipients’ peripheral blood after transplantation is presented as a 
percentage of the total number of CD4 T cells analysed (Figure 2.2). 
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A) 
 
B) 
 
C) 
 
D) 
 
 
Figure 2.2 A representative graph of flow cytometric analysis used for 
detection of donor CD4 T lymphocytes in recipients’ peripheral blood following 
primary lung transplantation.  
Recipient PBMCs obtained after transplantation were stained with CD3-FITC, CD4-PE and 
donor specific biotin-conjugated human monoclonal HLA antibodies followed by APC-
conjugated streptavidin and assessed by flow cytometry. A) Lymphocyte cell population was 
gated; B) Doublet cells were excluded from further analysis. C) Subpopulation of lymphocytes 
expressing cell surface CD3 and CD4. D) Donor CD4 T lymphocytes were detected as a 
subpopulation of double positive (CD3/CD4) recipient T lymphocytes. Depending on the blood 
sample size, whenever possible 1,000,000 recipient CD4 T lymphocytes were recorded. The 
number of donor CD4 T lymphocytes detected in recipients’ peripheral blood after 
transplantation is presented as a percentage of the total number of CD4 T cells analysed. 
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2.4.3 Isolation of donor CD4 T lymphocytes from recipients’ peripheral blood 
following transplantation 
 
Recipients’ PBMC obtained at regular time intervals after transplantation were 
processed as previously described in Section 2.4.2. Following cell preparation 
donor CD4 T lymphocytes were isolated using BD FACSAria™ III cell sorter 
and analysis was performed with BD FACSDiva software (both Becton 
Dickinson, San Jose, CA, USA). To discriminate dead cells, prior to donor 
CD4 T lymphocyte isolation the cell suspension was incubated with 10 µl of 7-
aminoactinomycin D ((7-AAD), Invitrogen, CA, USA)) for 10 mins on ice, in 
the dark. Donor CD4 T lymphocytes that did not stain for 7-AAD (live cells) 
were collected in 500 μl RNAlater® Solution (Ambion, Life Technologies, CA, 
USA) and stored at -20°C until further analysis.  
 
2.4.4 Flow cytometric analysis of passenger mononuclear cells mechanically 
removed from the donor lungs by Ex Vivo Lung Perfusion procedure 
 
Mononuclear cells isolated from the EVLP leucocyte filter, previously 
described in Section 2.3.4 were characterised using flow cytometry. In brief, 
mononuclear cells were simultaneously stained with seven fluorescent-
labeled primary anti-human monoclonal antibodies specific for CD3-PE, CD4-
FITC, CD8-APC, CD19-APC-Cy7, CD11b-Alexa Fluor-647, CD14-Brilliant 
Violet-421 and CD16-Brilliant Violet-510 (Table 2.3 and Table 2.5). In a 
separate test sample CD4 T lymphocyte population was characterised by 
simultaneous staining with seven fluorescent-labeled primary anti-human 
monoclonal antibodies specific for CD3-PE, CD4-Brilliant Violot-510, 
CD45RA-Brilliant Violet-650, CD45RO-APC-H7, CD62L-PE-CF-594, CXCR5-
Alexa Fluor-488 and CCR7-Brilliant Violet-421 (Table 2.4 and Table 2.5). 
Cells were washed twice with FACS buffer and test samples were re-
suspended in 300 µl of FACS buffer. Prior to analysis the test samples were 
incubated with 10 µl 7-AAD for 10 mins on ice, in the dark. LSR-Fortessa Flow 
Cytometer and BD FACSDiva software (both Becton Dickinson, San Jose, 
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CA, USA) were used for analysis of the mononuclear cell populations and 
CD4 T cell subsets.    
 
Table 2.3 Anti-human monoclonal antibodies used for characterisation of 
mononuclear cells isolated from the EVLP leucocyte filter using flow 
cytometric analysis. 
Antibody Conjugate Clone Working 
dilution 
Source 
FcγR - 130-059-
901 
1:10 Miltenyi Biotec Inc. 
CD3 PE HIT3a 1:100 BD PharmingenTM 
CD4 FITC RPA-T4 1:100 BD PharmingenTM 
CD8 APC RPA-T8 1:200 BD PharmingenTM 
CD19 APC-Cy7 HIB19 1:200 BioLegend 
CD14 Brilliant Violet-421 M5E2 1:50 BioLegend 
CD16 Brilliant Violet-510 3G8 1:100 BioLegend 
CD11b Alexa Fluor-647 M1/70 1:200 BD PharmingenTM 
7-AAD PerCP-Cy5.5 - - BD PharmingenTM 
 
 
Table 2.4 Anti-human monoclonal antibodies used for characterisation of CD4 
T lymphocytes isolated from the EVLP leucocyte filter using flow cytometric 
analysis. 
Antibody Conjugate Clone Working 
dilution 
Source 
FcγR - 130-059-
901 
1:10 Miltenyi Biotec Inc. 
CD3  PE HIT3a 1:50 BD PharmingenTM 
CD4 Brilliant Violot-510 OKT4 1:50 BioLegend 
CD45RA Brilliant Violet-650 HI100 1:500 BioLegend 
CD45RO APC-H7 UCHL1 1:100 BD PharmingenTM 
CD62L PE-CF-594 DREG-56 1:500 BD HorizonTM 
CXCR5 Alexa Fluor-488 RF8B2 1:50 BD PharmingenTM 
CCR7 Brilliant Violet-421 G043H7 1:50 BioLegend 
7-AAD PerCP-Cy5.5 - - BD PharmingenTM 
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Table 2.5 Function of the cluster of differentiation (CD) cell surface markers 
used for characterisation of mononuclear cells and CD4 T lymphocytes 
isolated from the EVLP leucocyte filter.   
 
Cluster of 
Differentiation (CD3) 
Function of the cluster of differentiation  
cell surface markers 
CD3 T cell co-receptor associated with T-cell receptor; helps to 
activate naïve CD4 and CD8 T cells.  
CD4 Glycoprotein predominantly found on the surface of T helper 
cells that serves as a co-receptor; interacts with β2-domain 
of MHC class II molecules.  
CD8 Glycoprotein predominantly found on the surface of cytotoxic 
T cells that serves as a co-receptor; interacts with α3-domain 
of the MHC class I molecules.  
CD19 Cell surface molecule expressed on B cells; acts as an 
adaptor protein to recruit cytoplasmic signaling proteins and 
is part of B cell receptor signaling complex.   
CD14 Expressed mainly on monocytes/macrophages and 
neutrophils; acts as a co-receptor for detection of bacterial 
LPS.  
CD16 Also know as FcyRIII expressed on the surface of NK cells, 
neutrophils, monocytes and macrophages; involved in 
ADCC.   
CD11b Protein subunit that forms heterodimeric integrin alpha-M 
beta 2 molecule also known as complement receptor 3. 
Expressed on monocytes, macrophages, granulocytes and 
NK cells.    
CD45RA Transmembrane signaling molecules that regulate cellular 
processes; expressed on naïve T cells.  
CD45RO Transmembrane signaling molecules that regulate cellular 
porcesses expressed on activated and memory T cells. 
CD62L Also know as L-selectin, a cell adhesion/homing receptor 
expressed on T cells; plays important role in T cell entry to 
secondary lymphoid tissue via high endothelial venules.  
CXCR5 Expressed on T follicular helper cells; enables their 
migration to B cell follicles.   
CCR7 T cell homing receptor to secondary lymphoid tissue such as 
lymph node and spleen.  
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2.4.5 Artificial chimerism  
 
Artificial chimerism was created by mixing a known number of carrier cells 
(lymphocyte main cell population) and a known number of “chimeric cells”. 
The HLA mismatched antigens were used as a target to detect chimeric cell 
(positive selection) or carrier cells (negative selection) using flow cytometric 
analysis, as previously described in Section 2.4.2. In the positive selection 
approach CD4 T cell chimerism was detected by targeting the HLA 
mismatched antigen expressed on the chimeric cell; and, in contrast, in the 
negative selection approach CD4 T cell chimerism was detected by targeting 
the HLA mismatched antigen expressed on the carrier cells. Table 2.6 shows 
the percentage of artificial CD4 T cell chimerism, number of chimeric cells per 
1x106 lymphocytes and percentage of chimeric CD4 T cell detected by both 
the positive and negative selection approach.   
 
Table 2.6 Artificial chimerism.   
 
Test 
tube 
No.  
Percentage of 
CD4 T cell 
chimerism in 
1x106 lymphocyte  
Number of 
chimeric CD4 T 
cells in 1x106 
lymphocyte  
Percentage of 
chimeric CD4 T 
cells detected  
(+ve selection) 
Percentage of 
chimeric CD4 T 
cells detected  
(-ve selection) 
1         5% 50,000 4.8 4.89 
2 2.5% 25,000 2.6 2.58 
3 1.25% 12,500 1.3 1.35 
4 0.625% 6250 0.7 0.73 
5 0.316% 3125 0.41 0.39 
6 0.156% 1562 0.21 0.22 
7 0.078% 781 0.096 0.082 
8 0.039% 390 0.067 0.053 
9 0.019% 195 0.04 0.04 
10 0.009% 97 0.001 0.005 
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2.5 Antibody detection 
 
Recipients’ sera were used for detection and characterisation of HLA and 
non-HLA antibodies. Specific protocols used are described bellow.   
 
2.5.1 HLA alloantibody detection and characterisation using Luminex 
LABScreen® Mixed and LABScreen® Single Antigen HLA Class I and 
Class II Antibody detection beads 
 
Patients’ sera obtained prior to transplantation and at regular time points after 
transplantation were thawed and centrifuged at 13.000 rpm for 3 mins to 
remove any aggregates, before the start of the assay. A 96-well filter plate 
(Multiscreen HTSTM, Millipore Co, MA) was pre-wetted with 300 µl of wash 
buffer (LABScreen® Wash Buffer, One Lambda Inc., Canoga Park, CA, USA) 
and incubated at 22°C on a rotating platform (100 rpm) for 10 mins. Twenty µl 
of negative control serum (One Lambda Inc., Canoga Park, CA, USA) and 
patient serum sample was added to the appropriate wells of the plate. For 
detection and characterisation of HLA antibodies, 3 µl of LABScreen® Mixed 
beads or LABScreen® Single Antigen Class I or Class II beads, respectively, 
(both One Lambda Inc., Canoga Park, CA, USA) was added to each well and 
the plate was incubated at 22°C on a rotating platform (100 rpm) for 30 mins, 
in the dark. Following incubation, to each well 270 µl of wash buffer was 
added and aspirated using the vacuum manifold. Washing was repeated five 
times. To each well 60 µl of PE-conjugated goat anti-human IgG (One 
Lambda Inc., Canoga Park, CA, USA) was added; the plate was further 
incubated at 22°C on a rotating platform (100 rpm) for 30 mins, in the dark. 
Washing was repeated five times, as previously described. Eighty µl of PBS 
was added to each well. The beads were re-suspended on a rotating platform 
(100 rpm) for five mins. Data were acquired and analysed using Luminex 
LifeMatch flow analyser (LABScan TM 100) and Luminex XY platform (both 
Luminex Co, Austin, TX, USA). 
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2.5.1.1 Luminex data analysis 
 
The patients’ serum reactivity, i.e. the level of IgG antibody binding to each 
HLA coated bead was assessed using the normalised fluorescent intensity 
(MFI) signal obtained during the analysis. The MFI values for each bead were 
normalised and corrected for non-specific binding in relation to the negative 
control (NC) bead (#001) MFI value. For LABScreen® Mixed the normalised 
fluorescent signal equals the value of the Class I or Class II coated bead 
minus the value of the NC bead. For LABScreen® Single Antigen Class I and 
Class II the normalised fluorescent value for each HLA coated bead equals 
the value of each bead divided by the value of the NC bead. 
 
For the purpose of this study MFI values ≥ 2,000 were considered positive. 
The MFI cut-off value was chosen based on the clinical experience of the 
Addenbrooke’s Tissue Typing Laboratory over the past ten years of Luminex 
based HLA antibody screening. MFI values ≥ 2,000 are considered clinically 
relevant.                                
 
2.5.2 Detection of anti-nuclear antibodies (ANA) using HEp-2 Indirect 
Immunofluorescence (IIF) Assay  
 
NOVA Lite® HEp-2 ANA Indirect Immunofluorescence (IIF) assay (INOVA 
Diagnostics, Inc., San Diego, CA, USA) was used for detection of anti-nuclear 
antibodies (ANA); all reagents required were supplied with the test kit. The 
assay was carried out according to the manufacturer protocol. In brief, 
patients’ sera were thawed just before the assay and diluted (1:40) with PBS. 
Twenty µl of diluted patient serum sample, positive and negative control 
serum were added to the appropriate well of the HEp-2 slide and incubated 
for 30 mins in a moist chamber at room temperature. Following incubation, the 
slides were washed with PBS. Twenty µl of FITC-conjugated goat anti-human 
IgG was added to each well and incubated as previously described. The 
slides were washed again and one drop of mounting medium was applied to 
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each well. The slides were covered with a coverslip and for each test sera; 
three images were photographed using an ORCA-ER digital Camera 
(Hamamatsu Photonics, Japan) and IX81 Microscope with a 20x 0,70 
UplanApo objective lens (Olympus, Japan). The fluorescent intensity was 
acquired with CellR 2.6 software (Olympus Soft Imaging Solutions GmbH, 
Germany). The mean fluorescent value was established for each test sera; 
and the MFI value is expressed as a percentage of IgG ANA binding to the 
HEp-2 cells in comparison to the MFI value of the positive control sample. The 
positive cut-off value was established as a MFI value of the negative control 
samples ± 2 x standard deviation (SD).  
 
2.5.3 Detection of anti-nuclear antibodies (ANA) using HEp-2 Enzyme-
Linked Immunosorbent assay (ELISA) 
 
ANA-Hep2 ELISA microplate (AESKU Diagnostics, Wendelsheim, Germany) 
was also used for detection of ANA. The assay was carried out according to 
the manufacturer protocol. In brief, 100 µl of each test sera (diluted 1:101 in 
sample buffer), cut-off calibrator; negative and positive controls (in duplicates) 
were incubated in a 96-well ELISA microplate coated with lysed HEp-2 cells 
for 30 mins at room temperature, in the dark. All incubations were carried out 
under the same conditions. Following incubation, the microplate was washed 
three times with 300 µl wash buffer. To each well 100 µl anti-human IgG 
conjugated to horseradish peroxidise was added and incubated. The plate 
was washed as previously described and incubated with 100 µl TMB 
(3,3’,5,5’-tetramethylbenzidine) substrate. After incubation, 100 µl of 0.16M 
sulfuric acid (stop solution) was added to each well and absorption was read 
in a FLUOStar OPTIMA ELISA plate reader (BMG Labtech, UK) at 450 nm. 
The mean optical density (OD) value was calculated for each test sera and 
the level of IgG ANA binding is expressed as an ELISA ratio (ER).  
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The positive cut-off value was established as a MFI value of the negative 
control sample ± 2SD.  
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2.5.4 Autoimmune response profiling using Protein Microarrays for 
Autoantibody Characterisation  
 
Invitrogen Human ProtoArray® v5.0 protoarray (Invitrogen, CA, USA) were 
used for characterisation of autoantibody profile in lung transplant recipients. 
Patients’ serum samples were processed as previously described. Twenty 
patients were selected based on the clinical diagnosis for the presence or 
absence of Bronchiolitis Obliterans Syndrome (BOS) according to the 
International Society of Heart & Lung Transplantation (ISHLT) scoring criteria 
(10 patients free from BOS and 10 patients with established BOS grade 2 and 
grade 3). For each patient the autoantibody profile was established at the time 
of transplantation and at a single time point after transplantation, reflecting the 
patients’ clinical status, i.e. presence or absence of BOS.   
 
2.5.4.1 Protein microarray composition  
 
The Invitrogen Human ProtoArray® v5.0 contains 9480 human proteins 
derived from UltimateTM ORF (open reading frame) collection. The proteins 
have been expressed in insect cells as glutathione-S-Trasferase (GTS) fusion 
proteins; and purified under native conditions. Each protein is spotted in 
duplicates onto a 1” x 3” glass slide coated with a layer of nitrocellulose. The 
proteins are printed in 110µm spots arrayed in 48 sub-arrays (4400-µm2 each) 
and equally spaced in vertical and horizontal directions with 22 columns and 
22 rows per sub-array. Each sub-array contains control proteins. Control 
proteins provide reference points for data acquisition and analysis.  
 
1. Alexa Fluor® conjugated antibody. The fluorescent antibody signal 
indicates that the array has been properly scanned; and, used as a 
reference spots to orient the microarray. 
2. Human IgG Signal. A protein gradient of purified human IgG is printed 
on each sub-array and serves as a positive control when anti-human 
IgG is used for detection. The human IgG signal is used to verify 
proper probing and detection reagents. 
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3. Anti-human IgG signal. A protein gradient of goat anti-human IgG is 
printed on each sub-array. The IgG from the human serum binds to the 
anti-human IgG on the array and is used to verify proper probing and 
detection reagents.  
 
2.5.4.2 Protein microarray: Immune Response Biomarker Profiling (IRBP) – 
probing and scanning 
 
The protein microarrays were used according to the manufacturer’s 
recommendation. In brief, the slides were equilibrated at 4°C for 30 min. Upon 
removal from the mailer the arrays were placed in a 4-chamber incubation 
tray (Greiner Bio-One, Germany) and incubated with 5 ml blocking buffer 
(Invitrogen, CA, USA) for 1 hour at 4°C on a circular shaker at 50 rpm, in the 
dark. All incubations were carried out under the same conditions unless 
otherwise stated. After incubation, the blocking buffer was aspirated. The 
slides were washed with 5 ml of wash buffer for 5 min at 4°C on a circular 
shaker set at 50 rpm. The wash buffer was aspirated and the slides were 
incubated with 5 ml of patient serum sample (diluted 1:400 in wash buffer) for 
90 min. After incubation the sample was aspirated and slides were washed 
with 5 ml wash buffer five times; as previously described. Human bound 
antibodies were detected after incubation with Alexa Fluor® 647 Goat Anti-
Human IgG (diluted 1:2000 in wash buffer) for 90 min at 4°C. After incubation, 
the arrays were washed with 5 ml of wash buffer five times, as previously 
described and dried by centrifugation in a 50 ml conical tube at 200g for 1 min 
at room temperature. After drying, the slides were placed in a slide box 
protected from light.  The scanning was performed immediately. Two negative 
control assays were performed in an identical manner to the experimental 
assays, except that the slides were incubated with buffer containing no serum, 
prior to incubation with Alexa Fluor® 647 Goat Anti-Human IgG detection 
antibody. To minimize variations between slides all assays were performed 
using arrays with the same lot specific number.  
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The scanning was performed using GenPix® 4000B (Molecular Devices 
Corporation) scanner at a wavelength: 635nm, PTM Gain: 800, Laser Power: 
100%, Pixel Size: 10µM, lines to Average: 1.0 and Focus Position: 0µM. An 
image was acquired for each slide and saved as a .tiff file for data acquisition 
and analysis.    
 
2.5.4.3 Protein array data acquisition 
 
The acquired images with the GenPix® 4000B scanner required analysis prior 
to the data interpretation. GenPIx Pro 6.0 acquisition and analysis microarray 
software (Molecular Devices Corporation) were used for image analysis. Prior 
to the image analysis the .GAL (GenePix Array List) files describing the 
location and identity of all spots on the protein microarray was downloaded 
from the Invitrogen Online Tools www.invitrogen.com/protoarray containing 
the Lot Specific Information. The .GAL file allows a grid of spots to be overlaid 
onto the image. Once the grid is aligned for each spot, the array pixel intensity 
is acquired for each array. The GenPIx Pro 6.0 software generates a .gpr file 
that is required for data analysis using ProtoArray® Prospector v 5.2 software 
(free software for analysis of ProtoArray, Invitrogen, CA, USA).  
 
2.5.4.4 ProtoArray® Prospector software data analysis 
 
ProtoArray® Prospector v5.2 software is a data analysis tool that provides 
rapid interpretation of numerical data generated using Invitrogen Human 
ProtoArray® used for IRBP assay (Invitrogen, CA, USA; now provided by 
ThermoFisher Scientific, CA, USA).  
 
The software is designed to identify proteins on the microarray (human protein 
features) that are bound to exogenous antibody (antibody present in the sera). 
Identification of proteins (positive targets) involves a 3-step process:  
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1. Single array analysis: for each protein on the array the software 
calculates the relative fluorescent signal. The fluorescent signal is then 
corrected for the background staining (protein fluorescent value minus 
the background fluorescent value). The corrected protein fluorescent 
value is expressed as Z-Factor. Z-Factor represents a confidence 
value that the signal for each protein on the array is significantly 
different from the negative control (cut-off value is 0.4).  
2. Group characterisation: signals for each individual protein across all 
samples from a given population (patients with established BOS group 
and patients without BOS group) are aligned for downstream analysis.   
3. Two groups comparison: identifies differences between two 
populations (BOS vs No BOS) using M-statistics. The M-statistics 
incorporates data normalisation analysis using Robust Linear Model 
(RLM). The RLM has been specifically developed for functional protein 
analysis [146].     
 
2.5.5 Detection of RUNX1T1 antibody using RUNX1T1 Enzyme-Linked 
Immunosorbent assay (ELISA) 
 
96-well ELISA plates (ImmunlonTM 2HBX, Thermo Fisher Scientific Inc.) were 
coated with RUNX1T1 (Runt-related transcription factor 1; translocated to, 1 
(cyclin D-related)) protein diluted in 1 M Na2CO3-NaHCO3 buffer (pH 9.6; 
concentration at 1 µg / 50µl) at 4°C overnight. Each plate was washed six 
times with 300 µl wash buffer (0.05% Tween in PBS) and non-specific binding 
sites were blocked with 5% Marvel dried skimmed milk powder (Premier 
International Foods, UK) in 1% PBS and 0.1% Tween (blocking solution) for 2 
hours at 37°C.  
 
Serum samples were diluted in blocking solution (1:100) and incubated on the 
plate in duplicates for 1 hour at 37°C. Serial dilutions of RUNX1T1 monoclonal 
mouse anti-human antibody (Novus Biological, Bio-Techne Ltd., UK, clone 
5A12) diluted 1:1000 in blocking solution were also incubated on the plate 
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(positive control standard curve). Known positive and negative control serum 
and blocking solution only (control for background binging) were also 
incubated on the plate. Following incubation the plates were washed six times 
with 300 µl wash buffer. Biotinylated anti-mouse and anti-human IgG antibody 
(Sigma-Aldrich Inc.) diluted 1:1000 in blocking solution were used for 
establishment of the positive control standard curve and detection of 
RUNX1T1 antibodies in test samples, respectively, followed by streptavidin-
HRP (Sigma-Aldrich Inc.) diluted 1:1000 in blocking solution. ELISA 
incubations were carried out in a 50 µl volume for 1 hour at 37°C followed by 
six washes with wash buffer. To generate a colorimetric signal 50 µl TMB 
substrate was added to each well and plates were incubated for 5 mins at 
room temperature. The reaction was stopped with 0.2M H2SO4 (stopping 
solution). The absorption was read in a FLUOStar OPTIMA ELISA plate 
reader (BMG Labtech, UK) at 450 nm.  
 
2.5.5.1 Analysis of RUNX1T1 ELISA           
 
Standard curve was generated using the absorbance value from the serial 
dilutions of the RUNX1T1 monoclonal mouse anti-human antibody (positive 
control); the concentration of the unknown samples was determined by 
interpolation from the standard curve. RUNX1T1 antibody levels are 
expressed as arbitrary units; 1000 is the highest point on the standard curve.      
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2.6 Molecular methodologies 
2.6.1 DNA extraction 
 
Blood samples obtained from the patients prior to transplantation and their 
respective donors was used for extraction of genomic DNA using QIAamp® 
DNA Blood Kit (Qiagen Ltd., Sussex, UK). All reagents required for DNA 
extraction were supplied with the kit. The DNA extraction was carried out 
according to the manufacturer’s recommendations. In brief, 200 µl of whole 
blood was mixed with 20 µl Protease and 200 µl buffer AL in a 1.5 ml 
microcentrifuge tube, and incubated in a water bath at 56°C for 10 mins. 200 
µl of ethanol was added to the mixture, and the mixture was transferred into a 
QIAamp Spin Column. The spin column was centrifuged at 8000 rpm for 1 
minute. The column was washed with 500 µl of buffer AW1 and centrifuged as 
previously described. Washing was repeated using buffer AW2 and further 
centrifuged at 14,000 rpm for 3 mins. The spin column was transferred into a 
new 2 ml collection tube and centrifuged at 14,000 for 1 minute. Finally, the 
column was transferred into a 1.5 ml microcentrifuge and 200 µl of distilled 
water was added to the column. To elute the DNA from the spin column, the 
column was incubated at room temperature for 5 mins and centrifuged at 
8000 rpm for 1 minute. The DNA concentration was established using a 
NanoDrop 1000 Spectrophotometer (Thermo Scientific, CA, USA). The ratio 
of absorbance at 260 nm and 280 nm was used to assess the DNA purity. A 
ratio of ~1.8 (1.7 – 1.9) was accepted as “pure” DNA.    
      
2.6.2 HLA genotyping  
 
The HLA genotype was established in order to assess the immunological 
compatibility between the patients and their respective donors. HLA 
genotyping was performed by low/medium resolution in-house PCR-SSP 
(Polymerase Chain Reaction - Sequence Specific Primers) methodology, 
previously described by Bunce et al. [147].  Genomic DNA was used as a 
template for the PCR-SSP reaction. The DNA was extracted as previously 
described in Section 2.6.1. PCR-SSP utilises a panel of oligonucleotide primer 
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mixes able to amplify HLA-A, -B, -Cw, -DRB1, -DRB3, -DRB4, -DRB5 and -
DQB1 alleles [147]. The PCR-SSP method is based on repeated cycles of 
denaturing, oligonucleotide primer annealing and extension, which generate 
exponential amplification of a targeted DNA sequence. Each PCR reaction 
contains an additional pair of primers that amplify “housekeeping” genes 
(genes present in all samples e.g. human growth hormone). The amplification 
of “housekeeping” genes allows identification of a negative and/or a failed 
reaction. In brief, 425.3 µl deionized water, 875 µl PCR buffer (PCR buffer IV 
(750mM Tris HCL pH 8.8, 200mM (NH4)2SO2, 0.1% Tween 20), 2mM MgCl2, 
5% glycerol, 100 µg/ml cresol red, 200 µM dNTP), 87.5 µl DNA at 
concentration of 225 ng/µl and 8.8 µl Taq DNA polymerase (Bioline Ltd., 
London, UK) were mixed by vortexing and 8 µl of the mixture was pipetted 
into each well of a 96-well pate containing 5 µl of sequence specific primers. 
The PCR was carried out in a GeneAmp 9700 Thermal Cycler (Applied 
Biosystems, Life Technologies, USA). Table 2.7 shows the PCR-SSP thermal 
cycler conditions. 
 
Table 2.7 PCR-SSP Thermal Cycler Settings  
 Hold  5 Cycle 21 Cycle 
Temperature 96°C 96°C  70°C 72°C 96°C 65°C 72°C 
Time 1 min 20 sec 45 sec 25 sec 25 sec 50 sec 30 sec 
 4 Cycles  Hold  Hold  
Temperature 96°C 55°C 72°C 20°C 4°C 
Time  30 sec 60 sec 90 sec 60 sec 10 min 
 
The PCR amplified products were loaded onto a 1.5% agarose gel containing 
Ethidium Bromide (10mg/ml) followed by electrophoresis at 180V for 40 mins. 
The gel electrophoresis was performed in a Helena Bioscience HU-25 gel tray 
(Helena Bioscience Europe, UK) containing 0.5 x TBE (Tris Boric acid EDTA) 
buffer. The PCR products were visualised under the UV light (Uvitec, 
Cambridge, UK). An example of recipient HLA class I genotyping is presented 
in Figure 2.3. 
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Figure 2.3 Human leucocyte antigen (HLA) A and B loci and Bw epitope 
genotyping of a lung transplant recipient. Genomic DNA was isolated from recipient 
peripheral blood collected prior to transplantation. HLA-A and –B loci and Bw epitope 
genotyping was performed by polymerase chain reaction using sequence-specific primers 
(PCR-SSP). The arrows represent positive reaction i.e. presence of specific alleles. The 
recipient HLA genotype was identified as HLA-A25, -A26; -B8, -B57; Bw4 and Bw6.  
 
2.6.3 Killer Immunoglobulin-like receptor (KIR) genotyping using quantitative 
KIR automated typing (qKAT) methodology  
 
KIR genotyping was carried out by the KIR typing service at the Department 
of Immunology, Cambridge University. Genomic DNA obtained as previously 
described in Section 2.6.1 was genotyped for KIR gene content and copy 
number, using a recently developed high-throughput technology known as 
qKAT, as described in detail by Jiang et al., [148, 149]. Briefly, a set of 10 
multiplex quantitative PCR (qPCR) assays was carried out in quadruplicate for 
each patient. Each assay detected two different KIR genes and one reference 
gene, using sequence specific primers and probes labeled with different 
fluorophores. Monitoring of fluorescence signal for each probe, in each 
reaction, and subsequent Ct determination, allowed relative quantification of 
copy number for the 17 KIR genes (2DL1-5, 2DS1-3, 2DS4 (2DS4f and 
2DS4v), 2DS5, 3DL1-3, 3DS1, 2DP1, and 3DP1) and their major variants. 
 
 
M 
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2.6.3.1 Natural killer (NK) cell alloreactivity mismatched definition 
 
NK cell activation is controlled by inhibitory and activating KIRs. The NK cell 
inhibitory KIRs have the ability to respond to HLA class I antigens; and 
absence of HLA class I ligands leads to loss of inhibition, thus resulting in NK 
cell activation. NK cell alloreactivity was predicted based on the presence or 
absence of the inhibitory KIR genes (2DL1-3 and 3DL1) and their 
corresponding HLA class I ligands (C1, C2 and Bw4) Table 2.8. Thus, NK cell 
alloreactivity was expected if there was at least one KIR-ligand mismatch 
between the recipient and donor pair. For example, NK cell alloreactivity is 
expected if an inhibitory KIR2DL1 gene and its corresponding HLA ligand (C2) 
was identified on the recipient’s cells, but the HLA ligand (C2) is absent on the 
donor cells.  
 
Table 2.8 KIR-ligand mismatch definitions. (Table adapted from van Bergen et al., 
2011)    
 
2.6.4 Gene expression analysis using reverse transcription – polymerase 
chain reaction (RT-PCR) methodology 
 
RT-PCR methodology is commonly used to detect RNA expression levels in 
biological samples. Traditionally, the first step for RT-PCR requires availability 
of pure RNA; extracted from the experimental sample. Due to the limited 
amount of experimental biological sample available we were not able to obtain 
sufficient amounts of RNA for gene expression analysis; therefore, an 
alternative method was utilised. TaqMan® Gene Expression Cells-to-CTTM 
(Ambion, Life Technologies, CA, USA) technology enables RNA reverse-
Recipient  Donor  Inhibitory  
KIR-ligand    KIR                         HLA HLA 
KIR2DL1/C2 
KIR2DL2/C1 
KIR2DL3/C1 
KIR3DL1/Bw4 
KIR2DL1 + 
KIR2DL2 + 
KIR2DL3 + 
KIR3DL1 + 
C2 + 
C1 + 
C1 + 
Bw4 + 
C2 – 
C1 – 
C1 – 
Bw4 – 
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transcription into complementary DNA (cDNA) directly from cell lysates 
without the requirements to isolate and purify the RNA. The manufacturer’s 
protocol was modified and adapted specifically for this study. The RT-PCR 
gene expression protocol used for gene expression profiling is described 
below.  
 
2.6.4.1 Donor CD4 T cell lysis 
 
Donor CD4 T lymphocytes isolated from the recipients’ peripheral blood 
samples (Section 2.4.3) were used as a substrate for reverse-transcription 
(RT) reaction. Cells were washed with 500 μl of sterile cold PBS and 
centrifuged for 10 min at 2 x g. The supernatant was aspirated and discarded 
without disturbing the cell pellet. The cell pellet was re-suspended in 1000 µl 
cold PBS and washed twice, as previously described. Following washing 
steps, the cell pellet was lysed in 20 µl of Lysis Solution and 0.2 µl DNase I by 
pipetting up and down 10 times. The lysed cells were incubated for 5 min at 
room temperature. The reaction was stopped with 5 µl of Stop Solution; mixed 
and further incubated for 2 min at room temperature. 
 
2.6.4.2 Reverse Transcription 
 
RT reaction was carried out in 50 µl reaction consisting of: 25 µl 2x RT Buffer, 
2.5 µl 20x RT Enzyme, 2.5 µl nuclease-free water and 20 µl of cell lysate. The 
reaction was mixed and centrifuged briefly to collect the content at the bottom 
of the 96-well plate (Thermo Scientific, CA, USA) and placed in a Thermal 
Cycler (Mx3005P, Stratagene, CA, USA). Table 2.9 shows the RT thermal 
cycler conditions.  
 
Table 2.9 Reverse Transcription Thermal Cycler Settings 
 Stage Repeated cycles Temperature  Time  
Reverse transcription 1 1 37°C 60 min 
RT inactivation 2 1 95°C 5 min 
Hold 3 1 4°C 5 min 
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The RT product i.e. cDNA was used as a template for the next reaction step. 
Firstly, in order to increase the amount of cDNA available for detection of the 
genes of interest, the cDNA for each gene was pre-amplified using gene 
expression assays.  
 
2.6.4.3 Pooling TaqMan® gene expression assays and Preamplification of 
genes of interest 
 
Equal volume of 20x TaqMan® gene expression assays (Table 2.10), 
(Applied Biosystems, Life Technologies, CA, USA) were combined and diluted 
with 1 x TE Buffer to a final volume of 0.2x. The pooled gene expression 
assays were used for preamplification of the genes of interest.  
 
Each preamplification reaction consisted of 25 µl TaqMan PreAmp Master Mix 
(2x) (Applied Biosystems, Life Technologies, CA, USA), 12.5 µl pooled gene 
expression assays, 2.5 µl nuclease-free water and 10 µl cDNA. The reaction 
was mixed and centrifuged briefly to collect the content to the bottom of the 
96-well plate and placed in a Thermal Cycler (Mx3005P, Stratagene, CA, 
USA) Table 2.10 shows the pre-amplification thermal cycler settings and 
Table 2.11 contains a list of gene expression assays used for characterisation 
of donor CD4 T lymphocyte subsets. A representative image of gene 
preamplification is presented in Figure 2.4.     
 
Table 2.10 Pre-amplification Thermal Cycler Settings 
 Hold 14 Cycles 
Temperature 95°C 95°C 60°C 
Time  10 min 15 sec 4 min 
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Table 2.11 List of gene expression assays used for characterisation of donor 
CD4 T lymphocyte subsets.  
Gene expression assays – 
manufacture catalogue ID 
 
Brief description of gene function  
GAPDH – Hs99999905_m1 Endogenous control. Involved in glycolysis 
(breakdown of glucose).   
SELL (CD62L) – Hs00174151_m1 Adhesion molecule expressed on naïve and 
central memory T cell subset. 
STAT5B – Hs00273500_m1 Transcription factor regulates differentiation of 
CD4 T cells into regulatory T cells.  
CD27 – Hs00386811_m1 Marker for regulatory T cells.  
CD44 – Hs01075861_m1 Marker for effector memory T cells involved in 
cell-cell interaction, cell adhesion and migration. 
RORC – Hs01076122_m1 Transcription factor regulates differentiation of 
CD4 T cells into Th17 cell subset. 
IL21 – Hs00222327_m1 Involved in differentiation of naïve T cells into 
Th17 cell subset.  
CCR6 – Hs00171121_m1 Regulates migration of Th17 cells to the 
inflammatory tissue. 
GATA-3 – Hs00231122_m1 Transcription factor regulates differentiation of 
CD4 T cells into Th2 cell subset. 
STAT6 – Hs00598625_m1 Transcription factor regulates differentiation of 
CD4 T cells into Th2 cell subset. 
BCL6 – Hs00153368_m1 Regulates CD4 T cell differentiation into follicular 
T cell subset. 
T-bet - Hs00203436_m1 
 
Transcription factor regulates differentiation of 
CD4 T cells into Th1 cell subset.  
STAT3 - Hs00374280_m1 Promotes differentiation of CD4 T cells into Th17 
subset. 
STAT4 - Hs01028017_m1 Transcription factor regulates differentiation of 
CD4 T cells into Th1 cell subset. 
FOXP3 – Hs01085834_m1 Transcription regulator for development of 
regulatory T cells. 
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Figure 2.4 A representative image of CD44 gene preamplification using 
TaqMan®  gene expression assay. Five cDNA samples were selected for CD44 gene 
expression analysis using cDNA without a preamplification step (dark red and gray 
amplification curves) and cDNA with previous preamplification step (orange and blue 
amplification curves). The preamplification step increased the signal for CD44 gene 
expression on average by four Ct cycles, which is equivalent to a 16-fold increase in the 
amount of cDNA available for the targeted gene. All samples tested were first subjected to 
preamplification of the gene of interest. The pre-amplified cDNA product was used as a 
template for gene expression analysis using Real Time - PCR (RT-PCR).    
 
2.6.4.4 Real-time – PCR 
 
RT-PCR was carried out in MicroAmp® Optical 384-well reaction plates 
(Applied Biosystems, Life Technologies, CA, USA) in a final volume of 5 µl. 
The RT-PCR reaction contained 2.5 µl TaqMan gene expression Master Mix 
(Applied Biosystems, Life Technologies, CA, USA), 0.25 µl 20x gene 
expression assay, 1 µl nuclease-free water and 1.25 µl pre-amplified cDNA. 
Each reaction was carried out in duplicates. The plate was vortexed and 
centrifuged briefly to collect the content at the bottom of the 384-well plate 
and placed in a 7900HT Fast Real-Time PCR instrument (Applied 
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Biosystems, Life Technologies, CA, USA), Table 2.12 shows the RT-PCR 
thermal cycler settings. A representative image of CD44 gene expression 
analysis using RT-PCR methodology is presented in Figure 2.5. 
 
Table 2.12 Real-time PCR Cycling Conditions  
 Hold Hold 40 cycles 
Temperature  50°C 95°C 95°C 60°C 
Time  2 min 10 min 15 sec 1 min 
 
 
 
 
 
Figure 2.5 A representative image of CD44 gene expression analysis using RT-
PCR methodology. RT-CPR amplification plot representing CD44 gene expression levels 
recipients’ peripheral blood isolated donor CD4 T cells. The RT-PCR was performed as 
previously described in Section 2.4.6. Each sample was tested in duplicates.   
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2.6.5 Relative quantification of the gene expression  
 
The RT-PCR gene expression levels were quantified using the relative 
quantification (RQ) method [150]. RQ is a widely applied method for gene 
expression analysis where the aim is to describe a particular cell type based 
on the gene expression levels or to study differences in the level of gene 
expression between two groups of patients. In addition, the RQ method is not 
dependent on the starting sample size, but instead the expression of the 
target gene i.e. gene of interest is quantified in relation to the endogenous 
control gene, also known as a reference gene [150]. Endogenous control 
represents a gene with a stable level of expression. In this study GAPDH was 
used as a reference internal control gene. DataAssistTM v3.01 software 
(ThermoFisher Scientific, CA, USA) was used to calculate the relative 
quantification (fold-change) of the gene expression.  
 
DataAssistTM v3.01 software performs the following step analysis:  
1. Performs mean Ct analysis.  
2. Performs sample Ct normalization known as delta Ct (ΔCt) relative to 
the mean Ct value of the endogenous internal control gene (GAPDH). 
ΔCt equals the Ct of the target gene minus the Ct of the reference gene 
(ΔCt = Ct (target gene) – Ct (reference gene - GAPDH)).  
3. Performs ΔCt normalization known as delta delta Ct (ΔΔCt) between 
two groups of patients or two samples obtained at different time points 
ΔΔCt equals ΔCt of the patient group/test samples minus the ΔCt of 
the calibrator. The calibrator represents patient group/test sample used 
for comparison analysis (ΔΔCt = ΔCt (test) – ΔCt (calibrator). 
4. Performs relative quantification (fold-difference) for sample comparison 
and t-test for biological group (patient group) comparison (2-(ΔΔCt) = 
Normalised relative gene expression). 
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2.7 Ex Vivo Lung Perfusion 
 
In the United Kingdom about 80% of potential donor lungs are deemed 
unsuitable for clinical lung transplantation. Thus, the shortage of donor lungs 
has impacted the donor selection criteria; which has resulted in an increased 
use of donor after cardiac death (DCD) and more “marginal” donors. Ex-Vivo 
Lung Perfusion (EVLP) is a novel technique originally described by Steen et 
al., in which unusable donor lungs can be assessed and potentially 
reconditioned for safe use in clinical transplantation [151, 152].  
 
In 2013, the United Kingdom launched a multi-centre EVLP clinical trial 
(DEVELOP-UK) to evaluate the effectiveness, safety and cost-effectiveness 
of EVLP. The EVLP was performed using Vivoline® system, which is a semi-
automated EVLP circuit consisting of bypass pump, oxygenator / 
deoxygenator, perfusion reservoir, organ contained unit and leucocyte filter.  
 
In brief, donor lungs were connected to a “modified” heart-lung bypass circuit 
to which a leucocyte filter is attached; two-litres of acellular Steen SolutionTM 
and two-units of packed red blood cells (RBCs) were continuously pumped 
through the lungs for four hours which warms the lungs to body temperature. 
After slow rewarming the lungs are ventilated with oxygen by connecting them 
to a standard ITU ventilator.  This is followed by one-hour cooling perfusion 
phase during which lungs are cooled-down to 6°C. During the whole EVLP 
procedure the leukocyte filter is attached to the circuit. At the end of the 
procedure, the leukocyte filter is removed and stored overnight in RPMI media 
at 4°C for further analysis. 
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2.8 Statistical analysis 
 
Recipient and donor demographics are presented as a median ± SD. 
Statistical analyses were performed using GraphPad Prism, GraftPad 
Software, Inc., San Diego, CA, USA. Comparison between two groups was 
assessed by chi-square or Fisher’s exact test where appropriate. Paired t-test, 
Mann-Whitney t-test or Wilcoxon matched pairs test were used to assess the 
change in the autoantibody levels in sera obtained at two different time points. 
The effects of HLA and KIR-ligand mismatching on both, duration of donor 
CD4 T cell chimerism and development of BOS were assessed using Kaplan-
Meier method. Nonparametric correlation Spearman r test was used for 
correlation analysis. A p value of <0.05 was considered significant. 
DataAssistTM v3.01 software (ThermoFisher Scientific, CA, USA) was used for 
gene expression relative quantification (fold-change). ProtoArray® Prospector 
v5.2 software provided by Invitrogen (Invitrogen, CA, USA; now provided by 
ThermoFisher Scientific, CA, USA) was used for protein microarray data 
analysis.  
 
Prior to commencement of this study the incidence of donor CD4 T cell 
chimerism and the development of autoantibody in lung transplant recipients 
were unknown entities. Power calculations will be applied whenever relevant. 
There is little data on which to base the number of human patients required 
for study, but assuming that approximately more than 30% of recipients 
develop autoantibody [153], and a similar percentage have detectable donor 
lymphocyte chimerism [132], 70 patients will allow a clinically-relevant 
proportional association of 70:30 to be statistically demonstrable. Papworth 
Hospital perform around 25 to 30 lung transplants each year, so it will take 
approximately 2.5 years to recruit 70 patients to the study. From previous 
publications [134], donor lymphocyte chimerism that persists for more than a 
year is likely to be physiologically relevant. We thus anticipate that if an 
association between donor lymphocyte chimerism persistence and 
autoantibody exists, it will be visible to demonstrate statistical significance 
within the study period of four years.   
 68 
 
 
 
3 Chapter 3 
 
 
 
Detection of donor CD4 T 
lymphocyte chimerism in lung 
transplant recipients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 69 
3.1 Introduction 
 
Donor-derived haematopoietic cells that are not flushed from the graft during 
retrieval will be transferred to the recipient at the time of transplantation. The 
presence and co-existence of these cells in the blood and tissues of the 
recipients results in a chimeric state - the co-existence of two or more 
genetically distinct cell populations. Depending on the proportions of chimeric 
cells present; the terms micro- and macrochimerism have been used to 
describe chimeric populations present at less than 1%, or greater than 1% of 
the total number of cells, respectively [129].   
 
Chimerism has also been defined according to the mechanism of its 
development: induced chimerism and spontaneously occurring chimerism. 
Induced chimerism has been used as a therapeutic approach in living renal 
transplant recipients, where transplantation of the allograft is accompanied by 
donor HSC infusion, with the aim of inducing donor-specific tolerance. In 
contrast, spontaneous chimerism occurs due to migration of donor leukocyte 
passengers from within the allograft into recipient peripheral blood and 
tissues, a phenomenon typically observed in recipients of solid organ 
transplants. Consequently, there is a fundamental difference between induced 
and spontaneous chimerism in terms of the type of cells transferred, their 
maturity, and presumably their role in solid organ transplantation.  
 
3.1.1 Historic overview of the immunologic implications of chimerism and 
induction of donor-specific tolerance 
  
From the beginning of the modern transplant era in the 1960s, chimerism has 
been considered to likely influence transplant outcomes. However, several 
decades later, the role of microchimerism in tolerance and/or rejection 
remains controversial. The immunological relevance of chimerism was first 
demonstrated by Owen’s observation that cattle twins contain a mixture of two 
distinct types of erythrocytes at birth, and in some cases, the chimeric state 
persists into adulthood [154]. Furthermore, Medawar et al., observed that 
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chimeric cattle twins were fully tolerant to skin grafts of each other, but that, 
as expected, skin transplanted from a third party was rejected [155].  
 
Billingham, Brent and Medawar recognised the significance of these 
observations and designed an experimental model to demonstrate “how to 
make tissue homografts immunologically acceptable to hosts which would 
normally react against them” [156]. They showed that inoculation of living cells 
from an adult mouse of one strain into allogeneic neonatal recipients led to 
chimerism that persisted into adulthood and that these mice were specifically 
tolerant to donor strain skin grafts, yet retained the ability to react to third-
party skin grafts [156]; a process described as “active acquired tolerance”.     
 
Strober et al. reported the first cases of acquired tolerance in humans, when 
three patients with end-stage renal disease were treated with total lymphoid 
irradiation and subsequently transplanted with a kidney transplant from a 
deceased donor [157]. Similar findings were observed in two patients who had 
received bone marrow transplants from HLA-identical donors. Both patients 
subsequently received a kidney from the same living donor and neither 
received immunosuppression [158].   
 
However, reluctance to expose patients to radiation has hampered the wider 
clinical application of this approach. Instead, administration of anti-lymphocyte 
serum and sirolimus, together with donor bone marrow has been investigated 
as an alternative approach for induction of donor-specific tolerance [159]. 
Using this approach Hale et al., in a completely mismatched murine model, 
have shown long-lasting donor-specific tolerance, which surprisingly was 
dependent on the presence of B cells [159]. These observations were further 
confirmed in T cell-knockout experimental model [160]; nevertheless, using 
the same conditioning protocol, Umemura et al., have reported prolonged skin 
allograft survival in a completely MHC-mismatched mouse model, even in the 
absence of B cell chimerism [160], suggesting that neither T nor B cells are 
essential for allograft tolerance induction. In contrast, Tomita et al., showed 
that long-term donor-specific tolerance is dependent on donor T cells [161]. 
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Umemura et al., have further reported that expression of MHC class II antigen 
on bone marrow cells is essential for induction of tolerance [162].  
 
3.1.2 The role of spontaneous chimerism in solid organ recipients 
 
The phenomenon of spontaneously occurring chimerism has been observed 
in solid organ transplant recipients. The first evidence for the presence of 
chimerism following solid organ transplantation was obtained in 1969, with 
karyotyping studies in female liver transplant recipients identifying persistent 
cells of male donor origin [131, 163].  
 
It was not until 1992 when Starzl et al., postulated that transfer of leukocytes 
from the donor can create a state of systemic mixed allogeneic chimerism, 
that if persistent, promotes graft acceptance and resistance to cellular and 
humoral rejection. This hypothesis was initially tested in female liver 
transplant recipients of male donors 10 to 19 years after transplantation, using 
in-situ hybridisation of Y chromosome. Evidence of Y chromosome was 
detected in the majority of patients’ blood and lymph node samples. In 
addition, donor cells were detected in skin biopsy samples in all patients [131, 
164].     
 
In support that persistent chimerism leads to allograft acceptance, Starzl et al. 
made similar observations in long-term living kidney transplant survivors. 
Interestingly, in this small cohort (n=5), chimerism was detected even three 
decades after transplantation [165]. In all patients, donor chimerism was 
detected in freshly obtained kidney and skin biopsy samples and/or lymph 
nodes obtained from the groin; using both immunocytochemistry and PCR 
methodology. In four out of the five patients, chimerism was detected by 
targeting donor mismatched HLA antigens and in one patient whose donor 
had died (father to daughter), chimerism was confirmed by identifying the sex-
mismatched Y chromosome. [165]. In addition, four patients, whose donors 
were still alive, underwent further in vitro analyses to assess the 
responsiveness to their donor, using unidirectional mixed lymphocyte reaction 
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(MLR) culture and cell-mediated lymphocytotoxicity. Non-responsiveness to 
irradiated donor cells was observed in two of the four kidney recipients, and a 
modest response was detected in the other two, whilst in all cases the 
recipients retained their ability to respond to third party lymphocytes. Similarly, 
the donor lymphocyte fraction in the chimeric recipients was not reactive to 
the recipients’ lymphocytes, but was responsive to third party lymphocytes 
[165].      
 
The phenomenon of spontaneously occurring chimerism has also been 
demonstrated in experimental models [166, 167], and human transplant 
recipients of multivisceral [168], and heart and lung [169] transplants. 
 
Despite these observations, the role of passenger leukocytes in solid organ 
transplantation remains unclear; and conflicting evidence has been reported 
that in some settings donor-derived passenger leukocytes can initiate graft 
rejection [140], whereas in others they can contribute to graft acceptance 
[131, 164, 165]. For example, experimental work in a rat heart transplant 
model of cyclosporine-induced tolerance demonstrated that depletion of 
donor-derived leukocytes at the time of transplantation resulted in acute 
rejection of the grafts by day 23 post-transplantation, whereas depletion of 
donor leukocytes at day 18 post-transplantation resulted in long-term allograft 
acceptance [170]; suggesting a beneficial immunemodulatory effect.   
 
These observations have raised the question of whether the immuno-
modulatory role of donor chimerism and its influence on transplant outcome is 
time-dependent. Two phases of donor chimerism have been proposed an 
early and late phase. In the early post-transplant stage, the donor chimerism 
comprises mature T, B and DC cells that have been “washed out” from the 
graft [171, 172]. In contrast, donor chimerism that can be detected in the late 
post-transplant phase may result from bone marrow engraftment of donor-
derived haematopoietic stem cells (HSC) originating from the graft itself [173].    
  
Several clinical and experimental studies have reported the presence of HSCs 
in the liver. Taniguchi et al., identified the existence of HSCs expressing c-kit+ 
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Sca+ Linlo/- in adult mouse liver: interestingly, adoptive transfer of these cells 
rescued lethally irradiated mice and reconstituted all linage blood cells [174]. 
Moreover, multilineage haematopoietic reconstitution was achieved in 
supralethally irradiated rat model following syngeneic liver transplantation. A 
similar approach in syngeneic heart transplantation significantly prolonged 
graft survival, but failed to fully reconstitute the haematopoietic compartment 
[175], presumably because the heart contains relatively few HSCs.  
Similar findings have been reported in long-term survivors of liver transplants, 
where donor CD34+ HSCs have been detected in patients’ bone marrow and 
peripheral blood [173].  
These studies suggest that long-term graft survival and donor-specific 
tolerance might be achieved via engraftment of graft passenger HSCs. 
Nevertheless, it is not clear whether other organs such as kidney, pancreas, 
heart and lungs contain HSCs and if they do, whether the numbers of resident 
HSCs are sufficient to maintain donor-specific tolerance. 
In contrast to these observations, donor chimerism can occasionally trigger 
onset of graft vs host disease (GvHD). In solid organ transplantation, GvHD is 
a rare post-transplant complication; nevertheless detrimental outcomes have 
been reported in liver [176, 177] and lung transplant patients [178, 179]. 
Based on the experimental and clinical evidence available, it is likely that graft 
outcomes depend upon a complex interplay between the donor-derived 
passenger leukocytes and recipients’ own immune responses The effect of 
this interplay will likely differ according to the different organs transplanted. 
Understanding the role of microchimerism and the underlying mechanisms 
involved may provide fundamental insights that ultimately inform the 
development of new strategies for improving transplant outcomes. 
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3.1.3 The role of donor CD4 T cell chimerism in the development of de novo 
autoimmunity following transplantation  
 
Win et al., in our department used a murine model of chronic heart graft 
rejection to study how donor CD4 T cells that were passengers within the 
heart graft influenced the host response to the graft. In Win’s model, the donor 
bm12 strain varies from the C57BL/6 (B6) recipient by three amino acid 
residues in the MHC class II I-A antigen (human HLA-DQ). Bm12 heart 
allografts are rejected slowly (median survival time 50 days), and this rejection 
was associated with the development of graft vascular pathology consisting of 
progressive intimal thickening and luminal narrowing. In addition, there was 
histologic evidence of humoral vascular rejection, characterised by C4d 
complement and IgG endothelial deposition. No evidence of rejection was 
observed in syngeneic transplants or the bm12 allografts transplanted into 
either MHC class II gene knockout mice or B cell-deficient recipients. . Further 
experiments revealed that the B6 recipients did not develop circulating IgG 
alloantibodies but instead developed long-lasting IgG antinuclear 
autoantibody [144].  
 
To investigate the involvement of T-cell-dependent responses; B6 recipients 
were primed with synthetic allopeptide corresponding to the disparate region 
of the I-Abm12 antigen 14 days prior to transplantation with a bm12 heart 
allograft. Bm12 heart grafts were rejected more rapidly than in unprimed, 
control recipients, but without evidence of alloantibody development. 
Moreover, despite the rapid rejection, the levels of circulating IgG 
autoantibodies were not augmented. These experiments suggested that 
development of autoantibody is independent of indirect pathway T cell 
responses. Given that indirect-pathway is thought to be the only means by 
which CD4 T cell help for alloantibody production is provided [79, 80], this 
result was surprising and suggested that an alternative mode of help was 
responsible for the development of autoantibody in the bm12-B6 model. On 
the basis that adoptive transfer of bm12 splenocytes triggers lupus-like 
humoral autoimmunity in B6 recipient mice [144, 145], the potential role of 
 75 
passenger donor CD4 T cells in the provision of help to host B cells was 
investigated. Surprisingly, transplantation with heart allografts from donor 
bm12 mice that either were depleted of CD4 T cells prior to heart allograft 
procurement or were genetically deficient in T and B cells did not prompt 
autoantibody production and heart allograft survival was prolonged [144].  
 
Win et al., concluded that in their model, help for autoantibody production was 
provided via a direct cognate interaction between the donor CD4 T cells and 
the recipient auto-reactive B cells, thereby replicating the normal interaction 
between a self-restricted host helper CD4 T cell and B cell [144]. Win’s 
studies further demonstrated that the autoantibody contributed to the 
development of chronic allograft vasculopathy.  
 
The aim of my thesis was therefore to address whether a similar mechanism 
may occur in human transplant recipients. We chose to examine the role of 
donor CD4 T cells in lung transplant recipients, because the lung graft is a 
large and leucocyte rich organ. In assessing the potential contribution of 
donor CD4 T cells to human allograft rejection, it was first necessary to 
demonstrate the presence of donor CD4 T cells in the lung recipient’s 
circulation following transplantation. 
 
Two questions will be addressed in this chapter: are donor CD4 T cells 
detectable in patients’ peripheral blood following lung transplantation; and if 
so, for how long do these donor CD4 T cells remain detectable in the 
recipient? The donor CD4 T cells were detected by targeting the donor HLA 
class I (HLA- A and/or HLA-B) mismatched antigens with human monoclonal 
HLA antibodies.     
 
 
 
 
 
  
 76 
3.2 Results 
3.2.1 Patient cohort 
 
Informed written consent was obtained from 63 patients awaiting diseased 
donor lung and heart and lung transplantation at Papworth Hospital. Twenty-
nine patients were transplanted during the study. Immediately after their 
transplant, eight patients were excluded from the study: five due to the lack of 
appropriate human monoclonal anti-HLA antibody to detect donor-
mismatched HLA class I antigens; and three patients were deemed unsuitable 
for participation in the study due to post-operative transplant-related 
complication.  
 
In total, 21 patients were clinically stable for participation in this study; 19 
patients received bilateral lung and two patients received single lung 
transplant. The presence of donor CD4 T cells and their persistence in the 
recipients’ peripheral blood was assessed for 12 months after lung 
transplantation.  
 
The recipient age varied between 18 and 66 years. Of the 21 patients who 
underwent lung transplantation, 8 were male and 13 female. Seven patients 
were sensitised to HLA antigens prior to transplantation. All patients received 
triple drug immunosuppression; in addition, two patients received induction 
therapy with Basiliximab, a humanised monoclonal antibody to α chain 
(CD25) of the IL-2 receptor expressed on T cells. A detailed representation of 
the recipients’ and donors’ demographic characteristics is presented in Table 
3.1.  
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Table 3.1 Lung transplant recipients and donors characteristics 
 
SLT – Single Lung Transplant; BLT – Bilateral Lung Transplant; DBD – Donation after brain 
steam death; DCD – Donation after cardiac death; COPD - Chronic obstructive pulmonary 
disease; A1AD- α1 antitrypsin deficiency; HLA – Human Leukocyte Antigen;  
MMF – Mycophenolate Mofetil.    
  
 
Recipient age (Median ± SD)   56 ± 13.6 (18-66 years) 
Recipient sex (M:F)     8:13 
Transplant type     
 SLT      2 
 BLT      19 
Donor age (Median ± SD)    48 ± 11.2 (19-60 years) 
Donor sex (M:F)     10:11 
Donor type  
 DBD      20 
 DCD      1 
Indication for transplantation 
 Cystic fibrosis    3 
 Emphysema      4 
 COPD      7 
 Pulmonary fibrosis     2 
 Bronchiectasis    2 
 A1AD      1 
 Emphysema + A1AD    2 
HLA Sensitisation      7  
Immunosuppression  
 therapy    Tacrolimus/MMF/Prednisolone 
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3.2.2 Identification of donor HLA class I mismatched antigens  
 
To detect the presence of donor CD4 T cell chimerism in patients’ peripheral 
blood following primary lung transplantation, donor HLA class I mismatched 
antigens were used as targets to distinguish between patient and donor cells. 
Recipient and donor blood samples and spleen and/or lymph node cells, 
respectively, were obtained prior to transplantation and used as a source for 
DNA extraction and HLA genotyping. 
 
Recipient and donor HLA class I mismatched antigens were identified using 
molecular PCR methodology. Genomic DNA obtained prior to transplantation 
was used as a template for PCR-SSP, previously described in Section 2.6.1 
and Section 2.6.2.  
 
Table 3.2 shows the genotype of the recipients and corresponding donors for 
HLA-A and HLA-B antigens and Bw epitope; donor HLA mismatched antigens 
are highlighted in red. All recipient-donor pairs had at least one HLA class I 
mismatched antigen that was used as a target for detection of donor CD4 T 
lymphocytes with human monoclonal HLA antibodies using flow cytometric 
analysis.  
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Table 3.2 Human leucocyte antigen (HLA) A and B loci and Bw epitope 
genotype of lung transplant recipients and their corresponding donors using 
PCR-SSP. Donor HLA mismatched antigens are highlighted in red. 
 
Patient 
No. 
Recipient HLA-A; -B; -Bw Donor HLA-A; -B; Bw (mismatched 
antigens highlighted in red) 
 
1 HLA-A1,32; -B8; Bw6 HLA-A2,3; -B44,62; Bw4,6 
2 HLA-A25,26; -B8,57; Bw4,6 HLA-A2; -B8,35; Bw6 
3 HLA-A1,3; -B7,57; Bw4,6 HLA-A2; -B51,27; Bw4 
4 HLA-A24,25; -B62,37; Bw4,6 HLA-A3,24; -B51,7; Bw4,6 
5 HLA-A2; -B44,61; Bw4,6 HLA-A3,33; -B7,65; Bw6 
6 HLA-A3; -B51,65; Bw4,6 HLA-A1,11; -B7,56; Bw6 
7 HLA-A1,68; -B8,65; Bw6 HLA-A2,3; -B7,44; Bw4,6 
8 HLA-A2,24; -B7,44; Bw4,6 HLA-A1,11; -B8,62; Bw6 
9 HLA-A2,30; -B7,44; Bw4,6 HLA-A1,23; -B44,42; Bw4,6 
10 HLA-A24,68; -B8,62; Bw6 HLA-A1,3; -B7,57; Bw4,6 
11 HLA-A2,24; -B65,57; Bw4,6 HLA-A1,29; -B52,44; Bw4  
12 HLA-A1,32; -B7,55; Bw6 HLA-A1,3; -B7,8; Bw6 
13 HLA-A1,2; -B51,8; Bw4,6 HLA-A2; -B7,56; Bw6 
14 HLA-A2,23; -B8,44; Bw4,6 HLA-A2; -B51,44; Bw4 
15 HLA-A2,24; -B7,44; Bw4,6 HLA-A2,24; -B60,62; Bw6 
16 HLA-A3,32; -B51,62; Bw4,6 HLA-A2; -B44; Bw4 
17 HLA-A1,2; -B7; Bw6 HLA-A1,11; -B7,8; Bw6 
18 HLA-A24,31; -B62,51; Bw4,6 HLA-A2; -B44,18; Bw4,6 
19 HLA-A1,3; -B7,57; Bw4,6 HLA-A2,3; -B44,35; Bw4,6 
20 HLA-A1,3; -B8,27; Bw4,6 HLA-A2; -B27,60; Bw4,6 
21 HLA-A2,3; -B7,62; Bw6 HLA-A68,36; -B57,71; Bw4,6 
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3.2.3 Selection of human HLA monoclonal antibody for detection of donor 
CD4 T cells in peripheral blood of lung transplant recipients    
 
A limited set of 14 human HLA monoclonal antibodies (mAbs) was used for 
detection of donor CD4 T cell chimerism (Table 2.1). We estimated that this 
panel enabled discrimination between recipient and donor lymphocytes in the 
majority of recipient-donor pairs. Human HLA mAbs with specificity to donor 
HLA class I mismatched antigens were not available for five recipient-donor 
pairs; subsequently, these patients were excluded from the study.  
 
The specificity of each mAb was initially tested using recipients’ PBMCs 
obtained prior to transplantation and donor lymphocytes obtained from spleen 
or lymph nodes at the time of donation. The HLA mAb selection was based on 
the binding capacity to the recipient and donor lymphocytes; HLA mAb that 
did not bind to recipient lymphocytes obtained prior to transplantation and at 
the same time showed >95% binding to the donor HLA antigens were 
selected for detection and isolation of donor CD4 T cells from the recipients’ 
peripheral blood at regular time intervals following transplantation. Figure 3.1 
is an example of flow cytometric analysis used for selection of human mAbs 
and detection of donor CD4 T lymphocytes.  
 
Recipients’ PBMCs obtained prior to transplantation served as a control to 
identify patients with pre-existing chimerism. In this patient cohort, pre-existing 
chimerism was not detected. Table 3.3 shows the recipient-donor pair HLA 
mismatched antigens and the specificity of the HLA mAbs used to target the 
donor CD4 T cells.  
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Figure 3.1 A representative image of flow cytometric analysis. Selection of 
human HLA monoclonal antibodies (mAbs) for detection of donor CD4 T cell 
chimerism in the peripheral blood of lung transplant recipients.  
Recipient and donor pair was mismatched for HLA-A68, 36; -B57, 71 and Bw4 epitope. Two 
biotin-conjugated HLA mAbs were tested, MUS4H4 and SN607D8 with specificity for Bw4 
epitope and HLA-68 antigen, respectively, using recipient and donor lymphocytes obtained 
prior to transplantation. Biotin-conjugated human HLA mAbs were detected with APC-
conjugated streptavidin. A) MUS4H4 with specificity for Bw4 epitope did not stain recipient 
cells obtained prior to transplantation, C), but it stained >95% of donor lymphocytes. B) 
SN607D8 with specificity for HLA-A68 antigen stained ~ 5% of recipient lymphocytes; and, D) 
>95% of donor lymphocytes. The MUS4H4 with specificity for Bw4 epitope was selected for 
detection of donor CD4 T lymphocytes chimerism in samples obtained at regular time 
intervals after transplantation.  
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Table 3.3 Human monoclonal HLA antibodies used for detection of donor HLA 
mismatched antigens. Targeted donor HLA mismatched antigens are 
highlighted in red. 
Recipient 
No. 
Donor  
HLA-A, -B and Bw 
mismatched antigens 
Human monoclonal HLA antibody 
specificity used to target the donor 
HLA mismatched antigens  
   
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
HLA- A2,3; -B44,62; Bw4 
HLA-A2, -B35 
HLA-A2; -B51,27 
HLA-A3, -B51,7 
HLA-A3,33; -B7,65 
HLA-1,11; -B7,56 
HLA-A3, 2; -B7,44, Bw4 
HLA-A1,11; -B8,62 
HLA-A1,23; -B42 
HLA-A1,3; -B57,7; Bw4 
HLA-A1,29; -B44,52 
HLA-A3; -B8 
HLA-B7,B56 
HLA-B51 
HLA-B60,B62 
HLA-A2, -B44 
HLA-A11; -B8 
HLA-A2, -B44,18 
HLA-A2; -B44,35 
HLA-A2; -B60 
HLA-A68,36; -B57,71; Bw4 
DK7C11- B12(44,45) 
SN607D8– A2/A28(68,69) 
SN607D8– A2/A28(68,69) 
OK2F3– A3 
OK2F3– A3 
VTM1F11– B27/B7/B60 
OK2F3– A3 
BVK1F9– B8 
GV5D1– A1/A9(23, 24, 2403) 
SN230G6– A2/B17(57,58) 
DK7C11– B12(44, 45) 
BVK1F9– B8 
OK6H10– B15/B21(49,50)/B56/B35/B72 
HDG8D9– B51/B35 
IND2D12– B15(62,63,75,76)/B35/B21/B70 
SN607D8– A2/A28(68,69) 
BVK1F9– B8 
SN230G6– A2/B17(57,58) 
DK7C11– B12(44,45) & HDG8D9-B51/B35 
JOK3H5- B40(60,61)/B21/B13/B12/B41 
MUS4H4– Bw4 
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3.2.4 Detection and longevity of donor CD4 T cell chimerism in recipients’ 
peripheral blood following primary lung transplantation 
 
To investigate the presence of donor CD4 T lymphocytes in the peripheral 
blood of lung transplant recipients (n=21), multiple blood samples were 
obtained in the first post-operative month and, where possible, three-monthly 
blood samples were obtained thereafter during the first year after 
transplantation. Donor CD4 T lymphocytes were detected and isolated as 
described in Sections 2.4.2 and 2.4.3.  
 
Donor CD4 T cell chimerism was detected in all recipients in the first post-
operative month as a proportion of the recipient total number of peripheral 
blood CD4 T cells. In all patients, the highest percentage of donor CD4 T cell 
chimerism detected was observed in the blood sample obtained within the first 
week after transplantation. In addition, we observed considerable variation in 
the percentage of donor CD4 T lymphocytes detected between patients, 
ranging from 0.06 to 6% of the circulating CD4 T cell population (donor and 
recipient). In addition to donor-derived CD4 T cells, we also assessed the total 
number of donor leucocytes in the recipients’ peripheral blood. The 
percentage of donor leucocytes detected ranged from 1 to 8%, suggesting 
that other cell types were also present in the recipients’ peripheral blood. 
Although, we did not characterise the whole donor leucocyte population, it is 
likely that these cells were B cell, NK cells and/or DCs. Interestingly, I 
observed that at least 50% of donor lymphocyte population were CD4 T cells 
ranging between 50 and 65%.  
 
The duration of donor CD4 T cells detectable in the recipient circulation was 
then assessed. Three patterns of donor CD4 T cell chimerism were observed:  
 
• Short donor CD4 T cell chimerism – donor CD4 T lymphocytes were 
detectable for six weeks after transplantation (n=13), 
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• Intermediate donor CD4 T cell chimerism – donor CD4 T lymphocytes 
were detectable between three and five months after transplantation 
(n=3); and, 
• Long-lasting donor CD4 T cell chimerism – donor CD4 T lymphocytes 
were detectable for more than six months after transplantation (n=5).  
 
Figure 3.2 represents one-year post-transplant follow-up for the presence and 
duration of donor CD4 T cell chimerism detectable in recipients’ peripheral 
blood after transplantation; where each dot represents the time point at which 
patients’ peripheral blood was obtained and tested for the presence of donor 
CD4 T lymphocytes. The green dot represents patients’ samples that were 
tested and donor CD4 T cells were detected, the red dot represents samples 
tested but donor CD4 T cells were not detected and the black dot shows time 
of death (n=3).    
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Figure 3.2 Detection and duration of donor CD4 T cell chimerism in lung 
transplant recipients, one-year post-transplant follow-up.  
Donor HLA class I mismatched antigens were used as a target for detection of donor CD4 T 
cell chimerism in lung transplant recipients using flow cytometry. Three patterns of donor CD4 
T cell chimerism were observed: short chimerism (donor CD4 T cells were detectable for six 
weeks after transplantation, patient 20, 8, 1, 2, 5, 6, 11, 13, 16, 17, 3, 4 and 19), intermediate 
chimerism (donor CD4 T cells were detectable between 3 and 6 months after transplantation, 
patient 9, 21 and 7), and long chimerism (donor CD4 T cells were detectable for more than six 
months after transplantation, patient 12, 15, 18, 14 and 10). Green dot - blood sample tested 
and donor CD4 T cells detected. Red dot – blood sample tested, but donor CD4 T cells were 
not detected. Black dot – patient died.      
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Interestingly, the initial proportion (detected in test samples obtained within 
the first week after transplantation) of donor CD4 T cells appeared to correlate 
with the length of time that the cells were detectable in the recipient 
circulation. Depending on the blood sample size (usually 40ml of recipient 
peripheral blood was obtained for chimerism analysis) whenever possible 
1,000,000 recipient CD4 T lymphocytes were recorded. Donor CD4 T 
lymphocytes were detected as a subpopulation of double positive (CD3/CD4) 
recipient T lymphocytes, Table 3.4 shows the initial percentage and duration 
of donor CD4 T cell chimerism in the recipients’ peripheral blood. 
 
 
Table 3.4 Initial proportion and duration of donor CD4 T cell chimerism in lung 
transplant recipients.  
  
Patient No. Initial proportion of  
donor CD4 T cell  
(%) 
Duration of 
donor CD4 T cell  
(days after transplant) 
 
1 0.059 13 
2 0.421 12 
3 0.469 55 
4 3.856 32 
5 0.767 17 
6 0.367 18 
7 0.332 101 
8 0.318 18 
9 0.544 62 
10 1.019 365 
11 0.534 24 
12 0.712 314 
13 0.167 27 
14 1.025 365 
15 0.927 314 
16 0.939 19 
17 0.821 38 
18 1.048 365 
19 5.972 27 
20 1.103 32 
21 2.821 132 
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Depending on the proportions of chimeric cells present; the terms micro- and 
macrochimerism have been used to describe chimeric populations present at 
less than 1%, or greater than 1% of the total number of cells, respectively 
[129]. Based on the percentage of donor CD4 T cell chimerism detected I 
have assessed whether the type of chimerism (macrochimerism vs 
microchimerism) has an effect on the longevity of donor CD4 T cell 
chimerism, Figure 3.3. In my study cohort donor CD4 T cell macrochimerism 
was detected in 8 patients and microchimerism was observed in 13 patients. 
Univariate analysis revealed significant association between the type of 
chimerism (macrochimerism vs microchimerism) and the longevity of donor 
CD4 T cells detectable in the recipients’ peripheral blood (log-rank; p=0.008). 
In majority of patients where macrochimerism was observed donor CD4 T cell 
were detectable for longer than 100 days post-transplant. However, the type 
of donor CD4 T cell present (macrochimerism vs microchimerism) was not 
associated with development of BOS during the first post-operative year 
(Fisher’s exact test, p=1.000).   
 
  
 
p=0.008 
Figure 3.3 Kaplan-Meier plot showing the percentage of lung transplant recipients 
with macrochimerism and microchimerism described as donor CD4 T cell chimerism 
detected in greater than 1% and less than 1%, respectively. 
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3.2.5 The levels and duration of donor CD4 T cell chimerism does not affect 
the clinical outcome of lung transplant recipients  
 
To investigate whether the percentage and the longevity of donor CD4 T cell 
chimerism was related to the incidence of rejection and the development of 
BOS, a nonparametric correlation analysis were performed.  
 
3.2.5.1 Incidence of BOS in lung transplant recipients 
 
In this study cohort, a sizable number of lung transplant recipients (33.34%) 
developed BOS grade 1 and 2 within the first postoperative year. In total, 
seven recipients developed BOS; of these, four recipients developed grade 2 
and three recipients developed BOS grade 1. At one year after the lung 
transplant, 14 recipients were free from BOS. The correlation analysis did not 
reveal an association between withers the levels or the longevity of donor 
CD4 T cell chimerism and the incidence of BOS (Spearman r, p=0.692 and 
p=0.188). Figure 3.4, shows the percentage of lung transplant recipients with 
established BOS (n=7) and recipients free from BOS (n=14) at one-year after 
transplantation. 
 
p=0.279 
 
Figure 3.4 Kaplan-Meier plot showing the percentage of lung transplant recipients 
with donor CD4 T cell chimerism who within one-year after the transplant developed 
BOS and recipients that remained free from BOS. 
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3.2.5.2 Incidence of rejection in lung transplant recipients 
 
During the first three months after transplantation, six patients (28.6%) had 
biopsy proven acute cellular rejection. Two patients had two episodes and 
four patients had one episode of acute cellular rejection. All patients were 
treated with intravenous steroids and responded well. Antibody mediated 
rejection was not observed in any of the patients. The correlation analysis 
revealed that the incidence of acute cellular rejection did not correlate with 
either the level of donor CD4 T cells detected in the recipients’ peripheral 
blood or the longevity of donor CD4 T cell chimerism (Spearman r, p=0.319 
and p=0.169, respectively).  
 
The incidence of acute rejection episodes is considered the most significant 
risk factor for development of BOS. In this cohort, only two recipients who 
experienced acute cellular rejection during the first three months post-
transplant developed BOS. One patient had two episodes and one recipient 
had one episode of acute cellular rejection; both recipients developed BOS 
grade 2. Nevertheless, the incidence of rejection did not correlate with the 
development of BOS during the first post-operative year (Spearman r, 
p=0.712). This reflects that five patients developed BOS without early acute 
rejection episode.  
 
3.2.5.3 Patient survival 
 
During the study period, two lung transplant recipients died (day 166 and day 
171 following lung transplantation), both from non-transplant related 
complications. Both were free from BOS and had a well functioning allograft at 
the time of death. One further recipient has died as a consequence of BOS 
after the post-transplant follow-up period (day 461). Figure 3.5, shows the 
percentage of patient survival at one-year after lung transplantation.  
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  p=0.257    
 
Figure 3.5 Kaplan-Meier survival curve for overall survival of lung transplant 
recipients with established BOS and recipients free from BOS. Vertical bars indicate 
censored events. P-values were based on the log-rank test on Kaplan-Meier plots.  P-value of 
<0.05 was considered statistically significant. 
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3.3 Discussion  
 
Two main findings emerged from the experiments described in this chapter. 
Firstly, it appears that the presence of donor CD4 T cell chimerism in the 
peripheral blood of lung transplant recipients is a uniform phenomenon. 
During the first post-operative month, donor CD4 T lymphocytes were 
consistently detectable in the recipients’ peripheral blood. Secondly, distinct 
patterns of donor CD4 T cell chimerism were evident the first post-operative 
year: short, intermediate and long-lasting. My findings are similar to other 
studies that have demonstrated that the dynamics of chimerism in solid organ 
transplantation fluctuates over time and vary between individual patients [171, 
172, 180].   
 
To ensure that detected CD4 T cells were of donor origin, I tested patients’ 
peripheral blood obtained prior to transplantation for the presence of pre-
existing chimerism. CD4 T cells expressing donor HLA antigens were not 
detected in the recipients’ peripheral blood prior to transplantation nor in the 
blood samples stained with third-party human HLA monoclonal antibodies, i.e. 
an HLA monoclonal antibody with specificity to an HLA antigen that is not 
expressed on both recipient and donor lymphocytes. These observations 
confirmed that detected CD4 T cells were of donor origin.  
 
To ensure clear separation between both lymphocyte populations the 
sensitivity (limit of detection) of the flow cytometric analysis was adjusted for 
each transplant pair. For this reason, the flow cytomertic analysis included 
negative control test sample (patient PBMCs obtained prior to 
transplantation), which identifies the “background staining” i.e. non-specific 
binding of the mAb used; and positive control test sample (donor lymphocytes 
obtained at the time of donation) that detects the binding capacity of the mAbs 
to the donor HLA antigens. The selection of mAbs for each patient is 
described in Chapter 2, Section 3.2.3. Tailoring of the flow cytometric analysis 
for each patient individually allowed precise detection of donor CD4 T 
lymphocytes.     
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Detection of CD4 T lymphocytes that express donor HLA antigens that are not 
of donor origin might be possible if recipient CD4 T cells have somehow 
acquired donor-derived HLA class I antigens onto their cell surface. This 
phenomenon, termed trogocytosis, has been described for dendritic cells 
(DCs) [84]. Whether CD4 T lymphocytes possess this ability is unclear. To 
test, it would be necessary to assess for expression of both donor and 
recipient HLA on the same CD4 T cell. Unfortunately, due to the limited 
amount of blood samples and the limited set of mAbs available this approach 
was not possible. Instead, I created an artificial microchimerism containing a 
known number of “chimeric cells” and flow cytometric analysis was performed. 
The “chimerism cells” were detected by two methods: positive selection where 
“chimeric cells” were targeted directly and negative selection where the main 
cell population was targeted instead of “chimeric cells”, previously described 
in Chapter 2, Section 2.4.5. The same number of “chimeric cells” were 
observed in both the positive and the negative selection methods; thus, 
uptake of soluble HLA class I antigens by donor CD4 T lymphocytes was not 
observed. These observations provide additional support that donor CD4 T 
lymphocytes detected in the recipients’ peripheral blood were truly derived 
from the donor.  
 
Although, donor CD4 T cell chimerism was detected in all patients, the 
percentage and the longevity of donor CD4 T cells detectable in the patients’ 
peripheral blood after lung transplantation varied between patients. The 
variation in the percentage of donor CD4 T cells was within the range of 
0.06% and 6%; whereas, the time-interval for which the donor CD4 T cells 
were detectable in the recipients’ peripheral blood varied between six weeks 
and one-year after transplantation. The level and the duration of donor 
chimerism detected in the first month after transplantation in lung transplant 
recipients was comparable to the study by Richter et al. [171], However, in 
their study, the donor lymphocyte population was detectable for only two to 
four weeks after transplantation. Similar findings have been reported for liver 
transplant recipients [181].  The reasons for the observed variations in both 
the levels and the longevity of donor CD4 T cells in the recipients’ peripheral 
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blood following lung transplantation in spite of the same immunosuppressive 
protocol are not apparent.  
 
I observed that 50% of donor lymphocytes detectable in the recipient 
circulation were CD4 T cells. This accords with Richter et al.’s, study [171]. 
Richter further reported detectable populations of donor–derived B and NK 
cells, whereas I did not characterise the cell types of the non-T cell donor 
lymphocyte population that was present in our cohort.   
 
In a separate study, Richter et al. have assessed the number and the type of 
lymphocytes present in discarded human lungs [139]. They have identified 
two main sources of lymphocytes; one derived from the lung associated 
lymphoid tissue (LALT) mainly comprising of resting T and B cells and the 
second cell populations derived from the lung tissue itself, comprising of 
activated lymphocyte and monocytes/macrophage population. In addition they 
observed considerable difference in the number of lymphocytes present 
between different human donor lungs [139].  
 
Taking into consideration the Richter et al. findings, it is possible that the 
observed variation in the percentage of the donor CD4 T cell chimerism 
detected is due to the nature of the donor lungs itself and, possibly related to 
both the donor history and to allograft conditioning. It has been reported that 
factors such as donor gender, age, days on ventilation and type of donor can 
affect the cell population transferred with the allograft. Increased levels of pro-
inflammatory cytokines in donors after brain-death (DBD) (in comparison to 
donors after circulatory death (DCD)) have been associated with increased 
number of lymphocytes in heart and lung allografts [182].   
 
In this cohort, 20 of the 21 patients received lungs from a DBD and only one 
patient received lung from a DCD; thus, due to the small numbers it was not 
possible to investigate whether there is a difference between both groups.  
 
Interestingly, I observed association between the donor CD4 T cells 
macrochimerism and the duration of donor CD4 T cells detectable in the 
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recipients’ peripheral blood following lung transplantation. This raises the 
question whether the longevity of donor CD4 T cell chimerism is largely a 
consequence of the level of CD4 T cells present within the lung at the time of 
transplantation or whether other factors, such as HLA mismatch, also 
influence the longevity of donor CD4 T cell chimerism in lung transplant 
recipients. 
 
Several factors that might influence the donor CD4 T cell longevity in the 
recipients’ peripheral blood have been taken into consideration. As previously 
discussed, presence of donor HSCs have been observed in the bone marrow 
of long-term liver transplant survivors [173]; nevertheless, Nerhoff et al., have 
not investigated the ability of the bone marrow derived donor HSCs to 
differentiate into different cell subsets; a phenomenon observed in mice 
models [174]. Thus, if similar mechanisms do exist in human allografts it is 
possible that the long lasting donor chimerism is associated with migration of 
passenger HSCs from within the allograft into the recipient bone marrow, 
where they can give rise to various cell types of donor origin.  
 
Previous studies have demonstrated that T cells have the ability to recirculate 
through non-lymphoid organs [136]; functionally and phenotypically these 
cells are a mixture of naïve, effector and memory T cells that express cell-
surface markers such as CCR7, LFA-1, VLA-4 and ICAM-1, that govern the 
homing to secondary lymphoid tissue and other peripheral tissues [136, 137, 
139, 183]. Migration of allograft passenger cells to non-lymphoid tissues such 
as the skin has been observed in liver [131] and kidney [165] transplant 
recipients even decades after transplantation. Thus, it is possible that rapid 
migration of donor CD4 T lymphocytes from within the allograft into other 
tissue sites might explain why, in the majority of lung transplant recipients 
(n=13), donor CD4 T lymphocytes were detectable in the recipients’ peripheral 
blood for only a few weeks after transplantation.  
 
Unfortunately, due to the nature of this study it was not possible to assess 
whether donor lungs contained HSCs and if present whether these cells have 
migrated to the recipients’ bone marrow. Similarly, I was unable to assess 
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donor CD4 T lymphocytes tissue distribution. To elucidate whether these 
factors affect the longevity of donor CD4 T cell chimerism in lung transplant 
recipients, will require further study. 
 
Donor chimerism can occasionally trigger GvHD, a condition that results as a 
consequence of immune responses of donor immunocompetent cells against 
the recipient cells. In solid organ transplantation, GvHD is a rare post-
transplant complication; nevertheless detrimental outcomes have been 
reported in liver [176, 177] and lung transplant patients [178, 179]. 
Immunogenetic discrepancies within the major and minor histocompatibility 
antigens are the main targets for allorecognition, and this response is 
bidirectional: graft vs host or host vs graft.   
 
In this cohort, all patients received HLA mismatched allografts. This raises the 
question whether the elimination of donor CD4 T lymphocytes from the 
recipients’ peripheral blood is due to recipient T and/or NK cells alloreactivity 
against donor passenger lymphocytes.  
 
The impact of the HLA and NK cell alloreactivity on the duration of donor CD4 
T cell chimerism in the recipients’ peripheral blood following primary lung 
transplantation is addressed in the following Chapter; Chapter 4.  
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3.4 Key points 
 
• Donor CD4 T cell chimerism is a uniform phenomenon that occurs in all 
lung transplant patients as a result of cell migration from within the 
allograft into the recipient peripheral blood following transplantation. 
 
• The percentage of donor CD4 T cells detected in recipients’ peripheral 
blood is extremely variable between patients.  
 
• The dynamics of donor CD4 T cell persistence in the recipients’ 
peripheral blood is different between patients, despite the fact that all 
patients were subjected to the same immunosuppressive regiment. 
 
• The longevity of donor CD4 T cells detectable in recipients’ peripheral 
blood was associated with the presence of donor CD4 T cell 
macrochimerism.   
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Determinants of longevity of donor 
CD4 T cell chimerism in lung 
transplant recipients 
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4.1 Introduction 
 
The immunological events that initiate allograft rejection, both cellular and 
humoral immune responses, occur due to allorecognition of the antigenic 
differences between the recipient and the donor major histocompatibility 
complex (MHC) proteins and minor histocompatibility antigens (mHA).  
 
Thus, allorecognition refers to detection of same-species, non-self-antigens 
by the host immune system. It is primarily driven by the ability of the recipient 
T cells to recognise both intact donor MHC molecules expressed on donor 
antigen presenting cells, known as a direct pathway of allorecognition, and 
processed donor derived MHC peptides presented in the form of self-MHC 
peptide complexes, an indirect pathway. A semi-direct pathway of 
allorecognition occurs when the recipient T cells recognise intact donor 
MHC:peptide complexes that have been acquired by the trafficking recipient 
dendritic cells (DCs) [58].  
 
In contrast to T cell allorecognition, NK cell allorecognition occurs due to lack 
of interaction between the NK cell inhibitory KIRs and a subset of MHC class I 
molecules that act as ligands for the NK cell KIRs; rather than due to the 
antigenic differences within the major histocompatibility antigens [184]. The 
main MHC class I molecules that act as ligands for NK cell inhibitory KIRs are 
HLAs, including HLA-Cw and some HLA-A and HLA-B antigens that express 
Bw4 epitope [184].  
 
4.1.1 Alloantigens  
 
Allorecognition of foreign antigens represents the main barrier for successful 
organ transplantation; the degree of alloantigen discrepancy between the 
recipient and donor pair determines the magnitude of acceptance or rejection 
of transplanted tissue and/or allograft. Broadly speaking, alloantigens are 
divided into two groups: major and minor histocompatibility antigens.  
 99 
4.1.1.1 Major histocompatibility antigens  
 
The genes that encode for MHC proteins, known as HLA, are clustered within 
the class I and class II MHC region located on the short arm of chromosome 
six [185].   
 
The MHC class I molecules are encoded by three genetic loci: HLA-A, HLA-B 
and HLA-Cw. They consist of two non-covalently linked polypeptide chains, 
alpha heavy chains anchored to the cell membrane and associated with β2-
microglobulin. The heavy chain α1 and α2 domains fold together creating a 
cleft, known as a peptide-binding site [32]. They are constitutively expressed 
on the surface of the all nucleated cells and present endogenous short (8-10 
amino acids) peptides to CD8 T cells [32, 33].  
 
The MHC class II molecules are encoded by HLA-DR, HLA-DQ and HLA-DP 
loci; they consist of two polypeptide chains, α and β both anchored to the cell 
membrane. The α1 and β1 domain form the peptide-binding site and present 
exogenous peptides (13 to 25 amino acids in length) to CD4 T cells. The class 
II molecules are constitutively expressed only on dendritic cells, macrophages 
and B cells, also known as professional antigen presenting cells [38, 39]; 
nevertheless, their expression can be induced on other cells in the presence 
of IFN-γ and TNF-α [40]. 
      
The most polymorphic region of the HLA class I and class II antigens is found 
within the α2 domain and β1 domain, respectively [39]. The extensive 
polymorphism of the HLA genes allows presentation of vast array of peptides 
derived from potentially pathogenic organisms in order to ensure efficient 
presentation and eradication of pathogens by CD8 and CD4 T cells.  
 
In transplant settings the differences within the HLA class I and class II genes 
between the recipient and donor pair limits the success of the transplant 
outcome due to the potential of triggering vigorous alloimmune responses, 
ultimately resulting in allograft rejection.   
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4.1.1.2 Minor histocompatibility antigens 
 
Any polymorphic non-MHC protein able to initiate immune responses in an 
HLA-matched recipient and donor pair is known as a minor histocompatibility 
(mH) antigen and represents a potential target for allorecognition [186]. The 
mH antigens are presented to T cells by both MHC class I and class II 
molecules.  
 
Several mH antigens have been identified that are able to elicit immune 
responses resulting in transplant rejection and/or GvHD following 
haematopoietic stem cell transplantation (HSCT); their role in solid organ 
transplantation is less convincing.  
 
The mHAs are peptides derived by genes encoded by: sex chromosome, 
autosomes and genes encoded by mitochondrial DNA (miDNA); including 
male H-Y antigens (encoded on the short arm of the Y chromosome), 
autosomal antigens such as HA-1, HA-2, HA-3, HA-8, myosin 1G, LCB 
oncogene and other; and, polymorphism in mitochondrial genes encoding for 
enzyme mt-ND1. These are the most studied mHA that have been associated 
with GvHD and graft rejection in HSCT [43, 187].  
 
4.1.2 T cell mediated alloresponses to major and minor histocompatibility 
antigens   
 
The term alloresponse is used to describe the effector arm of the immune 
system that is initiated due to allorecognition of immunogenic major and/or 
minor alloantigens. In an alloresponse the innate and adaptive immune 
system function together to reject the allograft.  
 
This Chapter focuses only on the T-cell and NK–cell mediated alloimmune 
responses. Humoral alloimmune responses are discussed in Chapter 6. 
Recognition of alloantigens by the recipient T cells; and, cognate interaction 
between the T-cell receptor (TCR) and its co-receptors CD8 or CD4 with MHC 
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class I and class II/peptide complexes, respectively, by itself does not lead to 
T cell activation. Naïve T cell activation and proliferation is dependent on the 
delivery of secondary co-stimulatory signals provided by the activated antigen 
presenting cells, manly DCs [188]. These signals are delivered via 
interactions between co-stimulatory molecules present on activated DCs such 
as B7.1 (CD80), B7.2 (CD86), CD40 and OX40 ligand and their 
corresponding receptors CD28, CD40 ligand (CD154) and OX40 expressed 
on the T cell membrane [188, 189]. These cell-cell interactions, and as a 
consequence T cell activation, take place in the T cell area of the secondary 
lymphoid organs (SLOs) such as lymph nodes or spleen [190], although there 
is increasing evidence suggesting that T cell activation can occur in the 
tertiary lymphoid organs (TLOs) [191, 192]. TLOs are non-capsulated ectopic 
lymphoid formations that display characteristics of SLOs [192].     
 
Activated CD4 helper T cells undergo proliferation, a process that is 
dependent on T cell growth factors (TCGF) such as IL-2, IL-4 and IL-5 and 
differentiation into various T cell subsets including T-helper 1 (Th1), T-helper 
2 (Th2), T-helper 17 (Th17), T follicular helper (Tfh) cell and regulatory T cell 
(Tregs); whose effector function is characterised by the type of cytokines they 
produce. CD4 T cell differentiation is described in more detail in Chapter 5.  
 
In the context of allograft rejection, the effector Th1 cells trigger activation of 
cytotoxic CD8 T cells, activation of macrophages and they provide help for B 
cell activation and synthesis of complement-fixing antibodies. In addition, CD4 
T cells may mediate cytotoxic activity via Fas-ligand/Fas receptor death 
pathway [193]. Conversely, the cytokines produced by effector Th2 cells 
trigger eosinophil activation and provide help for B cell activation and antibody 
production [194, 195].  
 
In contrast, activated effector cytotoxic CD8 T cells have the ability to directly 
kill the target cell via perforin/granzyme-mediated and Fas-mediated cell 
death pathways [196, 197]. Recognition and ligation of cytotoxic CD8 TCR 
with allo-MHC class I molecules triggers activation process, which induces 
formation of intracellular cytotoxic granules and expression of perforin and 
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granzymes. CD8 cell killing is achieved by formation of a tight junction with 
the target cells and release of the cytotoxic granules to the region of cell 
contact [198]. The perforin forms channels onto the target cell membrane, 
allowing insertion of granzyme A and B into the cell cytoplasm, leading to 
activation of a cascade of intracellular caspases resulting in DNA 
fragmentation and ultimately cell death by apoptosis [197]. These complex 
immune responses can result in allograft rejection and/or GvHD following 
HSCT.   
 
In direct and semi-direct allorecognition pathways, the CD4 or C8 T cells with 
direct allospecificity recognise conformationally intact allo-MHC molecules. 
The frequency of T cells with direct allospecificity responding to allogeneic 
MHC molecules is around 10% [59, 60]. Two hypotheses have been proposed 
to explain this phenomenon; “high determinant hypothesis” where the 
allogeneic MHC molecule itself, independent of the peptide bound, plays a 
major ligand for alloreactive T cells [61], and “multiple binary complex 
hypotheses” process driven exclusively by the peptide bound on the MHC 
molecule [62, 63]. 
 
In contrast, allorecognition of donor derived MHC peptides by the recipient T 
cells with indirect allospecificity mimics the conventional T cell response to 
foreign antigens. Thus, donor MHC molecules are first internalised, processed 
and presented as peptides bound within the self-MHC/peptide complexes 
[58].  
 
The degree of antigenic discrepancy between the donor and recipient is a 
major factor in determining the strength of the alloresponse. Thus, it has long 
been recognised that HLA matching between donor and recipient is 
associated with better allograft and patient survival; and in the case of HSCT, 
sex matching to avoid responses against H-Y mHA antigen results in better 
outcomes [199]. Nevertheless, finding non-related HLA matched tissue and/or 
organ donor has proven difficult and is not always possible and some degree 
of mismatching is typical. 
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4.1.3 HLA matching 
 
The Human Leukocyte Antigens represent the main targets for allorecognition 
in HLA mismatched transplants and the HLA discrepancies between the 
recipient and donor pair represent a limiting factor for successful solid organ 
and HSCT.  
 
In HSCT HLA matching at HLA-A, -B -Cw, -DR and -DQ loci is fundamental 
for successful clinical outcome [200]. Similarly, in renal transplantation, HLA 
matching plays an important role in organ allocation; patients who have 
received 0.0.0-mismatched kidneys referring to HLA-A, -B and -DR loci i.e. a 
fully matched kidney, have much better outcomes [201]. One-year graft 
survival rate varies from 98% vs 80% for patients that received 0.0.0 vs 2.2.2 
mismatched kidney transplant [201]. In more recent years, increased use of 
more potent immunosuppressive regiments has rendered the impact of HLA 
compatibility in renal transplantation [202]; hence, the new National kidney 
allocation criteria is not heavily based on HLA matching [50].    
 
Contrary to this, conflicting evidence has been generated supporting the 
significance of HLA matching in cardiothoracic transplantation; and, currently 
HLA matching is not taken into consideration for allocation of cardiothoracic 
organs, due to the smaller donor pool and to the requirements to limit organ 
cold ischemia.  
 
Tendrich et al., and others have demonstrated that HLA matching is not 
associated with prolonged graft survival in heart transplant recipients [51, 52]. 
In contrast, analysis from the UNOS/ISHLT Thoracic Registry showed that 
HLA matching has a beneficial impact on graft survival in heart and single-
lung transplant patients; primarily matching at HLA-A and HLA-DR loci [53]. In 
other studies, matching for HLA-A [54] or HLA-DR loci [55] has been 
associated with reduced incidence of BOS in lung transplant recipients. 
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4.1.4 Natural Killer cell mediated alloresponses 
 
NK cells are cells of the innate immune system: they mediate their effector 
function without prior exposure to antigens via a range of germline-encoded 
stimulatory and inhibiting killer-cell immunoglobulin-like (KIRs) receptors 
expressed at their cell surface [184]. The NK cell surface receptors interact 
with specific alleles of HLA class I antigens. This allows them to distinguish 
between self and non-self [184]. Two different NK cell subsets have been 
described CD56brightCD16- and CD56dimCD16+, with predominately cytokine 
producing and cytotoxic effector functions, respectively [203]. 
 
The NK cell activation is primarily controlled by a number of activating 
(KIR2DS2, KIR2DS1) and inhibitory (KIR2DL2, KIR2DL3, KIR2DL1 and 
KIR3DL1) KIRs that bind to HLA class I antigens, primarily to HLA-Cw and 
some HLA-A and HLA-B antigens that express Bw4 epitope [204]. The HLA 
class I KIR ligands have been divided into two groups based on the 
dimorphism at position 80 of the α helix within the HLA-Cw antigens: C1 
group (Cw1, 3, 7, 8, 12, 14, 1507 & 1601) ligands that contain asparagine at 
position 80 and C2 group (Cw2, 4, 5, 6, 1204, 1205, 15, 1602, 17 & 18) 
ligands containing lysine at the same position. Similarly, Bw4, a public epitope 
found on some HLA class I antigens (HLA-A24, HLA-B13, 27, 44, 51, 52, 53, 
57 and 58), contains either isoleucine or threonine at the same position [204, 
205].  
 
The inhibitory KIR2DL2 and KIR2DL3 receptors bind to HLA-Cw antigens that 
belong to the C1 group, KIR2DL1 binds to antigens belonging to the C2 
group, and KIR3DL1 is an inhibitory receptor that binds to HLA class I 
antigens that express the Bw4 epitope [204].     
 
Absence of interaction between the NK cell inhibitory KIRs and its 
corresponding HLA ligands leads to loss of NK cell inhibition, thus resulting in 
NK cell activation and target cell killing, a process termed as “missing self-
recognition” [206].  
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In the transplant setting, NK cell alloreactivity is bidirectional: graft-versus-host 
(GvH) and host-versus-graft (HvG) [207, 208]. The NK cell GvH alloreactivity 
occurs when the NK cells of the donor origin have a missing ligand for its 
inhibitory KIR receptors on the recipient cells; whereas HvG NK cell 
allorecognition occurs in the opposite manner, due to lack of engagement 
between the recipient NK cell inhibitory receptors and the appropriate ligands 
present on donor cells. 
 
Graft-versus-host NK cell alloreactivity can be beneficial, and is a strategy 
frequently adopted in HLA haplotype-mismatched (haploidentical) HSCT for 
patients with high-risk acute myeloid leukaemia (AML) [208]. In haploidentical 
HSCT, NK-alloreactive donors are selected based on the “missing-self” 
recognition, where donor NK cells express both the inhibitory KIR and its 
corresponding HLA class I ligand, but this HLA class I ligand is absent on 
recipient cells. Transplantation from NK-alloreactive donors has been 
associated with reduced leukaemia relapse rate, lack of GvHD and improved 
event free survival [209].        
 
The role NK cell alloreactivity in solid organ transplantation is less clear. The 
effect of NK cell alloreactivity on graft survival rates was examined in a study 
of 2,757 kidney transplant recipients [210], where KIR ligand incompatibility 
was determined based on the presence or absence of KIR ligand epitopes for 
C1 group, C2 group and Bw4 between the donor and recipients. The 10-year 
graft survival rates were comparable between all patient groups [210]. 
However, in this study the degree of HLA mismatching between the donor and 
recipients was not examined.  
 
Van Bergen et al. undertook a similar study where the role of KIR ligand 
mismatching was assessed in an HLA compatible (HLA-A, -B & -DR) kidney 
transplants and transplants compatible for HLA-DR but not for HLA-A and 
HLA-B antigens [211]. They have showed that the presence of one or more 
KIR ligand mismatches in HLA compatible kidney transplants was associated 
with reduced 10-year graft survival rates from 81% to 59%; whereas, KIR 
ligand mismatching did not affect the graft survival rates in HLA-A and/or 
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HLA-B incompatible (mismatched) transplants [211]. This is the first clinical 
study that showed that KIR ligand incompatibility might hamper the success of 
HLA compatible solid organ transplants.            
 
Moreover, in murine transplant models several studies have reported the role 
of NK cells in the induction of tolerance [212] and rejection [213]. Yu et al., 
have shown that long-term skin allograft survival was achieved in mouse 
model by rapid clearance of donor passenger APCs by the host NK cells; 
while, depletion of host NK cells prior to skin transplantation led to prolonged 
survival of donor APCs and rapid skin allograft rejection [212].      
 
Recent evidence suggests that NK cells contribute to rejection of human lung 
transplants. The NK cell frequency in patients’ peripheral blood at 3 months 
after lung transplantation was shown to be significantly lower in comparison to 
the NK cell frequency present at the time of transplantation and in healthy 
controls [214]. Furthermore, the number of CD56bright NK cell phenotypes, 
cytokine-producing NK cells, has been observed to be increased in the 
bronchoalveolar lavage (BAL) of patients experiencing acute rejection and/or 
CMV reactivation [214]. It remains unclear, however, whether NK cells play a 
direct causative role and/or amplify the proinflammatory local environment in 
the lungs.  
 
Moreover, Fildes et al., have shown that patients with bronchiolitis obliterans 
syndrome have predominantly activated NK cell phenotype in the peripheral 
blood when compared with stable patients; and they have observed a 
significant increase in the number of NK cells in the lung tissue itself [215].  
 
In contrast, in a separate study of 48 lung transplant patients, the 
development of BOS was not associated with KIR ligand mismatching [216]; 
but instead with the KIR haplotype. Patients carrying a KIR haplotype A were 
more likely to develop BOS in comparison to patients carrying KIR haplotype 
B or haplotype AB [216].     
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In lung transplantation, recipient-versus-donor (RvD) NK cell alloreactivity has 
been studied in relation to the incidence of allograft rejection and the 
incidence of BOS, with conflicting results. The impact of NK cell alloreactivity 
on the development and duration of circulating donor chimerism has not been 
examined.   
 
Having identified considerable variation in the extent and duration of 
circulating donor CD4 T cell chimerism between different lung transplant 
recipients (Chapter 3), the experimental work in this chapter addresses 
whether the duration of donor CD4 T cell chimerism is determined by the 
degree of HLA mismatching or by RvD NK cell alloreactivity. 
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4.2  Results  
 
4.2.1 Does HLA mismatching affect the duration of donor CD4 T cell 
chimerism detectable in the peripheral blood of primary lung transplant 
recipients?  
 
To address the question of whether the duration of donor CD4 T cell 
chimerism detectable in the recipients’ peripheral blood following lung 
transplantation is influenced by the HLA incompatibility, the degree of HLA 
mismatching for HLA-A, -B and -DR loci between the recipients and their 
donors was assessed.   
 
Genomic DNA was extracted and used as a template for HLA genotyping for 
each patient and their respective donor prior to transplantation. The HLA 
genotyping was performed using low/medium resolution in-house PCR-SSP 
methodology which utilises a panel of oligonucleotide primer mixes specific for 
amplification of HLA-A, -B, -Cw, -DRB1, -DRB3, -DRB4, -DRB5 and –DQB1 
alleles, previously described in Section 2.6.1 and Section 2.6.2.  
 
Following the assessment of the amplified PCR products the HLA genotype 
was identified and the degree of the HLA mismatched grade was established 
for each recipient and donor pair in this cohort (n=21). Table 4.1 represents 
the HLA genotype of each recipient and donor pair for HLA-A, -B and -DR 
antigens, highlighting the donor mismatched HLA antigens.  
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Table 4.1 Human leucocyte antigen (HLA) A, B and DR genotype (presented as 
serological equivalent) of lung transplant recipients and their corresponding 
donors using PCR-SSP methodology. Donor HLA mismatched antigens are 
highlighted in red.  
 
Patient No. Recipient HLA-A; -B; -DR  Donor HLA-A; -B; DR 
 
1 HLA-A1, 32; -B8; DR103, 17 HLA-A2, 3; -B44, 62; DR13, 15 
2 HLA-A25, 26; -B8, 57; DR17, 7 HLA-A2; -B8, 35; DR17, 11 
3 HLA-A1, 3; -B7, 57; DR1, 7 HLA-A2; -B51, 27; DR11, 16 
4 HLA-A24, 25; -B62, 37; DR4, 10 HLA-A3, 24; -B51, 7; DR15 
5 HLA-A2; -B44, 61; DR7, 13 HLA-A3, 33; -B7, 65; DR1, 17 
6 HLA-A3; -B51, 65; DR17, 4 HLA-A1, 11; -B7, 56; DR1, 4 
7 HLA-A1, 68; -B8, 65; DR15, 17 HLA-A2, 3; -B7, 44; DR7, 15 
8 HLA-A2, 24; -B7, 44; DR15, 16 HLA-A1, 11; -B8, 62; DR17, 13 
9 HLA-A2, 30; -B7, 44; DR15, 4 HLA-A1, 23; -B44, 42; DR18, 14 
10 HLA-A24, 68; -B8, 62; DR103, 7 HLA-A1, 3; -B7, 57; DR7, 15 
11 HLA-A2, 24; -B65, 57; DR13, 7 HLA-A1, 29; -B52, 44; DR15, 7  
12 HLA-A1, 32; -B7, 55; DR4 HLA-A1, 3; -B7, 8; DR17, 4 
13 HLA-A1, 2; -B51, 8; DR1, 17 HLA-A2; -B7, 56; DR1, 15 
14 HLA-A2, 23; -B8, 44; DR13, 10 HLA-A2; -B51, 44; DR4, 11 
15 HLA-A2, 24; -B7, 44; DR103, 13 HLA-A2, 24; -B60, 62; DR4, 13 
16 HLA-A3, 32; -B51, 62; DR1, 13 HLA-A2; -B44; DR11, 15 
17 HLA-A1, 2; -B7; DR1, 13 HLA-A1, 11; -B7, 8; DR15, 17 
18 HLA-A24, 31; -B62, 51; DR15,13 HLA-A2; -B44, 18; DR7, 11 
19 HLA-A1, 3; -B7, 57; DR1, 15 HLA-A2, 3; -B44, 35; DR4, 11 
20 HLA-A1, 3; -B8, 27; DR1, 17 HLA-A2; -B27, 60; DR4, 13 
21 HLA-A2, 3; -B7, 62; DR8 HLA-A68, 36; -B57, 71; DR17, 13 
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The majority of patients in this study group received poorly matched grafts; 
none of the patients received 0.0.0 mismatched primary lung transplant for 
HLA-A,  -B and -DR. Of 21 patients, three patients were matched for HLA-A, 9 
patients had one and 9 patients had two HLA-A mismatched antigens.  
 
In contrast, all patients in this study group were mismatched at a minimum 
one allele for HLA-B and HLA-DR. Seven patients had one mismatched HLA-
B antigen and 14 patients had two HLA-B mismatched antigens. The number 
of patients mismatched for HLA-DR was similar: 8 patients had one and 15 
patients had two HLA-DR mismatched antigens, Table 4.2 represents a 
summary of the number and the percentage of patients that received donor 
HLA mismatched primary lung transplant for HLA-A, HLA-B and HLA-DR 
antigens.     
 
 
Table 4.2 Number and percentage of patients that received donor HLA 
mismatched primary lung transplant for HLA-A, -B and -DR antigens.  
Donor HLA mismatched 
antigens (HLA-A, -B, -DR) 
Number and percentage of patients with 
mismatched donor HLA antigens  
n = 21 (%) 
 
HLA-A 
0 
1 
2 
 
3 (14.3) 
9 (42.8) 
9 (42.8) 
HLA-B 
0 
1 
2 
 
0 (0) 
7 (33.4) 
14 (66.4) 
HLA-DR 
0 
1 
2 
 
0 (0) 
8 (38.1) 
13 (61.9) 
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All patients (n=21) received allografts mismatched at minimum three out of six 
HLA antigens for HLA-A, -B and -DR. Only three patients were matched for 
HLA-A and none of the patients were fully matched for HLA-B or HLA-DR. 
Nearly half of the patients in this cohort received fully mismatched lung 
transplants; 8 patients were mismatched at six out of six HLA antigens and 4 
patients were mismatched at five out of six HLA antigens (Figure 4.1). 
 
In this study the relationship between HLA mismatching, and the duration of 
donor CD4 T cell chimerism was analysed separately for each locus (HLA-A, -
B and -DR). Based on the number of HLA mismatched antigens (0, 1 or 2) for 
each locus, patients were separated into three groups: patients with zero, 
patients with one and patients with two mismatched HLA antigens individually 
for HLA-A, -B and -DR.  
 
Univariate analysis did not reveal an association between the number of HLA 
mismatched antigens for HLA-A (p=0.493), (Figure 4.1, A) -B (p=0.839) 
(Figure 4.1, B) and -DR (p=0.841) (Figure 4.1, C) locus and the duration of 
donor CD4 T cell chimerism in the peripheral blood of lung transplant 
recipients following transplantation. 
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A) 
  p=0.493 
B) 
  p=0.839 
C) 
  p=0.841 
 
 
Figure 4.1 Impact of human leukocyte antigen (HLA); HLA-A, HLA-B 
and HLA-DR mismatching on the duration of donor CD4 T cell 
chimerism detectable in the recipients’ peripheral blood following 
primary lung transplantation. A) Number of HLA-A mismatched antigens, 
B) Number of HLA-B mismatched antigens and C) Number of HLA-DR 
mismatched antigens. P-values were based on the log-rank test on Kaplan-
Meier plots. P-value of <0.05 was considered statistically significant. 
 
 
Time after transplantation (Days)
% 
of
 p
at
ie
nt
s 
w
ith
 c
hi
m
er
is
m
0 100 200 300 400
0
20
40
60
80
100 0 HLA-A (n=3)
1 HLA-A (n=9)
2 HLA-A (n=9)
Time after transplantation (Days)
%
 o
f p
at
ie
nt
s 
w
ith
 c
hi
m
er
is
m
0 100 200 300 400
0
20
40
60
80
100 0 HLA-B (n=0)
1 HLA-B (n=7)
2 HLA-B (n=14)
Time after transplantation (Days)
%
 o
f p
at
ie
nt
s 
w
ith
 c
hi
m
er
is
m
0 100 200 300 400
0
20
40
60
80
100 0 HLA-DR (n=0)
1 HLA-DR (n=8)
2 HLA-DR (n=13)
 113 
The cumulative effect of HLA mismatched antigens for HLA-A, -B and -DR 
was also assessed. Based on the total number of HLA mismatched antigens 
patients were separated into three groups: patients with zero to two 
mismatched antigens (n=0), patients with three to four mismatches (n=9) and 
patients with five and six mismatched antigens (n=12). Univariate analysis did 
not reveal an association between the total number of HLA mismatched 
antigens for HLA-A, -B and -DR and the duration of donor CD4 T cells 
detectable in the recipients’ peripheral blood following lung transplantation 
(p=0.867), Figure 4.2. In addition, the number of HLA mismatched antigens 
was not associated with the incidence of acute cellular rejection and 
development of BOS within the first year after transplantation (Fisher’s exact 
test, p=1.000 and p=1.000, respectively).  
 
     
 
   
 
                                                                                                                                    p=0.867 
 
Figure 4.2 Cumulative effect of the human leukocyte antigen (HLA) (HLA-A, -B 
and –DR) mismatching on the duration of donor CD4 T cell chimerism 
detectable in the recipients’ peripheral blood following primary lung 
transplantation. P-values were based on the log-rank test on Kaplan-Meier plots. P-value 
of <0.05 was considered statistically significant. 
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4.2.2 Does NK cell alloreactivity affect the duration of donor CD4 T cell 
chimerism detectable in the peripheral blood of primary lung transplant 
recipients?  
 
To address the question of whether the duration of donor CD4 T cell 
chimerism detectable in the peripheral blood of primary lung transplant 
recipients is influenced by host NK cell alloreactivity, the presence and/or 
absence of RvD NK cell alloreactivity for each recipient and donor pair was 
predicted based on the “missing-self” hypothesis, previously described in 
Section 2.6.3.1.  
 
To predict the RvD NK cell alloreactivity the recipients and their donors were 
genotyped for HLA-Cw alleles and the Bw4 epitope using genomic DNA as a 
template for PCR-SSP, as described in Section 2.6.1 and Section 2.6.2. In 
addition, the recipients were also genotyped for presence of the inhibitory KIR 
genes including KIR2DL1, KIR2DL2, KIR2DL3 and KIR3DL1. The KIR gene 
content was analysed using high-throughput technology known as quantitative 
qKAT, described in Section 2.6.3.  
 
Recipient-versus-donor NK cell alloreactivity was expected if there was at 
least one KIR-ligand mismatch between the recipient and donor pair. Thus, 
KIR-ligand mismatch signifies the presence of a minimum one inhibitory KIR 
(KIR2DL1, KIR2DL2, KIR2DL3 and/or KIR3DL1) that during NK cell 
development has been educated to interact with “self” HLA ligand and 
presence of “self” HLA ligand (C1, C2 and/or Bw4) on the recipient cells; and, 
absence of the HLA ligand (C1, C2 and/or Bw4) on the donor cells. Under 
these conditions NK cell expressing an inhibitory KIR biding “self” HLA can be 
activated when challenged will allogeneic cells lacking an HLA ligand for the 
inhibitory receptor. Table 4.3 demonstrates a schematic description of the 
KIR-ligand mismatch definition. 
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Table 4.3 KIR-ligand mismatch definition. (Table adapted from van Bergen et al., 
2011) 
 
 
KIR-ligand mismatch definition applies only under the circumstances when a 
particular inhibitory KIR (KIR2DL1, KIR2DL2, KIR2DL3 and/or KIR3DL1) and 
its corresponding ligands are present on the recipient NK cells and at the 
same time the ligand is absent on the donor cells. It is essentially four 
examples where KIR inhibitory ligand mismatching occurs and is functional for 
recipient against donor, Table 4.3. Absence of inhibitory signalling will allow 
activating NK cell receptors to cause NK cell degranulation and target cell 
killing.  
 
Based on the KIR-ligand mismatch definition for each recipient and donor pair 
in this study (n=21), RvD NK cell alloreactivity was assessed. Table 4.4 shows 
the recipient and donor HLA class I genotype and its segregation into three 
groups based on the dimorphism at position 80 of the α helix within the HLA-
Cw antigens and the Bw4 epitope ((C1, C2 and Bw4), HLA class I segregation 
is described in Section 4.1.4), recipients’ inhibitory KIR genotype and 
predicted RvD NK cell alloreactivity for each recipient and donor pair. 
Recipient KIR gene content highlighted in red represents presence of KIR 
genes that were expected to have been educated during the NK cells 
development i.e. licenced to recognise “self” (recipient cells contain both the 
KIR gene and its corresponding ligand).  
 
 
 
Recipient  Donor  Inhibitory  
KIR-ligand    KIR                         HLA HLA 
KIR2DL1/C2 
KIR2DL2/C1 
KIR2DL3/C1 
KIR3DL1/Bw4 
KIR2DL1 + 
KIR2DL2 + 
KIR2DL3 + 
KIR3DL1 + 
C2 + 
C1 + 
C1 + 
Bw4 + 
C2 – 
C1 – 
C1 – 
Bw4 – 
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Table 4.4 Predicted recipient versus donor (RvD) NK cell alloreactivity based on the “missing-
self” theory. This Table shows the recipient and donor HLA class I genotype its segregation into C1 group, C2 
group and Bw4, recipients’ inhibitory KIR genotype and predicted RvD NK cell alloreactivity.  
 
Patient 
No. 
Recipient  
HLA-Cw / Bw4 
epitope 
Recipient HLA-
Cw groups  
(C1*, C2**) and 
Bw4*** 
Recipient KIR^ gene 
content (2DL1, 2DL2, 
2DL3, 3DL1)^^ 
 
Donor  
HLA-Cw / 
Bw4 epitope 
Donor HLA-Cw 
groups 
(C1*, C2**) and 
Bw4*** 
Predicted 
RvD’ NK” 
cell allo-
reactivity 
(Yes / No) 
1 Cw7, - / - C1  2DL1, 2DL3, 3DL1 Cw5, 6 / Bw4 C2, C2, Bw4 Yes  
2 Cw6, 7 / Bw4 C1, C2, Bw4 2DL1, 2DL2, 2DL3, 3DL1 Cw7, 4 / - C1, C2 No 
3 Cw7, 6 / Bw4 C1, C2, Bw4 2DL1, 2DL2, 2DL3, 3DL1 Cw15, 1/ Bw4 C2, C1, Bw4 No 
4 Cw9, 6 / Bw4 C1, C2, Bw4 2DL2, 3DL1 Cw16, 7/ Bw4 C2, C1, Bw4 No  
5 Cw16, 2 / Bw4 C1, C2, Bw4 2DL1, 2DL2, 2DL3, 3DL1 Cw7, 8 / - C1, C1 No 
6 Cw15, 8 / Bw4 C2, C1, Bw4 2DL1, 2DL2, 2DL3, 3DL1 Cw15, 1  / -  C2, C1 No  
7 Cw7, 8 / - C1, C1  2DL1, 2DL3, 3DL1 Cw7, 5 / Bw4 C1, C2, Bw4 No 
8 Cw7, - / Bw4 C1, Bw4 2DL1, 2DL3, 3DL1 Cw9, 7 / - C1, C1 No  
9 Cw7, 5 / Bw4 C1, C2, Bw4 2DL1, 2DL2, 2DL3, 3DL1 Cw7, 17/ Bw4 C1, C2, Bw4 No 
10 Cw7, 9 / - C1, C1 2DL1, 2DL3, 3DL1 Cw7, 6 / Bw4 C1, C2, Bw4 No 
11 Cw8, 6 / Bw4 C1, C2, Bw4 2DL1, 2DL2, 2DL3, 3DL1 Cw12, 16/Bw4 C1, Bw4 No 
12 Cw7, 9 / - C1, C1 2DL1, 2DL3, 3DL1 Cw7, - / - C1 No 
13 Cw1, 7 / Bw4 C1, C1, Bw4 2DL1, 2DL2, 2DL3, 3DL1 Cw1, 7 / - C1, C1 No  
14 Cw7, 4 / Bw4 C1, C2, Bw4 2DL1, 2DL2, 2DL3, 3DL1 Cw15, 5 / Bw4 C2, C2, Bw4 No  
15 Cw7, 5 / Bw4 C1, C2, Bw4 2DL2, 3DL1 Cw10, 9 / - C1, C1 No  
16 Cw1, - / Bw4 C1, Bw4 2DL1, 2DL2, 2DL3, 3DL1 Cw5, 7 / Bw4 C2, C1, Bw4 No 
17 Cw7, - / - C1 2DL1, 2DL2, 3DL1 Cw7, - / - C1 No 
18 Cw9, 15 / Bw4 C1, C2, Bw4 2DL1, 2DL3, 3DL1 Cw7, 16 / Bw4 C1, C1, Bw4 No 
19 Cw7, 6 / Bw4 C1, C2, Bw4 2DL1, 2DL3, 3DL1 Cw5, 4 / Bw4 C2, C2, Bw4 No  
20 Cw7, 1 / Bw4 C1, C1, Bw4 2DL1, 2DL2, 2DL3, 3DL1 Cw2, 10 / Bw4 C2, C1, Bw4 No 
21 Cw7, 1 / - C1, C1 2DL1, 2DL2, 2DL3, 3DL1 Cw2, 10 / Bw4 C2, C1, Bw4 No 
 
 
KIR^ – Killer-cell Immunoglobulin-like Receptors. 
2DL1, 2DL2, 2DL3, 3DL1^^ – inhibitory killer-cell immunoglobulin-like receptors. 
C1* group: HLA-Cw antigens that contain asparagine at position 80 of the α helix includes: Cw1, 3, 7, 
8, 12, 14, 1507 and 1601, ligands for KIR2DL2 and KIR2DL3. 
C2** group: HLA-Cw antigens that contain lysine at position 80 of the α helix includes: Cw2, 4, 5, 6, 
1204, 1205, 15, 1602, 17 and 18, ligands for KIR2DL1.   
Bw4***: public epitope found on some HLA class I antigens including: HLA-A24, B13, B27, B44, B51, 
B52, B53, B57 and B58 containing either isoleucine or threonine at 80 of the α helix, ligands 
for KIR3DL1. 
RvD’ – Recipient-versus-Donor. 
NK” – Natural killer cells. 
Dash ( - ) – presence of gene and/or epitope not detected.  
KIR genes highlighted in red – represent KIRs that were expected to have been educated during 
NK cell development i.e. licenced to recognise “self” (recipient cells contain both KIR gene 
and its corresponding ligand).   
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Twenty of 21 patients were matched for KIR-ligand, and only one patient was 
KIR-ligand mismatched. Thus, RvD NK cell alloreactivity was expected only in 
one patient that received a primary lung transplant from a donor that did not 
carry a ligand for the recipient inhibitory KIR.  
 
Patient one was genotyped as Cw7 (HLA-Cw antigen that belongs to the C1 
group) and was a carrier of the inhibitory KIR2DL1, KIR2DL3 and KIR3DL1, 
that ligate with HLA-Cw antigens belonging to C2 group, C1 group and Bw4 
epitope, respectively. However, the recipient contains an HLA ligand only for 
KIR2DL3 gene; thus KIR2DL3 is the only gene that is assumed to have been 
educated during NK cell development i.e. licensed to recognise “self”, Table 
4.4. The donor for this recipient was genotyped as Cw5 and Cw6: both belong 
to the C2 group and the Bw4 epitope. Thus, RvD NK cell alloreactivity was 
expected due to the absence of inhibitory KIR2DL3 ligand (HLA C1 ligand) on 
the donor cells; instead, the donor HLA-Cw antigens (Cw5 and Cw6) are 
ligands for KIR2DL1 and KIR3DL1 receptors, respectively. Under these 
circumstances absence of signalling through the inhibitory NK cell receptors is 
expected to trigger NK cell activation and donor CD4 T cell killing.   
 
In my study cohort RvD NK cell alloreactivity was expected only in the 
recipient-donor pair; thus, it was not possible to separate the patients into a 
group where NK cell alloreactivity is expected (n=1) and a group where NK 
cell alloreactivity was not expected (n=20).  
 
To investigate whether the strength of inhibition has an effect on the 
chimerism longevity, I separated the patient into two groups based on number 
of inhibitory KIR-ligands present in the RvD direction; group one contained 
between 1 and 2 inhibitory KIR-ligands (n=12) and group two contained 3 or 4 
inhibitory KIR-ligands (n=8). Univariate analysis revealed that the number of 
inhibitory KIR-ligands was not associated with the longevity of donor CD4 T 
cell chimerism in the recipients’ peripheral blood after primary lung 
transplantation, (log-rank: p=0.290, Figure 4.3).   
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                                                                                                                                                       p=0.397 
 
Figure 4.3 Impact of the number of inhibitory KIR-ligand on the duration of 
donor CD4 T cell chimerism detectable in the recipients’ peripheral blood 
following primary lung transplantation. For definition of KIR-ligand mismatches see 
Table 4.3. Vertical bars indicate censored events. P-values were based on the log-rank test 
on Kaplan-Meier plots.  P-value of <0.05 was considered statistically significant. 
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4.3 Discussion  
 
Clinical evidence showing the profound impact of HLA matching in renal 
transplantation and HSCT has influenced organ and tissue allocation; 
consequently, HLA matching for HLA-A, B- and -DR and HLA-A, -B, Cw, -DR 
and -DQ is a critical aspect determining kidney and HSCT allocation, 
respectively [200, 201]. In contrast, HLA matching in lung transplantation has 
not become clinical practice mainly due to the smaller donor pool, shorter 
ischemia time and patients’ clinical urgency for transplantation. Instead, 
matching of the lungs is based on ABO compatibility and the size of the organ 
irrespective of the clinical evidence showing that HLA mismatching has a 
beneficial impact on graft survival, incidence of rejection and development of 
BOS [53-55]; consequently, most lung transplant recipients receive poorly 
matched organs.  
 
Similar findings were observed in this study cohort: 12 out of 21 patients 
received lungs mismatched at minimum five loci for HLA-A, -B and -DR and 
none of the patient in this cohort received fully matched lungs (Table 4.1 and 
Figure 4.2). In addition, my analysis did not reveal an association between the 
degree of HLA mismatching and the longevity of donor CD4 T cells 
chimerism, either when the HLA antigens were assessed (HLA-A, HLA-B and 
HLA-DR) individually or as well as for the cumulative effect of all HLA 
mismatched antigens. To my knowledge, this is the first study that has 
assessed the impact of HLA mismatching on the development and duration of 
donor CD4 T cell chimerism following lung transplantation.  
 
In solid organ transplantation, matching for HLA-Cw has been overlooked due 
the lack of evidence supporting the impact of HLA-Cw matching on the clinical 
outcome [217, 218]; presumably due to the lower cell surface expression in 
comparison to HLA-A and HLA-B [219].  
 
Nevertheless, taking into consideration that HLA-B and HLA-Cw antigens are 
in strong linkage disequilibrium (a non-random association between alleles 
that are encoded at neighbouring loci), it is expected that most transplant 
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pairs that are mismatched for HLA-B will be mismatched for HLA-Cw 
antigens, as it has been reported to occur in approximately 50% of kidney 
transplant pairs [211]. Comparable observation was made in this study cohort 
where more than half of the patients (n=12) were mismatched at both HLA-Cw 
alleles.  
 
In addition to antigen presentation, the main role of the HLA-Cw antigens is to 
provide protection against cell lysis by the NK cells [220] via interaction with 
the inhibitory KIR receptors expressed on the NK cell membrane. HLA-Cw 
antigens represent the main ligands for KIRs and regulate NK cell activation. 
Extensive work has been undertaken to characterise the specificity of KIR-
ligands interactions; and, currently KIR-ligand mismatching has become a 
widely used approach to treat patients with high-risk AML in an HLA 
haplotype-mismatched HSCT in the hope of achieving graft-vs-leukaemia 
effect [207, 208].  
 
I adopted the inhibitory KIR-ligand mismatching approach to assess possible 
associations between the predicted NK cell alloreactivity (Table 4.3) and 
longevity of donor CD4 T cell chimerism in the recipients’ peripheral blood 
following primary lung transplantation. The analysis revealed that in my study 
cohort NK cell alloreactivity was expected only in transplant pair (patient No 1, 
Table 4.4); thus, based on a small number further analysis were not possible. 
Instead, I have assessed whether the cumulative number of inhibitory KIR-
ligands are more efficient at prolonging the survival of donor CD4 T cells in 
recipients’ peripheral blood (Figure 4.3). My data did not reveal differences in 
the duration of donor CD4 T cell chimerism between the two groups of 
patients.   
 
In kidney transplant patients, KIR-ligand mismatching is associated with 
reduced long-term graft survival only in HLA compatible transplant pairs, but 
does not have any effect in patients mismatched for HLA-A, -B and/or -DR 
[211]. It is believed that the impact of KIR-ligand mismatching is “unmasked” 
in the absence of HLA incompatibility between the transplant pair. In 
comparison, considering that HLA matching is not part of the lung allocation 
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criteria; majority of lung transplant recipients receive poorly matched lungs. As 
a consequence it would be very difficult to construct large enough cohort to 
assess the KIR-ligand mismatching in isolation of HLA mismatches. 
Unfortunately, due to the small number of patients in my study cohort I was 
not able to assess the impact of NK cell alloreactivity on the duration of donor 
CD4 T cell chimerism in HLA mismatched lung transplant recipients.  
 
It should also be noted that although predicting NK cell alloreactivity based on 
inhibitory KIR-ligand mismatching (as adopted in this study) is widely used in 
HSC transplantation, this approach has its own limitations. Firstly, in this 
cohort, recipient-versus-host NK cell alloreactivity was predicted by HLA 
genotyping the recipient and their donor, and by genotyping the recipient’s 
KIR ligands. This approach is indicative of in vivo NK alloreactivity but does 
not prove that the repertoire of each KIR encoded is also expressed on the 
NK cell membrane. It has been reported that KIR cell surface expression is in 
direct correlation with the encoded KIR gene content [221], but not all NK cells 
express the encoded KIR genes. It is now known that only a fraction of the 
total number of NK cells express a set of inhibitory KIR receptors [209, 221, 
222].  
 
Furthermore, the number and percentage of NK cell subsets (CD56dim – 
cytotoxic NK cells vs CD56bright – cytokine producing NK cells) vary between 
individuals [203]; and, the number and function of both can be affected by the 
use of current immunosuppressive therapy [223-225]. It has been reported 
that patients treated with anti-thymocyte globulin have an altered fraction of 
NK cells expressing KIRs; however, de novo KIR receptor expression has not 
been observed to occur in renal transplant recipients [224].   
 
Lastly, another feature that NK cells exhibit is the requirement for inhibitory 
KIR receptor “licensing”. Development of functionally competent NK cell is 
dependent on the inhibitory KIR “licensing” by self-MHC class I molecules 
which involves interaction between NK cell inhibitory KIRs and its 
corresponding self-MHC class I molecule, a process that enables them to 
discriminate self from non-self [226, 227]. NK cells that do not undergo this 
 122 
process are self-tolerant but functionally incompetent [228]; such cells will 
therefore not necessarily kill target cells that lack expression of the inhibitory 
MHC class I ligand. In addition, the level of KIR gene expression varies 
between different NK cell subsets (CD56dim – cytotoxic NK cells vs CD56bright 
cytokine producing NK cells); and, it has been implicated that CD56bright do not 
express KIRs. Analysis of peripheral blood of 20 healthy individuals have 
revealed that inhibitory KIRs such as CD158a (KIR2DL1), CD158B 
(KIR2DL2/L3) NKB1 (KIR3DL1) are almost exclusively expressed on CD56dim 
NK cells but not on CD56bright NK cells [229]; whereas expression of activating 
receptors (CD94/NKG1 and CD161) were found on both NK cell subsets and 
higher expression of CD94/NKG1 has been observed in CD56bright NK cells 
[229]. In my study the analysis of KIR gene content showed that all patients 
(n=21) carry different combination of inhibitory KIRs (KIR2DL1, KIR2DL2, 
KIR2DL3 and KIR2DL1), Table 4.4; suggesting presence of CD56dim NK cell 
population. Nevertheless, presence of CD56bright NK cells population cannot 
be excluded. Considering the frequency of the inhibitory KIR genes in different 
populations [148, 230, 231], it is not surprising that in my cohort all recipients 
contained at least two inhibitory KIR genes and at least one KIR gene was 
expected to have been licenced to recognise “self”; presence of KIR3DL1 
gene was detected in all patients (Table 4.4).      
 
Unfortunately, due to insufficient samples available the NK cell numbers, NK 
cell subsets and inhibitory KIR receptor expression pre- and post-transplant 
were not studied. Nevertheless, none of these NK cell features can be ruled 
out as potential factors that may influence the threshold for NK cell 
alloreactivity and consequently its impact on the duration of donor CD4 T cell 
chimerism in lung transplant recipients. In addition, it has to be stressed that 
the number of participants in this study is very small to reach firm conclusion 
including negative findings.  
 
My observations did not reveal an association between both the NK cell 
alloreactivity and the HLA mismatching and the longevity of donor CD4 T cell 
chimerism detectable in the peripheral blood of primary lung transplant 
recipients. Nevertheless, these observations have raised additional questions 
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regarding the type of donor CD4 T cell present in the recipients’ peripheral 
blood as well as their state of maturation.   
 
These questions are addressed in the following Chapter 5. Using a molecular 
gene expression profiling approach, I investigated whether there was a 
difference between the type of donor CD4 T cells present in the peripheral 
blood of patients with short chimerism (defined as donor CD4 T cells 
detectable for less than six weeks after transplantation) and patients with long 
chimerism (defined as donor CD4 T cells detectable for more than six months 
after transplantation).   
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4.4 Key points 
 
• The degree of HLA mismatching does not affect the duration of donor 
CD4 T cell chimerism detectable in the recipients’ peripheral blood 
following primary lung transplantation.  
 
• NK cell alloreactivity (based on the presence of KIR-ligand 
mismatches) was expected only in one transplant pair; thus, I was not 
able to assess the impact of NK cell alloreactivity on the duration of 
donor CD4 T cell chimerism in HLA mismatched lung transplant 
recipients. 
 
• The cumulative number of inhibitory KIR-ligand was not associated 
with the longevity of donor CD4 T cell chimerism detectable in the 
peripheral blood of lung transplant recipients.  
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5 Chapter 5 
 
 
 
Characterisation of donor CD4 T 
cell subsets 
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5.1 Introduction  
 
Common lymphoid progenitors generated from hematopoietic stem cells in 
the bone marrow that migrate to the thymus give rise to ether CD4 helper T 
cells or CD8 cytotoxic T cells. At point of entry into the thymus, lymphoid 
progenitors are characterised by cell surface expression of CD44 (thymus 
homing cell adhesion molecule that regulates early T-cell development) [232] 
and lack expression of T cell receptor complex (α/βTCR/CD3-), CD25 CD8 
and CD4 [233], termed as double negative thymocytes. Four key processes 
characterise thymic T cell development: death by neglect; negative selection; 
positive selection; and lineage-specific differentiation into mature CD4 or CD8 
T cells that are then released into the circulation (reviewed in Germain, 2002 
[233] and Singer et.al., 2008 [234]). In addition, a small fraction of natural 
regulatory T cells (nTregs) and Natural killer T cells (NKT) are also generated 
in the thymus [235]. Once released into the blood stream, they recirculate 
through peripheral lymphoid organs, where they can encounter target ligand 
and undergo antigen-mediated effector differentiation. Activation of naïve T 
cells is reviewed in Chapter 1 and Chapter 4.  
 
Effector CD4 T cell subtypes can be defined by their composition of cell 
surface markers, the transcription factors they express, and the type of 
cytokines they produce. Thus, CD4 T cells have been characterised into five 
distinct subtypes: T-helper 1 (Th1); T-helper 2 (Th2); T-helper 17 (Th17); T 
follicular helper (Tfh); and regulatory T cells (Tregs). 
 
5.1.1 CD4 T cell differentiation  
 
CD4 T cell lineage-specific differentiation mainly depends on the cytokine 
milieu present at the time of TCR cognate interaction with MHC class II 
peptide complex presented by APCs (DCs, B cells and/or macrophages). The 
cytokine milieu triggers a cascade of signaling transducer and activator of 
transcription (STAT) protein activation, upregulation of transcription factors 
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and production of cytokines that polarize CD4 T cells into different 
subpopulations.  
 
The existence of CD4 T cell subtypes was initially described in a murine 
model by Mosmann et al., [236]; mouse helper T cells were characterised as 
Th1 and Th2 cells based on the pattern of lymphokines they produce. Th1 
produce IFN-γ and IL-2 whereas Th2 produce IL-4, IL-5, IL-13, TNF-α and a 
small amount of IL-9, later distinguished as a separate Th9 subpopulation 
[237].  
 
Binding of IFN-γ to its receptor on naïve CD4 T cells triggers dimerisation of 
the IFNGR [238], phosphorylation of intracellular domains, and recruitment of 
STAT1 that is further phosphorylated and activated by JAK kinase intracellular 
signaling pathway. These events result in translocation of STAT1 to the 
nucleus where it activates gene transcription of T-bet (T-box transcription 
factor) and together promote IFN-γ production [238, 239]; thus, securing 
commitment of CD4 T cells into a Th1 subpopulation. T-bet is considered to 
be a major factor for induction of IFN-γ production and Th1 cell differentiation; 
animal work in T-bet knockout experiments have shown severe defects in Th1 
cell differentiation [239]. Another transcription regulator that promotes Th1 
differentiation and IFN-γ production is STAT4. STAT4 is activated by IL-12 
[240] and acts as a negative regulator of GATA3 [241], transcription factor 
that induces Th2 cell differentiation and production of IL-4, IL-5 and IL-13, Th2 
signature cytokine profile. On the other hand GATA3 suppresses the STAT4 
signaling pathway [194], thus preventing development of Th1 subpopulation.     
         
GATA3 is a major transcription factor of the Th2 subpopulation, regulated by 
IL-4 and STAT6 intracellular signaling pathway [242]. STAT6 indirectly 
regulates IL-4 production [242]. Another signaling transducer and activator of 
transcription protein that promotes Th2 differentiation of CD4 T cells is 
STAT5.  
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STAT5 driven Th2 differentiation is independent of GATA3 activation [243]; 
instead, it binds directly to the DNase I hypersensitive site II and III in the 
second intron of IL4 locus [243]. STAT5 deficient cells do not respond to IL-2 
but instead they are hypersensitive to IL-12, which leads to Th1 subpopulation 
[244].     
 
Moreover, STAT5 activation by IL-2 is vital for development of peripheral 
Treg. It has been suggested that STAT5 activation also regulates the 
expression of forkhead box P3 (Foxp3) by direct binding to its promoter in a 
dose dependent manner [245]. STAT5 activation suppresses Th1 and Th17 
subpopulations while promoting Th2 and Treg differentiation [246] presumably 
due to enhanced expression of Foxp3.  
 
Foxp3 is a master transcription regulator for development of Tregs cells that 
produce TGF-β. Binding of TGF-β to its receptor triggers activation of a JAK-
STAT signaling pathway, which regulates gene expression, including 
upregulation of Foxp3 and downregulation of STAT1 and STAT3, thus 
preventing CD4 T cell differentiation onto Th1 and Th17, respectively [247].        
 
The existence of Th17 cells was recognised following identification of IL-12 
congener IL-23 [248]; a heterodimer molecule that shares one subunit (p40) 
with IL-12, but that is coupled with a unique p19 subunit. Gene targeting 
experiments showed absence of IL-17 producing CD4 T cells in mice lacking 
the expression of IL-23 p19 subunit but normal IFN-γ production by Th1 cells. 
In contrast, IL-12 p35 deficient mice have an increased number of IL-17 
producing CD4 T cells [248, 249]. Further analysis revealed that TGF-β, IL-6, 
IL-21 and IL-23 are even more efficient at driving CD4 T cell differentiation 
onto Th17 subpopulation [250], via activation of STAT3. Deletion and/or 
mutation of STAT3 results in the loss of IL-17 producing CD4 T cells [251, 
252]. STAT3 regulates IL-17 production in conjugation with receptor-related 
orphan receptor gamma (RORγτ); both bind directly to IL17 gene [253].  
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STAT3 activation by TGF-β and IL-6 leads to downregulation of Foxp3 
expression, thus preventing CD4 T cell differentiation into periphery induced 
regulatory T cell (iTreg) subset [254].  
 
Another subset of CD4 T cells that have been identified as effector T cells that 
provide help for selection and affinity maturation of B cells are Tfh cells. B-cell 
lymphoma 6 (Bcl-6) transcription factor, whose expression is regulated by 
STAT5, is vital for Tfh differentiation [255]; and, together with the C-X-C 
chemokine receptor 5 (CXCR5) permits homing of Tfh cells into the B cell 
follicles [256].  
 
It is important to note that cytokines produced by each Th subpopulation play 
a positive feedback role in promoting further differentiation of a particular 
subtype, e.g. IFN-γ for Th1, IL-4 for Th2, IL-12 for Th17 and TGF-β for iTregs 
[257].     
 
5.1.2 CD4 T cell surface markers  
 
During CD4 T cell development, maturation and differentiation CD4 T cell 
subsets express wide repertoire of cell surface receptors that can be used as 
markers for their classification. Mature CD4 T cells can be classified as naïve, 
central memory and effector memory T cells.  
 
In humans, memory T cells are characterised by the expression of CD45RO 
isoform and by the lack of expression of CD45RA isoform. Thus, 
CD45RO+CD45RA- T cells comprise of heterogeneous populations of memory 
T cell subsets that co-express CD44 cell surface protein involved in cell-cell 
interaction and migration of memory CD4 T cells [258]. Naïve CD4 T cells lack 
expression of CD44.  
 
Furthermore, migration of CD4 T cell subsets is dependent on cell surface 
expression of homing receptors. CC-chemokine receptor 7 (CCR7) is a lymph 
node-homing receptor uniformly expressed on naïve T cells, reflecting their 
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predominant residence in the lymphoid tissue [259], whereas based on the 
co-expression of CCR7 and CD45RO memory T cells are divided into 
CD45RA-CCR7+ central memory T (TCM) which can migrate through the 
lymphoid tissue and CD45RA-CCR7- effector memory T (TEM), which migrate 
through peripheral tissue sites and display effector function [260]. Migration of 
naïve and CCR7+ memory T cells through the lymph nodes is enabled by co-
expression of CD62L adhesion molecule that allows T cell to role on the high 
endothelial venules [260]. This interaction slows down the T cells thus 
allowing firm CCR7-SLC interaction and transmigration of the T cells into the 
lymph node. Co-expression of CCR7 and CD62L is essential for naïve and 
TCM cells migration to lymph nodes [260].  
 
CCR6 is another homing receptor that plays a crucial role in trafficking of 
Th17 cells to the intestine and mucosal tissues [261]. TGF-β is required for its 
expression and in most instances CCR6 is co-expressed with STAT3, RORγτ 
and IL-21 [261], whole mark features of Th17 subpopulation.     
 
Another cell surface marker used to differentiate between naïve and activated 
CD4 T cells is CD27. Activation of T cells leads to CD27 cell surface 
expression; and, when co-expressed with Foxp3 has been used a cell surface 
marker for characterisation of Treg subpopulation [262].  
 
As previously discussed in Chapter 3 and Chapter 4, I observed substantial 
difference in the dynamics of donor CD4 T cell persistence in the recipients’ 
peripheral blood following lung transplantation. Interestingly, these variations 
were not affected by the degree of HLA mismatching between the recipients 
and their respective donors. Furthermore, my data showed that predicted NK 
cell alloreactivity due to inhibitory KIR-ligand mismatching did not influence 
the longevity of donor CD4 T cell chimerism.  
 
These observations have raised the question whether donor CD4 T cell 
subsets and/or activation state are responsible for the observed variation 
between patients with short and patients with long-lasting chimerism.  
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To address this question I have used gene expression analysis assay to 
characterise the donor CD4 T cell subpopulations based on the expression of 
genes encoding cell surface markers and transcription factors specific for 
different CD4 T cell subtypes.  
 
In addition, flow cytometric analyses were used to investigate the composition 
of migrating donor CD4 T cell subsets that have been immobilised within the 
leukocyte filter during ex-vivo lung perfusion. The Ex vivo Lung Perfusion 
procedure is described in Chapter 2, Section 2.7.  
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5.2 Results 
 
Gene expression profiling was used to characterise isolated donor CD4 T 
cells, by adopting standard RT-PCR methodology (Section 2.6.4.4.), with the 
level of gene expression quantified using relative quantification (RQ) (as 
described in Section 2.6.5). The RQ gene expression level for the genes 
targeted was measured in reference to the level of expression of the internal 
control gene, also known as “internal endogenous control” or “reference 
gene”. The reference gene represents a gene with a stable level of 
expression.  
 
To ensure precise analysis and interpretation of the data generated by 
expression profiling, the assay was first validated. Based on the longevity of 
donor CD4 T cell chimerism, patients were categorised into two groups: those 
with short (n=5) and those with long-lasting (n=5) chimerism (defined as donor 
CD4 T cells detectable in the recipients’ peripheral blood for less than six 
weeks and more than six months after transplantation, respectively). 
Recipients’ peripheral blood isolated donor CD4 T cells were characterised 
using gene expression profiling, having identified an internal endogenous 
control gene, and the gene expression profile was compared between the two 
groups of patients.  
 
In addition, to assess the type of cells that are migrating from the human 
lungs following revascularisation of the allograft I examined human lungs 
subjected to the Ex vivo Lung Perfusion procedure (previously described in 
Section 2.7) prior to revascularisation. Cells migrating out of the lungs during 
the EVLP procedure are immobilised on a leucocyte filter that is attached to 
the EVLP circuit. Characterisation of mononuclear cell populations was 
performed by flow cytometry, previously described in Section 2.4.4. 
Unfortunately, due to unforeseen circumstances the DEVLOP UK study was 
prematurely terminated and for the duration of my study lungs harvested from 
only one DCD donor were subjected to analysis.  
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5.2.1 Identification of stable internal endogenous control gene  
 
To identify an internal endogenous control gene with stable expression, the 
gene expression transcripts of three genes was measured: glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), beta-actin (ACTB) and cluster of 
differentiation 4 (CD4). GAPDH is an enzyme encoded by the GAPDH gene 
and is involved in glycolysis (breakdown of glucose) and other non-metabolic 
processes such as transcription and apoptosis [263]. ACTB is a non-muscle 
cytoskeletal protein involved in cell motility, structure and integrity and is 
encoded by β-actin gene [264]. CD4 is a glycoprotein encoded by CD4 gene 
found on the surface of T helper cells [265].    
 
Nine samples containing equal numbers of isolated donor CD4 T cells (20,000 
cells; previously described in Section 2.4.3), were selected and used for 
detection of stable internal endogenous control gene including (GAPDH, 
ACTB and CD4) using qRT-PCR methodology (Section 2.6.4.4). Each assay 
was carried out in duplicate. The results of the gene expression analysis for 
GAPDH, ACTB and CD4 are presented as average Ct value of the duplicates. 
Ct value is the point (PCR cycle number) where the PCR curve crosses the 
threshold in the linear part of the exponential phase of the PCR reaction 
(Section 2.6.5). Figure 5.1 A, represents the mean Ct value for each sample 
tested for the level of expression for GAPDH, ACTB and CD4. Massive 
variation was observed in the gene expression levels for ACTB and CD4 
ranging between Ct 15.8 to 17.4 and Ct 16.8 to 18.2, respectively. One Ct 
difference between two samples is equivalent to 2-fold change, which means 
that 4-fold difference existed between samples for both ACTB and CD4 gene 
expression.  
 
In comparison, the variation between the samples for GAPDH level of 
expression was less than one Ct cycle; the Ct value was ranging between Ct 
16.1 and Ct 16.8. Variation of less than one Ct cycle is considered not 
significant; thus, GAPDH was identified as a good candidate for internal 
endogenous control gene.   
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To further assess the validity of the assay, an additional test was performed to 
confirm the stability of the GAPDH gene expression. In this case the GAPDH 
level of expression was re-assessed using nine samples containing 20,000 
isolated donor CD4 T cells and an additional two samples containing 10,000 
cells. The average Ct value obtained for the samples containing 20,000 cells 
was Ct 16.5 and for the samples containing 10,000 cells the Ct value was 
17.5. Thus, the observed difference between samples containing 20,000 and 
10,000 CD4 T cells was one Ct cycle that is equivalent to 2-fold difference, 
which corresponds to the number of cells present in each test group; 20,000 
vs 10,000 donor CD4 T cells. These observations have confirmed the validity 
of the assay and the stability of the GAPDH gene expression, Figure 5.1 B.       
 
Lastly, serial dilutions of isolated donor CD4 T cells were prepared to test 
whether GAPDH level of expression correlates with the number of donor CD4 
T cells used as a starting amount of biological material. Six samples 
containing 100, 200, 500, 2,000, 10,000 and 20,000 isolated CD4 T cells were 
tested in duplicates. Figure 5.1 C represents the Ct values for each test 
sample Ct 25.5, Ct 24.5, Ct 23, Ct 21, Ct 18.5 and Ct 17.3, respectively.  The 
analysis revealed correlation between the Ct values and the number of cells 
present in each test sample. For example, one Ct cycle difference was 
observed between the samples containing 100 and 200 cells (Ct 25,5 vs 24.5) 
and samples containing 10,000 and 20,000 cells (Ct 18.5 vs 17.3), confirming 
that serial dilutions were equivalent to a 2-fold difference.       
 
The analysis revealed that the expression of GAPDH is stable, with minimal 
variation between duplicate samples. Thus, GAPDH was selected as an 
internal endogenous control. The level of expression of all target genes 
assessed for characterisation of the passenger donor CD4 T cells were 
normalised in reference to the GAPDH level of expression (Section 2.6.5).  
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A) 
 
B) 
 
 
C) 
 
Figure 5.1 Identification of stable internal endogenous control gene. A) 
Identification of the level of expression of GAPDH, ACTB and CD4 in nine test samples 
containing 20,000 isolated donor CD4 T cells; Ct value is the point (PCR cycle number) where 
the PCR curve crosses the threshold.  B) GAPDH level of expression tested in nine test 
samples containing 20,000 and two samples containing 10,000 isolated donor CD4 T cells. C) 
RT-PCR amplification plot representing GAPDH level of expression in samples containing 
100, 200, 500, 2,000, 10,000 and 20,000 isolated donor CD4 T cells. Each sample was tested 
in duplicates. 
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5.2.2 Patient cohort for characterising donor CD4 T cell gene expression 
profiling. 
 
Of 21 patients with donor CD4 T cell chimerism detectable in the recipients’ 
peripheral blood following primary lung transplantation, 10 patients were 
selected for characterisation of donor CD4 T cells using gene expression 
profiling. Based on the longevity of donor CD4 T cell chimerism, patients were 
categorised into two groups: patients with short chimerism (n=5) and patients 
with long-lasting chimerism (n=5), defined as donor CD4 T cell detectable in 
the recipients’ peripheral blood for less than six weeks and more than six 
months after transplantation, respectively.  
 
To my knowledge donor CD4 T cell gene composition has not been previously 
studies and at this stage the type of donor CD4 T cell chimerism is completely 
unknown entity. The number of patients in both groups is relatively small; 
nevertheless undertaking a small pilot experiment to evaluate the presence of 
donor CD4 T cell subpopulation in the recipients’ peripheral blood following 
lung transplantation may provide interesting findings that could drive further 
experimental directions. Recipient and donor demographics are presented in 
Table 5.1.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 137 
Table 5.1 Recipients and donor characteristics.  
 
Recipient and donor 
demographics 
Short donor CD4 T 
cell chimerism (n=5) 
Long donor CD4 T 
cell chimerism  (n=5) 
p Value 
 
Recipient age (Median ± SD)  58.1 (± 6.6) 55.8 (± 17.5) ns 
Recipient sex (M:F) 2:3 2:3 ns 
Donor age (Median ± SD)  56   (± 6.8)   46  (± 14.9) ns 
Donor sex (M:F) 3:2 3:2 ns 
Transplant type 
             SLT 
             DLT 
 
0 
5 
 
0 
5 
 
ns 
Indication for transplantation   
             Cystic fibrosis 
 Emphysema   
 COPD   
 A1AD   
 Emphysema + A1AD 
 
 
0 
1 
4 
0 
0 
 
1 
0 
2 
                 1 
1 
 
ns 
Pre-transplant  
         HLA sensitisation 
 
3/5 
 
1/5 
 
 
ns 
HLA mismatch grade 
          ≤ 3 
          ≥ 4 
 
0 
5 
 
2 
3 
 
ns 
Immunosuppression 
            Tac/MMF/Pred 
            Tac/MM/Aza 
            Tac/Pred 
 
3* 
                 1 
1* 
 
3 
1 
1 
 
 
ns 
 
SLT – Single lung transplant; DLT – Bilateral lung transplant; COPD - Chronic obstructive pulmonary 
disease; A1AD- α1 antitrypsin deficiency; HLA – Human Leukocyte Antigen; Tac – Tacrolimus; Aza – 
Azathioprine. Pred – Prednisolone; MMF – Mycophenolate Mofetil; *Induction therapy with Basiliximab.  
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5.2.3 Characterisation of isolated donor CD4 T cells using gene expression 
profiling    
 
To investigate whether the observed inconsistency in the longevity of donor 
CD4 T cells chimerism between patients with short (n=5) and patients with 
long chimerism (n=5) is due to the presence of different donor CD4 T cell 
subsets and/or their maturity state, we aimed to characterise the donor CD4 T 
cells isolated (Section 2.4.3) from the recipients’ peripheral blood following 
primary lung transplantation. Fourteen commercially available gene 
expression assays (Table 2.10) were used to investigate their level of 
expression including: CD44, CD27, CD62L, CCR6, FoxP3, ROR-γc, Bcl6, 
GATA3, T-bet (TBX21), STAT4, STAT6, STAT3, STAT5 and IL-21.  
 
In brief, CD44 is a marker for effector-memory T cells. Co-expression of CD27 
and FoxP3 represent a marker of regulatory T cell subset [266]. STAT5 is a 
transcription factor that regulates T cell development and their differentiation 
into regulatory T cell subset [245, 246]. CD62L is an adhesion molecule 
expressed on naïve and central memory CD4 T cells [260]. CCR6 regulates 
migration of Th17 cells to the inflammatory tissue [261] and is usually co-
expressed with STAT3, ROR-γc and IL-21 [253]. Naïve CD4 T cell 
differentiation into T follicular helper cell subset is regulated by the 
transcription factor Bcl6. T-bet, STAT4, STAT6 and GATA3 are transcription 
factors that regulate naïve T helper (Th) cell differentiation; T-bet and STAT4 
commits cell differentiation into Th1 lineage [239, 240], whereas STAT6 and 
GATA3 drive differentiation of naïve Th cells into Th2 subset [194, 242].      
      
Isolated donor CD4 T cells were lysed (Section 2.6.4.1) and used as a 
substrate for reverse-transcription and production of cDNA (Section 2.6.4.2). 
The cDNA was then used as a template for preamplification of the genes of 
interest, a method that allows an increase in the amount of cDNA available 
only for the targeted genes (Section 2.6.4.3); and, the pre-amplified product 
was used as a template for gene expression analysis by RT-PCR (Section 
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2.6.4.4). The gene expression levels were determined by relative 
quantification (RQ) method, Section 2.6.5. 
 
Donor CD4 T cell gene expression levels were assessed in donor samples 
obtained at the time of donation, identified as time zero for all patients in this 
cohort. In addition, for patients with short chimerism; gene expression levels 
were tested in donor derived CD4 T cells, previously isolated from the 
recipients’ peripheral blood samples at around two weeks (ranging from 
between 10 and 13 days) after transplantation; whereas, for patients with long 
chimerism the level of gene expression was tested in donor derived CD4 T 
cell isolated at around two weeks (ranging from 13 to 17 days); and six 
months after transplantation. Table 5.2 represents the RT-PCR average Ct 
value for each test sample.  
 
Furthermore, in order to establish the level of expression of targeted genes; 
the Ct value of each gene tested was normalised relative to the Ct value of 
the endogenous internal control gene (GAPDH); the normalised Ct values are 
presented as delta CT (ΔCt). The ΔCt equals the Ct of the target gene minus 
the Ct of the reference gene (ΔCt = Ct (target gene) – Ct (reference gene - 
GAPDH)). Table 5.3 and Figure 5.2 represent the gene expression levels for 
genes targeted in test samples obtained at time zero, two weeks and six 
months after transplantation.  
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Table 5.2 represents the RT-PCR average Ct value.  
Target 
genes 
av. Ct 
SCM P1 
 
SCM P2 
 
SCM P3 
 
SCM P4 
 
SCM P5 
 
LCM P1 LCM P2 LCM P3 LCM P4 LCM P5 
D0 D11 D0 D12 D0 D13 D0 D10 D0 D10 D0 D14 M6 D0 D17 M6 D0 D14 M7 D0 D17 M6 D0 D13 M6 
GAPDH 20 20 31 16 17 16 21 18 24 17 20 22 23 18 17 25 17 14 20 24 24 24 24 22 17 
CD44 18 18 28 14 16 14 19 16 26 16 18 20 21 16 16 21 15 13 18 22 22 23 23 17 15 
CD27 21 22 34 17 19 19 22 20 31 20 21 23 25 20 20 27 19 17 24 24 27 26 25 22 18 
CD62L 20 20 29 15 20 18 21 18 29 18 22 21 23 19 17 23 17 16 20 23 24 24 25 18 17 
CCR6 23 25 - 20 22 21 22 23 32 22 25 26 27 23 23 31 21 19 26 31 31 31 29 24 22 
FoxP3 21 22 33 17 21 19 25 20 30 19 22 25 25 22 20 27 19 17 25 27 26 27 28 22 19 
ROR-γc 23 24 - 18 21 21 28 21 34 20 24 25 28 21 21 28 20 18 25 30 28 33 30 25 21 
Bcl6 21 24 - 20 19 18 22 21 - 21 21 25 25 20 20 31 18 18 22 25 32 34 26 24 21 
GATA3 21 21 35 17 18 17 24 20 - 19 20 24 24 19 18 25 18 16 21 23 28 26 26 21 18 
T-bet 22 24 31 20 17 17 24 22 32 21 21 25 27 20 19 28 26 16 20 27 26 30 25 22 20 
STAT4 19 19 30 16 17 15 22 18 31 17 19 21 22 17 16 23 16 14 19 23 23 25 24 20 17 
STAT6 20 20 30 16 17 16 21 19 33 18 20 21 23 18 17 25 18 15 20 24 25 25 24 21 17 
STAT3 21 21 30 17 18 18 23 21 - 19 21 23 24 19 19 25 18 16 21 24 26 28 25 20 19 
STAT5 19 20 31 16 18 17 23 18 34 18 20 22 24 18 18 25 18 16 20 24 25 26 25 20 18 
IL21 26 28 - 22 22 26 29 24 - 25 24 - - 26 - - 22 23 - 33 34 - 34 28 26 
 
Av. Ct – average Ct value of duplicate samples tested for the genes listed above; SCM – patients with short donor CD4 T cell chimerism; LCM – patients with 
long donor CD4 T cell chimerism; P – patient; D0 – time zero (samples obtained prior to transplantation); D – days after transplantation; M – months after 
transplantation; “ – “ not amplified; Description of the targeted genes is presented in Table 2.10.     
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Table 5.3 represents gene expression levels for genes targeted in test samples obtained at time zero (prior to transplantation); two 
weeks and six months after transplantation.         
Target 
genes ΔCt 
SCM P1 
ΔCt 
SCM P2 
ΔCt 
SCM P3 
ΔCt 
SCM P4 
ΔCt 
SCM P5 
ΔCt 
LCM P1 
ΔCt 
LCM P2 
ΔCt 
LCM P3 
ΔCt 
LCM P4 
ΔCt 
LCM P5 
ΔCt 
D0 D11 D0 D12 D0 D13 D0 D10 D0 D10 D0 D14 M6 D0 D17 M6 D0 D14 M7 D0 D17 M6 D0 D13 M6 
GAPDH 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
CD44 -2.5 -1.8 -3.1 -2.2 -1.4 -1.1 -2.2 -1.5 2.0 -1.7 -2.0 -2.0 -2.1 -2.7 -1.7 -3.2 -2.2 -1.4 -2.1 -2.1 -2.0 -0.8 -2.0 -5.1 -1.9 
CD27 0.7 1.7 3.3 1.4 1.9 3.8 1.3 2.4 7.3 2.2 0.5 1.5 1.6 1.2 2.4 2.2 1.6 2.6 3.7 0.4 2.5 2.1 0.9 0.0 0.8 
CD62L 0.0 -0.3 -2.3 -0.6 2.4 2.4 -0.7 0.3 5.5 0.2 2.0 -0.3 -0.5 0.6 0.1 -1.4 -0.2 1.1 0.3 -1.1 -0.3 0.3 0.2 -4.0 -0.1 
CCR6 3.2 4.9  3.9 5.2 5.2 1.0 4.7 8.1 4.3 4.8 4.0 4.1 4.5 6.1 6.6 3.5 4.6 6.3 7.6 6.7 6.7 5.0 1.9 4.6 
FoxP3 0.9 1.8 2.2 1.5 3.4 3.3 4.2 1.7 6.1 1.8 1.6 2.8 1.6 3.1 2.6 2.7 1.3 2.8 4.6 3.5 2.2 2.5 3.0 0.2 2.2 
ROR-γc 3.0 4.0  2.1 3.4 5.1 6.7 2.8 10.1 2.4 3.8 3.5 4.8 3.0 3.8 4.0 2.9 3.5 4.8 6.5 4.1 9.2 5.8 2.5 3.7 
Bcl6 1.1 3.5  3.6 1.6 2.7 1.0 3.5  3.5 0.6 3.0 2.0 1.6 3.1 6.5 1.0 3.8 2.0 1.5 7.7 9.5 1.8 1.8 3.8 
GATA3 0.4 1.4 3.6 0.9 0.7 1.4 2.9 1.7  1.1 0.2 1.8 1.3 0.6 1.0 0.9 0.6 1.8 1.2 -0.9 3.3 1.4 1.2 -0.8 0.9 
T-bet 1.9 4.3 0.1 3.6 -0.2 1.4 2.9 4.3 8.6 3.8 1.0 3.0 3.5 1.4 1.6 3.8 8.3 1.8 0.5 2.9 1.9 5.5 1.0 0.0 2.7 
STAT4 -1.5 -0.6 -0.9 -0.4 -0.3 -0.9 1.1 -0.1 7.0 -0.3 -1.5 -1.0 -0.8 -1.7 -0.9 -1.5 -1.5 0.0 -1.3 -1.1 -1.1 0.8 -0.3 -2.7 0.0 
STAT6 -0.3 0.3 -1.0 0.1 0.2 0.4 -0.6 1.3 9.3 0.5 0.1 -0.4 0.1 -0.1 -0.4 0.1 0.4 0.5 0.3 0.3 0.6 0.9 -0.5 -1.1 -0.2 
STAT3 1.1 1.3 -0.7 1.5 0.9 1.8 1.4 2.8  1.8 0.9 1.2 1.1 0.8 1.5 0.8 0.8 1.9 1.4 0.4 1.7 3.6 0.7 -1.7 2.1 
STAT5 -1.0 0.5 -0.1 0.1 0.5 1.7 1.3 0.6 9.9 0.3 -0.1 0.1 0.5 0.1 0.4 0.1 0.4 1.6 0.6 0.4 0.8 1.6 0.5 -1.8 0.3 
IL21 6.0 7.9   5.3 10.0 7.6 6.2  7.5 4.2   7.7   4.6 8.2  9.0 9.6  9.3 6.1 8.3 
 
ΔCt – normalized gene expression levels of targeted genes in reference to the expression level of the endogenous internal control gene GAPDH; SCM – 
patients with short donor CD4 T cell chimerism; LCM – patients with long donor CD4 T cell chimerism; P – patient; D0 – time zero (samples obtained prior to 
transplantation); D – days after transplantation; M – months after transplantation, Description of the targeted genes is presented in Table 2.10.    
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Figure 5.2, heat map represents gene expression levels. The level of gene 
expression was evaluated in reference to the endogenous internal control gene GAPDH 
expression levels in all patients (red colour; patients with short chimerism - P1, P2, P3, P4 
and P5; and black colour; patients with long chimerism - P1, P2, P3, P4 and P5).  Test 
samples obtained at three different time points: day 0 (prior to transplantation), two weeks 
(ranging between day 10 and day 17) after transplantation and at six months after 
transplantation. Each square on the heat map represents an individual sample. Red colour 
indicates upregulated gene expression level in relation to the internal control GAPDH gene, 
black colour represents no change in the level of expression and green colour represents 
downregulation in relation to the internal control GAPDH gene. 
 
ΔCt – normalized gene expression levels of targeted genes in reference to the expression level of the 
endogenous internal control gene GAPDH; P – patient; D0 – time zero (samples obtained prior to 
transplantation); D – days after transplantation; M – months after transplantation; Description of the 
targeted genes is presented in Table 2.10. 
 
 
I observed three different patterns in the level of gene expression: overall the 
level of gene expression was increased in five target genes (CD44, CD62L, 
STAT4, STAT5 and STAT6) indicative of red colour (Figure 5.2); there was a 
minimal change in the level of expression in CD27, STAT3, FOXP3 and 
GATA3 (black colour, Figure 5.2); and the level of gene expression was 
decreased for RORC, T-bet, CCR6, IL-21 and BCL6 (green colour, Figure 
5.2).  
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The highest increase in the level of gene expression was observed in CD44, 
suggesting a predominant memory donor CD4 T cell phenotype. In the 
majority of test samples the level of gene expression was also increased for 
CD62L, STAT4, STAT5 and STAT6. Expression of CD62L was decreased in 
two samples and in six samples change was not observed. The expression of 
STAT5 and STAT6 was decreased in one patient with short chimerism in the 
test sample obtained prior to transplantation (Figure 5.2, P5 D0). In the 
remaining test samples there was a little increase in the expression of STAT5 
and STAT6. In contrast, the expression of STAT4 was increased in 23 out of 
25 samples tested.  
 
In contrast, expression of RORC, T-bet, CCR6, IL-21 and BCL6 was 
decreased in the majority of samples tested, with the exception of a few test 
samples where there was no difference in the expression levels; and, the 
expression of T-bet was increased in only one patient with short chimerism in 
the test sample obtained prior to transplantation (Figure 5.2, P3 D0).  
 
Expression of CD27, STAT3, FOXP3 and GATA3 was largely unchanged, 
with the exception of a few test samples where expression levels of FOXP3 
were decreased.  
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5.2.3.1 Comparison of CD4 T cell gene expression profile between patients 
with short and patients with long donor CD4 T cell chimerism  
 
DataAssistTM v3.01 software was used to calculate the relative quantification 
(fold-change) for the level of gene expression between both groups of patients 
at two different time points. The software also performs the following analysis: 
mean Ct, ΔCt, ΔΔCt between two groups of patients, RQ (fold-difference) and 
t-test for patient group comparison (Section 2.6.5).    
 
Firstly, we compared the level of gene expression between the patients with 
short and long chimerism at the time of donation. The analysis revealed that 
the expression levels of CD27 (1.4 fold), CD44 (1.1 fold), GATA3 (1.6 fold), 
IL21 (2.7 fold), RORC (1.1 fold), STAT4 (1.8 fold) and STAT5 (1.1 fold) were 
higher in the patients with long lasting chimerism.   
 
When we compared the level of gene expression in the test samples obtained 
at two weeks after transplantation we observed a different donor CD4 T cell 
profile. The fold-chance in the level of expression was higher in all genes 
tested with the exception of IL21 and RORC in the patients with long lasting 
chimerism than in the patients with short chimerism. The highest increase was 
observed in CCR6 (2.4 fold), CD44 (2.9 fold), CD62L (4.5 fold), STAT3 (3.5 
fold) and T-bet (2.9 fold); suggesting the presence of effector Th1 and Th17 
donor CD4 T cell subsets.  
 
However, despite the observed differences in the level of gene expression 
between the patients with short and patients with long chimerism, the fold-
change was not statistically significant (log10 fold-change >2, Benjamini-
Hochberg False Discovery Rate); presumably due to massive variations in the 
level of gene expression between test samples within the same biological 
group and between the two biological groups. Figure 5.3 shows the overall 
range of Ct distribution sorted by assay for each test sample.  
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Figure 5.3 shows the overall range of Ct distribution arranged by gene 
expression assay. The ends of the vertical lines (whiskers) indicate the minimum and 
maximum Ct value. The points outside the end of the whiskers are outliers or suspected 
outliers and are excluded from statistical analysis. 
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Similar observations were made when we compared the level of gene 
expression between test samples obtained at different time points for both 
patient groups.  
 
For patients with short chimerism, the fold change for RORC expression (2.5-
fold) was higher in the donor CD4 T cells obtained at week two post-
transplant in comparison to donor CD4 T cells obtained prior to 
transplantation, while the expression of all other genes was lower.  
 
Contrary to this, in patients with long chimerism the expression of 10 out of 14 
genes tested was increased in the donor CD4 T cells obtained at two weeks 
in comparison to test samples obtained prior to transplantation. The highest 
increase was observed in CCR6 (2.2-fold), CD44 (2-fold), and CD62L (4-fold); 
whereas, the expression of BCL6 and IL21 was lower, 0.25-fold and 0.04-fold, 
respectively. In addition, in this group of patients, with the exception of 
CD62L, the expression of all other genes was lower in the cells obtained at six 
months post-transplant in comparison to the cells obtained prior to 
transplantation.  
 
Due to the huge variation between the test samples, the observed difference 
in the level of gene expression between samples obtained at different time 
points for both groups of patients were not statistically significant. 
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5.2.4 Characterisation of passenger mononuclear cells mechanically 
removed from donor lungs by Ex Vivo Lung Perfusion procedure 
 
Ex vivo lung perfusion (EVLP); previously described in Section 2.7) is an 
alternative method of organ preservation, allowing prolonged time for careful 
evaluation and reconditioning of donor lungs that would otherwise be clinically 
rejected for transplantation. In addition, it provides a unique opportunity to 
study the immunological contribution and immune cell migration that donor 
lungs deliver at the time of transplantation.  
 
Five lung transplant centers in the United Kingdom undertook a National 
Clinical Study known as A Study of Donor Ex-Vivo Lung Perfusion in UK Lung 
Transplantation (DEVELOP-UK) to assess the potential usability of lungs 
deemed to be unsuitable for transplantation. As part of the existing study, I 
was granted additional ethical approval for the use of discarded leucocyte 
filters following the EVLP procedures performed at Papworth Hospital. 
Unfortunately, due to unforeseen technical difficulties the DEVELOP-UK study 
was suspended and for the duration of the study the composition of 
leucocytes trapped within the filter was assessed only for one EVLP filter.  
 
The EVLP procedure was performed on human lungs harvested from a 59 
year-old DCD donor. In brief, the lungs were connected to a modified heart-
lung bypass circuit to which a leucocyte filter is attached; two-litres of nutrient 
Steen solution and two-units of packed RBCs were continuously pumped 
through the lungs for 4 hours which warms the lungs to body temperature; 
followed by one-hour cooling perfusion phase during which lungs are cooled-
down to 6°C. At the end of the EVLP procedure, the leukocyte filter was 
removed and stored overnight in RPMI media at 4°C for further analysis. 
Mononuclear cells were isolated from the filter and characterised using flow 
cytometric analysis, previously described in Section 2.3.4 and Section 2.4.4, 
respectively.  
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5.2.4.1 Evaluation of passenger mononuclear cells mechanically removed 
with Ex Vivo Lung Perfusion procedure from DCD lungs  
 
The total number of mononuclear cells isolated from the EVLP leucocyte filter 
was at least 25-30 x 109 (counted in three test samples), previously described 
in Section 2.3.4 and Section 2.3.5. The mononuclear cells were analysed by 
flow cytometry (Section 2.4.4). The flow cytometric plot was set to display all 
mononuclear cells; then, based on the forward and side scatter (which 
measures the cell size and granularity respectively), three major cell 
populations were identified: lymphocytes; monocyte/macrophages; and 
granulocytes. Of the total number of mononuclear cells analysed, 59% were 
identified as lymphocytes, 22.0% as monocytes/macrophages and 18.5% as 
granulocytes.  
  
5.2.4.2 Immunophenotyping of lymphocyte population using flow cytometry  
 
Cell types present in each population were characterised by targeting cell 
surface markers with monoclonal antibodies using flow cytometry (Section 
2.4.4). Of the total number of mononuclear cells, 59% were lymphocytes. The 
percentage of dead cells (characterised as 7-AAD positive) was less than 1%; 
these were excluded from further analysis. Interestingly, 58% of the 
lymphocyte population were B cells, characterised by the expression of B cell 
surface marker CD19+. Of the remaining lymphocyte population, only 3.7% 
were identified as T cells expressing CD3+ cell surface marker; of which, 1% 
were CD4+ cells and 2.7% were CD8+ T cells, Table 5.4.  
 
The remaining 38.5% of the leucocyte population did not express CD3-, CD4-, 
CD8- nor CD19- cell surface markers. Further analyses of these cells revealed 
that 23.3% expressed a high level of CD11b+ cell surface marker, but were 
negative for CD14- and CD16-, suggesting presence of 
monocyte/macrophages and/or dendritic cells (DCs). The remaining cells 
(11.7%) lacked CD14-, CD11b- and CD16- cell surface expression; these cells 
were not further characterised, Table 5.4.  
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Table 5.4 Immunophenotyping of leucocyte population mechanically removed 
form donor lungs using EVLP.  
 
Cell surface markers (Immunophenotype) Percentage (%) Cell types 
CD3+ 3.7% T cells 
CD4+ 1% CD4 T cells 
CD8+ 2.7% CD8 T cells 
CD19+ 58% B cells 
CD11b+ 23.3% Dendritic cells 
CD3- CD4- CD8- CD19- CD14- CD11b- CD16- 11.7% Uncharacterised 
 
5.2.4.3 Immunophenotyping of leukocyte population using flow cytometry  
 
The flow cytomertic analysis of the monocyte/macrophage cell population 
revealed two main cell subsets; cells that expressed CD14+ cell surface 
marker (88.1%) and cells that did not express CD14- surface marker (11.9%). 
Of the CD14+ cells, 99.3% co-expressed CD11b+, but not CD16; a phenotype 
consistent with the monocyte population. Cells that did not express CD14- 
surface marker expressed both CD11b+ and CD16+ surface markers, a 
hallmark feature of macrophages, Table 5.5.    
 
In contrast, the analysis of the granulocyte population revealed that the 
majority of these cells were CD14-CD11b+CD16+/-, whereas cells that were 
CD14+ also co-expressed CD11b+ and CD16+/-, suggesting the presence of 
neutrophils Table 5.5.  
 
Table 5.5 Immunophenotyping of leucocytes population mechanically removed 
form donor lungs using EVLP.  
 
Cell surface markers (Immunophenotype) Percentage (%) Cell types 
Monocyte/macrophage population    
CD14+ CD11b+ CD16-  88.1% Monocytes 
CD14- CD11b+ CD16+ 11.9% Macrophages 
Granulocyte population    
CD14- CD11b+ CD16+/- 79.3% Unknown/Macrophages  
CD14+ CD11b+ CD16+/- 20.7% Neutrophils  
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5.2.4.4 Characterisation of donor CD4 T cells mechanically removed from 
donor lungs using EVLP  
 
Immunophenotyping of donor CD4 T cells was performed using simultaneous 
seven-colour flow cytometric analysis, previously described in Section 2.4.4. 
Of the total number of lymphocytes, only 1.7% of the cells analysed 
expressed CD4+ cell surface marker, Figure 5.4 A c). Of the CD4 T cell 
population, 45.1% expressed CD45RA, whereas 54.9% expressed CD45RO, 
consistent with naïve / resting and activated / memory CD4 T cells, 
respectively (Figure 5.4 A d).  
 
97% of the naïve CD4 T cells (CD45RA+ CD45RO-) expressed lymph node 
homing receptor L-selectin (CD62L); and, in addition, the majority of these 
cells (93.2%) also expressed CCR7 cell surface marker, another lymph-node 
homing receptor expressed on naïve and memory T and B cells. Interestingly, 
68.2% of the CD62L+ CCR7+ cells co-expressed the cell surface chemokine 
receptor CXCR5, suggesting the presence of naïve follicular T (Tfh) cells. 
Whereas, 25% of the CD62L+ CCR7+ did not express CXCR5 cell surface 
chemokine receptor, Table 5.6 and Figure 5.4 B a), b) and c). 
 
In comparison, 36.3% of the CD45RA- CD45RO+ activated/memory 
phenotype CD4 T cells also expressed CD62L; the remaining 63.7% were 
CD62Llow, compatible with central memory and effector memory CD4 T cells, 
respectively (Table 5.6). Further analysis revealed that the CD45RO+ cells 
expressed neither CXCR5 nor CCR7 receptor. lymph node homing receptor, 
suggesting that these cells are unable to recirculate through the lymph nodes, 
Figure 5.4 B d), e) and f). Table 5.6 shows subpopulations and surface 
marker expression of passenger CD4 T cells in human donor lungs 
mechanically removed from the lungs with EVLP. 
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Table 5.6 Immunophenotyping of donor CD4 T cell subpopulations 
mechanically removed from donor lungs using EVLP.  
 
Cell surface markers Percentage (%) and type of CD4 T cell subpopulations 
 
CD45RA+ CD62L+ CXCR5- CCR7+ 25% Naïve CD4 T cells 
CD45RA+ CD62L+ CXCR5+ CCR7+ 68.2% Follicular helper T cells  
CD45RO+ CD62L+ CXCR5- CCR7- 36.3 Central memory CD4 T cells  
CD45RO+ CD62L- CXCR5- CCR7-  63.7 Effector memory CD4 T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 152 
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B)	
 
Figure 5.4 Immunophenotyping of donor CD4 T cells mechanically removed 
from donor lungs using EVLP. A) Isolated donor CD4 T cells were incubated with 
fluorescence labeled primary anti-human monoclonal antibodies specific for CD4, CD45RA, 
CD45RO, CD62L, CXCR5 and CCR7 and 7-AAD (7-aminoactinomycin D, death cell 
exclusion marker) and analysed by flow cytometer (Section 2.4.4); a) Side and forward scatter 
were set to detect lymphocyte population; b) 5µl of 7-AAD were added to the cells for 
exclusion of death cells; c) CD4 expressing cells were selected and identified as a 
subpopulation; d) Cytometric plot showing CD4+ CD45RA+ and CD4+ CD45RO+ expressing 
cells. B) a) CD45RA+ and CD45RA- population was further characterised; b) Cytometric plot 
showing CD45RA+ cell population expressing CD62L surface marker, c) Two subpopulations 
of CD62L+ cells were identified CXCR5+CCR7+ and CXCR5-CCR7+. Flow-cytometric plot d, e 
and f showing CD45RA- cell subpopulation analysis for the expression of CD62L, CXCR5 and 
CCR7; d) Showing cell subpopulation expressing CD62L and cell subpopulation lacking 
CD62L expression; e) and f) Cytometric plots showing CD62L+ and CD62L- subpopulations; 
both lack co-expression of CXCR5 and CCR7 cell surface marker.    
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5.3 Discussion 
 
To evaluate whether different donor CD4 T cell subpopulations may account 
for the observed variation in the longevity of donor CD4 T cell chimerism in 
our lung transplant patient study group, I attempted to characterise the 
isolated donor CD4 T cells using the RT-PCR relative quantification method. 
The expression of multiple gene transcripts that are thought to characterise 
different CD4 T cell subpopulations were assessed in patients with short and 
patients with long lasting donor CD4 T cell chimerism.  
 
Previous studies have showed the presence of different cell populations, 
including donor CD4 T cells, in patients’ peripheral blood within the first four 
weeks after transplantation [139, 267]. Nevertheless, to my knowledge, our 
analysis is the first study that attempted to characterise the donor CD4 T cell 
subpopulations. 
 
I observed massive variations in the level of GAPDH gene expression in the 
patient samples (ranging between Ct 14 and Ct 31, Table 5.2), irrespective of 
the stable expression of the GAPDH internal control gene (Figure 5.1 B and 
C). The most likely explanation for the observed variation is the utilisation of 
different numbers of isolated donor CD4 T cells. For patients with short CD4 T 
cell chimerism the number of isolated CD4 T cells used ranged between 167 
and 40,000 cells and for patients with long chimerism the number of isolated 
CD4 T cells used ranged between 345 and 51,000 cells.  
 
In order to establish the gene expression levels, I calculated the delta Ct value 
for each gene tested. Delta Ct represents the level of gene expression in 
relation to the expression of GAPDH, Table 5.3. Heat map was generated to 
visualise the overall gene expression levels for each sample tested at different 
time points.  
 
The analysis did not reveal a unique pattern of genes being expressed at one 
particular time nor between patient groups. Overall, an increase in the gene 
expression levels was observed for CD62L, CD44, STAT4, STAT5 and 
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STAT6 (Figure 5.2, red colour), with minimal change in level of expression for 
CD27, STST3 and Foxp3 and decreased level of expression for RORC, 
CCR6, IL21 and Bcl6 (Figure 5.2; black and green colour, respectively).  
 
Of all genes tested the highest increase in the gene expression levels were 
observed in CD44, CD62L and STAT4 which may indicate the presence of 
memory Th1 phenotype; however, the observed differences were statistically 
not significant and inconclusive. It has to be stressed, the level of gene 
expression does not signify an absolute quantification; therefore, it is unknown 
whether these levels are sufficient and represent “true” effector memory Th1 
subpopulation.  
 
Ultimately, my aim was to determine whether different donor CD4 T cell 
subpopulations account for the observed variation in the longevity of donor 
CD4 T cell chimerism between the patients with short vs patients with long 
chimerism.  
 
In spite of the small difference in the level of gene expression between the 
two groups of patients including both, samples obtained prior to and after the 
transplant due to the massive variation in the gene transcripts, the 
comparison analyses did not reveal unique gene expression pattern and I was 
unable to characterise the donor CD4 T cell subpopulations.  
 
The number of cells utilised for the donor CD4 T cell characterisation and the 
size of study cohort limited this study. Unfortunately, due to the nature of the 
study it was not possible to correct for these limitations.  
  
Furthermore, I have assessed the immune cell composition of donor lungs 
that undergo EVLP prior to revascularisation. This procedure mimics the 
cardiovascular conditions encountered following revascularization of the 
transplanted lungs; thus, the procedure provides a unique setting to study 
leukocyte migration from within the lungs into the recipient. Under EVLP 
conditions, migrating leukocytes are immobilised in the leukocyte filler 
attached to the EVLP circuit.  
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Another limitation of this study is the number of utilised ELVP leukocyte filters. 
It was unfortunate that the DEVELOP-UK study was prematurely terminated; 
thus, for the duration of the study I was able to assess only one EVLP 
leukocyte filter. Assessment of one EVLP filter is not sufficient to reach any 
conclusions; however, it does demonstrate that such studies are feasible and 
further investigation is required to assess whether removal of leukocyte 
population has an effect on clinical outcome in lung transplant recipients.  
 
The first study that assessed the cell composition of human DBD lungs was 
reported by Richter et al.; they observed the presence of different cell 
populations localised in two different compartments of the lungs: the lymph 
nodes and the tissue of the lung itself [139]. Similarly, I have assessed the 
type of cells immobilised within the EVLP leukocyte filter; and to my 
knowledge this is the first study that attempted to characterise the EVLP 
isolated presenter mononuclear cells.  
 
My data revealed that migrating mononuclear cells comprise of three distinct 
cell populations: lymphocytes, monocyte/macrophage and granulocyte 
population. The lymphocyte population was dominant cell population (59%) in 
comparison to monocyte/macrophage (22%) and granulocyte (18.5%).  
 
Further analyses of monocyte/macrophage cell population revealed that the 
majority of these cells are monocytes (88.1%), characterised by the 
expression of CD14+ cell surface marker and lack of CD16- expression. 
CD14+CD16- cells have been described as classical blood monocytes [268]; 
suggesting that most likely these cells originate from the lung vasculature. 
Interestingly, these cells also expressed CD11b cell surface marker. CD11b is 
a β-chain integrin that associates with CD18 and forms complement receptor 
3 (CR3) heterodimer [269]. CD11b is predominantly expressed on 
macrophages, dendritic cells, neutrophils and other leukocytes including 
monocytes; and, play a role in leukocyte adhesion and migration to mediate 
inflammatory responses [269]; thus, it is possible that cells with 
CD14+CD11b+CD16- phenotype represent classical monocytes that are 
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undergoing differentiation into either macrophages and/or dendritic cells. The 
remaining 11% of the cells were identified as mature macrophage population, 
phenotypically characterised as CD14-CD11b+CD16+.   
 
Analysis of the EVLP leukocyte filter isolated lymphocyte population 
comprised of a mixture of lymphocytic cells that proportionally differed from 
the lymphocytic cell prevalence in the peripheral blood, suggesting that the 
lymphocyte population does not originate from the lung vasculature. 
Surprisingly, my data showed that the majority of lymphocytes isolated from 
the EVLP filter were B cells (58%; Table 5.4). Furthermore, only 3.7% of 
lymphocytes were T cells, of which 2.7% were identified as cytotoxic CD8 T 
cells and 1% of the cells were helper CD4 T cells. The percentage of DCs 
characterised as lymphocytes that express CD11b cell surface marker was 
23.3%.  
 
My findings are comparable with the Richter et al., observations in terms of 
the cell populations present in the human lungs. They showed that the 
majority of mononuclear cells present in the tissue of the lung itself were 
lymphocytes and monocyte/macrophage population; and, around 50% of 
these cells were lymphocytes [139]. Nevertheless, I have observed significant 
difference in the percentage of B cells. Richter et al., showed variable number 
of B cells, 19% vs 45% present in the lung parenchyma and lymph nodes, 
respectively. In comparison, my observation showed higher number of B cells 
(58% of the lymphocyte population were identified as B cells), which could 
suggest that these cells derive form the lymph nodes rather than from the lung 
parenchyma itself. Furthermore, B cell population in Richter et al., study was 
identified as CD20+ expressing cells, whereas I described the B cell 
population as CD19+ lymphocytes, Table 5.4 [139]. Another difference that I 
observed was the percentage of CD3, CD4 and CD8 expressing lymphocytes. 
It is rather unexpected that in my study the percentage of CD3+ T cells 
detected was very low (3.7%) in comparison to Richter’s study (55% in 
parenchyma vs 52% in lymph nodes) [139]; the reasons for these differences 
are not obvious. Furthermore, the number of mononuclear cells they detected 
varied between 20-30 x 109, which is also comparable to my study; however, I 
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assessed only one EVLP leukocyte filter and it is possible that the number 
and percentage of various cell populations if variable between different 
donors. Assessment of more EVLP leukocytes filer is necessary to reach firm 
conclusion.   
 
The remaining 11.7% of the lymphocyte population that did not express any of 
the targeted cell surface markers (CD3- CD4- CD8- CD19- CD14- CD11b- 
CD16-) were not further characterised; however, it is possible that these cells 
represent NK cell subsets. Two different subsets of NK cells have been 
previously described CD56brightCD16- and CD56dimCD16+ [270], with 
predominately cytokine producing and cytotoxic effector function, respectively 
[270]. In comparison, Richter et al., observations showed that 15% of the lung 
tissue lymphocytes were NK cells expressing CD56+ cell surface marker 
[139]. Unfortunately, due to the limitation of the sample size I did not use 
monoclonal antibody for detection of CD56 cell surface marker; thus, I am 
unable to confirm presence of NK cells, but the numbers are comparable to 
Richter’s study. 
 
Furthermore, Richter et al., have showed that the lymphocyte population 
varied between the lymph nodes and the lung tissue in regards to their cell 
surface marker expression and their activation state [139]; the lymph nodes 
cells consisted exclusively of naïve T and B cells, where most of the CD4 T 
cells were CD45RA+CD45RO-, whereas, majority of lung tissue T cells were 
activated CD45RA-CD45RO+ expressing cells [139].     
 
In comparison to my data, the CD4 T cell immunophenotyping analysis 
revealed four subpopulations including naïve T cells, T follicular helper cells, 
central memory and effector memory T cells. Firstly, based on the expression 
of CD45RA or CD45RO CD4 T cells we separated them into two populations’ 
naïve (45.1%) and effector/memory (54.9%) T cells, respectively.  
 
The majority of naïve CD45RA+ expressing cells (93.2%) co-expressed 
CD62L and CCR7 cell surface markers. CD62L is an adhesion molecule that 
plays an important role in lymphocyte-endothelial cell interactions [260], 
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whereas, CCR7 is a lymph-node homing receptor expressed on naïve and 
memory T and B cells [259]; implicating the ability of these cells to recirculate 
through the secondary lymphoid tissue. Interestingly, 68.2% of the CD62L+ 
CCR7+ cells co-expressed cell surface chemokine receptor CXCR5, defined 
as a hallmark feature of T follicular helper cells (Tfh), a CD4 Th cell subset 
that promotes germinal center reactions, selection and affinity maturation of B 
cells [255, 256].  
 
In comparison, CD45RO+ expressing CD4 T cells did not express CCR7 and 
CXCR5 cell surface markers, suggesting that these cells do not have the 
ability to recirculate through the secondary lymphoid organs. In addition, 
36.3% of these cells expressed CD62L and the remaining 63.7% lacked 
CD62L expression, suggesting presence of two CD4T cell subsets: central 
memory CD4 T cells and effector memory cells, respectively. In theory, if 
antigen challenged these cells may trigger a vigorous immune response.   
 
Although, only one EVLP filter was utilised in this study, our findings showed 
that the lung is a mononuclear cell rich organ and considerable number of 
immunocompetent CD4 T cell subsets bearing the ability to recirculate 
through the secondary lymphoid organs are transferred with the allograft at 
the time of transplantation.  
 
Removal of leukocytes by EVLP procedure has generated conflicting data in 
animal model. Stone et al., in a porcine model of EVLP, have demonstrated 
that depletion of passenger leukocytes reduces the incidence of acute 
rejection in lung transplantation [271]; whereas in a separate study the same 
group have showed no effect on leukocyte immobilisation in a kidney 
transplant porcine model [272]. Whether immobilisation of passenger 
mononuclear cells using the EVLP procedure will affect the clinical outcome in 
human lung transplantation remains to be seen and is beyond the scope of 
this study.  
 
Irrespective of the limited data set, my findings have increased our knowledge 
about the type of mononuclear cells that are transferred from within the lung 
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allograft into the recipient at the time of transplantation; and, in particular, the 
type of CD4 T cell subpopulations. A further work is required to confirm 
whether the observed cell populations are uniform between different lung 
donors or the lung cell composition depends on the type of donor and/or 
cause of donors’ death.   
 
In summary, due to the massive heterogeneity in the level of gene expression 
I was unable to characterise the peripheral blood isolated donor CD4 T cells; 
thus, it remains unclear whether the observed variation in the longevity of 
donor CD4 T cell chimerism in our lung transplant patient study group is due 
to the presence of different CD4 T cell subsets. At this particular stage, we are 
limited in gaining further knowledge to increase our understanding about 
factors that may influence the longevity of donor CD4 T cells following primary 
lung transplantation.  
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5.4 Key points 
 
• Due to the variation in the levels of gene expression I was not able to 
characterise the isolated donor CD4 T cells; thus, I cannot compare 
whether there is a difference in the CD4 T cell subpopulation between 
the patients with short and patients with long donor CD4 T cell 
chimerism.  
 
• Donor lungs contain large number of mononuclear cells consisting of 
three cell populations including lymphocyte, monocyte/macrophage 
and granulocyte population.  
 
• Donor lungs contain a mixture of naïve and activated/memory CD4 T 
cells that presumably originate from both the local lymph nodes and the 
tissue of the lung itself.  
 
• Immunophenotypically human donor lung CD4 T cells can be classified 
into four subpopulations: naïve, follicular helper T cells, effector 
memory and central memory T cells.   
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6 Chapter 6 
 
 
 
Humoral allo- and auto-immunity in 
lung transplant recipients 
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6.1 Introduction  
 
In solid organ transplantation, humoral immune responses are characterised 
by the production of alloantibody. The alloantibodies are generated 
predominantly against mismatched donor MHC class I and class II antigens 
[87], and occasionally against mHA [186]. In lung transplantation, 
histopathological evidence of small vessel intimitis or endothelialitis, together 
with immunohistochemical staining for complement deposition and presence 
of anti-HLA alloantibody is considered strongly suggestive of a humoral 
effector response, and is termed antibody-mediated rejection (AMR) [273]. 
Depending on the time of onset, AMR can occur within minutes to years after 
allograft transplantation. In more recent years, accumulating evidence 
suggests that in addition to alloantibody responses, transplantation may also 
generate humoral autoimmune responses against a diverse array of 
autoantigens [144].  
 
6.1.1 Clinical significance of allo- and autoantibody in solid organ 
transplantation  
 
Sensitisation to HLA antigens is acquired through prior pregnancy, transfusion 
or transplantation; and about 10% to 15% of patients awaiting lung transplant 
are sensitised to HLA antigens.   
 
Transplantation of organs into patients with pre-existing IgG alloantibodies 
directed against mismatched donor HLA class I (donor specific antibodies, 
DSA) and ABO blood group antigens is often associated with hyperacute or 
accelerated acute allograft rejection [87, 89, 274]. Consequently, 
transplantation of organs into recipients with existing donor specific anti-MHC 
class I alloantibody is avoided, particularly in the presence of a positive, 
complement-dependent cytotoxicity (CDC) crossmatch, unless desensitisation 
protocols are applied prior to transplantation [275]. There is a lack of evidence 
supporting the association of preformed HLA class II DSAs with hyperacute or 
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accelerated allograft rejection [276]; nonetheless, patients with class II DSA 
have poor re-graft survival.   
 
Clinical studies of kidney transplant recipients have revealed that 
development of de novo DSA following transplantation is more commonly 
directed against donor MHC class II, than MHC class I alloantigens. Such 
responses are associated with reduced graft survival and development of 
chronic allograft rejection [277, 278].  
 
Likewise, in a small cohort of lung transplant recipients, it was reported that 8 
out of 9 patients developed de novo anti-MHC class II DSA and only one 
patient developed anti-MHC class I DSA. The development of anti class II 
DSA has been associated with early onset of BOS [279]. For patients with 
pre-existing DSA, these are associated with an increased incidence of primary 
graft dysfunction and acute rejection episodes, with worse patient survival 
rates reported [280]. In addition, poor outcome has also been observed in 
lung transplant recipients with preformed HLA antibodies without specificity for 
donor mismatched antigens.       
 
Humoral rejection has been observed in lung transplant patients who 
developed antibodies to non-HLA self-antigen, even when anti HLA 
alloantibody is not detectable [281]. For, example, de novo autoimmunity to 
type V collagen [282] and K-alpha 1 tubulin (K-α1 tubulin) [283] has been 
implicated as an independent predictor for development of BOS. Interestingly, 
Hachem et al., in a large cohort of 108 lung transplant recipients, showed that 
patients who developed both anti-MHC alloantibody and autoantibodies to 
collagen V and K-α1 tubulin had increased risk of developing BOS. They 
further showed that patients that responded to antibody mediated therapy and 
cleared the autoantibodies were less likely to develop BOS in comparison to 
patients with persistent autoantibodies, irrespective of the presence or 
absence of alloantibodies [284].      
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The involvement of cellular and humoral immunity to type V collagen and its 
association with primary graft dysfunction (PGD) has also been confirmed in 
experimental rat models; passive transfer of collagen V immune serum 
resulted in PGD and increased levels of pro-inflammatory cytokines [285]. In a 
mouse models of lung transplantation, de novo autoimmune responses to 
collagen V and K-α1 tubulin were induced following injection of anti-donor 
HLA antibody directly into the lung [286], suggesting that both allo- and auto-
immune responses contribute to the development of BOS.        
 
Several other autoantigens have been recognised as a target for the 
development of autoimmune responses in organ transplant recipients.  These 
include: cardiac myosin [287, 288]; vimentin [289]; angiotensin II type 1-
receptor (AT1R) [290]; renal pelvis antigens [291]; smooth muscle and 
nuclear antigens [292]. All have been associated with increased risk of 
rejection and poorer outcomes.  
 
The pathophysiology of how allo- and autoantibody cause graft injury and as a 
consequence allograft dysfunction is not fully understood and remains the 
most challenging immunological barrier in human transplantation. AMR is 
often unresponsive to current immunosuppressive regimens; and, it has been 
recognised as a major cause of allograft loss. Thus, understanding the exact 
mechanisms by which alloantibodies (including both DSA and non-DSA) and 
autoantibody mediate allograft rejection is crucial for developing strategies 
specifically designed to ameliorate AMR and prolong allograft survival.   
 
6.1.2 Mechanisms of antibody-mediated allograft injury 
 
The mechanisms underlining antibody mediated allograft rejection involve: 
activation of the complement system via components of C1q-dependent and 
mannose-binding lectin (MBL) – dependent pathway; direct antibody ligation 
to the endothelial cells; and recruitment and activation of innate immune 
system effector cells, including monocytes, macrophages, neutrophils and NK 
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cells. These innate immune cells exert their effector function via Fcγ receptors 
(FcγRs) and complement receptors (CR).  
 
 Complement-dependent alloantibody mediated allograft injury  6.1.2.1
 
The complement system is part of the innate immune system that can result in 
non-specific tissue injury via three main pathways: classical, MBL and 
alternative pathway. Each pathway produces C3 convertase (C4bC2a is 
produced by the classical and lectin pathway and C3bBb is produced by the 
alternative pathway) that cleaves C3 protein. In humans, IgG1 and IgG3 
complement-fixing donor specific alloantibodies (DSA) activate the 
complement system primarily via the classical pathway initiating complement 
cascade by binding and activating the complement component 1 (C1). C1 is 
composed of C1q, an antibody binding component and two proteases, C1r 
and C1s. Activated C1 enzymatically cleaves C4 and C2 protein into two 
fragments C4a and C4b and C2a and C2b, respectively. The larger C4b 
fragment binds covalently to surrounding tissue and with C2a to form enzyme 
complex C3 convertase (C4bC2a). MBL pathway also generates C3 
convertase (C4bC2a) via activation of MASP-1, 2 and 3 associated serine 
proteases through binding to carbohydrates on microorganisms, IgM, some 
isotypes of IgG and injured or apoptotic cells; although the significance of 
MBL complement pathway in allograft rejection is not clear.  
 
The C4b component of C3 convertase is inactivated by Factor I and 
generates C4d fragments, which is the end product of C4 activation. C4d 
binds covalently to surrounding tissue and serves as a marker of antibody-
mediated rejection [293].  
 
C3 convertase cleaves C3 protein into C3b and C3a fragments. The C3b 
component then binds to C3 convertase to generate C5 convertase 
(C4bC2aC3b), which cleaves C5 protein into two biologically active products 
C5a and C5b. The split product C5b initiates the terminal phase of the 
complement system via binding to C6, C7, C8 and C9 proteins to form a 
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tubular structure known as the membrane attack complex (MAC; C5b-C9), 
which forms pores on the target cell membrane leading to cell lysis [294].  
 
Interestingly, lysis of allograft endothelial cells is not a prominent feature of 
AMR, possibly due to regulation of MAC formation by decay accelerating 
factor (DAF) and protectin (CD59) [295]. These are complement regulatory 
molecules that are also observed to be upregulated in allografts undergoing 
accommodation, for example, in biopsies of ABO incompatible heart 
transplant recipients [296]. However, in vitro studies have revealed that small 
amounts of MAC can activate endothelial cells to upregulate the expression of 
adhesion molecules such as E-selectin, intracellular adhesion molecule 
(ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 [297]; and promote 
production of chemokine mediators such as IL-1α [298], monocyte 
chemotactic factor (MCP)-1 and IL-8 [299, 300]. These pro-inflammatory 
mediators trigger recruitment and activation of leukocytes into the allograft. 
Similarly, in human heart transplant recipients, AMR has been associated with 
increased expression of P-selectin and von Willebrand factor (vWf) on the 
endothelium [301]; which promotes adhesion of platelets and monocytes to 
the endothelium and production of pro-inflammatory mediators [302]. Thus, 
endothelial activation alters endothelial cells from an anti-inflammatory 
protective barrier into a pro-coagulant, adhesive and chemoattractive layer 
that promotes inflammation; resulting in recruitment of platelets, neutrophils, 
monocytes, macrophages and NK cells to the site of injury.                   
 
The importance of MAC induced endothelial cell activation and antibody-
initiated cell injury has been highlighted in experiments incorporating C6-
deficient rats. C6-deficient hearts and lungs transplanted into C6-deficient 
recipients had moderate expression of endothelial cell adhesion molecules, 
minimal platelet aggregation and showed no evidence of alveolar hemorrhage 
and edema [303].  
 
Other components of the complement system are able to sustain allograft 
endothelial cell inflammation by recruitment of proinflammatory cells. C3b and 
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C4b are ligands for complement receptor 1 (CR1) and promote extravasation 
of neutrophils, macrophages and leukocytes into the graft [295]. C3b can 
trigger the alternative pathway of complement activation, thus amplifying the 
complement response. C3a and C5a split products promote chemotaxis and 
inflammation. In particular, C5a has a pivotal impact in AMR. C5a is a strong 
chemoattractant for neutrophils and macrophages, and triggers macrophage 
activation via upregulation of stimulatory FcγRII and downregulation of the 
inhibitory FcγRIIB [304]: macrophages thus become more responsive to 
antibodies and complement split products. Avoidance of MAC formation by 
targeting C5 complement fragment and generation of C5a with monoclonal 
antibodies such as Eculizumab have proved effective at reducing the 
requirements for dialysis after transplantation in kidney transplant recipients 
diagnosed with atypical hemolytic uremic syndrome (aHUS) [295, 305]. 
Siedlecki et al., have showed that at six mounts after transplantation graft 
function is significantly better in patients with aHUS that received Eculizumab 
before and after transplantation in comparison to patients that received 
Eculizumab after transplantation only [305]. Furthermore, in more recent 
years Eculizumab has been successfully used as a treatment for ameliorating 
AMR [306] and prevention of AMR in blood group incompatible kidney 
transplant recipients [307].  
 
 Complement-independent alloantibody mediated allograft injury 6.1.2.2
 
Several studies have shown that alloantibodies can mediate complement-
independent endothelial cell activation by cross-linking MHC molecules. This 
results in phosphorylation of tyrosine proteins, production of growth factors 
and increased cell proliferation [308]. The mechanism underlining this 
response is not clear. However, several studies have reported involvement of 
mTOR signaling pathway. Association of HLA class I with intergrin β4 subunit 
permits intracellular mTOR-signaling pathway; knockdown of intergrin β4 
subunit abrogates the ability of HLA class I to activate endothelial cells [309]. 
In further support, lung epithelial carcinoma cell line cultured in vitro with 
pooled serum from highly sensitised patients with BOS showed greater 
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tyrosine phosphorylation and cell proliferation, suggesting a direct action of 
HLA class I alloantibody on allograft endothelium [310]. Similarly, mouse 
endothelial cells undergo activation, characterised by exocytosis of vWf and 
cell surface expression of P-selectin, when cultured with monoclonal 
antibodies directed against their surface MHC class I antigen [311]. In cardiac 
transplant patients with active AMR, the endothelial cell activation correlates 
with activation of mTOR-signaling pathway [312].           
 
Alloantibody may also augment allograft injury mediated by monocytes, 
macrophages and NK cells through interaction with their surface Fc receptors 
and the Fc portion of IgG1, as classically occurs with antibody-dependent cell-
mediated cytotoxicity (ADCC) [313]. Engagement of IgG1 alloantibody with 
stimulatory Fcγ receptors causes recruitment and accumulation of neutrophils 
and macrophages, a key characteristic feature of AMR. In a mouse 
experimental model, Hirohashi et al., have demonstrated that passive transfer 
of non-complement fixing DSA in both B6.RAG-/- KO recipients and 
complement-deficient (RAG-/-C3-/-) models caused tissue injury and 
development of CAV that was dependent on NK cell and macrophage 
infiltration into the graft [314].      
  
 Autoantibody mediated allograft injury 6.1.2.3
 
In more recent years accumulating evidence suggests that, in parallel to 
alloimmune responses and production of alloantibody, transplantation also 
triggers humoral autoimmune responses against a diverse array of 
autoantigens [144]. These may be organ specific such as cardiac myosin 
[287], or ubiquitously expressed, such as smooth muscle and vimentin 
antigens found in liver [292] and heart transplant recipients [289], respectively. 
Autoantibody development in transplant patients without pre-existing 
autoimmune disease suggests that autoimmunity develops de novo after 
organ transplantation; these autoantibodies are mainly class switched IgG 
[144, 287], implying that their generation is T-cell dependent.   
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Despite the peripheral and central mechanisms of clonal deletion and receptor 
editing involved in regulation of B cell development to prevent self-reactivity, 
occasionally these mechanisms fail to eliminate all autoreactive B cells. Small 
populations of autoreactive B cells and the presence of IgM and/or low titre of 
IgG autoantibodies are thus found in healthy individuals [315]. These 
autoantibodies differ from the high-affinity somatically mutated IgG 
autoantibodies found in transplant recipients and patients with autoimmune 
diseases; they are mainly polyclonal and reactive to self and infectious 
antigens [315].  
 
In autoimmune diseases, multiple pathways lead to autoantibody-induced 
tissue injury (previously reviewed by Ludwig et al., [316]). Similar mechanisms 
may be involved in triggering autoimmune responses following 
transplantation. These include: early allograft damage (tissue injury) that may 
trigger release of cryptic self-antigens that have not been previously 
encountered by developing B and T cells [317]; formation and exposure of 
neoantigens generated by alteration of cellular proteins [318]; epitope 
spreading to encompass autoreactivity, secondary to prolonged alloimmune 
responses [319]; immune responses to polymorphic non-self mHAgs [320]; 
and cross-reactivity due to molecular mimicry of autoantigens with infectious 
agents [321]. All of these pathways could potentially result in autoantibody-
mediated complement-dependent and non-complement-dependent allograft 
injury. However, the exact mechanism by which autoantibody causes tissue 
injury is not established, and it has proven difficult to distinguish between the 
auto- and allo-immune contribution to allograft rejection.  
 
Lastly, work from our group has highlighted a unique transplant related 
mechanism for triggering autoimmunity following transplantation, previously 
described in Chapter 3, Section 3.1.3. In brief, Win et al., used a murine 
model of chronic heart graft rejection to study how donor CD4 T cells that 
were passengers within the heart graft influenced the host response to the 
graft. In this model, bm12 strain mouse heart allografts were transplanted into 
C56BL/6 strain recipients. These strains differ only by three amino acid 
residues within the MHC class II I-A antigens (HLA-DQ in humans); 
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consequently, bm12 hearts are rejected slowly (MST > 50 days). Win’s work 
demonstrated that rejection was associated with histologic evidence of 
antibody-mediated rejection, characterised by C4d complement and IgG 
endothelial deposition.  
 
Surprisingly, C56BL/6 recipients did not develop alloantibody, but instead 
graft vascular injury was associated with development of long-lasting IgG 
antinuclear autoantibody [144]. Further experiments revealed that 
development of autoantibody was independent of indirect pathway T cell 
responses; suggesting that an alternative mode of help was responsible for 
the development of autoantibody in the bm12-B6 model. Win thus 
investigated the potential role of passenger donor CD4 T cells in the provision 
of help to host B cells. Transplantation of heart allografts from donor bm12 
mice that lacked T and B cells or were depleted of CD4 T cells prior to heart 
allograft procurement did not prompt autoantibody production in the recipient, 
and heart allograft survival was prolonged [144]   
 
Win concluded that in her model, help for autoantibody production was 
provided via a direct cognate interaction between the donor passenger CD4 T 
cells and the recipient auto-reactive B cells [144]; highlighting a novel 
mechanism for how help for autoantibody production is delivered to recipient 
auto-reactive B cells. Further experiments provided evidence for a 
contributory role of autoantibody in the development and progression of 
chronic allograft vasculopathy.  
 
The work in my thesis was undertaken to investigate whether a similar 
mechanism may occur in human lung transplant recipients. In Chapter 3, I 
showed that donor CD4 T cell passengers within the allograft are readily 
detectable in the peripheral blood of primary lung transplant recipients. 
Surprisingly, the percentage and dynamics of donor CD4 T cell persistence in 
the recipients’ peripheral blood was variable between patients. Based on 
these observations, patients were characterised into three groups: patients 
with short donor CD4 T cell chimerism (donor CD4 T cells detectable for six 
weeks after transplantation, n=13), patients with intermediate donor CD4 T 
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cell chimerism (donor CD4 T cells detectable between three to six months 
after transplantation, n=3) and patients with long lasting donor CD4 T cell 
chimerism (donor CD4 T cells detectable for more than six months after 
transplantation, n=5). As detailed in the previous chapters, the variable 
patterns of survival of donor CD4 T cells in the recipient circulation neither 
correlated with the degree of donor / recipient HLA mismatching nor the gene 
expression profile of the donor CD4 T cells.  
 
To address this question, the following experiments had two aims. The first 
aim was to assess the humoral allo- and autoimmune responses in my study 
cohort of primary lung transplant recipients (n-21). Serum samples obtained at 
the time of transplant and at regular time intervals after transplantation were 
examined for the presence of IgG alloantibody and IgG autoantibody using 
Luminex methodology and HEp-2 Indirect Immunofluorescence (IIF) assay, 
respectively.  
 
Due to the small number of participants in my study cohort, an additional 43 
lung and heart and lung transplant recipients (retrospective cohort) were 
recruited retrospectively for participation in this study. The retrospective study 
cohort consisted of 23 bilateral lung, 2 single lung and 18 heart and lung 
transplant recipients. Humoral allo- and autoimmune responses (either pre-
existing or those that developed de novo after transplantation) were assessed 
by evaluating the presence of allo- and autoantibody using the same 
methodologies.  
 
The second aim was to evaluate the humoral autoimmune response in my 
cohort of transplant recipients, by using high-density protein microarrays to 
profile the autoantibody generated in long-term surviving lung transplant 
recipients with either well functioning allografts and free from BOS (n=10) or 
with established BOS (n=10). The reasoning behind this set of experiments 
was to explore the potential for characterisation of a novel set of “biomarkers” 
which could prompt new screening strategies to monitor and manage 
recipients in the hope of improving graft and patient survival.  
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6.2 Results 
 
Two study cohorts were subjected for assessment of humoral allo- and 
autoimmune responses in lung transplant recipients: a prospective cohort 
(lung transplant recipients recruited for participation in this study prior to 
transplantation); and a retrospective cohort (lung and heart and lung 
transplant recipients recruited for participation in this study at different time 
points after transplantation).  
 
The anti-HLA alloantibody response was characterized by testing recipient 
sera obtained at the time of transplant and at regular times thereafter, using 
Luminex LABScreen® Mixed and LABScreen® Single Antigen HLA Class I 
and Class II Antibody detection beads (detailed in Chapter 2, Section 2.5.1.) 
 
Reactivity to anti-nuclear antibody (ANA) was assessed using HEp-2 Indirect 
Immunofluorescence (IIF) assay and HEp-2 Enzyme-linked Immunosorbent 
assay (Chapter 2, Section 2.5.2 and 2.5.3, respectively).      
 
The autoantibody profiling was evaluated in pre- and post-transplant sera of 
20 lung and heart and lung transplant recipients, 10 with established BOS and 
10 without BOS, using Invitrogen Human ProtoArray® v5.0 protoarray, 
(Chapter 2, Section 2.5.4.).  
 
6.2.1  Prospective study cohort of lung transplant recipients 
 
The prospective cohort consisted of 21 lung transplant recipients; informed 
written consent was obtained prior to transplantation from each participant in 
this study cohort. All patients underwent lung transplantation at Papworth 
Hospital, Papworth Everard, Cambridge, UK; 19 patients received bilateral 
lung and two patients received single lung transplants.  
 
The recipient age varied between 18 and 66 years. Of the 21 patients who 
underwent lung transplantation, 8 were male and 13 female. All patients 
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received triple drug immunosuppression; in addition, two patients received 
induction therapy with Basiliximab, a humanised monoclonal antibody to α 
chain (CD25) of the IL-2 receptor expressed on T cells. Detailed 
representations of the recipient and donor demographic characteristics are 
presented in Table 6.1 (Table 6.1 is same as Table 3.1; considering that 
multiple cohorts are presented in this Chapter (Chapter 6), for clarity Table 6.1 
is presented again).  
 
Previously, in each participant in this study cohort donor CD4 T cell chimerism 
was detected in the peripheral blood obtained at various time points after lung 
transplantation. All patients were followed for 12 months after transplantation.   
 
 
Table 6.1 Prospective study cohort. Lung transplant recipients and donor 
characteristics (Table same as Table 3.1)  
 
Recipient age (Median ± SD)                56 ± 13.6 (18-66 years) 
Recipient sex (M:F)     8:13 
Transplant type     
 SLT       2 
 BLT      19 
 
Donor age (Median ± SD)    48 ± 11.2 (19-60 years) 
Donor sex (M:F)     10:11 
Donor type  
 DBD      20 
 DCD                  1 
 
Indication for transplantation 
 Cystic fibrosis                 3 
 Emphysema                  4 
 COPD                   7 
 Pulmonary fibrosis                 2 
 Bronchiectasis                 2 
 A1AD                  1 
 Emphysema + A1AD                 2 
 
Immunosuppression therapy*               Tacrolimus/MMF/Prednisolone 
 
SLT – Single Lung Transplant; BLT – Bilateral Lung Transplant; DBD – Donation after brain steam 
death; DCD – Donation after cardiac death; COPD - Chronic obstructive pulmonary disease; A1AD- α1 
antitrypsin deficiency; MMF – Mycophenolate Mofetil. 
*Two patients received induction therapy with Basiliximab. 
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6.2.1.1 Incidence of pre- and post-transplant HLA alloantibody in lung 
transplant recipients  
 
To assess the recipients’ sensitisation to HLA alloantigen, sera obtained at 
the time of transplant were screened for the presence of HLA alloantibody 
using Luminex LABScreen® Mixed detection beads (Chapter 2, Section 
2.5.1). All sera that tested positive for the presence of HLA alloantibody were 
further characterised using LABScreen® Single Antigen HLA Class I and 
Class II antibody beads (detailed in Chapter 2, Section 2.5.1) to establish the 
precise specificity of the anti-HLA. The same methodology was used for 
assessment of de novo humoral alloimmune responses using test serum 
samples obtained at regular time intervals after the transplant (1, 3, 6, 9 and 
12 months). Two patients died during the study follow-up period (one patient 
died at day 166 and one at day 171 after the transplant, due to non-transplant 
related complications); all other patients were followed for one year after the 
transplant.  
 
Of the 21 patients, 7 patients had detectable HLA class I antibody prior to 
transplantation and 14 were not sensitised to HLA antigens. None of these 
patients had DSA and the retrospective CDC crossmatch using sera obtained 
prior to transplantation was negative for all patients. Table 6.2 represents the 
patients’ HLA antibody profile in sera tested before the transplant and after 
transplantation transplant at 1, 3, 6, 9 and 12 months.    
 
In summary, all patients that were not sensitised to HLA antigens prior to 
transplantation tested negative for presence of HLA antibody during the first 
year after the transplant; except for one patient (P18, Table 6.2) that 
developed transient de novo class I and class II DSA with specificity to B8, 
DR52 and DQ2 antigens. 
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Table 6.2 represents the patients’ HLA antibody profile (DSA/non-DSA) in 
sera tested pre-transplant and post-transplant at 1, 3, 6, 9 and 12 months.   
 
Patient 
ID 
Pre-Tx  Post-Tx 
1 month 
Post-Tx 
3 months  
Post-Tx 
6 months 
Post-Tx  
9 months 
Post-Tx  
12 months 
 
P1 
 
NS 
 
No Ab 
 
No Ab 
 
No Ab 
 
No Ab 
 
No Ab 
P2 NS No Ab No Ab No Ab No Ab No Ab 
P3 NS No Ab No Ab No Ab No Ab No Ab 
P4 non-DSA non-DSA non-DSA non-DSA No Ab No Ab 
P5 NS No Ab No Ab No Ab No Ab No Ab 
P6 NS No Ab No Ab No Ab No Ab No Ab 
P7 NS No Ab No Ab No Ab No Ab No Ab 
P8 non-DSA  No Ab No Ab No Ab - - 
P9 NS No Ab No Ab No Ab No Ab No Ab 
P10 NS No Ab No Ab No Ab No Ab No Ab 
P11 NS No Ab No Ab No Ab No Ab No Ab 
P12 non-DSA non-DSA non-DSA No Ab DSA / 
non-DSA  
DSA / 
non-DSA  
P13 non-DSA non-DSA non-DSA non-DSA non-DSA DSA / 
non-DSA  
P14 NS No Ab No Ab No Ab No Ab No Ab 
P15 NS No Ab No Ab No Ab No Ab No Ab 
P16 non-DSA DSA / 
non-DSA  
DSA / 
non-DSA  
DSA / 
non-DSA  
DSA / 
non-DSA  
DSA / 
non-DSA  
P17 non-DSA non-DSA DSA/non-
DSA 
DSA/non-
DSA 
DSA/non-
DSA 
DSA/non-
DSA 
P18 NS DSA / 
non-DSA 
DSA / 
non-DSA 
No Ab No Ab No Ab 
P19 NS No Ab No Ab No Ab No Ab No Ab 
P20 NS No Ab No Ab No Ab - - 
P21 non-DSA No Ab No Ab No Ab No Ab No Ab 
 
P – patient 
Pre-Tx – prior to transplantation 
Post-Tx – after transplantation 
NS – non-sensitised patient prior to transplantation   
DSA – Donor Specific Antibody 
Non-DSA – non-donor specific antibody 
No-Ab – HLA antibody not detected 
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Interestingly, sera obtained at around 12 months after transplantation tested 
positive for the presence of both DSA and non-DSA antibody in four patients 
(P12, P13, P16 and P17, Table 6.2); all of which were sensitised to HLA 
antigens before the transplant. One patient had anti-class I DSA, one patient 
had class II DSA only, and two patients had both class I and class II DSA. 
HLA antibodies were not detectable in three patients that were sensitised 
before the transplant (P4, P8 and P21, Table 6.2). All other patients tested 
were negative for the presence of HLA alloantibody. Figure 6.1 represents the 
number of patients sensitised to HLA antigens prior to transplantation and the 
presence of both DSA and/or non-DSA antibody at 1, 3, 6, 9 and 12 months 
after transplantation.  
 
Surprisingly, the presence of pre-existing HLA antibodies was not associated 
with the onset of BOS. Of the 21 recipients, seven recipients had HLA 
antibodies at the time of transplant; of these four developed BOS within the 
first post-operative year and three remained free from BOS. In comparison, 
three out of 14 recipients who did not have HLA antibody prior to 
transplantation also developed BOS (Fisher’s exact test, p=0.156), Table 6.3. 
Likewise, the incidence of acute cellular rejection did not correlate with the 
presence of HLA antibody at the time of transplant. Only four out of seven 
patients with pre-existing HLA antibodies experienced acute cellular rejection 
(ACR); whereas, two out of the 14 recipients without HLA antibody prior to 
transplantation had ACR during the first post-operative year (Fisher’s exact 
test, p=0.119), Table 6.3. Antibody mediated rejection was not diagnosed in 
any of the recipients in this cohort. Table 6.3 details the patients’ HLA 
antibody profile, incidence of BOS and acute cellular rejection.              
 
In addition, in this study cohort we did not observe correlation between the 
onset of BOS and the development of de novo DSA. In total, seven recipients 
developed BOS within the first post-operative year; of these two recipients 
developed DSA and in five recipients DSA were not detected, (Fisher’s exact 
test, p=0.574), Table 6.3.   
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Figure 6.1 HLA sensitisation in lung transplant recipients before the transplant 
and development of de novo HLA antibody after transplantation. The graph 
shows the number of lung transplant recipients sanitised to HLA antigens prior to 
transplantation and development of de novo HLA antibody after transplantation. HLA antibody 
development was assessed in the recipients’ sera obtained at regular time intervals after 
transplantation (1, 3, 6, 9, and 12 months). Luminex LABScreen® Mixed beads and 
LABScreen® Single Antigen HLA Class I and Class II antibody beads were used for detection 
and characterisation of HLA antibody including both, donor specific antibody (DSA) and non-
donor specific antibody (non-DSA).  
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Table 6.3 Recipients’ HLA antibody profile, incidence of BOS and acute cellular 
rejection episodes.   
Patient 
ID 
Pre-Tx Post-Tx 
(12 months) 
BOS  
(Grade) 
Acute cellular rejection 
(No of episodes) 
 
P1 
 
NS 
 
No Ab 
 
Yes (2) 
 
No 
P2 NS No Ab No No 
P3 NS No Ab No No 
P4 non-DSA No Ab Yes (2) Yes (1) 
P5 NS No Ab No Yes (1) 
P6 NS No Ab Yes (2) Yes (1) 
P7 NS No Ab No No 
P8 non-DSA - No Yes (2) 
P9 NS No Ab No No 
P10 NS No Ab No No 
P11 NS No Ab No No 
P12 non-DSA DSA / non-DSA Yes (1) No 
P13 non-DSA DSA / non-DSA No Yes 
P14 NS No Ab No No 
P15 NS No Ab No No 
P16 non-DSA DSA / non-DSA Yes (2) No 
P17 non-DSA DSA / non-DSA No Yes 
P18 NS No Ab No No 
P19 NS No Ab Yes (1) No 
P20 NS - No  No 
P21 non-DSA No Ab Yes (1) No 
 
P – patient 
Pre-Tx – prior to transplantation 
Post-Tx – after transplantation 
NS – non-sensitised patient prior to transplantation   
DSA – Donor Specific Antibody 
Non-DSA – non-donor specific antibody 
No-Ab – HLA antibody not detected 
BOS – Bronchiolitis Obliterans Syndrome 
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6.2.1.2 Incidence of pre- and post-transplant anti-nuclear (ANA) autoantibody 
in recipients of primary lung transplants  
 
To assess the incidence of antinuclear autoantibody present in recipients’ 
sera, serum samples obtained before the transplant and at two time points 
after transplantation (one and twelve months) were tested using HEp-2 
Indirect Immunofluorescence (IIF) assay, Chapter 2, Section 2.5.2.  
 
HEp-2 cells provide a non-specific, but highly sensitive test for detection of 
antinuclear autoantibody. Because they grow as a monolayer on the 
microscopic slide, cells at different stages of the cell cycle are present on the 
same slide; this allows exposure of nuclear antigens expressed only at a 
particular stage of the cell cycle.  
 
The HEp-2 indirect immunofluorescence assay revealed test sera reactivity to 
various anti-nuclear antigens in all test samples, Figure 6.2. Interestingly, the 
anti-nuclear IgG autoantibody titre was highest in the patients’ sera obtained 
at the time of transplant in comparison to the sera obtained after 
transplantation. In comparison to the sera obtained at the time of transplant a 
significant decrease in the anti-nuclear IgG autoantibody titre was observed in 
the post-transplant test samples obtained at one-month (Paired t test, 
p=0.002) and at 12 months (Paired t test,, p=0.006) after transplantation, 
Figure 6.2. Difference in the anti-nuclear IgG autoantibody titre between the 
post-transplant serum samples obtained at one and 12 months after 
transplantation was not observed (Paired t test, p=0.372).   
 
Nonparametric correlation analysis revealed that the level of anti-nuclear IgG 
autoantibody present at the time of transplantation neither correlated with the 
onset of BOS nor with the recipient age at the time of transplant (Spearman r, 
p=0.645 and p=0.385, respectively).   
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Figure 6.2 Anti-nuclear IgG autoantibody level in lung transplant recipients 
detected using HEp-2 Indirect Immunofluorescence assay. The graph shows the 
anti-nuclear IgG autoantibody titres present in the recipients’ pre-transplant sera and sera 
obtained at one-month and 12 months after transplantation. The data is presented as a 
percentage of the positive control sera (human positive control serum supplied by the 
manufacture). Recipients’ sera reactivity to anti-nuclear antigens was strongest in the sera 
obtained prior to transplantation. A significant decrease in IgG anti-nuclear autoantibody titres 
was observed in the test sera obtained at one month (p=0.002; paired t test) and 12 months 
after transplantation (p=0.002; paired t test) in comparison to the sera obtained at the time of 
transplant. There was no significant change in the IgG anti-nuclear autoantibody titres 
between the sera obtained at one month and 12 months after transplantation (p=ns; paired t 
test). Paired t test was used to calculate significance. P-value of <0.05 was considered 
statistically significant. Red broken-lines show negative control sera cut-off values (pooled 
human serum from seven healthy individuals); represented as a mean ± 2SD.  
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6.2.2 Retrospective study cohort of lung and heart and lung transplant 
recipients 
 
Humoral allo- and autoimmune responses were assessed in another study 
cohort (retrospective cohort) of 43 lung and heart and lung transplant 
recipients. 23 patients received bilateral lung, 2 single lung and 18 heart and 
lung transplants at Papworth Hospital, Papworth Everard, Cambridge, UK. All 
patients gave written consent for participation in this study. Pre-transplant 
serum samples were not available for three patients (1 lung and 2 heart and 
lung transplant recipients), subsequently these patients were excluded from 
the study.   
 
The patients were divided into two groups: lung transplant only (n=24) and 
heart and lung transplant group (n=16). The recipient age, recipient gender, 
donor gender and time after transplantation were significantly different 
between the two groups, Table 6.4.  
 
Recipients’ serum samples were obtained at a single time point after 
transplantation and the timing was variable between patients in each group. 
The average time between transplantation and blood sampling was 
significantly shorter in the lung transplant group in comparison to heart and 
lung transplant groups (4.2 vs 9 years, respectively, p=0.023). All transplant 
recipients received comparable immunosuppression. However, the choice of 
immunosuppressive agents reflects a shift towards tacrolimus in more recent 
years. Table 6.4 shows detailed presentation of the recipient and donor 
demographics.  
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Table 6.4 Retrospective study cohort recipient and donor characteristics 
  
Lung transplant 
recipients 
(n=24) 
 
Heart and lung 
transplant recipients 
(n=16) 
 
 
p Value 
 
 
Recipient age (Median ± SD) 
 
54 ± 11.7 
 
31 ± 10.7 
 
0.001 
Recipient sex (M:F) 17:7 5:11 <0.001 
Donor age (Median ± SD) 42  ± 14.2 41 ± 13.9 ns 
Donor sex (M:F) 14:10 5:11 0.045 
Donor type 
            DBD 
            DCD 
 
22 
2 
 
16 
0 
 
ns 
 
Recipient-donor age 
difference (Median ± SD) 
 
 
10.5 ± 15.1 
 
16.5 ± 8.2 
 
ns 
Indication for transplantation                                 
      Cystic fibrosis  
      Histocytosis 
      Emphysema  
      Pulmonary fibrosis   
      Bronchiectasis  
      A1AD 
      Pulmonary hypertension 
      Congenital heart disease 
      Eisenmenger syndrome 
 
 
5 
1 
8 
4 
1 
2 
3 
- 
- 
 
8 
- 
- 
- 
1 
- 
3 
2 
2 
 
 
 
 
N/A 
Years after transplantation  
      Mean 
      Range (years) 
 
 
4.2 
(1-12 years) 
 
9.0 
(1-21 years) 
 
0.023 
HLA mismatches 
          ≤3 
          ≥4 
 
 
8 
16 
 
4 
12 
 
ns 
DBD – Donation after brain steam death; DCD – Donation after cardiac death; M – male; F – female; 
A1AD – α1 antitrypsin deficiency; HLA – Human leukocyte Antigen.  
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6.2.2.1 Incidence of pre- and post-transplant HLA alloantibody in lung and 
heart and lung transplant recipients   
 
The recipients' pre-transplant and post-transplant serum samples were 
assayed for detection and characterisation of HLA alloantibody using Luminex 
LABScreen® Mixed detection beads and LABScreen® Single Antigen HLA 
Class I and Class II antibody beads, respectively, Chapter 2, Section 2.5.1.  
 
Of the 25 patients that received lung transplant; pre-transplant serum sample 
was available for 24 patients; one patient was excluded from the analysis. Six 
patients (25%) were sensitised to HLA antigens prior to transplantation; 5 
patients had pre-transplant class I HLA alloantibody and one patient had class 
II HLA alloantibody; all HLA alloantibodies detected were non-DSA.  
 
Analysis of the sera obtained after transplantation did not indicate 
development of de novo HLA alloantibody. Only 4 patients with pre-existing 
non-DSA remained positive after transplantation. Additional specificities to 
HLA antigens were detected in all patients. Only one patient developed de 
novo class II non-DSA alloantibody and one patient developed class I and 
class II DSA with specificity to donor mismatched B8 and DQ2 antigens. In 
two patients with pre-existing HLA alloantibodies, the alloantibodies were no 
longer detectable in the post-transplant serum sample. Circulating HLA 
alloantibodies were not detected in the pre- and post-transplant sera of 
eighteen lung transplant recipients, Figure 6.3.  
 
In this cohort eighteen patients underwent heart and lung transplantation. Pre-
transplant serum samples were available for 16 patients; subsequently, two 
patients were excluded from further analysis. Of these, only one patient had 
pre-transplant class II non-DSA alloantibody, a change in the HLA specificity 
was not observed in the test samples obtained after transplantation. The 
remaining 15 patients did not have detectable HLA alloantibody in either the 
pre- or post-transplant serum samples, Figure 6.3.  
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Figure 6.3 HLA sensitisation in lung and heart and lung transplant recipients 
before the transplant and after transplantation. The graph shows the number of lung 
and lung and heart (H/Lung) transplant recipients sanitised to HLA antigens prior to 
transplantation. Development of de novo HLA antibody was assessed in the recipients’ sera 
obtained at one time point after transplantation. Sera were tested for the presence of both 
donor specific antibody (DSA) and non-donor specific antibody (non-DSA). 
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6.2.2.2 Incidence of pre- and post-transplant anti-nuclear autoantibody in 
lung and heart and lung transplant recipients   
 
Autoantibody responses were assessed by testing the recipients’ serum for 
the presence of IgG autoantibody with specificity for nuclear antigens using 
two commercially available methodologies, HEp-2 Indirect 
Immunofluorescence Assay (IIF) and HEp-2 Enzyme-Linked Immunosorbent 
Assay (ELISA), previously described in Chapter 2, Section 2.5.2. HEp-2 cells 
are a non-specific but highly sensitive substrate for detection of anti-nuclear 
autoantibody.  
 
The advantage of the HEp-2 cells IIF assay is that the cells are grown as a 
monolayer on microscopic slides, thus allowing detection of autoantibody with 
specificity to nuclear antigens that are expressed only at a particular stage of 
the HEp-2 cell cycle. In comparison, the HEp-2 ELISA contains HEp-2 cell 
extract (lysed cells) as a substrate; this methodology offers availability of total 
cellular components.  
 
Indirect immunofluorescent staining of the HEp-2 cells revealed weak sera 
reactivity to anti-nuclear antigens in the majority of patients in both groups, 
Figure 6.4.  Interestingly, overall the anti-nuclear IgG autoantibody levels were 
higher in the pre-transplant sera in comparison to the sera obtained after 
transplantation. The difference between the pre- and post-transplant sera was 
not significant in the recipients that received lung transplant only (Paired t test, 
p=0.541). In this test group a massive increase in the IgG autoantibody titres 
in the sera obtained after transplantation was observed in one patient, Figure 
6.4 A. In the heart and lung transplant group the anti-nuclear IgG 
autoantibody levels were significantly decreased in the sera obtained after 
transplantation in comparison to the pre-transplant sera (Paired t test, 
p=0.031), Figure 6.4 B.  
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In addition, HEp-2 IIF assay revealed various nuclear and cellular staining 
patterns, suggesting that the IgG autoantibody were directed to multiple 
nuclear and/or cellular targets. The staining patterns were different between 
patients and in several patients, different staining patterns were detected in 
the pre- and post-transplant sera; suggesting epitope spreading, development 
of de novo IgG autoantibody or increase in the IgG titre. In some patients IgG 
autoantibody with specificity to multiple nuclear and/or cellular antigens was 
observed, characterised by the presence of mixed staining pattern.  
 
Similar findings were observed in the HEp-2 ELISA assay; overall the IgG 
alloantibody titres were lower in the sera obtained after transplantation in 
comparison to the pre-transplant serum samples. The IgG autoantibody levels 
were significantly decreased in the sera obtained after transplantation in both 
groups; lung transplant recipients (Figure 6.5 A) and lung and heart transplant 
recipients (Figure 6.5 B), p<0.001 and p=0.004, respectively.   
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A) 
 
B) 
 
Figure 6.4 Anti-nuclear IgG autoantibody level in lung and heart and lung 
transplant recipients detected using HEp-2 Indirect Immunofluorescence 
assay. The graphs show the anti-nuclear IgG autoantibody titres present in the recipients’ 
pre-transplant and post-transplant sera obtained at one time point after transplantation 
(variable between patients and groups). The data is presented as a percentage of the positive 
control sera (human positive control serum supplied by the manufacture) Recipients’ sera 
reactivity to anti-nuclear antigens was stronger in the sera obtained prior to transplantation. A) 
Significant decreases in the anti-nuclear IgG autoantibody titres were not observed between 
the pre- and post-transplant sera (p=ns; paired t test) in the lung transplant recipients; B) 
Significant decreases in IgG anti-nuclear autoantibody titres was observed between the pre- 
and post-transplant serum samples in the lung and heart transplant recipients (p=0.031; 
paired t test). Paired t test was used to calculate significance. P-value of <0.05 was 
considered statistically significant. Red broken-lines show negative control sera cut-off values 
(pooled human serum from seven healthy individuals); represented as a mean ± 2SD. 
 
Pre-Tx Post-Tx
0
5
10
15
20
25
30
35
40
45
50
 Lung transplant recipients (n=24)
Pre-Tx
Post-Tx
ns
An
ti-
nu
cle
ar
 Ig
G 
au
to
an
tib
od
y 
lev
el
(%
 o
f t
he
 p
os
iti
ve
 c
on
tro
l s
er
a)
Pre-Tx Post-Tx
0
5
10
15
20
25
Heart and lung transplant recipients (n=16)
Pre-Tx
Post-Tx
p = 0.031
An
ti-
nu
cle
ar
 Ig
G 
au
to
an
tib
od
y 
lev
el
(%
 o
f t
he
 p
os
iti
ve
 c
on
tro
l s
er
a)
 189 
A) 
 
B) 
 
Figure 6.5 Anti-nuclear IgG autoantibody level in lung and heart and lung 
transplant recipients detected using HEp-2 Enzyme-Linked Immunosorbent 
(ELISA) assay. The graphs show the anti-nuclear IgG autoantibody titres present in the 
recipients’ pre-transplant and post-transplant sera obtained at one time point after 
transplantation (variable between patients and groups). The data is presented as an ELISA 
ratio (ER). ER equals the OD* value of the test sample minus the OD* value of the negative 
control divided by the OD* value of the positive control minus the OD* value of the negative 
control. Significant decreases in the anti-nuclear IgG autoantibody titres were observed 
between the pre- and post-transplant sera A) Lung transplant recipients (p<0.001; paired t 
test); and, B) Heart and lung transplant recipients (p=0.004; paired t test). Paired t test was 
used to calculate significance. P-value of <0.05 was considered statistically significant. Red 
broken-lines show negative control sera cut-off values (pooled human serum from seven 
healthy individuals); represented as a mean ± 2SD. *OD – optical density. 
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6.2.2.3 Correlation between anti-nuclear autoantibody and BOS development 
 
Nonparametric correlation analysis revealed that the presence of anti-nuclear 
IgG autoantibody detected by both HEp-2 IIF (Figure 6.6 A) and ELISA Figure 
6.6 B) did not correlate with development of BOS in lung and heart and lung 
transplant recipients (n=40). Spearman r test was used for correlation 
analysis.  
 
A) 
        p=0.187 
                                                                                                                                   p=0.553 
B) 
          p=0.428 
                                                                                                                                     p=0.767 
 Figure 6.6 Correlation between the level of anti-nuclear IgG autoantibody 
and development of BOS in lung and heart and lung transplant recipients. 
A) Level of anti-nuclear IgG autoantibody detected by Hep-2 IIF assay in pre- and post-
transplant sera of lung and heart and lung transplant recipients (n=40); B) Level of anti-
nuclear IgG autoantibody detected by ELISA assay in pre- and post-transplant sera of 
lung and heart and lung transplant recipients (n=40). Spearman r test was used for 
correlation analysis. P-value of <0.05 was considered statistically significant. 
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6.2.2.4 Correlation between anti-nuclear autoantibody and recipient age  
 
Nonparametric analyses revealed that the level of anti-nuclear IgG 
autoantibody detected by ELISA correlated with the recipient age at the time 
of transplant (6.7 A, p=0.023). This correlation was not observed when anti-
nuclear IgG autoantibody was measured using HEp-2 IIF (6.7 B, p=0.509).     
 
A) 
p=0.023  
B) 
                        p=0.509                                                       
 Figure 6.7 Correlation between the level of anti-nuclear IgG autoantibody 
and recipient age at the time of lung or heart and lung transplant. A) Level of 
anti-nuclear IgG autoantibody detected by Hep-2 IIF assay (n=40); B) Level of anti-nuclear 
IgG autoantibody detected by ELISA assay (n=40). Spearman r test was used for 
correlation analysis. P-value of <0.05 was considered statistically significant. 
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6.2.3 Evaluation of the HEp-2 Indirect Immunofluorescence assay 
   
The HEp-2 IIF and HEp-2 ELISA were performed according to the 
manufacturer’s recommendation using serum dilutions of 1:40 and 1:100, 
respectively, Chapter 2, Section 2.5.2 and Section 2.5.3. However, according 
to the guidelines for laboratory use of IIF tests to aid diagnosis of systemic 
autoimmune diseases, it is recommended that titres lower or equal to 1:40 
should be considered as negative, titres between 1:40 and 1:80 are weak 
positive and titres greater than 1:160 are considered positive.     
 
To comply with these recommendations [322], five serum samples with strong 
positive HEp-2 staining pattern were re-tested using serum serial dilutions of 
1:40, 1:80 and 1:160. Interestingly, all serum samples lost the reactivity to 
HEp-2 cells with dilution factor of 1:160.  
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6.2.4 Identification of autoantibody signature profile in lung plus heart and 
lung transplant recipients using protein microarray 
 
To expand the screening strategy, autoimmune responses were evaluated in 
lung plus heart and lung transplant recipients using a protein microarray 
platform (Invitrogen Human ProtoArray® v5.0 protoarray). This platform 
contains 9480 human recombinant proteins, previously described in Chapter 
2, Section 2.5.4. I reasoned that the application of a large protein panel to 
unveil autoantibody specificities may lead to characterisation of novel sets of 
“biomarkers”, which could prompt new screening strategies to monitor and 
improve allograft survival in lung transplant recipients.  
 
The humoral autoimmune responses were assessed in a sub-cohort of 20 
lung and heart and lung transplant recipients with (n=10 Grade 2 and 3 BOS: 
ISHLT scoring criteria, Table 1.4) and without (n=10, No BOS group) 
established BOS (the sub-cohort was selected from the primary retrospective 
cohort of 24 lung and 16 heart and lung transplant recipients). Humoral 
autoimmune responses were assessed at two time points: at the time of 
transplantation and after transplantation. The post-transplant serum sample 
was obtained at different time points after transplantation, ranging from 1 to 
11 years for patients free from BOS and from 2 to 20 years for patients with 
established BOS.  
 
Table 6.5 shows the recipients’ demographic characteristics; recipient and 
donor age, gender, and type of organ transplanted were comparable between 
the two groups. Circulating HLA alloantibody was not detected in the pre- and 
post-transplant sera in either group. Four patients in the BOS group had 
experienced a single episode of acute cellular rejection in the first six months 
after transplantation in comparison to only two patients in the No BOS group. 
Time of blood samples (years after transplantation), the number of HLA 
mismatched antigens and indication for transplantation were comparable 
between the two groups (Table 6.5).        
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Table 6.5 Recipient and donor characteristics (Sub-cohort for identification of 
autoantibody profile in lung transplant recipients with established BOS and 
recipients without BOS)  
  
BOS (n=10) 
 
No BOS (n=10) 
 
p Value 
 
Recipient age (Median ± SD) 43.5 ± 11.7 40 ± 10.6 ns 
Recipient sex (M:F) 5:5 4:6 ns 
Donor age (Median ± SD) 48.5  ± 12.5 35.5 ± 14.8 ns 
Donor sex (M:F) 4:6 4:6 ns 
Transplanted organ 
            Lung 
            Heart and lung 
 
5 
5 
 
6 
4 
 
 
ns 
Indication for transplantation 
COPD 
Cystic Fibrosis 
Idiopathic Pulmonary Hypertension 
Idiopathic Pulmonary Disease 
Congenital Heart Disease 
 
3 
3 
2 
1 
1 
 
3 
4 
1 
0 
2 
 
 
 
ns 
 
Pre-transplant HLA alloantibody 
Post-transplant HLA alloantibody 
 
 
0/10 
0/10 
 
0/10 
0/10 
 
ns 
ns 
Rejection episodes* 
 
4/10 2/10 ns 
Years after transplantation  
          Mean   
          Range 
 
7.6  
(2-15 years) 
 
6  
(1-20 years) 
 
ns 
 
HLA mismatch antigens 
          ≤3 
          ≥4 
 
 
 
2 
8 
 
 
3 
7 
 
 
ns 
ns 
BOS Grade 
          0 
          1 
          2 
          3 
 
0 
0 
7 
3 
 
10 
0 
0 
0 
 
 
<0.001 
 
M – male; F – female; COPD – Chronic Obstructive Pulmonary Disease; HLA – Human 
Leukocyte Antigen; BOS – Bronchiolitis Obliterans Syndrome; * Cell-mediated rejection. 
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6.2.4.1 Optimisation of the protein microarray scanning settings 
 
In order to maximise the protein microarray fluorescent signal (discovery of 
“true” positive reactions), while minimising the false protein discovery rate, the 
protein microarray scanning setting were first optimised using negative control 
arrays.  
 
Two arrays were probed with buffer containing no serum, followed by the 
incubation with secondary Alexa Fluor® 647 Goat Anti-Human IgG detection 
antibody. Scanning was performed using GenPix® 4000B scanner 
photomultiplier power (PMT) at three different optimization settings: PMT 600, 
PMT 700 and PMT 800 V (Figure 6.8) (detailed in Chapter 2, Section 
2.5.4.2.).  
 
The Alexa Fluor® conjugated antibody imprinted onto the arrays was used as 
a guide for correct positioning of each spot (imprinted protein) and indicates 
that the array has been scanned correctly.  
 
The protein microarrays contain internal control proteins that serve as a guide 
for correct assignment of positive signals. A protein gradient of goat anti-
human IgG is printed onto each sub-array; binding of the human IgG to the 
goat anti-human IgG generates a fluorescent signal that serves as a reference 
to verify correct probing. As recommended by the manufacturer, the signal 
obtained from the goat anti-human IgG imprinted at a highest concentration 
has to be just below the maximum saturation, Figure 6.9. The optimum near 
to saturation signal for the goat anti-human IgG was obtained with PMT of 800 
V, Figure 6.8 C. Subsequently, the experimental microarrays probed with 
patients’ serum samples were scanned under the same scanning conditions. 
 
In the negative control arrays positive signal was obtained for 95 proteins 
(<1%) spotted onto the microarrays. These proteins were excluded from 
subsequent analysis.    
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A) B) C) 
   
 
Figure 6.8 Optimisation of the protein array scanning settings. Two negative 
control protoarrays were tested for optimisation of GenPix® 4000B scanner photomultiplier 
power (PMT) performance settings. The protoarrays were probed with buffer containing no 
serum, prior to the incubation with Alexa Fluor® 647 Goat Anti-Human IgG detection 
antibody. Scanning was performed using three different settings: A) PMT 600 V, B) PMT 
700 V, C) PMT 800 V. To maximise the signal intensity recorded, the human IgG signal 
printed on the protoarray at a highest concentration has to be near to saturation. An 
optimum near to saturation signal was obtained with PMT of 800 V as showed in C. The 
experimental protoarrays probed with human test sera were scanned under same scanning 
conditions.  
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A) B) 
  
 
Figure 6.9 Visual schematic representative image of sub-array internal control 
proteins. The protoarray contain 9480 proteins imprinted in duplicates. The proteins are printed in 
110µm spots arrayed in 48 sub-array (4400-µm2 each) and equally spaced in vertical and horizontal 
directions with 22 columns and 22 rows per sub-array. Each sub-array contains control proteins. 
Control proteins provide reference points for data acquisition and analysis. This graph shows one 
sub-array containing 22 columns and 22 rows and the internal control proteins. A) Negative control 
assay, the protoarray was probed with buffer containing no serum, B) Experimental assay; the 
protoarray was probed with patient serum sample. Protoarray positive controls are highlighted: 
yellow, Alexa Fluor® conjugated antibody signal indicates that the protoarray has been properly 
scanned and serves as an indicator for correct positioning of the protoarray; green, Anti-human IgG 
signal used for verification of proper probing and detection reagents; blue, Human IgG Signal 
serves as a positive control when anti-human IgG is used for detection and red, protoarray negative 
controls (BSA and Buffer).   
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6.2.4.2 Characterisation of autoantibody signature profile in lung transplant 
recipients with established BOS and recipients free from BOS 
 
To characterise the IgG autoantibody signature profile present at the time of 
transplant and after transplantation in patients with established BOS (n=10) 
and patients free from BOS (n=10) the data obtained from the protein 
microarray assay was analysed with the ProtoArray® Prospector software 
provided by Invitrogen (detailed in Chapter 2, Section 2.5.4.4). Figure 6.10 
shows a representative image of the protein array probed with pre- transplant 
A) and post-transplant B) sera form a patient with established BOS.  
 
Data analysis is a 3-step process and involves single array analysis, group 
characterisation and two-group comparison analysis. Single array analysis 
was performed individually for each test sample using the manufacture 
recommendations; positive probes or hits were setup to a cutoff value of Z-
Score > 3 and Z-Factor ≥ 0.4. The relative fluorescent unit (RFU) for each 
protein is normalised against the background staining, and positive hits are 
identified based on the significant difference between the RFU value of 
individual protein and the negative controls.  
 
The number of proteins identified as positive hits varied between patients in 
both groups. In the BOS group, the number of positive hits ranged from 333 
hits (min., 3.55%) to 2892 hits (max., 30.82%) and 383 hits (min., 4.08%) to 
2819 hits (max., 30.04%), for the pre- and post-transplant sera, respectively, 
Table 6.6. Similar findings were observed in the patient group free from BOS; 
the number of positive hits in the pre-transplant sera ranged from 716 hits 
(min., 7.63%) to 3098 hits (max., 33.01%); and, in the post-transplant sera the 
number of positive hits ranged from 823 (min., 8.77%) to 2302 hits (max., 
24.53%). Table 6.6 and Table 6.7 show the number and percentage of 
proteins that were identified as positive in the recipients’ pre- and post-
transplant sera.  
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Table 6.6 Number and percentage of proteins identified as positive hits in lung 
transplant recipients with established BOS  
Patient ID 
(BOS Group) 
No. of positive 
hits (pre-
transplant sera) 
% of protoarray 
positive hits* (pre-
transplant sera) 
No. of positive 
hits (post-
transplant sera) 
% of protoarray 
positive hits* (post-
transplant sera) 
 
P1 
 
333 
 
3.55 
 
2819 
 
30.04 
P2 829 8.83 1557 16.50 
P3 960 10.23 1290 13.75 
P4 980 10.44 383 4.08 
P5 1113 11.86 1396 14.87 
P6 1420 15.13 1830 19.50 
P7 1617 17.23 1225 13.05 
P8 2640 28.13 2059 21.94 
P9 2745 29.25 1317 14.03 
P10 2892 30.82 2024 21.57 
 
*Single array contain 9480 proteins, 95 proteins show reactivity with the negative control assay and were excluded 
from the analysis; and recipients’ IgG autoantibody specificity was assessed for 9385 proteins. 
 
 
Table 6.7 Number and percentage of proteins identified as positive hits in lung 
transplant recipients without BOS 
Patient ID 
(No-BOS 
Group) 
No. of positive 
hits (pre-
transplant sera) 
% of protoarray 
positive hits* (pre-
transplant sera) 
No. of positive 
hits (post-
transplant sera) 
% of protoarray 
positive hits* (post-
transplant sera) 
 
P1 
 
716 
 
7.63 
 
1653 
 
17.61 
P2 1079 11.50 2059 21.94 
P3 1315 14.01 1055 11.24 
P4 1360 14.49 823 8.77 
P5 1625 17.31 1869 19.91 
P6 1971 21.00 1424 15.17 
P7 2343 24.97 1964 20.93 
P8 2426 25.85 1329 14.16 
P9 2821 30.06 2302 25.53 
P10 3098 33.01 1334 14.21 
 
*Single array contain 9480 proteins, 95 proteins show reactivity with the negative control assay and were excluded 
from the analysis; and recipients’ IgG autoantibody specificity was assessed for 9385 proteins.  
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A) B) 
 
 
 
 
 
 
 
 
 
 
Figure 6.10 Characterisation of IgG autoantibody specificity using protein array 
methodology. Protoarrays containing 9480 human proteins were probed with pre- and 
post-transplant sera from patients with established BOS (n=10) and patients free from BOS 
(n=10).  This figure shows representative image of IgG autoantibody reactivity of patient with 
established BOS. The array was probed with A) sera obtained at the time of transplant and B) 
sera obtained after transplantation. In both arrays a representative sub-array is enlarged 
showing the recipient IgG autoantibody reactivity: protein boxed in A) green and B) yellow 
show the same protein identified as positive hits in the pre- and post-transplant sera, except 
that the protein boxed in yellow show stronger reactivity. A) Blue boxed protein represents 
protein that was identified as positive hit in the pre-transplant sera, but is negative in the post-
transplant sera; and, B) Red boxed proteins identified as positive hits in the post-transplant 
sera only. Each protein is spotted onto the array in duplicates. ProtoArray® Prospector 
software (cutoff value of Z-Score > 3 and Z-Factor ≥ 0.4) was used to identify positive 
proteins or hits. Proteins are scored as positive hits if there is a significant difference in the 
mean fluorescent intensity (MFI) between the target protein and the negative controls.  
 
 
 
 
 
 201 
Group characterisation was performed according to the manufacturer’s 
recommendations; four groups were characterised: No BOS pre-transplant 
(n=10), No BOS post-transplant (n=10), BOS pre-transplant (n=10) and BOS 
post-transplant (n=10). In this analysis step the RFU value for each protein 
across all samples in each study group are aligned together for downstream 
analysis using Linear Model with internal reference protein features (positive 
controls used for normalisation are human IgG and anti-human IgG gradients 
printed in each sub-array) normalisation method.   
 
Lastly, two-group comparison analyses were performed; this step identifies 
differences between two groups using M-statistics (data normalisation 
analysis using Robust Linear Model), counts the proteins more prevalent in 
the test groups and generates P-Value (P-value of <0.05 was considered 
statistically significant), previously described in Chapter 2, Section 2.5.4.4.  
 
Two-group comparison analysis was performed between the BOS pre-
transplant and No BOS pre-transplant groups and between the BOS post-
transplant and No BOS post-transplant groups. One-hundred and thirty eight 
proteins were identified as more prevalent positive hits in the BOS pre-
transplant sera in comparison to the No BOS pre-transplant sera, (p < 0.5), 
whereas in the No BOS pre-transplant sera 787 proteins were identified as 
more prevalent targets when compared to BOS pre-transplant sera, (p < 0.5); 
interestingly, none of these proteins overlapped between both groups, Figure 
6.11.        
 
Comparison analysis of the autoantibody profile in the sera obtained after 
transplantation between the patients with BOS and patients without BOS 
revealed 316 protein positive hits were more prevalent in patients with BOS; 
and, 303 proteins were more prevalent in the No BOS group, (p < 0.5), Figure 
6.11.    
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To illustrate the number of proteins identified as positive hits in both groups of 
patients for the pre- and post-transplant sera, a Venn diagram was generated 
using R 2.9.2 software for statistical computing and graphics; in addition, we 
assessed whether the protein positive hits were present specifically in one 
test group or whether they were shared between the patient groups and/or 
test samples.  
 
The results revealed that IgG autoantibodies with specificity to 170 proteins 
were present at the time of transplantation in the patients free from BOS (No 
BOS pre vs No BOS post) and remained positive in the test sample obtained 
after transplantation, Figure 6.11. Autoantibody specific for eight proteins 
were found to be present in the pre-transplant sera of patients without BOS 
and the post-transplant sera of the patients with established BOS. Analysis of 
the patients with established BOS revealed the presence of IgG autoantibody 
with specificity to 44 proteins in both sera obtained at time of transplant and 
after transplantation.   
 
Interestingly, shared IgG autoantibody profile was not observed between the 
patients with BOS and patients free from BOS in the sera obtained at the time 
of transplant and after transplantation (Figure 6.11), suggesting a unique 
autoantibody signature profile may influence the development of BOS after 
transplantation.  
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Figure 6.11 Venn diagram illustrating the number of proteins identified as 
positive hits in sera obtained at the time of transplant and after transplantation 
in patients with established BOS and patients free from BOS. Two-group 
comparison analysis was performed using ProtoArray® Prospector software. The 
autoantibody profile present in sera obtained at the time of transplant and after transplantation 
was compared between patients with BOS and patients without BOS (BOSpre vs NoBOSpre 
and BOSpost vs NoBOSpost). 138 proteins were more prevalent in the BOSpre group, 787 
proteins were more prevalent in the NoBOSpre, 316 proteins were more prevalent in the 
BOSpost and 303 proteins were more prevalent in the NoBOSpost group, p-value < 0.05. The 
Venn diagram was generated using R 2.9.2 software for statistical comuting and graphics. P-
Value of < 0.05 was considered statistically significant. 
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In addition, a protein clustering analysis for the proteins identified as positive 
hits (n=1322, p-value of < 0.05) was performed to assess the autoantibody 
repertoire in the patients with established BOS and patients without BOS. 
Protein clustering is used to to construct group of similar proteins to be used 
for analysis. Heat maps with dendograms graphical representation was 
generated for the protein clustering analysis using R 2.9.2 software for 
statistical computing and graphics.  
 
The clustering analyses highlighted distinct patterns between the patients with 
established BOS and patients without BOS. Figure 6.12 A and B shows the 
cluster analysis of patients with BOS and patients without BOS for both sera 
obtained at the time of transplant (Figure 6.12 A) and sera obtained after 
transplantation (Figure 6.12 B).  
 
The autoantibody repertoire present at the time of transplantation revealed 
two distinct clusters between the patients that developed BOS and patients 
that remained free from BOS after transplantation, suggesting that the 
autoantibody repertoire present at the time of transplantation may influence 
development of BOS. Conversely, a “unique” autoantibody repertoire was 
observed in the sera obtained after transplantation in both groups of patients, 
Figure 6.12.  
 
In addition, we assessed the autoantibody repertoire in the pre- and post-
transplant sera in the patients with BOS alone. The clustering analyses show 
two distinct autoantibody patterns and most of the proteins identified as 
positive targets were present at the time of transplantation, signifying that the 
pre-transplant autoantibody repertoire may correlate with the development of 
BOS after transplantation, Figure 6.13.   
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A) 
 
B) 
 
Figure 6.12 Heat maps of autoantibody repertoire detected in patients with BOS 
and patients without BOS at the time of transplant and after transplantation. The 
heat maps show the total number of proteins identified as positive according to calculated 
prevalence with p-value of < 0.05. Each column represents individual serum sample and the 
rows are protein targets that were identified as positive in each serum sample. A) Autoantibody 
repertoire present at the time of transplantation in patients with established BOS (BOS pre-Tx, 
n=10; pale red) and patients without BOS (No BOS post-Tx, n=10; pale blue); B) Autoantibody 
repertoire present after transplantation in patients with established BOS (BOS post-Tx, n=10; 
dark red) and patients without BOS (No BOS post-Tx, n=10; dark blue). Cluster analysis was 
performed using R 2.9.2 software for statistical computing and graphics. P-Value of < 0.05 was 
considered statistically significant.  
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Figure 6.13 Heat map of autoantibody repertoire present in patients with BOS 
at the time of transplant and after transplantation. The heat map shows the total 
number of proteins identified as positive according to calculated prevalence with p-value of < 
0.05. Each column represents individual serum sample and the rows are protein targets that 
were identified as positive in each serum sample. The heat map shows the autoantibody 
repertoire in patients with BOS present at the time of transplantation (BOS pre-Tx, n=10; pale 
red); and, the autoantibody repertoire present after transplantation (BOS post-Tx, n=10; dark 
red). Cluster analysis was performed using R 2.9.2 software for statistical computing and 
graphics. P-Value of < 0.05 was considered statistically significant. 
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6.2.4.3 Classification of the protein of interest  
 
The purpose of utilising a large number of protein targets for characterising 
the autoantibody repertoire was to identifying specific protein targets that may 
serve as novel sets of “biomarkers” to aid and improve patient management.   
 
The clustering analyses highlighted two distinct patterns between test patients 
with established BOS and patients without BOS, and the presence of “unique” 
autoantibody patterns in the test sera obtained at the time of transplantation. 
These autoantibody repertoires appear to indicate patients that will either 
subsequently develop BOS or that will remain free from BOS.  
 
To narrow down the number of proteins identified as targets for autoantibody 
development, I selected the proteins with the highest prevalence in patients 
with established BOS. At the time of transplantation, eight proteins were 
identified as positive in the BOS group, with a prevalence of >65%, such that 
at least 7/10 patients in the BOS group had autoantibody with specificity to 
these proteins; in contrast only one patient in the No BOS group exhibited 
these autoantibody specificities. Analysis of the protein relative fluorescence 
units (RFU) revealed that the difference in the RFU was statistically significant 
(p<0.05) only for five proteins, Figure 6.14.  
 
Table 6.8 lists the proteins identified as positive with highest prevalence in 
patients with established BOS (database ID, description of the protein and 
protein function). Figure 6.14 shows the IgG autoantibody levels in the 
patients with established BOS and patients without BOS.          
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Table 6.8 List of proteins identified as positive with highest prevalence in 
patients with established BOS. 
No Database ID Description of the protein Protein function 
 
1 NM_001659.1	 ADP-ribosylation	factor	3	(ARF3)	
	
Involved	 in	 protein	 trafficking;	 may	
modulate	 vesicle	 budding	 and	 un-
coating	within	the	Golgi	apparatus.	
2 NM_175634.1	 Protein	CBFA2T1	
	
Protein	CBFA2T1	is	a	transcriptional	co-
repressor,	 which	 facilitates	
transcriptional	 repression	 via	 its	
association	 with	 DNA-binding	
transcription	factors	and	recruitment	of	
other	 co-repressors	 and	 histone-
modifying	enzymes.	
	
3 NM_006949.1	 Syntaxin-binding	protein	2	
	
Involved	 in	 intracellular	 vesicle	
trafficking	 and	 vesicle	 fusion	 with	
membranes.	 Regulates	 cytotoxic	
granule	exocytosis	 in	natural	 killer	 (NK)	
cells.	
	
4 NM_004349.2	 Runt-related	transcription	
factor	1;	translocated	to,	1	
(cyclin	D-related)	(RUNX1T1),	
transcript	variant	1	
	
DNA	 binding	 transcription	 factor	 that	
regulates	 expression	 of	 numerous	
genes.	 Chromosomal	 translocation	
results	 in	 a	 fusion	 protein	 that	 down-
regulated	 the	 expression	 of	 another	
transcription	 factor	 called	 RUNX1.	
RUNX1	 is	 a	 main	 transcription	 factor	
that	 regulates	 naïve	 T	 cell	
differentiation	 into	 either	 Th17	 or	
regulatory	T	cell	subsets.	
	
5 NM_007194.2	 CHK2	checkpoint	homolog		
(S.	pombe)	(CHEK2),	transcript	
variant	1	
Checkpoint	 kinases	 (Chks)	 are	
serine/threonine	 kinases	 that	 are	
involved	in	the	control	of	the	cell	cycle;	
in	response	to	double	strand	breaks.	
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Figure 6.14 Autoantibody levels present at the time of transplant in patients with 
established BOS and patients without BOS. The graph shows IgG autoantibody level to five 
proteins present in the recipients’ sera at the time of transplant. Recipients’ serum reactivity was 
assessed using protein microarray comprising of 9840 proteins. ProtoArray® Prospector software was 
used for data analysis. A) ADP-ribosylation factor 3 (ARF3); B) Protein CBFA2T1; C) Syntaxin-binding 
protein 2; D) Runt-related transcription factor 1; translocated to, 1 (cyclin D-related) (RUNX1T1), transcript 
variant 1; and E) CHK2 checkpoint homolog (S. pombe) (CHEK2), transcript variant 1 were identified as 
positive target proteins with highest prevalence in recipients with established BOS (BOS group) in 
comparison to recipients without BOS (No BOS group). The autoantibody levels were significantly higher 
in the patients with BOS in comparison to patients without BOS. The autoantibody levels are presented as 
mean Relative Fluorescent Units (RFU). Mann-Whitney t-test was used to calculate significance. P-value 
of <0.05 was considered statistically significant.  
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In theory, each protein identified as a potential candidate “biomarker” should 
be evaluated on a confirmatory study cohort, using a different detection 
methodology. I therefore assessed the validity of RUNX1T1 as a potential 
candidate protein for autoantibody development, because, given its potential 
role in influencing Th17 differentiation (see Table 6.6 (4)) and the likely 
contribution of Th17 T cells to autoimmune responses against Col (V) and K-
α1 tubulin [284], RUNX1T1 appeared as an attractive candidate “biomarker” 
for lung transplantation.    
 
I therefore developed a RUNX1T1 specific ELISA (Chapter 2, Section 2.5.5) 
to assess the presence of autoantibody against RUNX1T1 in the “discovery” 
cohort (BOS group, n=10 and No BOS group, n=10), and in another, 
unrelated study cohort (confirmatory study cohort; n=41) of lung and heart and 
lung transplant recipients, that included 24 patients with BOS grade 1, 2 and 3 
and 17 patients free from BOS, Table 6.9 and Figure 6.16. Initially, I screened 
the discovery study cohort for RUNX1T1 specific autoantibody by ELISA, 
Figure 6.15 A. The IgG antibody level is presented as arbitrary units 
interpolated from a standard curve. The results obtained by ELISA 
methodology did not highlight differences in the RUNX1T1 IgG antibody level 
between the two groups of patients in comparison to the RUNX1T1 IgG 
antibody level detected by protein microarray methodology, Figure 6.15 B. In 
addition, I have also included a control group of seven healthy volunteers; we 
observed significant difference between the test groups and the controls, but 
there was no difference between the patient groups, Figure 6.15 C.  
 
Likewise, we did not observe differences in the RUNX1T1 antibody level 
between the patients with BOS and patients without BOS in the confirmatory 
study cohort, Figure 6.16. Table 6.9 shows the confirmatory study cohort 
recipient and donor characteristics.   
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Figure 6.15 RUNX1T1 antibody level present at the time of transplant in patients 
with established BOS and patients without BOS. The graph shows RUNX1T1 IgG 
autoantibody level tested using ELISA (A and C) and protein microarray methodology (B). 
ProtoArray® Prospector software was used for protein microarray data analysis; B) autoantibody 
levels are presented as mean Relative Fluorescent Units (RFU); A) and C) autoantibody levels 
are expressed as arbitrary units interpolated from a standard curve. The standard curve was 
constructed using serial dilution of RUNX1T1 monoclonal antibody (1000 is the highest point on 
the curve). A) Significant difference in the RUNX1T1 antibody level was not observed between 
the patient groups (BOS vs No BOS) when tested by ELISA; B) The RUNX1T1 antibody level 
was significantly higher in patients with BOS when tested by protein microarray; C) Significant 
difference in the RUNX1T1 antibody level was observed between the test groups and the controls 
(healthy volunteers), but there was no difference between the patient groups when tested by 
ELISA. Mann-Whitney t-test was used to calculate significance. P-value of <0.05 was considered 
statistically significant.  
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Table 6.9 Confirmatory study cohort recipient and donor characteristics 
 BOS (n=24) No BOS (n=17) P value 
 
Recipient age (Median  SD) 
 
56  15.8 56  12.2 ns 
Recipient sex (M:F) 
 
13:11 10:7 ns 
Transplanted organ  
          SLT 
          BLT 
          HLT 
 
 
3 
15 
6 
 
1 
15 
1 
 
 
ns 
Donor age (Median  SD) 
 
46  14.7 45  11.8 ns 
Donor sex (M:F) 
 
12:12 12:5 ns 
Indication for transplantation 
          COPD 
          Cystic fibrosis 
          Emphysema 
          Other  
 
 
3 
5 
7 
9 
 
5 
3 
5 
4 
 
 
ns 
HLA sensitisation (pre-transplant) 
 
9 3 ns 
Years after transplantation  
         Mean 
         Range (years) 
 
 
3.9 
(1-13 years) 
 
2.1 
(1-21 years) 
 
ns 
BOS grade 
          BOS 0 
          BOS 1 
          BOS 2 
          BOS 3 
 
0 
10 
9 
5 
 
17 
0 
0 
0 
 
 
<0.0001 
 
BOS – Bronchiolitis Obliterans Syndrome; M – male; F – female; COPD - Chronic obstructive pulmonary 
disease; SLT – Single Lung Transplant; BLT – Bilateral Lung Transplant; HLT – Heart and Lung 
Transplant; HLA – Human Leukocyte Antigen. 
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Figure 6.16 RUNX1T1 antibody level present at the time of transplantation in 
patients with established BOS and patients without BOS.  The graph shows 
RUNX1T1 IgG autoantibody level in patients with established BOS (n=24) and patients 
without BOS (n=17). The autoantibodies were detected using RUNX1T1 specific ELISA and 
the autoantibody levels are expressed as arbitrary units interpolated from a standard curve. 
The standard curve was constructed using serial dilution of RUNX1T1 monoclonal antibody 
(1000 is the highest point on the curve). Significant difference in the RUNX1T1 antibody 
levels was not observed between patients with BOS and patients without BOS. Mann-Whitney 
t-test was used to calculate significance. P-value of <0.05 was considered statistically 
significant. 
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6.3 Discussion  
 
To evaluate the humoral allo- and autoimmune responses in lung transplant 
recipients’, sera obtained at the time of transplant and after transplantation 
were tested for presence of HLA alloantibody and anti-nuclear autoantibody.  
HLA alloantibodies were detected and characterised using Luminex 
methodology, whereas, presence of autoantibody with specificity for anti-
nuclear antigens was tested using HEp-2 IF and HEp-2 ELISA assay.   
 
The analysis of humoral alloimmune responses revealed that 33.33% of the 
patients in the prospective study cohort (n=21) were sensitised to HLA 
antigens prior to transplantation (Figure 6.1) in comparison to 17.5% of 
patients in the retrospective study cohort (n=40, Figure 6.3). These 
observations are slightly higher than the average percentage of sensitised 
patients awaiting lung transplantation ranging between 10% and 15% [6].  
 
In the prospective cohort development of de novo humoral alloimmune 
responses to donor mismatched antigens was observed in 4 patients (21%); 
these patients were also sensitised to HLA antigens prior to the transplant. 
Interestingly, humoral alloimmune responses did not develop during follow up 
in patients that were not sensitised prior to transplantation, except for one 
patient that developed transient HLA antibodies (P18, Table 6.2).   
 
In comparison, only one patient in the retrospective group (2.5%) developed 
de novo DSA. In this cohort, humoral alloimmune responses were assessed 
at different time points after transplantation, ranging from 1 to 21 years; and 
approximately 50% of the patients were long-term survivors (more than 6 
years after transplantation). Previous studies have reported that patients that 
do not develop HLA alloantibody (including both DSA and/or non-DSA) have 
better clinical outcome [323].  
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Assessment of the humoral autoimmune responses revealed that the majority 
of patients in both study groups (prospective and retrospective study group) 
had IgG autoantibody directed to various cellular and nuclear antigens at the 
time of transplant. Interestingly, significant reduction in the autoantibody 
reactivity was observed in the test samples obtained after transplantation 
(Figure 6.2, Figure 6.4 and Figure 6.5), irrespective of the time of serum 
sample collection. In the prospective study cohort significant reduction in the 
autoantibody profile was observed in the serum samples obtained at one 
month after the transplant, Figure 6.2, and the autoantibody level remained 
unchanged at 12 months after transplantation. There was no significant 
difference in the autoantibody levels between sera obtained at one and 12 
months after transplantation.      
 
Similar findings were observed in the retrospective cohort, Figure 6.4; 
however, there was a difference between the HEp-2 IIF and the HEp-2 ELISA 
assay. The reduction of the autoantibody levels was more prominent in the 
post-transplant serum samples tested by ELISA (Figure 6.5) in comparison to 
the HEp-2 IIF assay (Figure 6.4). Although direct comparison between two 
different methodologies cannot be made, it is tempting to speculate that the 
observed difference is probably due to the higher sensitivity of the ELISA 
assay. The HEp-2 ELISA uses lysed HEp-2 cells as a substrate allowing 
exposure of the total cellular components; however, the autoantibody 
specificity cannot be characterised with the HEp-2 ELISA; whereas, in 
contrast HEp-2 IIF assay offers higher specificity allowing detection of 
autoantibody to specific antigens characterised by unique staining patterns.      
 
The HEp-2 IIF assay revealed various nuclear and cellular staining patterns; 
suggesting that the IgG autoantibody were directed to multiple nuclear and/or 
cellular targets. In addition, several patients’ had different staining patterns in 
the pre- and post-transplant sera, suggesting development of de novo IgG 
autoantibody, epitope spreading and/or increase in the autoantibody titres. In 
some patients IgG autoantibodies with specificity to multiple nuclear and/or 
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cellular antigens were observed, characterised by the presence of mixed 
staining pattern.  
 
This study demonstrated the presence of autoantibody with specificity to 
multiple anti-nuclear antigens at the time of transplant in the majority of lung 
transplant recipients; interestingly, a significant decrease in the autoantibody 
levels was observed after transplantation. In contrast, Porcheray et al, have 
reported increased reactivity to HEp-2 cells in kidney transplant patients with 
chronic humoral rejection in comparison to patients without chronic humoral 
rejection in the serum samples obtained after transplantation, but not at the 
time of transplant [324].  
 
HEp-2 IIF and HEp-2 ELISA are widely used screening assays for systemic 
autoimmune diseases [325, 326], many of which are characterised by the 
presence of anti-nuclear antibody to a specific antigen; however, these tests 
are not diagnostic tests. Therefore, positive HEp-2 screening tests are 
reported as a titre; and disease differential diagnosis is dependent on a 
confirmatory antigen specific immunoassay. Additionally, clinical usefulness of 
HEp-2 assay is only considered when interpreted in conjugation with patient 
clinical symptoms. Therefore, it has been recommended that the assay should 
not be used as a screening test for individuals without any clinical symptoms, 
due to the observed weak serum reactivity of healthy individuals, older 
people, pregnant woman, cancer patients, patients with chronic infections, 
and other diseases [322].  
 
My findings have raised questions regarding the clinical significance of 
autoantibody titres present in the recipients’ serum at the time of transplant 
and the adequacy for utilisation of HEp-2 IIF and HEp-2 ELISA assays in lung 
transplantation. It is quite possible, for example, that the autoantibody levels 
observed are below a cut-off of what is deemed clinically relevant, irrespective 
of the significant difference between the pre- and post-transplant test 
samples.  
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Assessment of the patients’ sera with strong positive HEp-2 staining pattern 
using serial dilutions revealed absence of sera reactivity to HEp-2 cells 
(dilution factor 1:160), Section 6.3. These finding suggest that the 
autoantibody titres present in the patients’ sera at the time of transplant may 
not represent “true” positive findings. It is questionable whether the use of 
serial dilutions is suitable for interpretation of our findings. Unfortunately, at 
this stage the application of HEp-2 assays for assessment of humoral 
autoimmune responses in lung transplantation is not obvious.  
 
It is important to stress that a control population of a random collection of 
disease-free, non-transplanted patients was not included in the study. Thus, it 
is extremely difficult to know whether the autoantibody responses that I have 
observed are real findings or simply represent non-specific binding. It is quite 
possible that autoantibody responses observed in BOS free lung transplant 
recipients are due to the nature the underlining chronic lung disease. 
Therefore, assessment of autoantibody responses in an appropriate reference 
population would be crucial to be able to draw a firm conclusion.   
 
In addition, it is possible that the observed reduction in the autoantibody IgG 
titres might be due to the reduction of the total IgG levels, a known post-
transplant complication in solid organ transplantation [327] observed in kidney 
[328], liver [329], heart and lung transplant recipients [330]. The total IgG 
levels present at the time of transplant and after transplantation were not 
measured in my study and I cannot confirm whether the observed reduction in 
the autoantibody levels is due to reduction of the total IgG levels.    
 
To widen my screening strategy, the humoral autoimmune responses were 
assessed in a sub-cohort of lung transplant recipients in whom alloimmune 
responses were not detected. Thus, in the absence of alloimmune responses 
I aimed to evaluate the autoantibody repertoire in lung transplant recipients 
with established BOS (n=10) and recipients free from BOS (n=10) using 
protein microarray methodology. The platform allows simultaneous 
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characterisation of IgG autoantibody specificity to 9480 human recombinant 
proteins.  
 
This study examined the variations in serum reactivity between samples 
collected at two different time points in predefined study groups (BOS pre vs 
No BOS pre and BOS post vs No BOS post). Several observations can be 
made from my set of data. Firstly, a significant proportion of the proteins 
imprinted onto the array were identified as positive hits; ranging between 
3.5% and 30.8% and 4.08% and 30.04% in the pre- and post-transplant 
serum obtained from patients with established BOS (Table 6.6). Surprisingly, 
the percentage of proteins identified as positive in patients without BOS was 
slightly higher in comparison to patients with established BOS for both, the 
pre- and post-transplant serum ranging from 7.6% to 33% and 8.7% to 25.5%, 
respectively (Table 6.7).  
 
Secondly, group comparison analysis showed a unique set of autoantibody 
profile present at the time of transplant in both groups of patients. 
Interestingly, serum reactivity among patients free from BOS was five times 
higher in comparison to patients with BOS (Figure 6.11); suggesting that the 
autoantibody repertoire present at the time of transplant may impact whether 
the patients will develop BOS after the transplant or whether they will remain 
free from BOS. Overall, the serum reactivity was more prominent in patients 
without BOS at the time of transplant in comparison to the serum obtained 
after transplantation; and, in contrast, in patients with BOS the autoantibody 
repertoire was more diverse in the sera obtained after transplantation, Figure 
6.11.     
 
Lastly, the clustering analyses have highlighted two distinct autoantibody 
patterns between the patients with BOS and patients without BOS for both 
test serum samples (pre- and post-transplant), Figure 6.12. Considering the 
extent of the graft damage in the patients with established BOS perhaps it is 
not surprising that there is a variation in the autoantibody specificity between 
the patients with BOS and patients without BOS. In this cohort the post-
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transplant autoantibody repertoires reflect only a single time point after 
transplantation; thus, it is not possible to assess whether these autoantibody 
developed prior to the onset of BOS and have a causative effect in the 
development of BOS or their appearance is a consequence of BOS.  
 
Clustering analysis of the autoantibody profile in the patients with BOS alone 
have highlighted a distinct autoantibody pattern present at the time of 
transplantation (Figure 6.13); these findings agree with the HEp-2 analysis.  
 
The obvious question raised by these observations is whether the 
autoantibodies to these protein targets are clinically relevant; in other words 
are any of these pre-existing autoantibody potential “biomarkers” that can 
predict which patients are more likely to develop BOS after transplantation?  
 
To address this question I looked at the top ranked proteins with the highest 
prevalence (>65%) in patients with established BOS in the serum samples 
obtained prior to transplantation. Eight proteins were identified; of these the 
autoantibody levels were significantly higher in the patients with BOS in 
comparison to patients without BOS only for 5 protein targets, Figure 6.14. Of 
these, the validity of the RUNX1T1 protein as a potential candidate protein 
was assessed using RUNX1T1 ELISA assay in a confirmatory study cohort 
(n=41) consisting of 24 patients with established BOS grade 1, 2 and 3 and 
17 patients without BOS, Table 6.9.  
 
The RUNX1T1 ELISA did not highlight differences between the two groups of 
patients in the “discovery” cohort, Figure 6.15 A; significant difference was 
observed between the test group and the controls; but there was no difference 
between the patient groups (Figure 6.15 C). Similarly, the RUNX1T1 
autoantibody levels were not different between both groups of patients in the 
confirmatory study cohort, Figure 6.16.      
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Overall the difference observed by protein microarray was not so apparent by 
the RUNX1T1 ELISA; nevertheless, the pattern is similar between the protein 
microarray and the ELISA (Figure 6.15 A and B), suggesting that we might be 
looking at slightly different epitope. The ELISA does not offer the 
conformational target as the protein on the microarray. Furthermore, it is 
possible that the protein microarray are more sensitive in comparison to the 
ELISA methodology; thus, the level of autoantibody detected by protein 
microarray may not be clinically relevant. In addition, the possibility for 
presence of IgG autoantibody that may cross react with different protein 
targets cannot be excluded.    
 
It has to be acknowledged that this study has its own drawbacks; firstly, the 
numbers are small; perhaps screening a larger cohort for presence of 
RUNX1T1 autoantibodies may provide a more definite conclusion regarding 
its validity as a potential “biomarker”.  
 
The Prospector software used for data analysis has its own integrated 
characteristics in the sense that it can only assess the data between pre-
defined study groups and at this stage we don’t fully understand what this 
level of autoantibody means in clinical settings. Thus, exploring an alternative 
way to analyse the data sets may prove more useful at eliminating the 
background noise and characterisation of “true” positive protein targets.  
 
Ultimately, characterisation of clinically relevant protein targets requires 
further data analysis and assessment of other protein targets that were 
identified as potential candidate proteins. Lastly, perhaps an in depth 
assessment of IgG autoantibody subclasses may provide better 
understanding of the pathogenicity to these antibodies and their contribution 
to development of BOS after transplantation.                    
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6.4 Key points 
 
• My data suggest that the pre-existing autoantibody signature may 
correlate with development of BOS.  
 
• Distinct autoantibody signature patterns were identified in the patients 
with established BOS and patients without BOS; thus, the protein 
microarray may prove to be a useful tool that can discriminate between 
patients with established BOS and patients without BOS.   
 
• The clinical relevance of these protein targets has to be evaluated on a 
separate cohort.  
 
• Protein targets identified using protein microarray may prove difficult to 
evaluate using different methodology.    
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7.1 Final discussion 
 
Chronic allograft rejection remains the main obstacle that limits the success of 
transplantation; and in particular, long-term outcomes for lung transplantation 
remain disappointing. As many as 50% of lung transplant recipients develop 
progressive BOS by 5 years after the transplant [6]. Traditionally, 
transplantation research has focused on the role of T-cell mediated cellular 
immunity, as highlighted by the development of highly potent T-cell depleting 
immunosuppressant regiments. Although these have led to significant 
improvements in short-term outcomes, long-term allograft survival has not 
altered dramatically.  
 
The development of extremely sensitive antibody screening methodologies, 
allied to the ability to precisely identify alloantibody specificity, has, however, 
highlighted the contribution of humoral alloimmunity to chronic allograft 
rejection. In addition, in the last decade, several experimental and clinical 
studies have demonstrated that cellular and humoral responses to autologous 
‘self’ antigens may play a causative role in the onset of BOS [144, 282].  
 
Work from our research group has highlighted a novel mechanism for 
triggering autoimmunity following transplantation [144]. Win et al., in a murine 
model of chronic heart rejection (Bm12 to B6) showed that transplant-induced 
autoimmunity - characterised by production of class-switched anti-nuclear 
autoantibodies and development of chronic graft rejection - was dependent 
upon provision of help from donor CD4 T cells that were passengers within 
the graft. Surprisingly, donor CD4 T cell help was provided via a direct 
cognate interaction with recipient B cells [144].  
 
I have designed a pilot experimental work firstly to evaluate both the incidence 
of donor CD4 T cell chimerism and the autoantibody responses following lung 
transplantation. Secondly, to address the question whether a similar 
mechanism is responsible for the development of autoantibody in human 
transplantation, I have studied the presence and the impact of passenger 
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donor CD4 T cells on the humoral auto- and alloimmune responses in a 
prospective cohort of primary lung transplant recipients (n=21).    
 
My work suggests that the presence of donor CD4 T cell chimerism in the 
peripheral blood of lung transplant recipients is a uniform phenomenon. Donor 
CD4 T lymphocytes were consistently detected in the recipients’ peripheral 
blood during the first post-operative month; however, the number of 
detectable donor CD4 T cells fluctuated over time, and varied between 
individual lung transplant recipients. In a follow-up period of one year after 
transplantation, three distinct patterns of donor CD4 T cell chimerism were 
observed: short (donor CD4 T cells detectable for up to six weeks after 
transplantation, n=13), intermediate (donor CD4 T cells detectable between 
three to six months after transplantation, n=3) and long-lasting chimerism 
(donor CD4 T cells detectable for more than six months after transplantation, 
n=5).  
 
Immunogenic discrepancies within the HLA antigens between the recipient 
and donor pair are the main targets for allorecognition and rapid cell killing of 
passenger DCs within the first few weeks after transplantation [212, 331]. 
Similarly it may be possible that donor passenger CD4 T cells are also 
subjected to rapid killing soon after transplantation. My work suggests that the 
degree of HLA mismatching does not correlate with the longevity of donor 
CD4 T cell chimerism. Furthermore, the HLA mismatching did not affect the 
incidence of acute cellular rejection episodes and the development of BOS 
during the first post-operative year.  
 
In kidney transplant recipients, KIR-ligand mismatching is associated with 
reduced long-term graft survival only in HLA compatible transplant pairs 
(n=137), but does not have an effect in patients mismatched for HLA-A, -B 
and/or -DR [211]. It is believed that the impact of KIR-ligand mismatching is 
“unmasked” in the absence of HLA incompatibility between the transplant pair. 
In my study RvD NK cell alloreactivity was predicted only in one recipient; 
thus, association between NK cell alloreactivity and longevity of donor 
chimerism was not assessed. In addition, taking into an account the number 
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of lung transplants performed each year and that fact that all lung transplant 
recipients receive poorly matched lungs it will be very difficult to assess the 
role of KIR-ligand mismatching in a large cohort of HLA matched lung 
transplants.  
  
Predicting NK cell alloreactivity based on KIR-ligand mismatching is a widely 
used approach in HSCT. NK cell alloreactivity is dependent on the absence of 
an interaction between the NK cell inhibitory KIRs and its corresponding HLA 
ligands; the loss of inhibition results in NK cell activation and target cell killing 
[206, 208]. NK cell alloreactivity was similarly assessed in my study, but it 
should be acknowledge that this approach is not without limitations. Predicting 
NK cell alloreactivity based on HLA genotyping of both recipients and their 
corresponding donors and recipients’ KIR genotype in a recipient-versus-
donor direction is indicative of in vivo NK alloreactivity but does not prove that 
the repertoire of each KIR encoded is also expressed on the NK cell 
membrane. It has been reported that KIR cell surface expression is in direct 
correlation with the encoded KIR gene content [221] but not all NK cells 
express the encoded KIR genes. It is now known that only a fraction of the 
total number of NK cells express a set of inhibitory KIR receptors [209, 221, 
222]. Furthermore, development of a functionally competent NK cell is 
dependent on the inhibitory KIR “licensing” by self-MHC class I molecules. 
This involves interaction between NK cell inhibitory KIRs and their 
corresponding self-MHC class I molecules, a process that enables them to 
discriminate self from non-self [226, 227]. NK cells that do not undergo this 
process are self-tolerant but functionally incompetent [228].  
 
Considering the frequency of the inhibitory KIR genes in different populations 
[148, 230, 231], it is not surprising that in my cohort all recipients contained a 
combination of at least two inhibitory KIR genes; presence of KIR3DL1 gene 
was detected in each participant. In addition, based on the recipient HLA-C 
and Bw4 epitope genotyping all patients had at least one KIR gene that was 
expected to be “licenced” to recognise self-MHC class I molecules. Five 
patients (patient 1, 7, 10, 12 and 17; Table 4.4) had one KIR gene; four 
patients had 2 KIR genes, four patients had 3 KIR genes and eight patients 
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had 4 KIR genes that were expected to be “licenced” to recognise “self”. Of 
the 20 transplant pairs that were matched for KIR ligands, 12 donors 
contained between 1 and 2 inhibitory KIR ligands in the RvD direction and 8 
donors contained 3 or 4 inhibitory KIR ligands. Univariate analysis showed no 
association between the cumulative number of inhibitory KIR ligands and the 
longevity of donor CD4 T cell chimerism.       
   
Due to insufficient test samples available, the NK cell numbers, NK cell 
subsets, inhibitory KIR receptor expression pre- and post-transplant and the 
strength of inhibition between different KIR-ligands were not studied. Precise 
determination of the NK cell alloreactivity between each recipient and donor 
pair would require adoption of an ex vivo NK cell assay.  Notwithstanding, my 
work suggests that the duration of donor CD4 T cell chimerism is neither 
dependent upon the degree of HLA mismatching nor the degree of KIR-ligand 
inhibition.   
 
A separate study from our research group investigating the impact of donor 
CD4 T cells on humoral alloimmune responses has shown that provision of 
help by donor CD4 T cell to host B cells is dependent upon avoidance of host 
NK cell recognition and donor CD4 T cell survival early after transplantation 
[332]. Interestingly, once donor CD4 T cells have provided efficient help to 
recipient B cells (resulting in generation of allo- and autoantibody), the donor 
CD4 T cells were rapidly cleared (within the first week after transfer). This 
would imply that long lasting donor CD4 T cell chimerism represents not only 
avoidance of NK cell allorecognition early after transplantation, but also a lack 
of cognate interaction between the donor CD4 T cells and recipient B cells, 
because otherwise alloantibody responses would be generated that would 
result in donor cell lysis. In my study only five recipients had long lasting 
donor CD4 T cells chimerism and NK cell alloreactivity was not expected in 
any of the recipients with long lasting chimerism; interestingly only one of 
these patients developed anti-HLA antibodies, suggesting that the donor CD4 
T cells have avoided NK cell allorecognition and that they had been ineffective 
at interacting with recipient B cells. The findings in my study do not mirror 
Harper et al., observations [332]; possibly because the lung transplant 
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recipients receive an immunosuppression regimen that affects cell behaviour. 
In comparison, in Harper’s et al., and Win’s et al., work the experimental 
models were not subjected to immunosuppression and their experimental 
work were carried out in a completely sterile germ free environment.    
       
In addition, the mice strains used in their work were inbred strains. Mating of 
brother-sister mice for at least 20 generations generates inbred strains; 
eventually they become almost entirely homozygous and with each 
generation half of the pre-existing heterozygosity is lost. The sex difference is 
the only heterogeneity remaining [333].  
 
In Harper’s work most experiments were carried out on different mice models 
that have a C57BL/6 (B6) genetic background H-2Kb, Db, I-Ab [332]; in 
humans these antigens are equivalent to HLA-A, HLA-B and HLA-DQ antigen; 
and most importantly this strain lacks the H-2L gene (human HLA-C antigen).  
 
In my work the NK cell alloreactivity was predicted based on the KIR ligand 
mismatching which mainly relies on the mismatching at HLA-C antigens (H-2L 
gene in mice); a gene that is not encoded in Harper’s mice model. Instead, in 
her model the role of NK cells was studied either by transfer of CD4 T cells 
purified from a completely mismatched BALB/c (H-2Kd, Dd, I-Ad, I-Ed; 
equivalent to human HLA-A, -B, -DQ and -DR) donor strain into B6 mice 
model that lacked T and B cells because of deficiency of the Recombinase 
Activating Gene 2 (B6 Rag-2 -/-) or by depletion of NK cells by administration 
of anti-NK1.1 antibody in B6 Rag-2 -/- recipients [332].               
      
Although, Harper’s work has been carefully designed and showed that 
provision of help by donor CD4 T cell to host B cells is dependent upon 
avoidance of host NK cell recognition and donor CD4 T cell survival early after 
transplantation [332]; it has proven difficult to relate the same experimental 
design to human studies. My findings have not mirrored previous mice 
findings but considering the differences between the mice and human 
perhaps my observations are not surprising. A similar mechanism may exists 
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in humans; however, in human studies it is almost impossible to tease-out 
individual effector arms of the immune system and to study them separately.  
 
Another important aspect of donor chimerism that was not addressed in my 
study is the migration of donor CD4 T cells. Previous studies have 
demonstrated that T cells have the ability to recirculate through non-lymphoid 
organs [136]. Functionally and phenotypically these cells are a mixture of 
naïve, effector and memory T cells that express cell-surface markers such as 
CCR7, LFA-1, VLA-4 and ICAM-1, that govern the homing to secondary 
lymphoid tissue and other peripheral tissues [136, 137, 139, 183]. Migration of 
allograft passenger cells to non-lymphoid tissues such as the skin has been 
observed in liver [131] and kidney [165] transplant recipients even decades 
after transplantation. Thus, it is possible that rapid migration of donor CD4 T 
lymphocytes from within the allograft into other tissue sites might explain why, 
in the majority of lung transplant recipients (n=13), donor CD4 T lymphocytes 
were detectable in the recipients’ peripheral blood for only a few weeks after 
transplantation.  
 
Using a molecular gene expression profiling approach, I investigated whether 
the type of donor CD4 T cell present in the recipients’ peripheral blood is a 
contributing factor for the observed variation in the longevity of donor CD4 T 
cell chimerism. Unfortunately, in this small pilot study cohort a unique pattern 
of donor CD4 T cell subpopulation was not observed due to massive variation 
in the level of gene expression between the test samples and the test groups.  
 
I also characterised the immune cell composition of donor lungs that undergo 
reconditioning with the EVLP procedure. The procedure provides a unique 
setting to study leukocyte migration from the lungs into the recipient where, 
under EVLP conditions, migrating leukocytes are immobilised in the leukocyte 
filter on the EVLP circuit. I showed that migratory leukocytes consist of a 
mixture of lymphocytes, monocyte/macrophage and granulocyte population 
and only 1% of lymphocytes were characterised as CD4 T cells.  
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Most importantly, I showed that the CD4 T cells comprise of four 
subpopulations including naïve T cells, T follicular helper cells, central 
memory and effector memory T cells; and, the majority of naïve CD4 T cells 
co-expressed CD62L and CCR7. A fraction of these cells also expressed 
CXCR5, consistent with the presence of follicular helper T cells. These 
findings imply that donor CD4 T cells have the ability to recirculate through 
secondary lymphoid tissue, and potentially, if engaged in cognate interaction 
with recipient B cells, provide help for B cell activation and antibody 
production, as previously suggested by the work generated from our 
laboratory [144, 332].       
 
The lung is a mononuclear cell-rich organ and considerable numbers of 
immunocompetent cells bearing the ability to recirculate through the 
secondary lymphoid organs are transferred with the graft at the time of 
transplantation. Whether immobilisation of passenger mononuclear cells using 
the EVLP procedure will affect the clinical outcome in human lung 
transplantation remains to be seen and is beyond the scope of this study. 
With regards to the role of donor CD4 T cell chimerism it would be intriguing 
to investigate the presence and duration of donor CD4 T cells in another study 
cohort of lung transplant recipients that have received lungs subjected to 
EVLP conditioning prior to transplantation.  
 
It has to be stressed that my observations were made based on one EVLP 
filter and I cannot generalised and reach firm conclusion regarding the cell 
composition of the EVLP filters; however, as a prove of principle I have shown 
that this studies are feasible. Considering that the ELVP filter cell composition 
is completely unknown entity; I cannot envisage how many filters have to be 
assessed in order to reach any conclusion. Assessment of at least 10 filters is 
necessary to give us better understanding of the EVLP filter cell composition.  
 
I also investigated whether donor CD4 T cell chimerism is associated with 
development of transplant-induced autoimmunity and whether the donor CD4 
T cell affects humoral alloimmune responses. The premise for this 
examination was the previous murine work performed in our laboratory, which 
 230 
demonstrated in a murine model of chronic heart allograft rejection that donor 
CD4 T cells that are passengers within the heart grafts provide help to host B 
cells through donor CD4 T-cell allorecognition of MHC class II on host B cells. 
The donor (bm12) and recipient (B6) strains differ by three amino acids within 
the MHC class II I-A antigens (HLA-DQ in humans); thus, irrespective of 
bound peptide donor CD4 T cells provide equal non-specific help to all host B 
cells, resulting in production of autoantibodies with specificity to multiple anti-
nuclear antigens. The antibody mediated graft injury was associated with 
development of long-lasting IgG anti-nuclear autoantibody [144]. 
Subsequently, in a more disparate MHC mismatched model it was reported 
that passenger donor CD4 T cells significantly augment recipient cellular and 
humoral alloimmunity resulting in severe allograft vasculopathy and 
accelerated graft failure. The impact of donor CD4 T cells was dependent 
upon avoidance of host NK cell recognition and class-switched alloantibody 
production was dependent on simultaneous ligation of BCR with the target 
antigen and interaction with host CD4 T cells with indirect allospecificity; thus, 
resulting in production of auto- and alloantibodies [332]. If the same 
mechanism applies to human lung transplant recipients, one could expect 
augmented humoral alloimmune responses in the recipients with short donor 
CD4 T cell chimerism in which NK cell alloreactivity was not expected.   
  
Contrary to this, in my cohort (n=21) 13 patients had short-lasting donor CD4 
T cell chimerism and NK cell alloreactivity was not expected in 12 of these 
recipients, suggesting that donor CD4 T cell can avoid NK-cell mediated 
killing at least early after transplantation. Nevertheless, none of these 
recipients developed HLA antibodies after the transplant.  
 
My work showed that at the time of transplant seven recipients were 
sensitised to HLA antigens, none of which were donor specific. At one month 
after the transplant, in addition to the pre-existing non-DSA, two recipients 
developed de novo DSA and interestingly in the sera of two recipients that 
were previously sensitised to HLA antigens, HLA antibodies were no longer 
detectable. Sera tested at one-year post-transplant revealed that only four 
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recipients with pre-existing non-DSA developed de novo DSA and non-DSA, 
all other recipients tested negative for HLA antibodies. Of these, two 
recipients had long-lasting donor CD4 T cell chimerism and NK cell 
alloreactivity was not expected in any of these recipients. The other two 
recipients that developed DSA had short donor CD4 T cell chimerism and NK 
cell alloreactivity was also not expected in both patients. Considering the size 
of this cohort and the fact that recipients are subjected to a highly potent 
immunosuppressive regimen, it is not possible to firmly conclude that 
passenger donor CD4 T cells have a similar impact at augmenting host 
humoral alloimmune responses, as observed in our previous murine studies. 
At this stage, the role of donor CD4 T cell chimerism in human transplantation 
is not apparent.   
 
In comparison, only one patient in the retrospective group developed de novo 
DSA. In this cohort humoral alloimmune responses were assessed at different 
time points after transplantation ranging from 1 to 21 years; and 
approximately 50% of the patients were long-term survivors (more than 6 
years after transplantation). Numerous clinical studies have reported that 
patients that do not develop HLA alloantibody, including both DSA and/or non-
DSA, have better clinical outcome [323]; thus, this cohort may mirror previous 
clinical findings and perhaps it is not surprising that development of humoral 
alloimmune responses were observed only in a small fraction of patients. 
Donor CD4 T cell chimerism studies were not applied to this cohort.  
 
In comparison to Win et al., murine model observations, in my study the 
assessment of the humoral autoimmune responses revealed unexpected 
findings. Anti-nuclear IgG autoantibody levels were more profound in the 
recipients’ sera before the transplant in comparison to sera obtained at one 
and 12 months after transplantation. The reduction of autoantibody titre was 
statistically significant and there was no change in the autoantibody titre 
between the test samples obtained at one month and 12 months post-
transplant. Similar findings were observed in the retrospective cohort of 24 
lung and 18 heart and lung transplant recipients. Contrary to the previous 
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findings in a murine model studies, this would apply that irrespective of donor 
CD4 T cell dynamics, NK cell allorecognition and presumably interaction 
between the donor CD4 T cells with recipients B cells, the donor CD4 T cells 
have not been efficient at providing adequate help to recipient B cells; thus, as 
a consequence transplant-induced autoimmunity and augmentation of 
humoral alloimmune responses was not demonstrated.               
    
In Win et al., work the effector role for autoantibody was confirmed by the 
early rejection and development of sever vasculopathy in bm12 hearts 
transplanted into animals primed for humoral autoimmunity by transfer of 
donor CD4 T cells. If this is the case than passenger donor CD4 T cell should 
augment the humoral autoimmune responses in recipients with pre-existing 
IgG anti-nuclear autoantibody [144]. In contrast, in my study the level of anti-
nuclear IgG autoantibodies was much higher before the transplant in 
comparison to the levels in test sera obtained after transplantation.  
     
The obvious explanation for the lack of evidence that donor CD4 T cells are 
involved in the development of transplant-induced autoimmunity and 
augmentation of humoral alloimmune responses is that solid organ transplant 
recipients are highly immunosuppressed and most of the immunosuppressive 
drugs are T cell depleting reagents which can alter the number and the 
function of T cells.   
 
Furthermore, it is possible that the observed reduction in the autoantibody IgG 
titres might be due to the reduction of the total IgG levels instead, a known 
post-transplant complication in solid organ transplantation [327] observed in 
kidney [328], liver [329], heart and lung transplant recipients [330]. The total 
IgG levels present at the time of transplant and after transplantation were not 
measured in my study and I cannot confirm whether the observed reduction in 
the autoantibody levels is due to reduction of the total IgG levels.    
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Win et al., used two inbred strain experimental models; bm12 mice (C57BL/6 
B6 H-2Kb, Db, I-Abm12) as a donor and B6 mice (C57BL/6 B6 H-2Kb, Db, I-Ab) 
as a recipient. The bm12 mice has three non-consecutive nucleotide changes, 
resulting in three amino acid substitutions in the β1 exon [334]. Thus, both 
strains differ by only three amino acids within the MHC class II I-A antigens 
(HLA-DQ in humans). In addition, bm12 model has number of impaired 
physiological systems including: abnormal T cell physiology, abnormal levels 
of surface class II molecules, decreased susceptibility to autoimmune 
disorders and increased anti-double stranded and single-stranded DNA 
antibody levels [334]. Perhaps the most striking feature of this model is that 
adoptive transfer of bm12 splenocytes or purified bm12 CD4 T cells into B6 
results in development of common characteristics with human systemic lupus 
erythematosus (SLE) [335]. This model has been used as an inducible model 
to study SLE, an autoimmune disease that is characterised by production of 
anti-nuclear antibodies.  
 
Furthermore, Win et al., showed that irrespective of bound peptide donor 
bm12 CD4 T cells provide equal non-specific help to all host B cells, resulting 
in production of autoantibodies with specificity to multiple anti-nuclear 
antigens [144]. Accordingly, bearing in mind the physiological features of 
bm12 experimental model, perhaps Win’s observations are not surprising. 
However, this raises the question whether Win’s murine model observations 
are suitable for comparison to human studies of transplant-induced 
autoimmunity.  
 
One important aspect of transplant-induced autoimmunity and its contribution 
to development of BOS might depend on the nature of the target antigen. In 
lung transplantation humoral allograft rejection has been observed in patients 
who developed antibodies to other non-HLA associated antigens without 
presence of HLA antibodies [281]. De novo autoimmunity to type V collagen 
[282] and K-alpha 1 tubulin (K-α1 tubulin) [283] has been implicated as an 
independent predictor for development of BOS. Interestingly, Hachem et al., 
in a large cohort of 108 lung transplant recipients, showed that patients who 
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developed both allo- and autoantibodies to collagen V and K-α1 tubulin had 
increased risk of developing BOS; furthermore, they showed that patients that 
responded to antibody mediated therapy and cleared the autoantibodies were 
less likely to develop BOS in comparison to patients with persistent 
autoantibodies, irrespective of the presence or absence of alloantibodies 
[284].    
 
My work suggests that presence of anti-nuclear autoantibodies at the time of 
transplant do not correlate with development of BOS; however, it is possible 
that these target autoantigens may not have clinical relevance in lung 
transplantation. Porcheray et al. have reported increased reactivity to HEp-2 
cells in kidney transplant patients with chronic humoral rejection in 
comparison to patients without chronic humoral rejection in the serum 
samples obtained after transplantation, but not at the time of transplant [324]; 
which might not be the case in lung transplantation.  
 
In addition, clinical usefulness of HEp-2 assay is only considered when 
interpreted in conjugation with patient clinical symptoms. It has been 
recommended that the assay should not be used as a screening test for 
individuals without any clinical symptoms, due to the observed weak serum 
reactivity of healthy individuals, older people, pregnant woman, cancer 
patients, patients with chronic infections, and other diseases [322, 331]; thus, 
raising questions regarding the clinical significance of autoantibody titres 
detected in the recipients’ serum at the time of transplant and the adequacy 
for utilisation of HEp-2 IIF and HEp-2 ELISA assays in lung transplantation.  
 
Lastly, despite the fact that in the prospective cohort 7 lung transplant 
recipients developed BOS within the first year after transplantation, it has to 
be emphasised that BOS is a disease that develops between 2 and 5 years 
after transplantation; therefore, a longer post-transplant period and larger 
study cohort might be necessary in order to assess the association between 
the longevity of donor CD4 T cell chimerism and development of transplant-
induced autoimmunity.  
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From a clinical prospective, discovering markers of early graft damage is 
essential to help identify the cohort of recipients who may be more susceptible 
to developing of BOS and therefore, require more aggressive surveillance and 
treatment for mitigating the harmful effects of autoantibodies.   
 
In a pilot experiment a sub-cohort of lung transplant recipients with 
established BOS (n=10) and recipients free from BOS (n=10) in whom 
humoral alloimmune responses were not detected, I also performed 
simultaneous characterisation of IgG autoantibody specificity to 9480 human 
recombinant proteins. My results suggest that a significant proportion of lung 
transplant recipients display autoreactivity to a large number of protein 
antigens at the time of transplant. Furthermore, in the sera obtained at the 
time of transplant a unique set of autoantibody patterns were identified in both 
groups of patients. Interestingly, serum reactivity among patients free from 
BOS was five times higher in comparison to patients with BOS; suggesting 
that the autoantibody repertoire present at the time of transplant may impact 
whether the patients will develop BOS after the transplant or whether they will 
remain free from BOS.  
 
The autoantibody levels against five protein targets were significantly different 
between both groups of patients. The clinical relevance was assessed only for 
RUNX1T1 protein using RUNX1T1 specific ELISA in a confirmatory study 
cohort of 41 lung and heart and lung transplant recipients (24 patients with 
established BOS grade 1, 2 and 3 and 17 patients without BOS). The findings 
did not reveal differences in the RUNX1T1 autoantibody titres between 
recipients with BOS and recipients without BOS; thus, its usefulness as a 
potential “biomarker” was not established.  
 
The Prospector software used for the protein microarray data analysis has its 
own integrated characteristics in a sense that it can only assess the data 
between pre-defined study groups and at this stage we don’t fully understand 
what these level mean in clinical settings. Thus, exploring an alternative way 
to analyse the data sets may prove more useful at eliminating the background 
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noise and characterisation of “true” positive protein targets. Characterisation 
of clinically relevant protein targets requires further data analysis and 
assessment of other proteins targets that were identified as potential 
candidate proteins.  
 
The obvious questions raised by these observations is whether the 
autoantibodies with specificity to these protein targets are clinically relevant 
and if any of these pre-existing autoantibodies represent potential 
“biomarkers” that can predict which patients are more likely to develop BOS 
after transplantation? Clarification of these questions requires further data 
analysis, conformation using different methodology and utilisation of a larger 
study cohort.  
 
One potential approach to utilize larger study cohort for autoantibody profiling 
in lung transplant recipients is through combining data with other research 
groups. Nayak et al., have recently undertaken similar study where 
autoantibody profiling was performed using protein microarrays in lung 
transplant recipients with developed CLAD (n=12) and recipients free from 
CLAD (n=11), (Abstract, [336]). Interestingly, they also observed a unique 
autoantibody repertoire in patients that subsequently developed CLAD [336]. 
My intensions are to contact Dr Mohanakumar, a principal leader of the same 
research group to express my interest for sharing my findings with them; and 
the possibility to combine and re-analyse the protein microarray data. It would 
be interesting to assess whether similar autoantibody profiling patterns will be 
observed in the combined cohort of 43 patients in which the patients will not 
be segregated into pre-defined groups.   
 
In conclusion, although the presence of donor lymphocytes in the circulation 
of recipients of solid organ allografts was first demonstrated more than two 
decades ago, the extent to which they affect the recipients’ auto- and 
alloimmunity has remained unclear and this study has not reflected previous 
murine model findings. Nevertheless, consideration the physiological nature of 
the murine models perhaps it is not surprising that I was not able to reproduce 
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the same findings. The question is whether a similar mechanism of transplant-
induced autoimmunity does exist in humans or the proposed mechanisms is 
dependent on the type of model used? If, a similar mechanism does exist in 
humans, it is tempting to speculate that the mechanism may not be so 
apparent in the presence of the current immunosuppression regiments. 
However, prior to addressing these questions I believe that it is inevitable to 
study larger cohort of primary lung transplant recipients (at least 70 lung 
transplant recipients) for longer post-transplant follow-up period. 
Nevertheless, at present the role of donor CD4 T cell chimerism in the 
development of transplant-induced autoimmunity and augmentation of 
humoral alloimmune responses in lung transplantation was not established.   
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7.2 Summary 
 
In summary, my work confirmed that the donor chimerism is a uniform 
phenomenon in lung transplantation. However, the longevity of donor CD4 T 
cell in the recipients’ peripheral blood is variable between patients and 
independent of the degree of HLA mismatching and degree of KIR-ligand 
inhibition. The involvement of donor CD4 T cell in the development of 
transplant-induced autoimmunity and augmentation of humoral alloimmunity 
previously observed in a murine model in our research group was not 
confirmed in human lung transplant recipients and the role of donor CD4 T 
cells remains unclear. Understanding the clinical relevance of the 
autoantibody repertoire present at the time of transplant may prove 
particularly relevant at identifying recipients with predisposition to develop 
BOS and improve their clinical management.  
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Date: 1 st February 2011   
Version No: 3  
Participant Information Sheet 
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 CONFIDENTIAL Page 1 of 7 
 
 
NHS
S 
Study Title: Humoral autoimmunity and allograft vasculopathy 
 
Chief Investigator: Mr Gavin Pettigrew 
Investigator: Miss Olivera Gjorgjimajkoska 
Sponsor: University of Cambridge and Papworth Hospital NHS Foundation Trust 
Host organisation: University of Cambridge 
Funder: British Heart Foundation 
 
 
Brief description: 
We would like to invite you to take part in our research study.  
• This study is an observational study and is being undertaken as part of an 
educational (PhD) project.  
• We aim to study the development of autoimmune responses (immune 
responses directed against the recipient’s own tissues) following heart and/or 
lung transplantation.  
• The research will involve multiple blood sampling during your post-transplant 
follow-up visits.  
• Before you decide we would like you to understand why the research is being 
done and what it would involve for you.  
• One of our team will go through the information sheet and answer any 
questions you may have. Please ask about anything you do not fully 
understand or wish to have explained in more detail.  
• If you would like this information in another format or language, please ask a 
member of our staff.   
• We suggest that reading this information sheet is likely to take about 10 
minutes of your time.  
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1. What is the purpose of the study? 
Transplantation is the only treatment option for end-stage heart and lung failure. 
However, transplants do not last indefinitely and almost all transplants suffer a slow 
deterioration in function, through a process termed chronic rejection; characterised 
by thickening of the graft arteries, know as allograft vasculopathy.  
 
In the last few years, it has become clear that ‘auto-immune responses (immune 
responses directed against the recipient’s own tissues) can develop following 
transplantation and can contribute to allograft vasculopathy. We have recently 
demonstrated in a mouse heart transplant model that specialised immune cells of the 
donor, that are passengers within the graft at the time of transplant, can migrate to 
the recipient and trigger an antibody response that is directed against the recipient’s 
own proteins.  
 
The reason we are doing this research is to formally study whether the presence of 
donor cells in the recipient’s blood is associated with the development of 
autoantibody and whether the autoantibody has a damaging effect on the graft and 
contributes to development of allograft vasculopathy. If this were the case, this would 
lead to evaluation of new strategies to remove donor cells from the grafts prior to 
transplantation, in the hope that this would minimise the autoantibody responses and 
lead to improved graft survival.    
 
 
 
 
 
 
 268 
 
Date: 1 st February 2011   
Version No: 3  
Participant Information Sheet 
                                  
                      Papworth Hospital 
                                  NHS Foundation Trust 
  
 
 
 CONFIDENTIAL Page 3 of 7 
 
 
NHS
S 
2. Why have I been invited? 
This study is purely observational. We are inviting you because we aim to observe 70 
prospective and 100 retrospective heart or lung and heart and lung transplant 
patients and study the following: 
• Presence of donor cells in the recipients’ blood circulation after 
transplantation; 
• Development of autoantibody; 
• To see whether there is an association between the presence of donor cells 
and autoantibody development; and  
• The contribution of autoantibody to allograft vasculopathy.  
 
3. What will happen to me if I take part?  
If you decide to take part in this study you will be asked to give a small blood sample 
for our research. This will be requested at different time points:   
• Immediately before transplantation prospective transplant patients only: 60mls 
blood sample (4 tablespoons ) will be obtained to test for autoantibody. 
• After transplantation: 60mls blood sample (4 tablespoons; prospective 
transplant patients only) or 10mls (2 teaspoons; retrospective transplant 
patients only) will be obtained at regular intervals to test for the presence of 
donor cells and/or development of autoantibody. To test for donor cells in your 
blood we will use either cells or DNA extracted from your blood sample.   
• During the study, you will have to have your blood taken up to a maximum of 
18 times over a three-year study period. In most cases, this will happen at 
your regular post-transplant follow-up clinics; or we will send you a pre-
labelled envelope with blood tube containers so you can have your blood 
taken at your local GP surgery.  
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• In order to analyse the study results we will have to compare the results with 
your medical records, therefore sections of your medical notes may be looked 
at by the individuals involved in the study. 
 
4. Do I have to take part in this study? 
It is up to you to decide whether to join the study. We will describe the study and go 
through this information sheet. If you agree to take part, we will then ask you to sign 
a consent form. Also, it up to you whether you want your GP to be informed of your 
participation in this study. Not taking part in this study will not affect your medical 
care.  
 
5. What are the possible benefits of taking part? 
This is an observational study. You will not benefit from this study directly, but your 
participation and the information we obtain from the investigations may contribute to 
advancing our understanding of the immune responses involved in the development 
of allograft vasulopathy.  
 
6. What are the possible risks of taking part? 
The risks of taking part in this study are minimal. You will simply have blood samples 
taken from your arm with a needle and syringe.   
 
7. What happens when the research study stops? 
The duration of this study is three years. On completion of the study, you and your 
GP will receive written confirmation of the end of study. Your transplant follow-up will 
continue at your normal post-transplant clinic according to departmental protocols. 
Any blood samples collected during the study will be discarded in accordance with 
the Human Tissue Authority’s Code of Practice.  
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8. Will my taking part in the study be kept confidential?  
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence.  
 
9. What will happen if I do not want to carry on with the study? 
You are free to withdraw at any time, without giving reason. This would not affect the 
standard of care you receive. However, any data collected up to the point of consent 
withdrawal will be included for analysis.  
 
10.  What will happen to the results of the research study? 
Because this is an observational study and we are not at this stage sure what the 
results mean for an individual patient until they are fully analysed, you will not be 
informed directly about your results. The study results will be disseminated in the 
form of peer review publications; alternatively you may find some information about 
the progress of our research on the British Heart Foundation website 
(www.bhf.org.uk) or the NIHR Clinical Research Network Portfolio website 
(www.ukcrm.org.uk).     
 
11. Who is organising and funding the research? 
The study is taking place in the Department of Surgery, University of Cambridge and 
in collaboration with Papworth Hospital. The British Heart Foundation is the funder of 
this study and the study is being undertaken as part of a PhD project. 
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12. Who has reviewed the study? 
The project has been independently reviewed; scientifically by the British Heart 
Foundation, and ethically by the Cambridgeshire 4 Research Ethics Committee. The 
sponsors of this study are the University of Cambridge and Papworth Hospital 
Research & Development Department.    
 
13. Further information and contact details. 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers and we will do our best to answer your questions. For further information 
please contact Mr Gavin Pettigrew or Miss Olivera Gjorgjimajkoska at the 
Department of Surgery, Box 202, Level E9, Addenbrooke’s Hospital, Hills Road, 
Cambridge, CB2 0QQ; Tel: 01223 763 103; E-mail: gjp25@cam.ac.uk or 
og241@cam.ac.uk. Alternatively, you can contact Dr Clive Lewis, Consultant 
Cardiologist, Department of Surgery, Box 76 , Transplant Unit, Papworth Hospital, 
Papworth Everard, Cambridge, CB23 3RE;  Tel: 01480 830 541; E-mail: 
clive.lewis@papworth .nhs.uk.        
Please ask if you require this information in another format or language.    
 
14. What do I need to do to take part in this study?  
If you decide that you wish to participate in this study, you need to sign the consent 
form. Once you have signed the consent form, you do not have any responsibilities 
until you are called for transplantation. When you are called for transplantation a 
health care professional will collect  pre-transplant blood sample (prospective 
transplant patients only). Further blood sampling will take place at regular intervals 
over a three-year study period (For your information please see the tables below). 
Please do not worry about the blood collection times, each time you will be remained 
by a member of the health care team. We are very grateful for your consideration. 
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Table 1: Post-transplant blood sample collection times (prospective transplant 
patients):  
1st year post-transplant  Day 3;  
Day 7; 
Week 2; 
Week 4; 
Week 6; 
Week 8; 
Month 4; 
Month 6; 
Month 8; 
Month 10; 
Month 12. 
2nd and 3rd year post-
transplant  
During the second and third year post-transplant blood samples will be 
collected every four months.  
 
Table 2: Post-transplant blood sample collection times (retrospective transplant 
patients):  
Post-transplant blood 
sample 
During the post-transplant period maximum of 3 blood samples will be 
collected every 6 months. 
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Study Number:  
Participant Identification Number for this study: 
CONSENT FORM 
Study Title: Humoral autoimmunity and allograft vasculopathy 
Name of Chief Investigator: Mr Gavin Pettigrew  
Name of Investigator: Miss Olivera Gjorgjimajkoska 
Please tick box 
1. I confirm that I have read and understood the information sheet dated    
01/02/2011, Version No: 3 for the above study. I have had the opportunity to consider 
the information, ask questions and have had these answered satisfactorily. 
2.  I understand that my participation is voluntary and that I am free to withdraw   
at any time without giving any reason, without my medical care or legal rights  
being affected.  
3. I understand that relevant sections of my medical notes and data collected  
during the study, may be looked at by individuals involved in this study from the NHS  
Trust. I give permission for these individuals to have access to my records.  
4.  I agree to my GP being informed of my participation in this study. 
5.  I agree to take part in the above study.       
    
 
  Name of Participant    Date    Signature 
 
  Name of Person    Date     Signature  
  taking consent      
 
When completed: 1 for participant; 1 for research site file; 1 (original) to be kept in medical notes.  
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allografts from T cell–deficient bm12.TCRƴņƴ donors did not trigger 
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tion of heart allografts from donor bm12 mice that had received 
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We have analyzed the relationship between donor
mismatches at each HLA locus and development of HLA
locus–specific antibodies in patients listed for repeat
transplantation. HLA antibody screening was undertaken
using single-antigen beads in 131 kidney transplant
recipients returning to the transplant waiting list following
first graft failure. The number of HLA mismatches and the
calculated reaction frequency of antibody reactivity against
10,000 consecutive deceased organ donors were determined
for each HLA locus. Two-thirds of patients awaiting repeat
transplantation were sensitized (calculated reaction
frequency over 15%) and half were highly sensitized
(calculated reaction frequency of 85% and greater). Antibody
levels peaked after re-listing for repeat transplantation, were
independent of graft nephrectomy and were associated with
length of time on the waiting list (odds ratio 8.4) and with
maintenance on dual immunosuppression (odds ratio 0.2).
Sensitization was independently associated with increasing
number of donor HLA mismatches (odds ratio 1.4). All
mismatched HLA loci contributed to the development of HLA
locus–specific antibodies (HLA-A: odds ratio 3.2, HLA-B: odds
ratio 3.4, HLA-C: odds ratio 2.5, HLA-DRB1: odds ratio 3.5,
HLA-DRB3/4/5: odds ratio 3.9, and HLA-DQ: odds ratio 3.0 (all
significant)). Thus, the risk of allosensitization following
failure of a first renal transplant increases incrementally with
the number of mismatches at all HLA loci assessed.
Maintenance of re-listed patients on dual
immunosuppression was associated with a reduced risk of
sensitization.
Kidney International (2014) 86, 1039–1048; doi:10.1038/ki.2014.106;
published online 9 April 2014
KEYWORDS: HLA; immunosuppression; matching; nephrectomy;
re-transplantation; sensitization
The immune response to a kidney allograft is directed pri-
ncipally against mismatched human leukocyte antigen (HLA)
glycoproteins expressed on donor tissue. Historically, deceased
donor kidney allocation policies aimed to minimize the
number of HLA mismatches between donors and recipients
in order to help reduce the incidence of acute rejection and to
improve graft survival.1 In the context of modern immuno-
suppressive therapy, the beneficial effect of HLA matching
on graft survival has diminished and kidney allocation
algorithms now place considerably less emphasis on HLA
matching.2–4 HLA matching, however, remains important for
those patients who have developed HLA-specific antibodies
after prior exposure to HLA alloantigens, because of preg-
nancy, blood transfusion, or a failed renal transplant.5 It is
important in such patients to avoid donor HLA mismatches
to which they are sensitized as this may result in antibody-
mediated rejection that is refractory to treatment. For highly
sensitized patients who have antibodies to the majority of the
potential donor population, the need to identify an HLA
antibody–compatible (cross-match negative) donor kidney
markedly prolongs the waiting time to transplantation and
may make transplantation almost impossible.
Recipients of a deceased donor kidney transplant can
expect, on average, to maintain a functioning transplant for
approximately 12–15 years, after which repeat transplantation
is required, particularly in younger patients with a longer life
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expectancy. Around 23% of patients listed for renal trans-
plantation in the United Kingdom are awaiting a repeat
transplant and most have developed donor HLA–specific
antibodies. Such antibodies are frequently cross-reactive and
bind a wide range of HLA specificities with shared epitopes
commonly expressed on many different HLA alleles,6 limiting
the opportunity for repeat transplantation.7–9
It is generally assumed that recipients of a kidney allograft
mismatched for multiple HLA alleles are more likely to develop
donor HLA–specific antibodies, although the evidence to
support this assumption is very limited and is based on an
old technology that is unable to resolve complex alloantibody
profiles.10–13 The relative influence of HLA mismatches at
individual loci on alloantibody responses in recipients
returning to the transplant waiting list after a failed first
transplant has not been reported previously.
We have used Luminex single-antigen bead technology to
assess the influence of an HLA-mismatched first kidney
transplant on development of alloantibodies in patients
returning to the transplant waiting list following graft failure.
RESULTS
The demographic and clinical details of the 131 patients
studied are shown in Table 1. The UK allocation policy for
deceased donor kidneys favors HLA-DR matching over
HLA-A and -B matching and, as a consequence, the cohort
generally received first kidney transplants that were moder-
ately well HLA matched, particularly for HLA-DR. In the case
of HLA class I (HLA-A, -B, and -C), there were 0–1
mismatches in 14 (11%) patients, 2–4 mismatches in 93
(71%) patients, and 5–6 mismatches in 24 (18%) patients. In
the case of HLA class II (HLA-DRB1, -DRB3/4/5, and
-DQB1), there were 0–1 mismatches in 64 (49%) patients, 2–4
mismatches in 61 (46%) patients, and 5–6 mismatches in
6 (5%) patients.
HLA mismatch and calculated reaction frequency (cRF)
determined using Luminex single-antigen HLA antibody-
detection beads
Of the 131 patients studied, 17 (13%) were sensitized to HLA
class I (415% cRF) before their first transplant; 12 of these
patients (71%) received kidneys with 0–4 HLA class I
mismatches, reflecting the requirement to avoid a positive
cross-match (Figure 1a). At the time of return to the
transplant waiting list, 44 (34%) patients were sensitized to
HLA class I; when serum samples with peak cRF were
considered, 80 (61%) patients were sensitized, of whom 50
(38% of the total) were highly sensitized (cRF X85%).
Patients who received kidneys with the greatest number of
HLA-A, -B, and -C mismatches more commonly developed
antibodies to HLA class I while on the waiting list for
re-transplantation: it was notable that none of the 24 patients
who received a kidney with 5–6 class I mismatches were
highly sensitized at the time of transplantation, whereas 13 of
the 24 (54% of the total) became highly sensitized while
awaiting a second transplant.
Donor mismatches at each of the HLA-A, -B, and -C loci
all contributed to an increasing likelihood of developing
sensitization to HLA class I, but HLA-C less than HLA-A and
-B (Figure 1b–d and Table 2, column 1). Donor mismatches
at HLA-A and -B were also associated with development of
antibodies to an increasing number of HLA-A and -B speci-
ficities, as defined by increasing cRF (Figure 1 and Table 2,
column 2; odds ratio (OR): 1.4, 95% confidence interval
(CI): 1.2–1.8 per mismatch for HLA-A, P¼ 0.002 and OR:
1.3, 95% CI: 1.1–1.6 per mismatch for HLA-B, P¼ 0.006).
We also considered whether mismatches at ‘public’ HLA
class I epitopes had a disproportionally strong effect on the
development of high cRF levels. We examined the effect of
Table 1 | Study population characteristics
Patient cohort characteristics N¼ 131 (%)
Primary transplant donor typea
DBD donor 76 (58)
DCD donor 25 (19)
Live donor 25 (19)
Simultaneous kidney and pancreas transplant (DBD) 4 (3)
Recipient ethnicity
White Caucasian 117 (89)
Black African 3 (2)
Asian (Indian/Pakistani) 8 (6)
Oriental 3 (2)
Recipient gender
Male 87 (66)
Female 44 (34)
Donor age (years), median (range) 49 (10–78)
Recipient age (years), median (range) 38 (14–73)
Number of HLA-A, -B, -C mismatchesb
0–1 14 (11)
2–4 93 (71)
5–6 24 (18)
Number of HLA-DRB1, -DRB3/4/5, -DQB1 mismatches
0–1 64 (49)
2–4 61 (46)
5–6 6 (5)
Primary diagnosis
Glomerulonephritis 22 (17)
Vasculitis 10 (7)
Polycystic disease 8 (6)
Reflux nephropathy 8 (6)
Diabetes 14 (11)
Hypertension 6 (5)
IgA nephropathy 19 (15)
Other 44 (33)
Time from 1st transplant to re-listing (days),
median (range)
1298 (3–5132)
Time from re-listing to end of follow-up (days),
median (range)
937 (14–4809)
Abbreviations: DBD, donation after brain death; DCD, donation after circulatory
death; HLA, human leukocyte antigen; IgA, immunoglobulin A.
aDonor type (DBD or DCD) was not known for one deceased donor kidney
transplant.
bHLA-C typing information was not available for six cases. When HLA-C type was
missing, HLA class I mismatch grade was calculated based on HLA-A and -B types.
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mismatches at the most common ‘public’ epitopes Bw4 and
Bw6 and found that the impact of a mismatch at Bw4 or Bw6
on cRF was no greater than that observed for HLA-B
mismatches when there was no mismatch at either Bw4 or
Bw6 (Supplementary Figure S1 online).
In the case of HLA class II (Figure 2a), only 7 (5%) of the
131 patients were sensitized to HLA class II (415% cRF) at
the time of their first transplant and none were highly
sensitized (cRF X85%). On return to the waiting list, 29
(22%) patients were sensitized, and when serum samples
with peak cRF were considered this number rose to 56 (43%)
patients, of whom 29 (22% of the total) became highly
sensitized. Patients who received kidneys with the greatest
number of HLA-DRB1, -DRB3/4/5, and -DQ mismatches
more commonly developed alloantibodies to HLA class II
while on the transplant waiting list (Figure 2a), although
few (n¼ 6) patients received a kidney with 5–6 class II
mismatches.
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Figure 1 | Association between first transplant human leukocyte antigen (HLA) class I (HLA-A, -B, and -C) mismatches and HLA-specific
sensitization expressed as calculated reaction frequency (cRF). HLA class I–specific alloantibodies were detected using single-antigen HLA
beads (with a median fluorescence intensity (MFI) cutoff threshold of 2000); the likelihood of identifying an antibody-compatible organ donor
(cRF) was determined by comparing individual patient HLA-specific antibody profiles with the HLA types of 10,000 consecutive UK deceased
organ donors. Panel (a) shows cRF levels attributable to antibodies against HLA-A, -B, and -C considered collectively according to the total
number of donor–recipient HLA-A, -B, and -C mismatches (0–6) at the three different time points: pretransplant, on return to the transplant
waiting list, and at peak cRF while on the waiting list. Panels (b–d) show the cRF attributable to antibodies against HLA-A, HLA-B, and HLA-C,
respectively, according to the number of HLA specificities (0, 1, or 2) mismatched at the individual HLA loci. Patients were categorized
according to the likelihood of identifying an antibody-compatible organ donor as cRF 0–15%, cRF 16–50%, cRF 51–84%, and cRF 85–100%. cRF
levels attributable to antibodies against each of the HLA class I loci and for HLA class I loci considered collectively increased between the three
different time points (Stuart–Maxwell test Po0.01), with the exception of the comparison between pretransplant and return to the transplant
waiting list for HLA-C (P¼ 0.427). The number of patients within each cRF category at the three different time points is depicted in
Supplementary Table S1A online stratified according to the number of HLA mismatches.
Table 2 | Influence of HLA mismatches on the likelihood of
developing HLA-specific allosensitization after re-listing for
repeat transplantation
Likelihood of developing
sensitization to individual
HLA loci per mismatch
Likelihood of increasing cRF
for individual HLA loci per
mismatch
OR (95% CI) P-value OR (95% CI) P-value
HLA-A 3.2 (2.0, 4.7) o0.001 1.4 (1.2, 1.8) 0.002
HLA-B 3.4 (2.2, 4.9) o0.001 1.3 (1.1, 1.6) 0.006
HLA-C 2.5 (1.5, 3.5) o0.001 1.2 (1.0, 1.5) 0.074
HLA-DRB1 3.5 (2.3, 5.5) o0.001 1.3 (1.0, 1.6) 0.015
HLA-DRB3/4/5 3.9 (2.4, 7.8) o0.001 1.3 (1.1, 1.7) 0.011
HLA-DQ 3.0 (2.0, 4.3) o0.001 1.4 (1.1, 1.8) 0.003
Abbreviations: CI, confidence interval; cRF, calculated reaction frequency; HLA,
human leukocyte antigen; MFI, median fluorescence intensity; OR, odds ratio.
The influence of mismatches at individual HLA loci on the likelihood of developing
HLA locus–specific alloantibodies is shown in column 1, using an MFI threshold
of 42000. Column 2 shows the influence of mismatches at individual HLA
loci on the likelihood of developing HLA locus–specific alloantibodies to an
increasing number of HLA specificities, as defined by increasing cRF, using an MFI
threshold of 42000.
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Donor mismatches at each of the HLA-DRB1, -DRB3/4/5,
and -DQ loci all contributed to sensitization to HLA class II,
which became most apparent after return to the waiting list
for re-transplantation (Figure 2b–d and Table 2, column 1).
Donor mismatches at each HLA class II locus were associated
with development of antibodies to an increasing number of
HLA class II specificities as defined by increasing cRF
(Figure 2 and Table 2, column 2; OR: 1.3, 95% CI: 1.0–1.6
per mismatch for HLA-DRB1, P¼ 0.015, OR: 1.3, 95% CI:
1.1–1.7 per mismatch for HLA-DRB3/4/5, P¼ 0.011 and OR:
1.4, 95% CI: 1.1–1.8 per mismatch for HLA-DQ, P¼ 0.003).
When HLA class I and class II were considered collectively
(HLA-A, -B, -C, -DRB1, -DRB3/4/5, and -DQ combined),
analysis of peak reactive sera while on the list for re-
transplantation showed that the percentage of sensitized
patients with a cRF 415% was 47% for first grafts
mismatched for 0–2 HLA specificities, rising to 65% for 3–5
mismatched specificities, and 80% for 6–12 mismatched
specificities (Figure 3). The percentage of sensitized patients
with a cRF X85% for 0–2, 3–5, and 6–12 HLA mismatches
was 32%, 44%, and 63%, respectively. This and all previous
calculations of cRF are based on an median fluorescence
intensity (MFI) cutoff threshold of 2000, the widely used
threshold above which donor-specific antibodies are con-
sidered to have potential clinical relevance. For MFI cutoff
levels at higher thresholds (45000 and 48000), indicating
higher levels of circulating alloantibody, cRF values also
increased markedly with the total number of HLA class I and
II mismatches, and even for an MFI cutoff of48000, 41% of
patients transplanted with a poorly matched first graft (6–12
mismatches) were classified as highly sensitized (Figure 3).
As expected, mismatches at individual HLA class I loci
were commonly associated with the development of alloan-
tibodies to epitopes shared by serologically cross-reactive
specificities but there was no evidence for development of
alloantibodies against alleles of a different HLA class (donor
mismatches at HLA class II did not influence the develop-
ment of alloantibodies against HLA class I, and vice versa).
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Figure 2 | Association between first transplant human leukocyte antigen (HLA) class II (HLA-DRB1, -DRB3/4/5, and -DQ) mismatches
and HLA-specific sensitization expressed as calculated reaction frequency (cRF). HLA class II–specific alloantibodies were detected using
single-antigen HLA beads (with a median fluorescence intensity (MFI) cutoff threshold of 2000); donor organ incompatibility (cRF) was
determined by comparing individual patient HLA-specific antibody profiles with the HLA types of 10,000 consecutive UK deceased organ
donors. Panel (a) shows cRF levels attributable to antibodies against HLA-DRB1, -DRB3/4/5, and -DQ considered collectively, according to the
total number of donor–recipient HLA-DRB1, -DRB3/4/5, and -DQ mismatches (0–6) at the three different time points: pretransplant, on return to
the transplant waiting list and at peak cRF while on the waiting list. Panels (b–d) show the cRF attributable to antibodies against HLA-DRB1,
HLA-DRB3/4/5, and HLA-DQ, respectively, according to the number of HLA specificities (0, 1, or 2) mismatched at the individual HLA loci.
Patients were categorized according to the likelihood of identifying an antibody-compatible organ donor as cRF 0–15%, cRF 16–50%, cRF
51–84%, and cRF 85–100%. cRF levels attributable to antibodies against each of the HLA class II loci and for HLA class II loci considered
collectively increased between the three different time points (Stuart–Maxwell test Po0.01). The number of patients within each cRF category
at the three different time points is depicted in Supplementary Table S1A online stratified according to the number of HLA mismatches.
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Although the focus of our analysis was on the use of
Luminex-based single-antigen beads to determine the effect
of HLA mismatch at individual loci on allosensitization,
sera were also tested for the presence of clinically relevant
immunoglobulin G lymphocytotoxic antibodies to lympho-
cyte panels (peripheral blood lymphocyte and B-cell chronic
lymphocytic leukemia) incorporating a broad range of HLA
types. The results are summarized in Supplementary Figure
S2 online and show that an increasing number of HLA class I
and class II mismatches results in increasing levels of
immunoglobulin G lymphocytotoxic panel-reactive anti-
bodies (PRAs).
Analysis of factors associated with development and levels of
HLA-specific antibodies after return to the kidney transplant
waiting list
Table 3 shows a univariate analysis of the association of
donor–recipient HLA mismatch and other clinical variables
with the development of sensitization after re-listing for
repeat transplantation. First graft HLA mismatch was
strongly associated with sensitization and each additional
HLA class I and class II donor mismatch increased the
likelihood of developing HLA-specific alloantibodies incre-
mentally (OR 1.41, 95% CI: 1.15–1.74 per mismatch,
P¼ 0.001). An additional clinical variable associated with
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Figure 3 | Association between first transplant human leukocyte
antigen (HLA) class I and II mismatches and peak HLA-specific
sensitization according to different levels (median fluorescence
intensity (MFI)) of circulating alloantibodies. HLA-specific
alloantibodies were identified in sera from patients re-listed for
repeat transplantation, using HLA single-antigen beads. Donor organ
incompatibility (calculated reaction frequency (cRF)) was determined
by comparing individual patient HLA-specific antibody profiles with
the HLA types of 10,000 consecutive UK deceased organ donors. The
figure shows cRF levels in peak reactive sera attributable to
antibodies against HLA-A, -B, -C, -DRB1, -DRB3/4/5, and -DQ
considered collectively, according to the total number of first
transplant donor HLA mismatches (0–12). Alloantibodies were
analyzed at the three different MFI cutoff thresholds (2000, 5000, and
8000), where alloantibodies present at increasing thresholds indicate
increasing immunological risk for repeat kidney transplantation.
Patients were categorized according to the likelihood of
identifying an antibody-compatible organ donor as cRF 0–15%, cRF
16–50%, cRF 51–84%, and cRF 85–100%. The number of patients
within each cRF category is depicted in Supplementary Table S1B
online stratified according to the number of HLA class I and class II
mismatches.
Table 3 | Influence of donor and patient factors on the
likelihood of developing HLA-specific alloantibodies
(adjusted for pretransplant sensitization, MFI threshold of
42000)
Variable Value
Adjusted
odds ratio 95% CI Wald P
Donor typea Deceased (n¼ 106) 1.79 0.70, 4.58 0.224
DBD (n¼ 79) 1.64 0.62, 4.37 0.315
DCD (n¼ 26) 2.25 0.70, 7.69 0.183
Live (n¼ 25) — — —
Donor ageb 0–17 (n¼ 3)
18–49 (n¼ 59) 0.87 0.48, 1.89 0.731
50þ (n¼ 53) — — —
Recipient age 0–17 (n¼ 4)
18–49 (n¼ 97) 0.65 0.24, 1.61 0.357
50þ (n¼ 30) — — —
HLA class Iþ II
mismatchesc
Per mismatch 1.41 1.15, 1.74 0.001
Immunosuppression None (n¼ 48) — — —
at time of re-listingd Single (n¼ 27) 1.08 0.38, 3.31 0.871
Dual (n¼ 53) 0.68 0.28, 1.59 0.377
Immunosuppression None (n¼ 61) — — —
while on the Single (n¼ 36) 0.90 0.33, 2.51 0.841
waiting liste Dual (n¼ 30) 0.15 0.05, 0.40 o0.001
Nephrectomy Yes (n¼ 56) 3.42 1.51, 8.30 0.004
No (n¼ 75) — — —
Blood transfusion Yes (n¼ 118) 2.01 0.61, 6.64 0.253
after transplantation No (n¼ 13) — — —
Blood transfusion Yes (n¼ 41) 1.91 0.73, 4.26 0.225
after listing for
re-transplantation
No (n¼ 90) —
Recipient gender Female (n¼ 44) 1.61 0.67, 4.09 0.292
Male (n¼ 87) — — —
Pregnancy Yes (n¼ 31) 1.44 0.88, 2.74 0.185
No (n¼ 13) — — —
Time from first p1 year (n¼ 45) — — —
transplant to re-listing 1–5 years (n¼ 40) 0.77 0.29, 2.02 0.595
45 years (n¼ 46) 0.49 0.19, 1.22 0.133
Time from re-listing p1 year (n¼ 27) — — —
to end of follow-up 1–5 years (n¼ 68) 3.53 1.38, 9.43 0.010
45 years (n¼ 36) 8.36 2.58, 31.16 o0.001
Abbreviations: CI, confidence interval; DBD, donation after brain death; DCD,
donation after circulatory death; HLA, human leukocyte antigen; MFI, median
fluorescence intensity.
aDonor type (DBD or DCD) was not known for one deceased donor kidney
transplant.
bDonor age information was missing for 16 cases.
cHLA-C typing information was not available for six cases.
dImmunosuppression information was not available for three patients at the time
of re-listing.
eImmunosuppression information was not available for four patients while on the
waiting list.
Bold values indicate greater significance than Po0.05.
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development of HLA-specific antibodies was the length of
time on the waiting list (45 years vs.o1 year after re-listing,
OR 8.36, 95% CI: 2.58–31.16, Po0.001). Continuation of
two or more immunosuppressive agents (but not single-
agent immunosuppression) following re-listing for trans-
plantation was associated with a reduced likelihood of
sensitization (OR 0.15, 95% CI: 0.05–0.40, Po0.001). Of
the 36 patients maintained on single-agent immunosuppres-
sion, 32 (89%) were given prednisolone. Of the 30 patients
receiving multiple agents, 28 (93%) were on prednisolone, 21
(70%) on a calcineurin inhibitor, 16 (53%) on an anti-
proliferative agent (mycophenolic acid or azathioprine), and
2 (7%) on a mammalian target of rapamycin inhibitor.
Multivariate analysis confirmed that HLA mismatch, length
of time on the waiting list following re-listing, and use of
dual-agent immunosuppression while on the waiting list
remained significantly associated with the likelihood of
sensitization (Table 4). Graft nephrectomy was associated
with HLA-specific sensitization on univariate analysis (OR
3.42, 95% CI: 1.51–8.30, P¼ 0.004), but this effect was not
apparent when withdrawal of immunosuppression was
taken into account (79% of patients who underwent graft
nephrectomy had immunosuppression completely with-
drawn).
Table 5 shows a univariate analysis of the association of
HLA mismatch and other variables with increasing cRF levels
in the 92 patients who became sensitized while listed for
repeat transplantation. When donor HLA mismatches for all
loci (0–12 mismatches) were considered collectively, each
additional HLA mismatch was associated with an incre-
mental increase in cRF level (OR 1.16, 95% CI: 1.00–1.36,
P¼ 0.065), although the average effect size of each additional
HLA mismatch was reduced by the inclusion of HLA-C
(where there was no effect, Table 2, column 2), and because
the effect of increasing number of HLA mismatches became
less marked as the total number of mismatches rose.
Multivariable analysis showed that maintenance of dual-
agent immunosuppression and length of time on the waiting
list after re-listing were independently associated with
increasing cRF levels (Table 4).
DISCUSSION
The results of renal transplantation have improved progres-
sively over the last two decades, but many recipients are likely
to require repeat transplantation during their lifetime. The
chances of a suitable HLA-compatible kidney being available
for patients who require repeat transplantation are markedly
reduced by the presence of HLA-specific antibodies that arise
during or following failure of their first transplant. The
results of this study show that the extent to which a failed
first graft was mismatched for HLA is strongly associated
with the development of HLA-specific antibodies while
awaiting a repeat transplant. A strength of our study is that
it is the most comprehensive analysis of this type to date and
the first to use Luminex single-antigen bead technology to
examine the effect of mismatches at each HLA locus on both
the range and level of HLA-specific alloantibodies developing
posttransplant, and their influence on likely access to
re-transplantation. A weakness of the study is that HLA-DP
typing data were not available for the study cohort and so we
Table 4 |Multiple variable analysis: influence of donor and patient factors on the development of HLA-specific alloantibodies
(adjusted for pretransplant sensitization, MFI threshold of 42000)
Variable Value Adjusted odds ratio 95% CI Wald P
Likelihood of developing HLA-specific alloantibodies
HLA class Iþ II mismatches Per mismatch 1.40 1.10, 1.79 0.009
Immunosuppression while on the waiting list
None (n¼ 61) — — —
Single (n¼ 36) 1.19 0.35, 3.05 0.975
Dual (n¼ 30) 0.24 0.06, 0.61 0.005
Time from re-listing to end of follow-up
p1 year (n¼ 27) — — —
1–5 years (n¼ 68) 2.80 0.80, 7.28 0.119
45 years (n¼ 36) 6.33 1.28, 20.4 0.024
Likelihood of developing increasing levels of HLA-specific sensitization (increasing cRF)a
HLA class Iþ II mismatches Per mismatch 1.13 0.97, 1.30 0.115
Immunosuppression while on the waiting list
None (n¼ 61) — — —
Single (n¼ 36) 1.11 0.53, 2.05 0.899
Dual (n¼ 30) 0.43 0.14, 0.96 0.048
Time from re-listing to end of follow-up
p1 year (n¼ 27) — — —
1–5 years (n¼ 68) 3.25 1.35, 6.74 0.008
45 years (n¼ 36) 4.68 1.76, 10.35 0.002
Abbreviations: CI, confidence interval; cRF, calculated reaction frequency; HLA, human leukocyte antigen; MFI, median fluorescence intensity.
aThis analysis included those patients from the initial cohort that developed HLA-specific alloantibodies following allograft failure (cRF40).
Bold values indicate greater significance than Po0.05.
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are not able to comment on the potential role of mismatches
at HLA-DP to sensitization after graft failure.
There is a surprising paucity of published studies seeking
to clarify the relationship between HLA matching for renal
transplantation and subsequent sensitization following graft
failure.10–12,14,15 Previous studies have been limited to
assessment of allosensitization using cytotoxicity against a
peripheral blood lymphocyte panel (PRA) that primarily
detects only HLA-A- and -B-specific antibodies. The use of
PRA alone does not provide information about antibodies
directed against individual HLA loci, nor sensitization to
HLA class II. Moreover, PRA is subject to wide inter-
laboratory variation, and may detect clinically irrelevant
immunoglobulin M non-HLA-specific lymphocytotoxic anti-
bodies.13 A large registry analysis from the United States of
patients re-listed for transplantation after loss of their first
kidney transplant14 demonstrated a combined effect of HLA-
A and -B mismatches on PRA levels at the time of listing for
repeat transplantation and, notwithstanding the limitations
of PRA, suggested the importance of HLA-A and -B
matching of first grafts for patients who may subsequently
require repeat transplantation.
In this study, Luminex single-antigen beads were used to
enable precise antibody specification against individual HLA
loci.13,16 The results show for the first time that an increasing
number of mismatches at both HLA class I and class II is
associated with higher likelihood of allosensitization after
re-listing for repeat transplantation, and mismatches at
HLA-A, -B, -DR, and -DQ all contribute to higher levels of
sensitization and donor incompatibility (increased cRF).
Importantly, the association between donor HLA mismatch
and likelihood of HLA-specific sensitization was apparent for
the three MFI cutoff thresholds (X2000, X5000, and
X8000) that reflect increasing immunologic risk for repeat
kidney transplantation.17,18 The detection of alloantibodies at
MFI values below 2000 is subject to technical artifact and
the clinical significance of antibodies detected at such low
threshold is controversial19–21 and we did not, therefore,
formally evaluate the impact of alloantibodies with an MFI
below 2000 on cRF. However, we found that using an MFI
cutoff value for antibody detection of 1000 resulted in
only three additional donor-specific antibodies becoming
apparent.
The majority of patients who developed HLA-specific
antibodies in this study only did so 412 months after they
had been re-listed for repeat transplantation. This reflects the
fact that patients were often still being maintained on
immunosuppression at the time of re-listing, and immuno-
suppression was then typically reduced or withdrawn to
obviate potential adverse effects. This highlights the
importance of continuing immunosuppression to prevent
development of alloantibodies when early re-transplantation
is likely, usually because of the availability of a potential live
kidney donor, but unless prompt re-transplantation is
anticipated, continued immunosuppression is more difficult
to justify in view of the side effects. Maintenance on steroids
Table 5 | Influence of donor and patient factors on the
likelihood of developing HLA-specific alloantibodies to an
increasing number of HLA specificities (increasing cRF)
(adjusted for pretransplant sensitization, MFI threshold of
42000)a
Variable Value
Adjusted
odds ratio 95% CI Wald P
Donor typeb Deceased (n¼ 106) 0.79 0.36, 1.91 0.600
DBD (n¼ 79) 0.86 0.40, 2.00 0.737
DCD (n¼ 26) 0.61 0.24, 1.57 0.305
Live (n¼ 25) —
Donor agec 0–17 (n¼ 3)
18–49 (n¼ 59) 0.75 0.40, 1.39 0.355
50þ (n¼ 53) — — —
Recipient age 0–17 (n¼ 4)
18–49 (n¼ 97) 1.64 0.87, 3.18 0.133
50þ (n¼ 30) — —
HLA class Iþ II
mismatchesd
Per mismatch 1.16 1.00, 1.36 0.065
Immunosuppression None (n¼ 48) — — —
at time of re-listinge Single (n¼ 27) 1.78 0.78, 3.82 0.154
Dual (n¼ 53) 1.12 0.56, 2.17 0.759
Immunosuppression None (n¼ 61) — — —
while on the waiting listf Single (n¼ 36) 1.22 0.61, 2.39 0.565
Dual (n¼ 30) 0.39 0.14, 0.99 0.058
Nephrectomy Yes (n¼ 56) 0.99 0.54, 1.85 0.985
No (n¼ 75) — — —
Blood transfusion Yes (n¼ 118) 1.01 0.98, 1.03 0.624
after transplantation No (n¼ 13) — — —
Blood transfusion Yes (n¼ 41) 1.65 0.84, 2.86 0.155
after listing for
re-transplantation
No (n¼ 90)
Recipient gender Female (n¼ 44) 2.24 1.20, 4.14 0.010
Male (n¼ 87) — — —
Pregnancy Yes (n¼ 31) 1.38 1.04, 1.76 0.016
No (n¼ 13) — — —
Time from first p1 year (n¼ 45) — — —
transplant to re-listing 1–5 years (n¼ 40) 2.97 1.38, 5.99 0.004
45 years (n¼ 46) 0.90 0.44, 1.79 0.760
Time from re-listing p1 year (n¼ 27) — — —
to end of follow-up 1–5 years (n¼ 68) 2.81 1.29, 6.59 0.012
45 years (n¼ 36) 4.00 1.63, 10.32 0.003
Abbreviations: CI, confidence interval; cRF, calculated reaction frequency; DBD, donation
after brain death; DCD, donation after circulatory death; HLA, human leukocyte antigen.
aThis analysis included those patients from the initial cohort who developed HLA-
specific alloantibodies following allograft failure (cRF40).
bDonor type (DBD or DCD) was not known for one deceased donor kidney transplant.
cDonor age information was missing for 16 cases.
dHLA-C typing information was not available for six cases.
eImmunosuppression information was not available for three patients at the time
of re-listing.
fImmunosuppression information was not available for four patients while on the
waiting list.
Bold values indicate greater significance than Po0.05.
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alone did not protect from the development of sensitization,
whereas those maintained on two or more agents while on
the waiting list were much less likely to develop HLA-specific
antibodies. Previous studies have reported that transplant
nephrectomy is associated with the development of allosen-
sitization, although the timing of nephrectomy and main-
tenance of immunosuppression influence the temporal
relationship between nephrectomy and emergence of alloanti-
body making direct comparisons between studies difficult.22,23
In this study, less than half of the recipients underwent graft
nephrectomy and after the effect of first transplant HLA
mismatch and withdrawal of immunosuppression were taken
into account, nephrectomy was not an independent risk
factor for allosensitization.
Our analysis shows that mismatches at HLA-A, -B, -C,
-DR, and -DQ all contribute independently to allosensitiza-
tion and that, for each locus, two mismatches contribute
significantly more than one mismatch. Given that no
mismatch (except HLA-C) is worse than any other mismatch,
there are two potential approaches to HLA matching to
minimize the subsequent risk of sensitization. One is to focus
on avoiding more than one mismatch at any given loci, and
another is to focus on reducing the total number of HLA
mismatches with no regard to the number of mismatches
within a given locus. Our data do not support one approach
over the other and a practicable clinical strategy would be to
avoid six or more antigen mismatches across all loci when
possible, irrespective of the number of mismatches within
any given locus. Although our data provide a convincing
argument for improved HLA matching when repeat trans-
plantation is a likely future possibility, the degree of HLA
matching likely to be achievable through most kidney
allocation schemes is such that many patients will still
receive grafts that lead to some degree of sensitization when
they fail. A further practical approach to preventing sensitiza-
tion is to continue immunosuppression after graft failure
with the aim of early re-transplantation, but the additional
risks of maintaining immunosuppression after return to
dialysis have to be balanced carefully against the chance of
early re-transplantation. In patients who have already
developed high levels of allosensitization despite immuno-
suppression, there is no advantage of maintaining them on
immunosuppression when listed for re-transplantation. In
patients with an HLA-mismatched graft, who have little or no
allosensitization, a careful risk benefit assessment should be
made to decide on whether continuation of maintenance
immunosuppression can be justified. Although the additional
risks of immunosuppression, in terms of infection, cardio-
vascular and metabolic complications, and increased risk
of malignancy, seem justifiable if early re-transplanta-
tion is facilitated, they are more difficult to justify for
those who do not proceed to re-transplantation in a short
timescale.
In this study, we focussed on the traditional approach
to HLA matching that assigns equal weight to all HLA
mismatches within a given HLA locus. This strategy is widely
used to inform most national kidney allocation schemes but
does not take into account variation in donor immunogenicity
according to recipient HLA type. Analysis of HLA alloanti-
body profiles based on mismatches at broadly reactive public
epitopes (Bw4 and Bw6) did not provide any additional
insight into HLA immunogenicity. However, there is increas-
ing interest in the concept of predicting HLA immuno-
genicity on the basis of mismatched HLA epitopes using
programs such as HLAMatchmaker that defines immuno-
genicity according to exposed epitopes (triplets/eplets) on the
surface of HLA molecules.24–26 Although adopting such an
approach was beyond the scope of this study, the ability to
define and avoid donor kidneys expressing epitopes that
are particularly immunogenic for a given individual is very
attractive and should be the focus of future studies.27
In summary, the results of this study show a clear
relationship between the level of mismatch at the HLA-A, -B,
-C, -DR, and -DQ loci of a first kidney transplant and the
development of HLA-specific alloantibodies after subsequent
graft failure and listing for repeat transplantation, and high-
light the role of continued immunosuppression in preventing
alloantibody production. Allosensitization to HLA markedly
restricts the number of antibody-compatible kidney donors,
severely limiting opportunities for repeat transplantation.
This problem could be reduced by placing more emphasis on
HLA matching in national kidney allocation schemes for
those recipients who are likely to require repeat transplantation.
Existing matching schemes are predicated on graft survival
rather than sensitization and often place most emphasis on
HLA-DR matching rather than on HLA class I matching or
HLA-DQ matching. However, because all mismatched HLA
loci contribute to sensitization, existing allocation schemes are
unlikely to solve the problem of allosensitization. A more
practical approach may be to continue immunosuppression
and aim for early re-transplantation, but the risks of
immunosuppression will have to be balanced carefully against
the chance of early re-transplantation.
MATERIALS AND METHODS
Patients
The study population comprised 131 consecutive patients who
received a first kidney transplant between September 1995 and April
2010 (inclusive) and returned to the Cambridge kidney transplant
waiting list following failure of their graft during this time period.
On 31 January 2012 (study census date), 26 patients were active on
the waiting list, 3 were transferred to a different transplant center, 68
had undergone repeat transplantation (for these patients and for the
purpose of this study, the follow-up was terminated at the time of
repeat transplantation), 13 had died on the waiting list, and 21 had
been permanently suspended for clinical reasons. Transplant
nephrectomy was performed in 56 (43%) patients.
HLA-specific antibody screening
Serum samples for antibody screening were obtained at the time of
first kidney transplant, on return to the transplant waiting list, and
3 monthly thereafter. Sera were screened using unmodified and
dithiothreitol-modified complement-dependent lymphocytotoxicity
1046 Kidney International (2014) 86, 1039–1048
c l in i ca l inves t iga t ion V Kosmoliaptsis et al.: Donor HLA mismatch and antibodies in patients listed for repeat transplantation
 292 
 
against a panel of HLA-typed peripheral blood lymphocytes from
healthy blood donors (expressing HLA-A, -B, and -C specificities),
and a B-cell panel comprising HLA-typed patients with B-cell
chronic lymphocytic leukemia–expressing HLA-A, -B, -C, -DRB1,
-DRB3/4/5, -DQ, and -DP specificities.13 Immunoglobulin G PRAs
(% IgG-PRA) were calculated for the peripheral blood lymphocyte
and chronic lymphocytic leukemia panels to reflect HLA class I and
class I/II lymphocytotoxic alloreactivity, respectively.
In addition, sera were screened for HLA-specific antibodies using
solid-phase Luminex HLA antibody-detection beads and selected
HLA-specific antibody-positive samples were analyzed using Lumi-
nex single-antigen HLA class I and class II antibody-detection beads
(One Lambda, Canoga Park, CA). HLA single-antigen bead–defined
antibody reactivity was determined using MFI with cutoff thresholds
of 2000, 5000, and 8000 to reflect increasing antibody levels.
Calculated reaction frequency
The HLA antibody specificities identified in sera using Luminex
single-antigen beads were used to determine the cRF. cRF defines the
percentage of a standardized panel of 10,000 consecutive HLA-typed
UK deceased organ donors (identified by NHSBT) that is incompa-
tible with the alloantibody profile of a potential transplant recipient
and therefore reflects the chance of identifying a suitable donor
organ for a given recipient.16,28 It is dependent on the individual
antibody specificities present in the sera and the frequency of the
corresponding HLA alleles in the donor population. At each MFI
threshold, the cRF was determined for individual loci (HLA-A, -B,
-C, -DRB1, -DRB3/4/5, and -DQ), HLA class I (HLA-A, -B, and -C
combined), HLA class II (HLA-DRB1, -DRB3/4/5, and -DQ combined),
and HLA class I and class II combined.
The ‘peak’ reactive serum for each patient re-listed for trans-
plantation was identified as that showing the highest cRF. Although
a low cRF (p15%) is considered antibody compatible with the large
majority of the organ donor pool, patients with 415% cRF are
defined as ‘sensitized’ and expected to be antibody incompatible
with a proportion of the organ donor pool; patients with X85%
cRF are defined as ‘highly sensitized’, being antibody incompatible
with the majority of the organ donor pool.13,28
Statistical methods
For descriptive purposes, patient characteristics are summarized as
the number (%) in each category or the median (range) for
continuous variables. Simple comparisons in the frequencies in each
of these categories between pre- and posttransplantation used the
Stuart–Maxwell marginal homogeneity test.29 As cRF is zero for a
large proportion of cases, and is bounded above by one (i.e., 100% is
the maximum possible cRF), we use a (hurdle jump) zero-inflated
beta model for the associations between cRF and covariates.30 These
models have two parts, one to assess the relationship between
covariates and non-zero cRF and one to assess the relationship
between covariates and each unit increase in the level of cRF in those
for whom it is non-zero. Results are summarized as ORs and their
95% CIs for the effects of covariates on the probability of having
non-zero cRF. The relationship between covariates and cRF level (for
non-zero CRF) is modeled as a proportion using a logit link, and
summarized as the OR per percentage increase in cRF, with 95% CI.
The P-values were taken from the Wald tests. These analyses
included baseline sensitization as a covariate. Variables that had a
significant association with sensitization were entered into a
multiple-variable model to assess independence of relationships.
Missing covariates were imputed multiple times in order that the full
data set could be used, but the uncertainty associated with estimation
of the covariates was fully incorporated. This analysis was completed
in Stata/IC version 12.0 (StataCorpLP, College Station, TX) and in
WinBUGS version 1.4 (MRC Biostatistics Unit, Cambridge
University, Cambridge, UK), with non-informative prior distri-
butions for all parameters. As some similarity between the mis-
matches at different loci was expected, we used random effects
models for the relationship between the number of mismatches
within a locus and the locus-specific cRF response and these results
are given in Table 2. These results were similar to analyses that
assumed that all loci were independent (data not presented).
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Figure S1. Association between first transplant mismatches at the
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Figure S2. Association between first transplant HLA class I and class II
mismatches and lymphocytotoxic HLA-specific alloantibody
responses expressed as %IgG PBL-PRA and %IgG B-CLL-PRA.
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Donation after Cardiac Death (DCD) is an increasingly
important source of kidney transplants, but because of
concerns of ischemic injury during the agonal phase,
many centers abandon donation if cardiorespiratory
arrest has not occurred within 1 h of controlled with-
drawal of life-supporting treatment (WLST). We report
the impact on donor numbers and transplant func-
tion using instead a minimum ‘cut-off’ time of 4 h.
The agonal phase of 173 potential DCD donors was
characterized according to the presence or absence
of: acidemia; lactic acidosis; prolonged (>30 min) hy-
potension, hypoxia or oliguria, and the impact of these
characteristics on 3- and 12-month transplant outcome
evaluated by multivariable regression analysis. Of the
117 referrals who became donors, 27 (23.1%) arrested
more than 1 h after WLST. Longer agonal-phase times
were associated with greater donor instability, but sur-
prisingly neither agonal-phase instability nor its dura-
tion influenced transplant outcome. In contrast, 3- and
12-month eGFR in the 190 transplanted kidneys was
influenced independently by donor age, and 3-month
eGFR by cold ischemic time. DCD kidney numbers are
increased by 30%, without compromising transplant
outcome, by lengthening the minimum waiting time
after WLST from 1 to 4 h.
Key words: DCD, expanding pool, kidney donation,
organ recovery
Abbreviations: CI, confidence interval; CIT, cold is-
chaemic time; DBD, donation after brain-stem death;
DCD, donation after cardiac death; DGF, delayed graft
function; eGFR, estimate of glomerular filtration rate;
PNF, primary nonfunction; SD, standard deviation;
UK, United Kingdom; US, United States; WLST, with-
drawal of life-supporting treatment.
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Introduction
The major problem facing transplantation worldwide is un-
availability of organs. In the United States over 85 000 peo-
ple are now waiting for a kidney transplant but there were
less than 7300 deceased donors in 2009 (1). Similarly, the
UK kidney waiting list has doubled in the last decade to
over 7000, whereas deceased donor rates have remained
relatively constant, at approximately 800 per year (2).
Organ scarcity has prompted medical and political initia-
tives to improve donor rates (3).
One initiative has been re-appraisal of the use of organs
from potential donors, who do not fulfill brain-stem death
criteria, but whose clinical condition is futile; upon car-
diorespiratory arrest followingwithdrawal of life-supporting
treatment (WLST), organ recovery is possible, if performed
promptly. Organs retrieved from such ‘donation after car-
diac death’ (DCD) donors differ from conventional ‘donation
after brain-stem-death’ (DBD) donors in that they are sub-
ject to warm ischemia during the period from cardiores-
piratory arrest to organ perfusion with cold preservative
solution. Nevertheless, despite an increased incidence of
delayed graft function (DGF), transplant survival rates of
DCD kidneys are broadly comparable to those of DBD kid-
neys (4–12) and they have become an important resource,
providing 32% of deceased kidney allografts in the United
Kingdom in the 2008–2009 financial year (2).
However, concerns persist regarding additional ischemic
damage; incurred not only after cardiorespiratory arrest,
but also from prolonged preterminal hypotension during
the period from WLST to cardiorespiratory arrest [termed
hereafter the agonal phase (13)]. Consequently, extended
criteria donors, such as donors older than 60, are often not
considered for DCD kidney donation, because of fears that
the additional ischemic insult, when allied to an already-
marginal kidney, will result in very poor transplant out-
comes. Perhaps more tellingly, very few centers pursue
‘uncontrolled’ (Maastricht category 1 or 2) DCD donors
(14) and instead only use kidneys from Maastricht cate-
gory 3 donors, whereby WLST is performed in a controlled
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fashion, with the recovery team scrubbed awaiting donor
cardiorespiratory arrest.
For logistical reasons and to minimize the perceived po-
tential for ischemic kidney injury, several consensus doc-
uments recommend a cut-off time of 1 h from WLST
to cardiorespiratory arrest, after which organ donation is
abandoned (13,15). Surprisingly however, this cut-off time
has not been validated, in that no publication has ad-
dressed the association between length of agonal phase
and kidney transplant outcome. To maximize donor num-
bers, when we established our recovery policy for poten-
tial DCD donors, we chose a minimum cut-off period from
WLST of 4 h before the organ recovery team stands down.
We report here our experience applying this policy for all
controlled DCD donors referred to our center and demon-
strate that the number of potential donors from whom
kidneys are retrieved is increased substantially. Whereas
some donors remained relatively stable for an extended pe-
riod after WLST before quickly deteriorating and undergo-
ing cardiorespiratory arrest, others had extended periods
of instability in the agonal phase characterized, for exam-
ple, by prolonged hypotension, hypoxia or oliguria. Such
extended donor instability might be expected to have a
detrimental effect on the quality of the kidneys retrieved,
and this report aims to analyze how such instability influ-
enced outcome of the transplanted kidneys.
Materials and Methods
Donor selection, recovery operation and recipient management
Between 1 June 2004 and 31 May 2009, 425 potential controlled DCD
donors (Maastricht category 3) were referred to the Cambridge Transplant
Centre. If there were no contraindications to donation, treatment was with-
drawn either in the Intensive Care Unit or in the theatre anesthetic room,
vital signs monitored regularly and upon cardiorespiratory arrest, death cer-
tified by an independent medical practitioner, with a minimum ‘stand-off’
time of 5min observed between arrest and commencement of organ recov-
ery. Data on the agonal phase characteristics were recorded prospectively
by donor coordinators and held within a central library of donor records.
Donation was pursued for a minimum of 4 h after WLST from a potential
DCD donor. For logistical reasons, donation was abandoned at this point,
unless arrest thought imminent. Donation at later time-points was however
possible for selected referrals from our base hospital; Cambridge University
Hospitals NHS Trust, when the team could re-attend rapidly (within 30 min)
once the potential donor became unstable.
Kidneys were assessed visually following recovery and discarded if poorly
perfused, damaged, or gross macroscopic disease, such as severe aor-
tic atherosclerosis, was present. Preimplantation histopathological scoring
[from 0 to 12, according to Remuzzi et al. (16)] of wedge biopsies was
performed when deemed clinically necessary, and kidneys also discarded
if chronic disease, as indicated by a score >4, was revealed. These were
performed more frequently as the DCD program developed and more el-
derly donors, with an increased incidence of cardiac comorbidities, were
considered. DCD kidneys were used locally and allocated according to a
national algorithm that awards points to potential recipients depending on:
age matching to the donor; HLA mismatch; and time spent on the waiting
list (17). Immunosuppression was administered postoperatively according
to standard protocols, as described previously (6).
Analysis
The impact of donor characteristics and agonal-phase and
recovery/implantation variables on kidney transplant func-
tion [the presence or absence of DGF and the estimated
glomerular filtratation rate (eGFR) at 3 and 12 months] was
examined. DGF was defined as the provision of postopera-
tive dialysis in the first week and onwards after transplanta-
tion, exceptwhen required for hyperkalemia in the first 24 h
after surgery. eGFR was calculated using the four variable
Modification of Diet in Renal Disease formula 7 [MDRD7,
Ref. (18)] and is expressed inmilliliters perminute, adjusted
for body surface-area. Primary nonfunction (PNF) was de-
fined as a graft that never achieved sufficient function to
allow discontinuation of dialysis, excluding acute vascular
thrombosis.
Donors were scored for the presence of hypotension, hy-
poxia, oliguria, acidosis and lactic acidemia using prede-
termined cut-off values (see Table 1, chosen empirically
as representing a clinically relevant deterioration). The im-
pact of these variables and also donor characteristics on
transplant outcome was assessed by multivariable regres-
sion analysis [WinBUGS software Ref. (19)] using linear
and logistic regression for analyzing relationship to 3- and
12-month eGFR and DGF. HLA mismatch between donor
and recipient was categorized according to differences at
the HLA-A, HLA-B and HLA-DR loci: with 0–1 of 6 possi-
ble mismatches categorized as level 1; 2–4 mismatches
as level 2 and 5–6 as level 3. The statistical dependence
between the pair of kidneys from each donor was incor-
porated using a random effect on the intercept for each
regression.
Two regression models were fitted to each of these
outcome measures: in model 1, the agonal phase vari-
ables were evaluated as separate predictors; whereas
in model 2, each donor was scored (0–5) according to
the presence or absence of each variable and the over-
all agonal-phase score assessed against outcome. When
possible, arterial blood gasses were sampled immediately
prior to WLST and hourly thereafter, but because of either
absence of arterial line in the donor or inability to assay lac-
tic acid on the available blood gas analyzer, acidemia and
lactic acidosis were only assayed in 114 (65.9%) and 78
(45.0%) of patients, respectively. Missing data for these
variables are included by performing Bayesian multiple im-
putation (19,20). A paired t-test was used to compare 3-
month eGFR values in kidneys transplanted from the same
donor. Proportional-odds ordinal regressionwas used to as-
sess the impact of agonal phase duration on agonal phase
996 American Journal of Transplantation 2011; 11: 995–1005
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Table 1: Input donor, agonal phase and implantation variables for multivariable regression analysis on renal transplantation outcomes
Mean (SD, range)/frequency
Donor characteristics
Age (years) 45.5 (19.2, 17–74)
Female gender 34%
Serum creatinine (lmol/L) 97.6 (67.4, 36–504)
Trauma death 31%
Recipient characteristics
Age (years) 49.0 (14.4, 19–73)
HLA mismatch Level I 11.6%
Level II 84.9%
Level III 3.5%
Agonal phase factors
Hypotension (systolic BP < 85 mmHg for >30 min) 19%
Oliguria (<30 mL/h) 24%
Hypoxia (SaO2 < 70% for > 30 min or arterial pO2 < 6 kPa) 26%
Acidemia (arterial pH < 7.30) 35%
Lactatemia (arterial lactate >2.0 mmol/L) 34%
Agonal phase duration (h) 1 h 25 (0–31 h)
Recovery/implantation variables
Warm ischemic time (>15 min) 43%
Cold ischemic time (h) 13 h 40 (3 h 49, 5 h 46–23 h 07)
score. The relationship between age and eGFR was as-
sessed using linear regression.
A contemporaneous group of kidneys from DBD donors
was selected for comparison by choosing, for the first
4 years of study, the DBD kidney transplants undertaken
immediately before and after each pair of transplants from
the DCD donor. When only one DCD kidney was trans-
planted, the DBD kidney transplant that preceded it was
selected. For the last year of the study all DBD kidneys
were included, because by then, numbers of DCD kidney
transplants exceeded that of DBD kidneys. The t-test was
used to compare 3-month eGFR in the kidney transplants
from the DBD and DCD groups.
Kaplan–Meier curves were plotted to depict kidney trans-
plant outcome. Graft survival was censored for patient
death. Curve comparison was performed with the Mantel–
Cox test.
Data was analyzed following discussion with our Local Re-
search and Ethics Committee as appropriate service eval-
uation.
Results
Referrals for potential DCD donation.
This study reports the Cambridge Transplant Centre’s ex-
perience of controlled DCD kidney donation from 2004 to
2009 (Figure 1A); a period characterized by marked expan-
sion in the DCD program, with increasing numbers of refer-
rals (Figure 1B) of increasingly elderly donors (Figure 1C).
In the final year, approximately twice as many DCD as DBD
kidney transplants were performed (Figure 1B) and this
represents the most active DCD program in the United
Kingdom (Figure 1D). In total, 425 patients (Figure 1E)
were referred for consideration as potential DCD donors
(52.0%males, median age 60 [range 16–92]). The majority
(55.5%) were not pursued either because of medical un-
suitability or relative refusal (Figure 1A). Of the 173 who
underwent WLST, 117 (67.6%) became donors; donation
was abandoned in the remaining 56 (32·4%), because a
minimum of 4 h had elapsed and cardiorespiratory arrest
had not occurred (51, 29.5%) or, in a small number of cases
(5, 2.9%), because of concerns of protracted agonal-phase
instability within the initial 4 h wait period.
Our practice of waiting 4 h followingWLST differs from the
commonly observed standard waiting time of a 1 h max-
imum (13,15). The impact of our protocol on the conver-
sion of potential DCD donors to actual donors is depicted
in Figure 2, which demonstrates that although the majority
of donors arrested within the first hour (90 of 117, 76.9%),
many additional donors (27, an increase of 30%) were re-
alized by a longer minimum wait time of 4 h. Of these,
eight occurred between 1 and 2 h following WLST and
11 between 2 and 4 h. A further eight potential donors in
our base hospital were converted successfully after more
than 4 h had elapsed becauseWLST; the longest time from
withdrawal to cardiorespiratory arrest was 31 h.
The principal reason for ‘standing-down’ in the 56 poten-
tial donors that were abandoned after WLST had occurred
was the logistical inability to pursue donation for longer
than 4 h. Thus the 27 donors with agonal phases of greater
than 1 h that were successfully pursuedwere not preferen-
tially selected according to favorable donor characteristics.
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Figure 1: Development of Cam-
bridge DCD program 2004–2009.
(A) Outcomes of referrals for con-
sideration as potential DCD donors.
(B) Yearly development of DBD and
DCD programs. The majority of DCD
referrals did not proceed to dona-
tion. ‘Nondonors after WLST’ refers
to potential donors in whom dona-
tion was abandoned after controlled
withdrawal of life-supporting treat-
ment, but before cardiorespiratory ar-
rest had occurred. (C) Boxplot depic-
tion of age of potential DCD donors
for each year of program. Potential
donors were, on average, 2.5 years
older in each successive year (lin-
ear regression, p < 0.001). (D) Donor
rates per million population for each
of the 20, anonymized UK renal trans-
plant centers for the year 2008 to
2009. ∗Cambridge Transplant Centre.
Data from NHS BT (2). (E) Outcome
of referrals for consideration of DCD
donation.
Indeed, these 27 donors were older (mean 57.1 years,
range 21–75 years) than the 90 donors that arrested less
than 1 h after WLST (mean 48.6 years, range 17–74 years,
p= 0.01) and a similar age to those patients in whom dona-
tion was abandoned (mean 56.3 years, range 17–78 years,
p = 0.79).
Agonal phase characteristics
The agonal phase of those donors proceeding toWLSTwas
characterized according to the presence or absence of the
hemodynamic and biochemical indices listed in Table 1.
Agonal phase instability occurred frequently, with donors
suffering prolonged periods of hypotension (19%), hypoxia
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Figure 1: Continued
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Figure 2: Time to cardiorespiratory
arrest following WLST in potential
DCD donors. The time to cardiores-
piratory arrest fromWLST is depicted
for proceeding donors (blue) and non-
proceeding donors (red). Although
five potential donors were abandoned
within 4 h after withdrawal of life-
supporting treatment due to concerns
regarding prolonged agonal phase in-
stability, all but one died after more
than 4 h had elapsed.
(26%), oliguria or anuria (24%), acidemia (35%) and lactic
acidosis (34%) after WLST. Compared to agonal phases
of less than 1 h, longer agonal phases were associated
with a higher incidence of hypotension, hypoxia, oliguria,
acidosis and lactic acidemia (Figure 3A). Similarly, higher
global agonal phase scores were associated with longer
agonal phases (Figure 3B), although a number of donors
with agonal phases of less than 1 h had become unstable
during assessment prior to WLST and thus also scored
highly (Figure 3B).
The influence of agonal phase on transplant outcome
The impact of a prolonged agonal phase on immediate and
long-term function of the retrieved kidneys has not been
reported previously, and without consensus from the liter-
ature, the decision to abandon the recovery process before
4 h had elapsed in five patients with unfavorable agonal-
phase characteristics was made on an individual basis by
the recovery surgeon. Nevertheless, agonal-phase insta-
bility developed in a number of donors (and not just those
with agonal phases greater than 1 h) that was seemingly at
least as severe (Figure 3B) and donation was still pursued.
We thus sought to clarify how such instability influences
kidney transplant outcomes. Of 234 kidneys retrieved, 31
(13.2%) were not implanted due to poor perfusion with
preservative fluid (7, 3.0%) or, more frequently, because
chronic disease, apparent macroscopically or on preim-
plantation biopsy analysis, was present (24, 10.3%). The
proportion of kidneys discarded from donors with agonal
phases greater than 1 h (10 of 54, 18.5%) was not different
from those discarded from donors with agonal phases less
than 1 h (21 of 180, 11.7%, p = 0.9). PNF occurred in a fur-
ther six grafts (2.6% incidence, including 1 anastomotic de-
hiscence following Escherichia coli septicemia) and seven
(3.0%) developed acute arterial or venous thrombosis, but
neither PNF nor vascular thrombosiswere related to agonal
phase duration. The mean 3-month eGFR in those kidneys
transplanted was 45.5 mL/min (SD, 19.2), which is com-
parable to the group of contemporaneously-transplanted
DBD kidneys (47.3 ± 20.2, p = 0.4). Patient and graft sur-
vival curves for the first three years for all transplanted
kidneys are depicted in Figure 4.
The impact of unfavorable agonal phase characteristics and
agonal phase duration on transplant outcome (develop-
ment of DGF and 3- and 12-month eGFR values) was as-
sessed by multivariable regression analysis. Donor factors
(gender, age, mode of death and creatinine), demonstrated
previously to have an association with transplant outcome
(9,21,22) were included in the analysis, as were: degree
of sensitization; and the cold ischemic and warm ischemic
1000 American Journal of Transplantation 2011; 11: 995–1005
 300 
 
Expanding Pool Using DCD with Prolonged Agonal Phase
Figure 3: Donor agonal phase duration and the development
of hemodynamic/biochemical instability. Instability during the
agonal phase (fromWLST to cardiorespiratory arrest) in each donor
(n = 117) was characterized according to the presence of five
abnormal physiological/biochemical parameters (Table 1). (A) Inci-
dence of each parameter in donors with agonal phase <1 h vs.
>1 h. Chi-squared test p values as indicated (B) Global agonal
phase instability was assessed by scoring for the presence of
each positive parameter (total out of five) and plotted against Log
of agonal phase duration. One unit of log (duration in min) is as-
sociated with a 43% (CI = 21%–70%) increase in the odds of
higher agonal phase score. Those donors with high agonal phase
scores, but with short agonal phase durations (<30min) represent
donors who had developed instability prior to WLST. The points
in red represent the five potential DCD donors in whom donation
was abandoned before 4 h had elapsed because of unfavorable
agonal phase characteristics and depict the agonal phase score at
the time donation was abandoned.
times. Recipient age and degree of HLA mismatch were
not included in this multivariate model as they showed no
univariate associations with 12-month eGFR. Mean eGFR
was 44.4 mL/min (SE 3.2) for 0–1 HLA mismatches and
mean 43.7 mL/min (SE 1.4) for 2 or more mismatches (p =
0.86). Pearson correlation of 12-month eGFRwith recipient
age was –0.12 (p = 0.09).
As depicted in Table 2(A), multivariable regression anal-
ysis did not identify a statistically significant association
between any of the agonal phase characteristics, or its
duration, and eGFR at 3 or 12 months. Instead, the only
identifiable variables that impacted upon eGFRwere donor
age [with a 10-year increase associated with a decline in
recipient 12-month eGFR of 4.24 mL/min (95% CI 2.49,
6.02)] and CIT [with each hour’s increase associated with
a decline in 3-month eGFR of 1.27 mL/min (95% CI 0.58,
1.95)]. However, by 12 months the association between
CIT and eGFR was no longer statistically significant. The
detrimental impact of CIT on early graft function is also re-
flected by paired analysis of outcomes for kidneys from the
same donor, with the 3-month eGFR of the kidney trans-
planted second on average 6·91 mL/min (95% CI 1.61,
12.22, p = 0·012) lower than the kidney transplanted first.
By 12 months this difference has lessened to 2.67 mL/min
and was no longer significant (95% CI –4.78, 5.66, p =
0.87). Figure 5 depicts the relationship between eGFR
and donor age, CIT and agonal phase duration as scatter
plots. The impact of agonal phase duration on graft out-
come is depicted in the multivariate analysis in Table 2,
comparing agonal phase duration <1 h to >1 h. Agonal
phase duration was also assessed as a continuous variable
following log transformation to normalize the distribution
(data not shown). Again this showed no correlation with
outcome.
Although not apparent on analysis of 3- and 12-month
eGFR values, the presence of agonal phase instability, such
as hypotension and oliguria, might have been expected to
have a more discernible impact on the development of
acute tubular necrosis (ATN) and DGF. DGF occurred in
94 (49.5%) of 190 DCD kidneys, but logistic regression
analysis revealed a surprising lack of association with the
agonal phase characteristics. Confidence intervals were
however, very wide and we cannot rule out clinically im-
portant effects (Table 2A). In comparison, elderly donors
and prolonged CIT were both associated with an increased
incidence of DGF, although this did not reach statistical sig-
nificance. Linear regression analysis of the days to dialysis
independence was also performed, in the expectation that
more profound agonal phase instability might lead to more
severe ATN and hence more prolonged DGF; again there
was no association with agonal phase characteristics (not
shown).
To assess whether the presence of a combination of unfa-
vorable characteristics (such as hypotension plus hypoxia
plus oliguria) had a detrimental impact on graft outcome,
the analysis was repeated using the global agonal-phase
score. This again demonstrated donor age and CIT as inde-
pendent predictors of 3-month eGFR, but there was no sig-
nificant association with the agonal-phase score (Table 2B).
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Figure 4: Kaplan-Meier plot for pa-
tient and graft survival. (A) Kaplan–
Meier graft and patient survival curves
for kidneys with agonal phase duration
>1 h are comparable to those with ag-
onal phase duration of <1 h to those
with agonal phase duration >1 h at both
1 and 3 years posttransplant (p = 0.22).
(B) Graft and patient survival of kidneys
with agonal phase scores of 2–5 (98.2%,
100.0%) were no worse than those with
low agonal phase scores (0–1) at 1 year
(94.0%, 97.0%). Similarly, at 3 years graft
and patient survival of kidneys with high
agonal phase scores were no worse than
those with low scores and, if anything,
graft survival was significantly better
(p = 0.032).
This analysis also revealed terminal donor creatinine as an
independent predictor of DGF. This presumably reflects
our policy of not declining potential DCD donors with
acute renal impairment; donor terminal creatinine ranged
widely (Table 2A), and was greater than 200 lmol/L in
10 donors.
Kaplan–Meier plots (Figure 4) for kidneys from donors with
agonal phase durations >1 h demonstrated comparable
survival at 1 and 3 years posttransplant to thosewith agonal
phase durations <1 h. Similarly, patient and graft survival
for kidneys from donors with higher agonal phase scores
(2–5) was no worse than from donors with lower agonal
phase scores and, if anything, was surprisingly better in
the former group (Figure 4B).
Discussion
The finding that agonal-phase instability did not impact
upon 3-month eGFR values for controlled DCD kidneys
is surprising. However, although consensus documents
advise abandoning DCD kidney donation 1 h after WLST
(13,15), these recommendations are based on earlier stud-
ies that adopted a cut-off time of 1 h as standard proto-
col at the onset of their programs; a formal examination
of the relationship between the agonal phase and DCD
kidney transplant outcomes has not been performed pre-
viously. Poor results have certainly been reported for liver
transplants from controlled DCD donors with prolonged
agonal phases (23,24), and the reason why similarly se-
vere hypotensive/hypoxic insults do not influence kidney
1002 American Journal of Transplantation 2011; 11: 995–1005
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Table 2: Predictors of kidney allograft outcomes
Estimated difference in Estimated difference in Odds ratio for
3-month eGFR (95% CI) 12-month eGFR (95% CI) DGF (95% CI)
(A) Agonal phase variables analyzed independently
Age∗ –4.24 (–6.02, –2.49) –3.99 (–5.68, –2.30) 1.65 (1.04, 3.11)
Female sex –1.24 (–7.30, 4.90) –3.55 (–9.05, 2.00) 3.85 (0.80, 32.46)
Trauma death 3.77 (–2.44, 10.14) –4.47 (–10.42, 1.50) 1.11 (0.23, 6.83)
Creatinine∗∗ (lmol/L) –0.32 (–7.05, 6.37) –0.49 (–6.95, 5.95) 5.17 (0.93, 47.70)
Hypotension 3.21 (–5.39, 11.93) 3.52 (–4.84, 11.66) 0.42 (0.035, 3.93)
Oliguria –5.18 (–13.10, 2.80) –3.54 (–10.96, 3.88) 1.51 (0.20, 14.01)
Hypoxia 8.47 (–1.10, 18.06) 4.31 (–4.77, 13.59) 0.51 (0.033, 6.77)
Acidemia –1.63 (–9.46, 6.28) 1.60 (–5.64, 8.83) 0.87 (0.078, 8.93)
Lactatemia –8.27 (–16.78, 0.52) –4.80 (–13.21, 3.77) 2.61 (0.23, 53.25)
Agonal phase duration >1 h –6.99 (–14.63, 0.59) –6.07 (–13.38, 1.17) 2.08 (0.29, 19.91)
Warm Ischemic time >15 min –5.05 (–11.01, 0.75) –1.58 (–7.12, 3.94) 2.94 (0.62, 19.85)
Cold ischemic time (h) † –1.27 (–1.95, –0.58) –0.54 (–1.18, 0.10) 1.08 (0.95, 1.25)
PRA > 20% –1.24 (–7.30, 4.90) –3.55 (–9.05, 2.00) 3.85 (0.80, 32.46)
(B) Agonal phase variables analyzed combined as global score (0–5)
Age∗ –4.52 (–6.24, –2.79) –4.21 (–5.86, –2.56) 1.51 (1.05, 2.38)
Female sex –2.05 (–7.92, 3.72) –3.72 (–9.32, 1.85) 2.60 (0.75, 10.89)
Trauma death 3.50 (–2.66, 9.66) –4.10 (–10.02, 1.83) 1.12 (0.30, 4.45)
Creatinine∗∗ –4.64 (–10.20, 0.92) –2.75 (–8.05, 2.59) 5.09 (1.49, 24.85)
Agonal score (2/3 vs. 0/1) 0.35 (–6.48, 7.11) 0.67 (–5.79, 7.18) 0.41 (0.080, 1.73)
Agonal score (4/5 vs. 0/1) 1.16 (–8.41, 10.59) 3.33 (–5.93, 12.42) 2.24 (0.25, 26.74)
Agonal phase duration > 1 h –5.79 (–12.90, 1.43) –5.35 (–12.26, 1.52) 1.73 (0.37, 8.93)
Warm ischemic time > 15min –5.91 (–11.68, –0.17) –2.06 (–7.52, 3.45) 1.96 (0.57, 7.81)
Cold ischemic time† –1.22 (–1.89, –0.53) –0.48 (–1.12, 0.16) 1.07 (0.95, 1.21)
PRA > 20% –2.05 (–7.92, 3.72) –3.72 (–9.32, 1.85) 2.60 (0.75, 10.89)
Multivariable regression analysis of the impact of donor and agonal phase and recovery/implantation variables on the outcome (eGFR at
3-months and the development of DGF) of the 190 kidneys transplanted.
The impact on eGFR is presented for: ∗every additional 10 years of donor age; ∗∗for 1 unit of log(lmol/L creatinine); †for every additional
1 h cold ischemia. Only seven kidneys were transplanted with mismatch level III; these were analyzed combined with the level II group.
transplant function is not clear, but presumably reflects
organ-specific differences, possibly relating to the ability of
the kidney to maintain its blood supply, through autoreg-
ulation, even during systemic hypotension. By the same
reasoning, the higher incidence of PNF and poor graft
function in uncontrolled, as opposed to controlled, DCD
kidney transplants (25) perhaps relates to cessation of au-
toregulation during the prolonged periods of asystole com-
monly observed. Irreversible cortical necrosis from pro-
found hypotension, thought responsible for PNF in uncon-
trolled DCD kidney transplants, was not a feature of our
series.
The surprising nature of our results mandates careful con-
sideration of possible sources of error that obscure a true
detrimental impact of agonal phase instability on transplant
outcome. First, like all retrospective studies it suffers from
the potential for confounding variables and reporting bias.
Against this, the data on each donorwas collected prospec-
tively and held centrally. Equally, we chose deliberately to
examine only a limited number of recipient factors to avoid
weakening the strength of the statistical analysis, and it is
theoretically possible that a deleterious impact of the ago-
nal phase on outcomewasmasked by somehow assigning
kidneys from donors with poor agonal phase characteris-
tics to better ‘quality’ recipients. However this was not
the case, because kidneys were allocated according to the
same algorithm that is used nationally for DCD and DBD
kidneys, as demonstrated by the very few patients who re-
ceived a level III mismatched kidney. This algorithm does
not consider agonal-phase characteristics. Furthermore, for
most donors, a pair of kidneys was transplanted into dif-
ferent recipients, making selection bias inherently difficult.
Finally, donor age and CIT were included deliberately in the
analysis to act as internal, positive controls; it is unlikely
that recipient selection could have been manipulated to
negate the impact of agonal phase on eGFR, yet maintain
the impact of age and CIT.
Another potential source of error is that outcome com-
parisons in this study were performed by analysis of
3- and 12-month eGFR and graft and patient survival at
one and three years following transplantation and it is pos-
sible that the impact of the agonal phase characteristics
on transplant outcome does not become apparent until
later. This will be addressed in future studies, but seems
unlikely; we have recently reported that 1- and 5-year
survival rates for DCD kidney transplants performed at our
center between 1996 and 2006 are similar to contempo-
raneous DBD kidney transplants (6). It is also possible that
an association between agonal phase characteristics and
eGFR may have been revealed if larger numbers of DCD
American Journal of Transplantation 2011; 11: 995–1005 1003
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Figure 5: Relationships of donor age, cold ischemic time and agonal phase duration to kidney transplant function at 3 and
12 months, with fitted univariate linear regressions. Scatter plot diagrams depicting univariate relationships between donor age, cold
ischemic time and agonal phase duration to kidney transplant function at 3 and 12 months.
transplants had been included in the study. Against this,
there was no apparent trend in the impact of individual
agonal-phase variables on eGFR (donor hypotension and
hypoxia are associated with higher values) and likewise
higher global agonal phase scores did not confer a greater
risk of poor graft function (Table 2). Similarly, agonal phase
instability was not confined to donors with agonal phases
of greater than 1 h, reflecting our policy of pursuing DCD
donors despite the development of instability during the
assessment stage prior to WLST, and thus analysis of un-
favorable agonal phase characteristics on kidney function
is influenced by the 19.7% of all donors with agonal scores
≥3 (Figure 3B). In contrast, our data, representing one of
the largest single center-experiences in DCD transplanta-
tion (5,26), identified donor age and CIT as independent
predictors of outcome, which mirrors the findings of a re-
cently published analysis of 2562 DCD kidney transplant
records in the United Network for Organ Sharing (UNOS)
database (9).
Analysis of the paired outcomes of kidneys from each
donor has not been reported previously but, by essen-
tially excluding donor-specific variables, provides important
confirmation of the detrimental impact of CIT on graft out-
come. Notably, the impact of CIT on eGFR that was evident
at 3monthswas not sustained at 12months, either onmul-
tivariable and univariate regression analysis, or on analysis
of paired outcomes. Presumably, this reflects a reversible
component to the damage induced by long cold ischemic
times, albeit recovery takes several months.
Although our data indicate that DCD kidney donation rates
can be improved, without prejudicing transplant outcome,
by lengthening waiting time fromWLST, a policy of waiting
a minimum of 4 h is undoubtedly labor intensive and lo-
gistical problems are created by the organ recovery team
being mobilized for extended periods. Nevertheless, with
the marked expansion in the DCD program, we now per-
form approximately twice as many DCD as DBD kidney
transplants and estimate that our policy of waiting a mini-
mum of 4 h following WLST is responsible for generating
20% of the deceased kidney transplants performed annu-
ally in our center. The expansion in the DCD program was
unexpected and indicates that numbers of potential DCD
donors, at least in our region, are several-fold greater than
those of DBD donors (Figure 1B). The UK Organ Donation
Taskforce, on behalf of the Department of Health, has tar-
geted a 50% increase in organ donation within 5 years (3).
Our experience suggests that this could be readily achieved
by expanding DCD donation. DCD kidney recovery rates in
the United Kingdom [currently 9.0 per million population
(pmp) annually] are gradually increasing (2); matching to
those in our center (currently 35.2 pmp, Figure 1D) would
approximately double the number of deceased-donor
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kidney transplants currently performed in the United King-
dom each year (∼1500), with a quarter of these provided
by pursuing donors for more than 1 h after WLST.
In summary, a minority of DCD referrals proceed to kid-
ney recovery. Our results demonstrate that DCD kidney
numbers are increased substantially, without compromis-
ing transplant outcome, by extending thewaiting time from
WLST to beyond 1 h. The presence of unfavorable agonal
phase characteristics should not be regarded as a con-
traindication to kidney recovery, but CIT should be mini-
mized to optimize transplant outcome.
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